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Abstract 
Background: There have been a number of conflicting findings from 
epidemiological studies investigating the association of drug use and cancer risk. 
Methodological issues such as biased study designs and differences in case 
identification have been postulated as potential reasons for differing results. 
However, the impact of these methodological variants is unclear. 
Aims: The principal aims of this thesis were to develop and validate case definitions 
that identified incident cancer diagnosis in the Clinical Practice Research Datalink 
(CPRD), and to measure and compare the impact of several potential drivers of 
conflicting findings within a practical setting. 
Methods: Firstly, for breast, colorectal, lung, and prostate cancer, two sets of 
incidence rates were estimated and compared to national estimates: (i) based on 
cancers identified in the CPRD; and (ii) estimates from the CPRD incorporating 
linked cancer registry data. Secondly, the statin-cancer association was investigated 
as an exemplar, and several potential drivers of conflicting findings were examined 
including study bias, case definitions, and data linkage. Study bias included 
immortal time, protopathic, prevalent user, healthy user, and time-window bias.  
Results: Cancer incidence rates based on the CPRD alone were lower compared to 
national estimates across all cancer types. Compared to national estimates, 
incidence rates incorporating linked cancer registry data were similar for colorectal 
and lung cancer, but higher for breast and prostate cancer. Of the seven potential 
drivers of discrepant results in the example study of statins and cancer, only time-
window bias yielded substantial and consistent biased effects, with bias towards a 
protective association and corrected analyses yielding a null association. Immortal 
time, protopathic, prevalent user, and healthy user bias had minimal impact on the 
estimated association between statin use and cancer risk. 
Conclusions:  CPRD cancer incidence rates were lower compared to national 
estimates. Incorporating linked cancer registry data, breast and prostate cancer 
incidence rates were higher than expected, implying that a proportion of the cancer 
cases identified in the CPRD were either false-positive cases or not registered 
nationally. A number of common design flaws and decisions were postulated as 
drivers of discrepant results. However, in practical study settings these flaws and 
differences did not uniformly lead to large changes in the estimated association of 
statin use and cancer risk.
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1 Background 
1.1 Introduction 
In this chapter, observational pharmacoepidemiological studies are first placed in 
the context of the regulatory stages of drug development and safety assessment. 
Second, the concept of bias in observational studies is introduced, including a 
description of the specific biases that will be examined in this thesis. Third, UK 
primary care databases are introduced with particular focus on methods related to 
case identification and validation for such databases. Lastly, there is a brief 
overview of interventional and observational studies that have examined the risk of 
cancer among patients prescribed statins. 
1.2 Safety assessment of new medicines 
1.2.1 Phases I-III: pre-licensing 
Before a medication can be widely used, it must first be subjected to a series of 
clinical tests before a license is granted (marketing authorisation). There are three 
clinical phases in the drug development process prior to market authorisation.1 
Phase I trials assess the medication’s safety, tolerability, and pharmacokinetics of 
escalating doses, typically among a small (<100) number of usually healthy 
volunteers. Phase II trials test the efficacy of the medication, i.e. how well the 
medication works at selected doses, as well as continuation of phase I safety 
assessment in a moderate number of people (several hundred) with the target 
condition or disease. Phase III studies (randomised controlled trials, RCT) aim to 
assess the effectiveness of the new medication usually in comparison with the 
current “gold standard” treatment. Phase III studies are conducted in several 
hundred to several thousand people over a period that can last for several years. 
18 
 
Phase IV studies (post market surveillance) are conducted once a drug has been 
approved for use in patients.1 
1.2.2 Phase IV: post marketing surveillance  
Once the medication is approved for use among patients, further monitoring 
outside clinical trial settings is required. Post-marketing surveillance is generally 
divided into two main stages: signal detection and signal evaluation. 
The importance of post-marketing surveillance is illustrated by the withdrawal of 
co-proxamol by the Medicines and Healthcare products Regulatory Agency (MHRA), 
over an increased risk of suicide amongst patients prescribed this medication.2 
1.2.2.1 Signal detection 
After licensing is approved, safety of medications is predominantly monitored 
through a system of spontaneous reports. In the UK, the MHRA oversees the Yellow 
Card Scheme, whereby healthcare professionals and patients themselves report 
adverse events via a “Yellow Card” form.3 Once spontaneous reports are collected 
they are screened for signals and are then evaluated further in terms of causality, 
frequency, clinical implications, and preventability. 
1.2.2.2 Observational drug safety studies 
Once potential signals have been identified, further evaluation is needed to decide 
whether the medicinal product should be maintained, changed, suspended or 
withdrawn. Evaluation of signals can be assessed either by conducting further 
clinical trials or observational (pharmacoepidemiological) studies, for example, 
cohort or case-control studies. The importance of such observational studies is 
illustrated by their contribution toward the decision-making process of over a third 
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of all drugs withdrawn (due to safety concerns) from the European market between 
2002-2011.4 
There has been a surge in observational studies conducted in recent years.5 This 
increase has undoubtedly led to significant contributions to existing medical 
literature. However, cautious interpretation of such findings is needed due to the 
susceptibility of observational studies to bias.  
1.3 Bias 
The concept of bias is the lack of internal validity or incorrect assessment of the 
association between an exposure and outcome which deviates from the true 
relationship.6 Biases are often classified into three main groups: (i) selection bias, 
(ii) information bias, and (iii) confounding. Selection bias is related to study subject 
recruitment or retention procedures. Information bias is concerned with 
procedures used to measure the information about study variables and 
confounding is the distortion caused by other variables related to both exposure 
and outcome. 
Unlike RCTs, pharmacoepidemiological studies are particularly prone to 
confounding bias due to their observational nature. More specifically, RCTs limit the 
potential of confounding (observed or unobserved) by randomly allocating subjects 
to a treatment group, whereby the chance of observing differences between 
treatment groups is minimised. Epidemiological studies are observational in the 
sense that no experimental intervention takes place; events that take place are an 
occurrence of “real world” settings. Although experimental studies may be less 
susceptible to confounding, they have several limitations with respect to their use 
in safety studies. First, trials are generally not powered to assess secondary or 
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relatively uncommon safety outcomes such as cancer. Second, follow-up periods in 
trials are relatively short due to the cumulative cost of long-running trials which 
limits their capability of examining outcomes with long latency periods (e.g. 
cancer). Last, eligibility criteria and drug-dose selection in RCTs often do not reflect 
the general patient population or drug dose for which the medicine will eventually 
be used, which limits generalisability. 
Bias in medical studies are numerous and well documented, some of which are 
specific to study-type (e.g. clinical trials, and ecological studies). This thesis 
concentrates on a subset of biases that have been commonly cited as possible 
reasons for conflicting results in pharmacoepidemiological studies.  
A systematic review of an established drug-cancer association is described in 
Chapter 3, with a detailed focus on specific biases including immortal time, 
protopathic, healthy user, prevalent user, and time-window bias. 
1.4 Electronic health records  
Existing data sources containing longitudinal health data can be utilised by 
observational studies to answer questions about suspected adverse events from 
medications. The following sections provide a summary of the various sources of 
routinely collected data that can be utilised for pharmacoepidemiological research. 
1.4.1 UK primary care databases 
In UK primary care settings, general practitioners (GP) are often the first point of 
contact and continuing point of care for most patients. The UK National Health 
Service (NHS) provides universal primary care coverage to most UK residents which 
extends from birth. GPs provide a wide range of health services, including: advice 
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about health problems, vaccinations, examinations and treatment, prescriptions for 
medicines, and referrals to secondary health services.  
Currently, there are several databases in the UK that collect data from GP practices, 
three of the principal ones being: the Clinical Practice Research Datalink (CPRD; 
formerly known as the General Practice Research Database, or GPRD - throughout 
the remainder of this thesis, the GPRD will be referred to as the CPRD), 
QRSESEARCH, and The Health Information Network (THIN). Intricacies of the 
recording systems used by each database differ slightly; the CPRD and THIN use the 
Vision IT system, while QRESEARCH uses EMIS software. To date, primary care 
databases have been used to conduct observational research covering many broad 
themes, such as: pharmacoepidemiology, drug utilisation, public health, and health 
services research.7 
1.4.2 US claims databases 
The US healthcare system generally consists of three main entities: (i) beneficiaries 
e.g. patients; (ii) healthcare providers e.g. clinics, and hospitals; and (iii) “payers”, 
e.g. the US government, private health insurance companies, and patients (self-
payers). In general, utilisation of healthcare services by a patient (beneficiary) in the 
US incurs a cost: a healthcare provider requests payment (a “claim”) which is 
usually sent to the “payer”. The majority of US residents are either covered by the 
government or privately insured, mainly as part of a health program offered by 
their employer.8 
Examples of government co-ordinated healthcare programmes include Medicaid, 
Medicare, and the Veterans Affairs program.8 Eligibility criteria for enrolment in 
these programmes vary: Medicaid provides medical coverage for low-income 
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individuals and families without private health insurance. Medicare provides 
medical insurance to US residents aged 65 years or older, and the Veterans Affairs 
program covers beneficiaries who have served in the US military. Private insurance 
companies, such Kaiser Permanente, offer medical coverage to members. Available 
health plans are usually employee-sponsored but can also be purchased privately. 
Medical coverage provided by these organisations varies but at the bare minimum 
includes hospital, medical and prescription drug costs. 
Data from such claims databases have been used in various observational studies 
examining questions related to drug utilisation, drug safety, and comparative 
effectiveness.9-15 
1.4.3 Scandinavian registries 
In the Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden), several 
patient registries are available for epidemiological research. Although the 
healthcare systems across the Nordic countries are not identical they all share 
similar characteristics. In all Nordic countries, the national government is largely 
responsible for the co-ordination and financing of primary and secondary health 
care.8 All Nordic residents are provided tax-supported health care by the national 
health service, a personal identification number is allocated to all citizens at birth 
(and immigrants) by the respective tax agencies as part of a population register. The 
population register can be linked unambiguously to the nationwide prescription 
and disease registers including medical birth, cancer, causes of death, and hospital 
discharge.8, 16 
Since the 1980s, pharmacies in Nordic countries have computerised their records 
enabling archiving of dispensed prescriptions. As part of the national public health 
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insurance, universal coverage with unrestricted access to healthcare services is 
provided as well as partial or complete reimbursement for the cost of medicines 
prescribed by a physician.16 The data collected are determined by country-specific 
regulations but all include information on dispensed and prescribed prescriptions, 
clinical diagnoses, and patient demographics together with information from 
different administrative registries. According to the legislation of each country, no 
informed consent is required for collection of the prescription data, but individuals 
may seek information about themselves by request.16 
1.5 Discrepant results: observational drug safety studies 
An increasing number of observational drug safety studies have utilised electronic 
data sources from routinely collected healthcare data.17, 18 However, conflicting 
findings between such studies limit their usefulness when assessing the benefit or 
risks posed by marketed medicinal products. Differing populations might contribute 
to the discrepancy of study results. Moreover, different data sources collect 
information for various reasons, which directly influences what is collected from 
patients. For example, a drug-cancer study conducted in a US claims database may 
not be able to adjust for smoking status because lifestyle factors are not routinely 
collected from insurance claims. In contrast, a study utilising a UK primary care 
database might be able to adjust for the effect of smoking status as a confounding 
factor on the drug-cancer association. 
Conflicting findings from studies conducted in the same data source limit the 
variability introduced by differing populations. Within the same study population, 
differing results might arise due to small changes in study conduct and design 
choices, such as: outcome definitions and ascertainment; exposure definitions, age-
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matching, and control sampling. There are a number of recent conflicting findings 
from pharmacoepidemiological studies conducted in the same data source; for 
example: statin use and risk of fracture,19, 20 oral bisphosphonates and cancer 
risk,21-23 diabetes medications and cancer risk, and statin use associated with cancer 
risk.24-30 
In a study utilising the CPRD, fracture risk was found to be associated with an 88% 
reduction in statin users compared to non-users (OR= 0.12; 95% CI; 0.04, 0.40).31 
However, another study conducted in the CPRD reported no significant effect of 
statin use on fracture risk (OR=0.59; 95% CI; 0.31, 1.13). de Vries et al.19 examined 
design differences between the two studies and described a number of variations 
that might have contributed to the conflicting findings including: case definitions, 
age-matching, and time-window of exposure to statin use. 
Similarly, studies from different settings have shown conflicting findings when 
examining the association between the use of diabetes related medications and the 
risk of cancer. For example, a study set in Germany reported an increased incidence 
of malignancy among patients taking insulin.32 In contrast, a UK database study 
observed no significant effects of insulin on cancer risk.33 In a commentary by 
Pocock et al.34 methods employed by the German study may have been subject to 
selection bias when defining exposure status; partially explaining the increased risk 
of cancer. Exposure time related biases were also shown to have potentially 
affected studies showing a decreased risk of cancer associated with metformin 
use.35  
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1.5.1 Example of conflicting findings: statin use and the risk of cancer 
1.5.1.1 Statins 
Statins are effective hypolipidemic drugs commonly used to treat 
hypercholesterolemia and to prevent cardiovascular disease. They are among the 
most commonly prescribed drugs worldwide. Simvastatin was the first statin to be 
introduced to the UK market in 1989; the early 1990s saw the release of 
pravastatin, fluvastatin, and lovastatin in the UK. The use of statins has increased 
dramatically over the last decade following reports from RCTs of substantial risk 
reductions in cardiovascular disease and related mortality.36-41 The ageing 
population and recent availability of over-the-counter low-dose statin formulations 
are likely to continue their increased utilisation. Apart from cardiovascular disease, 
there are increasing questions being raised about possible protective properties 
against other diseases and conditions including cancer,42-44 dementia,45 and 
fractures.31 
1.5.1.2 Cancer 
Cancer is a major public-health issue worldwide, with approximately 14 million new 
cases and 8.2 million cancer related deaths worldwide in 2012.46 Cancer, known 
medically as a malignant neoplasm, is a broad group of diseases. A defining feature 
of cancer is the division of cells which grow uncontrollably, forming malignant 
tumours.46 
1.5.1.3 Risk Factors 
The causes of cancer are diverse, complex, and only partially understood. Known 
risk factors vary by cancer type and their effects are more pronounced among some 
cancer types. Many factors affect the risk of cancer, including tobacco use, dietary 
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factors, certain infections and co-morbidities, exposure to radiation, physical 
activity, obesity, and environmental factors.46 For breast cancer, specific risk factors 
include use of hormone replacement therapy and oral contraceptive use. For 
colorectal cancer, several risk factors have been established in epidemiological 
studies such as family history of colorectal cancer, inflammatory bowel disease, 
smoking, excessive alcohol consumption, and high consumption of red and 
processed meats. The most important risk factor for lung cancer is tobacco 
smoking, with evidence suggesting that 90% of lung cancer cases can be attributed 
to tobacco smoking.47 Unlike other cancer types mentioned, risk factors for 
prostate cancer have not been well established. Age, ethnicity, and geography are 
strongly correlated with the  risk of prostate cancer: however, there is no evidence 
suggesting a link to smoking tobacco. Some studies have suggested a link between 
prostate cancer and diet as well as obesity, although the overall findings are 
inconclusive. 
1.5.1.4 Diagnosis and screening 
Cancer can be detected in a number of ways, including: the presence of certain 
signs and symptoms, screening tests, or medical imaging. Once a possible cancer is 
detected, it is diagnosed by microscopic examination of a tissue sample. In the UK, 
the NHS offers screening programmes for breast, cervical, and colorectal cancer. 
Screening for breast cancer involves a mammogram8 of both breasts; women aged 
47-73 years are invited for breast cancer screening every 3 years. Colorectal cancer 
screening in the UK involves a process called Faecal Occult Blood Testing. Testing 
kits are sent to eligible patients and processed on return. Varying ages are eligible 
for colorectal cancer screening depending on region. In England, men and women 
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aged between 60-69 years are invited for colorectal cancer screening, while in 
Northern Ireland and Wales the age range is 60-74 years, and in Scotland it is 50-74 
years.  
1.5.1.5 Treatment 
Each cancer type requires a specific treatment plan which depends on the 
development (stage and grade) of the cancer at diagnosis. A wide range of 
treatment types are used, including: surgery, chemotherapy, radiation therapy, and 
biological therapy. In some cases, active monitoring of the cancer is considered the 
optimum management strategy. 
1.5.2 Statin use and the risk of cancer 
A brief overview of findings from experimental and observational studies examining 
the risk of cancer associated with statin use is given in the following sections. A 
detailed systematic review of statin use and cancer risk among studies that have 
utilised electronic healthcare records is described in Chapter 3 with a focus on 
methodological considerations. 
1.5.2.1 Early findings 
Early concerns of carcinogenic properties from statins were first raised in animal 
studies. A review of findings on rodent carcinogenicity of lipid-lowering drugs 
reported that all statins available in 1994 initiated or promoted cancer in rodents at 
concentrations equivalent to those commonly prescribed in humans.48 Later that 
year, a clinical trial lasting 5 years examining pravastatin for the prevention of 
cardiovascular disease found an increased risk of breast cancer in subjects 
randomised to statins (12 cases vs. ref. 1 case; p=0.002).49 In a separate trial, an 
increased risk of total and gastrointestinal cancer was found.41 However, no other 
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large RCTs of statins have demonstrated an altered risk of incident cancer.40, 50, 51 
Findings from a meta-analysis of 35 RCTs found no association between statin use 
and cancer risk.52 Evidence from clinical trials should be considered as part of a 
drug-safety assessment, but these trials were generally not powered to assess 
uncommon or delayed safety outcomes such as cancer. Therefore, further 
investigation from observational studies was required to confirm or refute the 
limited evidence from trials indicating an association between statin and cancer 
risk.  
1.5.2.2 Pharmacoepidemiological studies 
 
A number of studies have examined breast, colorectal, lung, and prostate cancer 
risk associate with statin use. Aggregations of results from observational drug 
safety studies do not lend themselves to support an association between statin use 
and the risk of cancer.53 However, there have been reports of increased or reduced 
risks of cancer associated with statin use from observational studies. A cohort study 
by Cauley et al.54 found hydrophobic (simvastatin, lovastatin, and fluvastatin) statin 
use to be associated with an 18% (HR=0.82; 95% CI 0.70-0.97) risk reduction of 
breast cancer. Coogan et al.55 conducted a case-control study reporting a non-
significant increased risk of breast cancer associated with statin use (OR=1.5; 95% 
CI, 1.0-2.3). In contrast, Smeeth et al.56 observed a null association between statin 
use and breast cancer risk (HR=1.17; 95% CI 0.95-1.43). 
A meta-analysis conducted by Bonovas et al.57  observed a null association between 
statin use and the risk of colorectal cancer in three cohort studies (rate ratio = 0.96; 
95% CI, 0.84-1.11). In contrast, Poynter et al.58 conducted a case-control study 
based in Israel and found a reduced risk of colorectal cancer among statin users 
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(adjusted OR=0.53; 95% CI, 0.38-0.74). This decreased risk was also reported by 
Bonovas et al.57 in a meta-analysis of nine case-control studies (RR = 0.91; 95% CI, 
0.87-0.96).   
Several case-control studies reported of no strong associations between statin use 
and lung cancer risk.59-63 A cohort study conducted in Canada64 reported a 
borderline increased risk of colorectal cancer associated with statin use (rate 
ratio=1.13; 95% CI; 1.02, 1.25). Findings from studies that utilised patient data from 
veteran populations in the US have found strong reduced risk estimates of lung 
cancer ranging from 30-40% risk reduction.26, 27 In contrast, Friedman et al. 
observed an increased incidence of lung cancer among women prescribed statins 
(HR=1.16; 95% CI 1.06-1.28). 
Two case-control studies utilising data from veteran populations in the US reported 
a reduced risk of prostate cancer, ranging from 54-65% reduced risk.65, 66 There 
have been occasions where an increased risk of prostate cancer have been reported 
including: a cohort study by Haukka et al.67, a case-control study conducted in 
Taiwan,68 and a non-significant 30% increase observed by Kaye et al.62 in the CPRD 
1.6 Rationale for research 
The emergence of electronic patient records has seen a wealth of 
pharmacoepidemiological studies investigating various drug-cancer associations.5, 7 
However, there have been inconsistent findings from some of these studies19, 21 
which have led to questions about possible explanations of such deviations in 
observed findings. Various design flaws and study decisions have been postulated 
as drivers of these conflicting findings.35, 69-71 However, the impact of such 
methodological variants in a practical setting is unclear. Based on this rationale, the 
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impact of several commonly cited biases and alternative methods of case 
identification on a well-established association, namely the risk of cancer among 
patients prescribed statins, will be examined in this thesis.  
1.7 Aims 
1. To review the methods utilised by current and past studies that have 
identified breast, colorectal, and prostate cancer cases from UK primary 
care databases. 
2. To review the literature to date regarding the effects of statin use and the 
risk of breast, colorectal, lung, and prostate cancer. 
3. To develop case definitions to identify breast, colorectal, lung, and prostate 
cancers using primary care data, and to validate these definitions by 
comparing primary care incidence rates to published national rates based on 
cancer registrations, and by assessing the agreement of recorded cancer 
diagnoses between primary care data and linked cancer registry data. 
4. To measure and compare the impact of several potentially biased study 
designs and case identification methods on the estimated association 
between statin use and cancer risk.  
1.8 Outline of thesis 
Chapter 2 describes a systematic review of breast, colorectal, and prostate cancer 
case identification methods from studies that have utilised UK primary care 
databases. From this review there was evidence suggesting fatality may influence 
case ascertainment in primary care data. In order to investigate this hypothesis lung 
cancer was added to the existing three cancer types examined in this thesis. 
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Chapters 3 describes a systematic review of studies that have utilised electronic 
patient records to examine the risk of breast, colorectal, lung, and prostate cancer 
among statin users. In particular, methodological aspects of each study will be 
assessed. 
Chapter 4 describes the main data sources and an overview of the analytical 
methods applied to this thesis, including the main case definitions that were 
developed for breast, colorectal, lung, and prostate cancers. 
Chapters 5 and 6 present the main analyses of this thesis; in each of these chapters 
the specific methods are detailed and the corresponding results are presented and 
discussed. 
Chapter 5 presents the first main analysis of this thesis, which measures agreement 
of recorded diagnosis from primary care (CPRD) compared to the cancer registry. In 
addition, this chapter also includes two sets of estimated incidence rates which are 
compared to national rates based on cancer registrations. The first set includes 
estimated incidence rates from primary care. The second set includes primary care 
incidence rates that incorporate linked cancer registry data. 
Chapter 6 presents the second main analysis of this thesis, which measures and 
compares the impact of potential drivers of discrepant results within the context of 
the statin-cancer association. 
Chapter 7 summarises the main findings and discussion points from the body of this 
thesis. 
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2 The identification of incident cancers in UK primary care 
databases: a systematic review 
 
2.1 Introduction 
This chapter reviews case ascertainment methods implemented by past 
observational studies that have utilised UK primary care databases to investigate 
incident cancer outcomes of the breast, colorectum, and prostate. A version of this 
chapter was published in the Journal of Pharmacoepidemiology and Drug Safety, 
the full paper is provided in Appendix A.1. 
2.2 Methods 
2.2.1 Databases and Sources 
MEDLINE and EMBASE were searched between January, 1980 – April, 2013 using 
MeSH terms. Reference lists of relevant studies were also screened for publications 
that may have been missed by the initial database search. Bibliographies of the 
CPRD, THIN, QRESEARCH, and the Boston Collaborative Drug Surveillance Program 
were also screened to identify additional articles that may have been missed by the 
initial search.17, 18, 72, 73 74-76 
2.2.2 Search Keywords and Terms 
The search of MEDLINE (April 8, 2013) included exploded key terms to identify 
publications that utilised a UK primary care database and examined incident cancer 
as an outcome of interest. For EMBASE, which does not use the MeSH classification 
system, the nearest equivalent search terms from the EMBASE indexing system 
were used. 
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MEDLINE MeSH terms: 
The following MeSH keywords were used in the primary search: 
[Malignant or Cancer or Neoplasm (plus all sub-terms in the MeSH tree)] 
and 
[ [GPRD; CPRD; THIN; QRESEARCH; and DIN-LINK (and exploded synonyms)] 
or [Database (plus all sub-terms in the classification tree)] ] 
2.2.3 Inclusion and Exclusion Criteria 
A publication was considered for initial inclusion when incident cancers of the 
breast, colorectum, or prostate were included as primary or secondary outcomes, 
and a UK primary care database was utilised as a data source. Studies with a main 
outcome of prevalent, recurring, or metastatic cancer were excluded. Articles 
presented as conference abstracts, review articles, or letters to the editor were also 
excluded. 
2.2.4 Procedure 
Titles and abstracts were initially screened; full-text versions were then obtained 
and examined to determine whether they met inclusion criteria. Data were 
extracted from each manuscript and included first author, year of publication, study 
type (e.g. drug safety, epidemiological, or incidence), database(s), cancer 
outcome(s) of interest, methods used to create code lists (as reported in the paper, 
e.g. methods section or supplementary material), case definitions, validation 
methods and results.  
For each study, an electronic copy of the study code list was requested and the first 
author was sent a questionnaire which included specific questions on the 
development of their code list(s). Details of the questionnaire are given in Appendix 
A, Questionnaire A.1. Three emails were sent to authors. First, the corresponding 
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author was contacted; if no response was received after 3 weeks then a reminder 
email was sent to the same author and additionally to the first or last author (if 
different). A final reminder was sent after a further 3 weeks if necessary. If an error 
reply was received stating that the email address had expired, a search for a current 
email address in more recent publications and through an internet search engine 
was conducted. 
Medical codes were classified into eight groups: malignant neoplasms, in-situ 
tumours, malignant morphology; secondary or history of cancer, borderline 
(uncertain whether malignant or benign), suspected (suspected cancer, abnormal 
screening test, or fast track referral), benign tumours, and non-cancerous codes 
(procedure, or condition that was not related to a direct malignant neoplasm 
diagnosis). Codes were stratified by cancer site and study type. The ICD-10 
dictionary and medical references were used to aid in the classification of OXMIS 
and Read codes.76-79 All codes were reviewed and classified by Krishnan Bhaskaran 
(KB), Michael Rañopa (MR), and Liam Smeeth (LS); any disagreements were 
reviewed again until resolved.  
All studies in the review were published after the release of the 5-byte Read or 
Read version 2 dictionary, therefore study code lists were based on the same broad 
dictionary version. However, codes are continually added to the dictionary over 
time (though never removed). To assess whether variation in study code lists might 
have been driven by such changes over time, a full list of code additions (updates 
were documented every 6 months from 1991-2013) from the NHS Health and Social 
Care Information Centre (HSCIC) was obtained. This HSCIC code list was used this to 
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identify codes added during the time period over which the studies were conducted 
(which was assumed to be in the 2-year period prior to year of publication). 
2.3 Results 
2.3.1 Databases, Cancer Site, and Study Type 
Overall, 84 relevant studies were included in this review (Figure 2.1 and Appendix 
A, Table 8.1). Studies utilised the CPRD (n=63); THIN (n=9); QRESEARCH (n=10); 
both the CPRD and THIN (n=1); and both the CPRD and QRESEARCH (n=1). Of the 84 
studies, 30 examined >1 cancer types included in this review:  breast (n=51); 
colorectal (n=54); and prostate cancer (n=31). A broad range of study types were 
included: 51 examined the association between drug use and cancer; 28 examined 
cancer incidence among patients with a particular disease or symptom; and 5 
estimated population-level cancer incidence (Figure 2.1). 
2.3.2 Study Code list Creation, Availability, and Comparison 
In total, only 5 of the 84 studies (6%) described methods used to create study code 
lists (Table 2.1). Five studies (6%) included details directly in the publication, 2 (2%) 
included the list itself as an appendix,80, 81 and 3 (4%) stated which Read code 
chapters and sections were used; a further 6 (7%) stated that the list was ‘available 
on request’.63, 82, 83 
Overall, there were 43 responses from 84 questionnaires sent to the authors 
(Figure 2.1 & Table 2.1). 37 (86%) studies reported using a keyword search of 
cancer related terms to identify potential cancer related codes, 26 (60%) utilised a 
previous code list, and 43 (100%) consulted with a health care professional during 
the creation of the study code list. For all studies, >1 assessor reviewed the code 
list. 
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Figure 2.1: Flow diagram of article search, retrieval, and review process; code list availability and questionnaire replies; database, study type, 
and validation methods. 
2,750 non-duplicate abstracts
99 initial publications included for full-text 
search
84 publications were included in the final 
review
Code list availability stated in publication
6 (7%) “Available on request”
5 (6%)  stated selected codes in publication
73 (87%) None
84 questionnaires sent to the corresponding 
authors with requests for study code lists
43 (51%) replies
4 (5%) email no longer valid
3 (4%) decline
5 (6%) inadequate response
29 (35%) non-response
28 (33%) code lists received
2,653 publications were excluded because they did not meet 
the inclusion criteria
2 additional publications identified from GPRD, THIN, 
QRESEARCH, BCDSP bibliographies and reference lists from 
papers examined †
65 CPRD*ǂ
20 Studies examined >1 
cancer type:
41 Breast Cancer*
37 Colorectal Cancerǂ 
21 Prostate Cancer
10 THIN*
4 Studies examined 
>1 cancer type:
5 Breast Cancer* 
7 Colorectal Cancer 
4 Prostate Cancer
11 QRESEARCHǂ 
7 Studies examined >1 
cancer type:
6 Breast Cancer 
11 Colorectal Cancerǂ  
6 Prostate Cancer
19 Disease-Cancer 
Association
43 Drug-Cancer 
Association*ǂ
3 Cancer Incidence
18 Internal validation
11 External validation
8 Both methods
3 Comparison of rates
23 None 
7 Internal validation
4 External validation
2 Both methods
0 Comparison of rates
10 None 
2 Internal validation
1 External validation
1 Both methods
2 Comparison of rates
1 None
4 Drug-Cancer 
Association*
4 Disease-Cancer 
Association
2 Cancer 
Incidence
0 Internal validation
0 External validation
0 Comparison of rates
4 None
0 Internal validation
0 External validation
0 Comparison of rates
4 None
0 Internal validation
0 External validation
1 Comparison of rates
1 None
6 Drug-Cancer 
Associationǂ
5 Disease-Cancer 
Association
0 Cancer Incidence
0 Internal validation
0 External validation
1 Comparison of rates
5 None
0 Internal validation
0 External validation
0 Comparison of rates
5 None
4,207  abstracts identified from Medline, 
EMBASE
15 publications were excluded because they did not meet the 
inclusion criteria
   -6 Not cancer of interest
   -5 Incident cancer not main outcome
   -4 Study was not conducted in UK primary care database
† Boston Collaborative Drug Surveillance Program (BCDSP) 
 * 1 study utilised both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)
ǂ 1 study utilised both the CPRD and QRESEARCH  
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In total, 28 of a potential 84 (33%) study code lists were received (Figure 2.1); 
frequencies of all codes included across the 28 studies are provided in Appendix A, 
Table 8.2.  All 28 studies included malignant neoplasm diagnosis codes, but there 
was variation in the specific codes used: for breast cancer, 42 malignant disease 
codes were included across lists, but only 15 were included by all studies. The 
variation was not explained by changes in the Read code dictionary: all 42 codes 
were in the dictionary throughout the period when these studies were conducted 
(Appendix A, Table 8.2). Similar variation for colorectal cancer (64 malignant codes 
mentioned but only 18 appeared in all lists; all but 2 of the 64 codes were in the 
Read dictionary throughout), and for prostate cancer was found (8 malignant codes 
mentioned but only 1 appeared in all lists; all 8 codes present in the Read dictionary 
throughout).  
There was also variability between lists in terms of other types of codes included: 
20/28 (71%) code lists included in-situ tumours; 17 (61%) included malignant 
morphology codes; 20 (71%) included secondary or history of cancer codes; 16 
(57%) included “borderline” codes; and 3 (10%) included suspected codes. In 
addition, a few lists included benign (n=5, 18%) and non-cancerous codes (n=4, 
14%). It was not clear from the available information precisely how these various 
classes of codes were used for case ascertainment (Table 2.1).  
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Table 2.1: Code list availability, questionnaire replies, and comparison of lists received, by cancer and study type 
  Cancer Type* 
 
Study Type 
 All studies Breast Colorectal Prostate Drug-Cancer Disease-Cancer Incidence 
 n (column %, n/N) 
         
Total number of studies N=84 N=51 N=54 N=31  N=51 N=28 N=5 
Any code list creation methods reported** 5 (6) 4 (8) 3 (2) 2 (6)  3 (6) 2 (7) 0 (0) 
          
Code list availability in publication         
Available on request 6 (7) 2 (4) 6 (11) 2 (6)  3 (6) 2 (7) 1 (20) 
Stated in publication 5 (6) 4 (8) 4 (7) 3 (10)  4 (8) 1 (4) 0 (0) 
None 73 (87) 45 (88) 44 (81) 26 (86)  44 (86) 25 (89) 4 (80) 
         
Questionnaire results: number of replies N=43 N=24 N=30 N=15  N=30 N=10 N=3 
Keyword-synonym search 37 (86) 21 (88)  24 (80) 12 (80)  25 (83) 9 (90) 3 (100) 
Utilisation of previous study code list 26 (60) 15 (63) 14 (47) 9 (60)  18 (60) 7 (70) 1 (33) 
Consultation with heath professional 43 (100) 24(100) 30 (100) 15 (100)  30 (100) 10 (100) 3 (100) 
         
Number of study code lists obtained N=28 N=17 N=23 N=11  N=21 N=5 N=2 
Studies including specific code-types         
Malignant neoplasm 28 (100) 17 (100) 23 (100) 11 (100)  21 (100)  5 (100) 2 (100) 
In-situ  20 (71) 12 (70) 15 (65) 6 (55)  13 (62) 5 (100) 2 (100) 
Malignant morphology 17 (61) 13 (76) 11 (48) - (-)
Ɨ  12 (57) 3 (60) 2 (100) 
Secondary or history of cancer 20 (71) 13 (76) 17 (74) 8 (73)  16 (76) 2 (40) 2 (100) 
Non-malignant codes 16 (57) 8 (47) 11 (48) 2 (18)  10 (48) 4 (80)     2 (100)  
Borderline codes 16 (57) 7 (41) 11 (48) 2 (18)  10 (48) 4 (80) 2 (100) 
Suspected 3 (10) 2 (11) 2 (9) 1 (9)  1 (5) 1 (20) 1 (50) 
Benign tumour codes 5 (18) 2 (11) 4 (17) 0 (0)  2 (10) 1 (20) 2 (100) 
Non-cancerous or site-unrelated 4 (14) 1 (6) 4 (17) 0 (0)  1 (5) 2 (40) 1 (50) 
*
One study could contribute to >1 cancer type 
**Code list creation methods include: keyword search of dictionary; review of code list by health professional; utilisation of previous code list 
ƗThere are no malignant morphology codes for prostate cancer found among the 11 prostate cancer studies 
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Stratification by study type indicated a possible difference in code inclusion 
between study types (Table 2.1). Both incidence studies included non-malignant 
codes (borderline, suspected, benign, and non-cancerous). Although lists were not 
received for 2 other incidence studies, they both stated using non-malignant codes 
within their publication.84, 85 In contrast, only 14/26 (56%) drug safety and 
epidemiological studies included non-malignant codes. 
2.3.3 Identification and Validation of Cancers 
Of the 84 studies, the majority (n=57) only required ≥1 cancer diagnosis Read code 
to identify cases (Table 2.2). 27 studies specified additional criteria to confirm case 
status, for example, chemo-radiotherapy (n=13); biological treatment (n=12), 
surgical procedures (n=13). The requirement for further evidence was more 
common for breast cancer studies (76%) compared to colorectal (44%) and prostate 
cancer studies (50%). 11 studies mentioned a manual review process but did not 
report the criteria used to confirm or refute case status (Table 2.2). Where present, 
descriptions of diagnostic algorithms were typically brief; only one study provided a 
schematic of the algorithm used to identify and confirm case status.84 Few studies 
(4/27) reported on the proportion of cases included once additional confirmatory 
evidence was applied. Gonzalez-Perez et al.86 reported that 3708/3886 (95.4%) 
incident breast cancer cases had supporting evidence of diagnosis. Charlton et al.84 
identified 1,809 potential colorectal cancer cases, of which 1,599 patients (88.3%) 
had additional supporting evidence of diagnosis: colorectal cancer related surgery 
confirmed 927 cases (51.2%) and non-surgical support such as chemo-radiotherapy 
or palliative care confirmed 278 cases (15.4%). Of note, Bodmer et al.87 assessed 
the effect of metformin on colorectal cancer incidence within the CPRD. Similar 
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estimates were obtained regardless of the requirement for confirmatory evidence 
of diagnosis (OR for ≥50 prescriptions vs. never use =1.43; 95% CI, 1.08-1.90 when 
cases were defined by codes alone and OR=1.46; 95% CI, 1.03-2.06 when restricting 
to those with further supportive evidence of cancer).  
14 CPRD studies validated a sample of potential cases using information external to 
the database, namely by GP questionnaire or through a request of patient records 
(Table 2.3). The proportion of confirmed cases was high [median positive predictive 
value (PPV) = 0.99; Range, 0.90-1.00], although validity measures were limited to 
PPV. The number of potential cases sampled was low [median % 4.0; range, 0.8-
11.1]. The median proportion of responses received was high [median proportion 
0.95; range, 0.87-1.00]. External validation results stratified by cancer type were 
generally similar. 
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Table 2.2: Criteria used to identify, validate, and exclude potential cancer cases by cancer and study type 
  Cancer Type* 
 
Study Type 
 All studies Breast Colorectal Prostate 
 
Drug-Cancer Disease-Cancer Incidence 
 n (column %, n/N) 
  
n (column %, n/N) 
 
         
Total number of studies N=84 N=51 N=54 N=31  N=51 N=28 N=5 
         
Number of studies requiring ≥1 cancer diagnosis code 
only 
57 (68) 34 (67) 45 (83) 23 (74) 
 
33 (65) 21 (75) 3 (60) 
         
Internal validation or requirement for supportive 
evidence of diagnosis: number of studies 
N=27 N=17 N=9 N=8 
 
N=18 N=7 N=2 
Cancer related surgery 13 (48) 11 (65) 4(44) 3 (38)  8 (44) 3 (43) 2 (100) 
Chemo/radiotherapy 13 (48) 10 (59)  4 (44) 4 (50)  7 (39) 4 (57) 2 (100) 
Biological treatment 12 (44) 10 (59) 2 (22) 4 (50)  8 (44) 3 (43) 1 (50) 
Treatment unspecified 1 (4) 1 (6) 0 (0) 0 (0)  1 (6) 0 (0) 0 (0) 
Consultation with oncologist 8 (30) 7 (41) 2 (22) 1 (13)  6 (31) 1 (14) 1 (50) 
Other Ɨ 3 (11) 2 (12) 3 (33) 1 (13)  1 (6) 1 (14) 1 (50) 
Unspecifiedǂ 11 (41) 4 (24) 5 (56) 4 (50)  8 (44) 3 (43) 0 (0) 
         
Cancer related exclusion criteria: number of studies         
Previous diagnosis of any cancer 43 (51) 31 (61) 25 (46) 19 (61)  29 (57) 12 (43) 2 (40) 
Previous diagnosis of cancer of interest 25 (30) 10 (20) 18 (33) 6 (19)  16 (31) 6 (21) 3 (60) 
Time related exclusion periods 59 (70) 32 (63) 39 (72) 24 (77)  37 (37) 19 (68) 3 (60) 
*One study could contribute to >1 study type 
Ɨ Other includes: specific oncology codes, terminal illness, palliative care, death within 180 days of diagnosis. 
ǂA manual review process was conducted, however criteria used to confirm case status was not described.   
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Table 2.3: External validation of potential cases by cancer type 
  Cancer Type* 
 All studies Breast Colorectal Prostate 
 n (column %), median [Range], unless otherwise specified 
     
Total number of studies N=84 N=51 N=54 N=31 
     
Number of studies that validated cases externally by 
questionnaire or request for patient records (%)
¥
 
14 (20) 5 (12) 4 (10) 3 (14) 
Number of potential cases sampled for external 
validation 
100 [23-200] 114 [30-114] 85 [23-200] 100 [100-100] 
Proportion of cases randomly sampled for external 
validation from patients initially fulfilling inclusion 
criteria 
4.03 [0.81-11.06] 3.07 [0.81-3.07] 6.40 [3.49-11.06] 7.21 [4.58-9.85] 
Proportion of responses received 0.95 [0.87-1.00] 0.95 [0.95-1.00] 0.96 [0.87-1.00] -ǂ 
Proportion of cases confirmed 0.99 [0.90-1.00] 1.00 [1.00-1.00] 0.95 [0.90-1.00] 0.98 [0.98-0.98] 
Number of studies that validated cases externally by 
linkage to cancer registry (%) 
N=2 N=1 N=2 N=1 
Number of potential CPRD cases sampled for external 
validation 
703 [-] 560 [-] 1228 [681-1775] 725 [-] 
Proportion of cases confirmed in cancer registry 
median [range] 
0.90 [0.83-0.94] 0.90 [-] 0.94 [0.91-0.98] 0.83 [-] 
*One study could contribute to >1 cancer type 
ǂOnly one study reported the number of responses received – Ronquist et al: 88 responses received from a request of 100 patient records  
¥ 
Two studies included in “All studies”, but were not included in specific cancer type columns as they externally validated overall cancer - not distinguishing by cancer type 
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Two studies examined the concordance of recorded cancer diagnosis between the 
CPRD and UK cancer registry.80, 88 Estimates of concordance between the CPRD and 
cancer registry were high [median PPV 0.9; range, [0.8-0.9]. Dregan et al.80 reported 
a PPV of 0.98 for colorectal cancer and Boggon et al.88 reported similarly high PPVs 
for cancer of the breast (503/560=0.90), prostate (600/725=0.83); and colorectum 
(618/681=0.91). Sensitivity estimates of the CPRD in capturing registered cancers 
estimates were also high: Boggon et al.88 reported sensitivity estimates ranging 
from 95% for colorectal cancer to 99% for prostate cancer; similarly, Dregan et al.80 
reported 92% sensitivity for colorectal cancer in capturing cancer registry recorded 
diagnoses.  
2.3.3.1 Comparison of cancer incidence rates 
A database-level method of validation can be applied by comparing database 
cancer incidence rates to incidence rates from a reputable external source. Seven 
studies compared database specific incidence rates of cancer diagnosis to an 
external data source, of which three reported lower database incidence rates 
compared to published rates estimated by the Office for National Statistics (ONS) 
(Table 2.4). Seven studies compared cancer incidence rates to different external 
data sources. Four studies found similar incidence rates (2 breast cancer, 1 
colorectal, 1 prostate), while three studies reported lower colorectal cancer 
incidence rates when compared to external data sources. Colorectal cancer 
incidence rates were reported by four studies with conflicting findings.84, 89-91 A 
recent study by Charlton et al.84 reported lower colorectal cancer incidence rates in 
the CPRD (incidence rate per 100,000 person years (100k PY); Men: 63.7, Women: 
48.4) compared to UK cancer registries (year 2007: men, 70.2; women, 56.6 per 
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100,000 PY). Similarly, Vinogradova et al.90 reported an overall incidence rate of 
49.8 per 100,000 PY (men: 56.1, women: 43.6 per 100,000 PY) in the QRESEARCH 
database which was lower compared to published ONS incidence rates in 2003 
(men: 62.3; women 49.5 per 100,000 PY). In contrast, Garcia Rodriguez et al.91 
reported an overall CPRD incidence rate of 73 per 100,000 PY for colorectal cancer. 
However, despite the study period being between 1994-1997, the overall rate was 
significantly higher compared to the estimated rates observed by Charlton et al.84 
and Vinogradova et al.90 and the National Cancer Intelligence Network between 
1995-2004 (men: 62.3; women: 53.4).92 Of note, 6 of the 7 studies compared crude 
cancer incidence rates (both estimated from the UK primary care database and 
crude estimates reported by the ONS). Only 1 study compared age-standardised 
incidence rates estimated from THIN to equivalent age-standardised rates reported 
by the ONS.
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Table 2.4: Comparison of incidence rates by cancer type 
  Cancer Type* 
 All studies Breast Colorectal Prostate 
 n (column %), median [IQR], or otherwise specified 
     
Total number of studies N=69 N=41 N=42 N=22 
     
Comparison of Incidence Rates (IR)**     
No. of studies comparing database IR to 
an external data source 
7 (10) 2 (5) 4 (10) 1 (5) 
IR per 100,000 person years [range] - 156.0 [-] 49.8 [49.5-73.0] 161 [-] 
Result of IR comparison: higher, lower, 
similar ƚ 
4 similar; 3 lower 2 similar85, 93 
1 similar;94 3 
lower84, 90, 95 
1 similar96 
*One study can contribute to >1 cancer type 
ƚ Incidence rate percentage differences could not be estimated due to non-reporting of database incidence rates by two studies investigating  
colorectal95 and breast cancer85 
**6 of the 7 studies reported crude cancer incidence rates. Only Haynes et al95. reported age-standardised incidence rates 
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2.4 Discussion 
2.4.1 Overview 
This review has revealed several common shortcomings related to the description 
of methods used to identify cancer cases in UK primary care database studies. Few 
studies reported the methods used to compile code lists, or made code lists 
available, limiting the reproducibility of studies. Furthermore, where information 
was available, substantial variation in codes included was observed. High positive 
predictive value estimates were reported for all three cancer types from studies 
that used information external to the database to validate cases, but other 
measures of validity such as sensitivity and specificity were not generally explored.  
2.4.2 Accessibility of code lists 
Only 11/84 studies made their code lists available in the publication or specifically 
mentioned that they could be requested. Code lists may not have been made 
available for several reasons. For the earlier studies included, there may have been 
no practical way of publishing a long code list. More recently, most journals have 
started accepting web appendix materials without space limits, and other 
alternatives have emerged, such as including a web link in the paper to a central 
code lists repository or registry of studies. Making code lists ‘available on request’ is 
problematic since there may be difficulties in contacting the original corresponding 
author, particularly as time elapses after publication. Some authors simply may not 
have considered code lists to be important supplementary information, suggesting 
a need to raise awareness of the need for clear reporting of case definitions. Lastly, 
there may be some reluctance among researchers to release code lists due to 
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concerns that they could be used by competing research groups and without due 
credit.  
2.4.3 Variation in case definitions and code lists  
There was considerable variation in the specific codes used by researchers to 
identify cancers. The Read code dictionary is updated regularly but was not found 
to be an important driver of variation between code lists; the vast majority of codes 
used by investigators were available throughout the period during which the 
included studies took place. It is worth noting that variation in code lists does not 
necessarily translate to an equivalent variation in selected cases, which will also 
depend on how commonly specific codes are used. For example, if a majority of 
cases of breast cancer have a Read code for ‘Malignant Neoplasm of Female Breast’ 
(B34..00, which was included in all code lists for reviewed breast cancer studies) 
then these cases will be identified regardless of content in the rest of the code list. 
In the other direction, including a code which is never used in practice will have no 
effect on case ascertainment.  
As well as variation in individual codes, variation in types of codes included was 
observed. All lists included definite malignant diagnosis codes, but some included 
other code types such as carcinoma in-situ or suspected cancer. Some of the 
variation in definitions is likely to have arose from differing study objectives; 
differences by study type was noted, as may be expected. For example, 
pharmacoepidemiological studies aiming for high specificity may only include 
definite malignant neoplasms and exclude borderline codes.63, 97 While incidence 
studies may use a broad code list to maximise sensitivity, and then attempt to 
confirm diagnosis in a second stage of review.84, 85 Some studies included benign 
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tumour and non-cancer codes without explanation; whether such codes were 
included mistakenly or were used specifically to exclude cases is unclear. 
The majority of studies required only a cancer diagnosis code as part of their case 
definition, but around a third of studies required some form of further supportive 
evidence to confirm case status. Again, there were limited details in many study 
reports on the specific diagnostic algorithms used; one study presented a full 
schematic illustrating the case definition algorithm,84 routine use of such diagrams 
might help to improve clarity.  
2.4.4 External validation of cancer cases 
A number of studies validated cases externally by request of patient records or by 
GP questionnaire and were generally able to confirm a high proportion of cases. 
However, not all practices participate in validation or linkage studies, which may 
limit the generalisability of validity findings if participating practices differ from 
non-participating practices in terms of record-keeping practices. It is also unclear 
whether GP practices asked to validate cases in this way are accessing extra 
information, or simply referring to the same electronic record, which would 
inevitably lead to optimistic validity estimates. 
2.4.5 Comparison of incidence rates 
Few studies compared database specific cancer incidence rates to ONS published 
incidence rates. Disparities by age and calendar year were observed for colorectal 
cancer, while similar rates were observed for breast and prostate cancer. Although 
disparities were observed, the majority of compared incidence rates reported (6 
out of 7 studies) were crude and not age-standardised which may limit comparative 
interpretations if age distributions differ between data sources. That being said, age 
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and sex distributions have been shown to be representative of the UK population.98 
Another possible validation method is the comparison of survival/mortality 
estimates from UK primary care databases to national estimates.  Only Boggon et 
al.88 compared survival estimates in the CPRD to that of the cancer registry among a 
cohort of diabetic patients. Boggon et al.88 observed consistently higher survival 
estimates in primary care compared to linked cancer registry estimates. Breast 
cancer had the largest difference among 11 other cancer types, suggesting 
discrepancies in terms of diagnosis dates between the two data sources. 
Importantly, comparison of cancer survival estimates would capture problems with 
the recording of incident cancer diagnosis, date of diagnosis, cause of death, and 
date of death recording.  However, it may be difficult to identify the exact cause(s) 
of the discrepancy based on a survival estimate alone. 
2.4.6 Limitations of this review 
This review had several limitations: firstly, results were limited to cancers of the 
breast, colorectum, and prostate, and may not apply to other malignancies. 
Nonetheless, many of the studies included in this review examined multiple 
cancers, and applied case ascertainment in a global fashion rather than separately 
for each cancer type. Secondly, this review was limited to UK primary care database 
studies; whether the variation observed in this review occurs in non-UK databases 
is unknown. Lastly, authors who completed questionnaires and sent code lists may 
have been a selective group; therefore, their responses may not be generalisable to 
all researchers. Non-response or an unwillingness to share code lists may have 
arisen due to concern about methodological criticism, or protectiveness over 
intellectual property. 
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2.4.7 Importance and implications 
Our study highlights the variation and lack of transparency in many studies to date 
on a critical methodological feature of database studies of cancer outcomes, 
namely the definition and ascertainment of cancer cases. Primary care databases 
and routine healthcare records are increasingly used in cancer research. A total of 
84 relevant articles covering just 3 cancer sites; a broader search not restricted by 
site finds >250 articles published in leading general medical journals and influential 
specialist journals. Clarity over case ascertainment methods is important for 
interpreting study findings, reproducing analyses, and understanding the drivers of 
discrepant results.19, 99 Recent work by the Observational Medical Outcomes 
Partnership has highlighted that design decisions in observational 
pharmacoepidemiology studies profoundly affect study results,100 further 
emphasising the importance of clear and transparent reporting. As well as directly 
highlighting the need for such transparency and thus influencing future studies, this 
work can also inform guidelines aimed at improving the quality of reporting for 
electronic healthcare record research, which are currently in development as part 
of the RECORD project.101 
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2.4.8 Updated review studies 
An update of the systematic review was conducted to examine the current findings 
from studies undertaken after the original systematic review. Twelve studies were 
identified from a re-run of the original literature search in July 2015. Six studies 
examining breast cancer,102-107 6 studies colorectal cancer,102, 103, 105, 107-112 and 6 
studies prostate cancer (a study could examine >1 cancer type).102, 103, 105-107, 113 Of 
the 13 studies, 2 made their code list available through a published appendix,102, 103 
and one study mentioned excluding chapter B7 from the final code list. Most 
studies (N=11) defined cancer by requiring one malignant diagnosis code and only 
one study implemented a diagnostic algorithm to identify cases of colorectal 
cancer. Findings from the additional studies were generally consistent with the 
original systematic review. 
2.5 Conclusion 
This review comprehensively investigated several aspects of case ascertainment 
from studies utilising primary care databases for research related to cancer. 
Methods used to develop case definitions were often unclear and specific code lists 
were seldom published or made available. Where provided, considerable variation 
in case definitions and code lists was observed, and its impact on case 
ascertainment is unclear. Future research might clarify the extent to which 
methodological variations identified in this review impact on findings in applied 
epidemiological studies, and further explore ways of validating cancer case 
definitions, including through the use of linked data sources and free-text 
information.80, 88, 114 It is hoped that this study will help to promote clearer 
reporting of cancer case ascertainment methods, better access to code lists, and a 
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resulting improvement in the transparency and reproducibility of research in this 
growing field. 
2.6 Addition of lung cancer to cancer outcomes of interest: rationale 
This review concentrated on breast, colorectal, and prostate cancer. However, from 
this review there is evidence suggesting fatality may influence case identification in 
primary care. In comparison to national rates reported by the ONS, primary care 
incidence rates for colorectal cancer were lower (colorectal cancer 1-year survival, 
76%). Although data on breast (1-year survival, 96%) and prostate cancer (1-year 
survival, 94%) were limited, similar rates were observed from primary care 
compared to ONS reported rates for the two cancer types. In order to assess the 
impact of fatality on case identification and conflicting findings between studies, 
lung cancer (1-year survival, 32%) was added to the cancer outcomes initially 
planned for investigation in this thesis. 
2.7 Summary 
 Methods used to create outcome code lists were not transparent in the 
majority of studies included in this review, and the overall accessibility of 
study code lists was low. 
 Substantial variation in the way cancer cases were defined was observed, 
including in the specific diagnosis codes used, and the requirements for 
further confirmatory evidence. This could potentially impact case 
ascertainment and study findings. 
 Cancer outcomes defined using database-recorded information had high 
positive predictive value, when validated against external data sources, but 
53 
 
few data were available on other measures of validity such as sensitivity and 
specificity. 
 Compared to national estimates, lower primary care incidence rates were 
observed in three studies. However, reasons for the disparity are unclear.  
 Transparency and reproducibility of research would be improved by clearer 
reporting of methods used to develop case definitions, and by making code 
lists available for all published studies.
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3 Systematic review of conflicting findings in observational 
studies utilising electronic patient records to investigate 
statin use and cancer risk  
3.1 Introduction 
This chapter reviews existing observational studies that have utilised electronic 
healthcare records to investigate the association between statin use and the risk of 
breast, colorectal, lung, and prostate cancer. 
3.2 Aims 
The aims of this chapter were to collate published literature and to: 
1. Describe and summarise the results of observational studies utilising electronic 
healthcare records to investigate the association between statin use and the 
risk of breast, colorectal, lung, and prostate cancer. 
2. Investigate the discrepancies between studies, and identify potential 
methodological limitations that might contribute to inconsistent findings.  
3.3 Methods 
3.3.1 Databases and sources 
Medline and EMBASE were searched for abstracts published between January 1, 1987– 
November 30, 2011 using key words and related synonyms. In addition, reference lists 
of review studies were searched for articles that may have been missed by the 
database searches. Conference abstracts and unpublished studies were excluded from 
this review. 
3.3.2 Search keywords and terms 
The search of MEDLINE (via OvidSP) included exploded key terms to identify 
publications that investigated the association between statin use and specific cancer 
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types: breast, colorectum, lung, and prostate. For EMBASE, which does not use the 
MeSH classification system, the nearest equivalent search terms from the EMBASE 
indexing system was used. 
The following MeSH keywords were used in the primary search: 
[*Statin OR Hydroxymethylglutaryl-CoA Reductase OR *CoA OR Simvastatin (plus all 
sub-terms in the MeSH tree)] 
AND 
[Cancer OR Neoplasm OR Malig*(plus all sub-terms in the MeSH tree)]  
AND 
[Epidemiologic OR observational OR Case-control OR Cohort OR Retrospective (plus all 
sub-terms in the MeSH tree)];  
AND 
Limited to article types: JOURNAL ARTICLE; limited to subjects: HUMANS; limited to 
language: ENGLISH 
3.3.3 Inclusion and exclusion criteria 
Inclusion criteria: 
1. Observational study. 
2. Utilisation of routinely collected electronic patient data. 
3. Incident cancer of the breast, colorectum, lung or prostate as the primary 
outcome. 
4. Statin drug use as the main exposure of interest. 
5. Study on humans. 
6. Manuscript in English. 
Exclusion criteria: 
1. Conference abstracts. 
2. Review articles. 
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Table 3.1: Description of biases assessed 
Bias Description of the bias 
Direction of 
bias 
Methods to minimize bias 
Immortal time bias 
Immortal time bias refers to a period of follow-up time during which, by design, death or the study outcome cannot 
occur.
69 This bias arises when the treatment status of a patient is defined by a set criterion of minimum exposure or  
a wait period during which follow-up time is accrued. 
 
Bias is introduced when this unexposed wait period e.g. cohort entry until first prescription (immortal time – since a 
patient has to survive to first prescription in order to be classified as exposed) is misclassified as exposed. As 
exposed subjects include unexposed immortal time, risk estimates may be biased downward in favour of the 
exposed group. 
 
Downward 
 Analysis incorporating a time dependent exposure 
(Poisson or Cox proportional hazards 
regression).
115
 
 Exclusion of immortal time bias.
115
 
Protopathic bias 
Protopathic bias can occur if symptoms of a pre-existing cancer are associated with patients being prescribed 
statins by their GP, which can lead to an artificial increase in cancer risk.
71
 
 
In the other direction, patients who are ineligible to receive statins, or discontinue statin therapy due to cancer 
related symptoms, may lead to a falsely low rate of statin usage in patients who have cancer, which could bias risk 
estimates downward.
116
 
Upward or 
downward 
 Lag-time prior to index date to assure minimum 
period of exposure for case-control studies.
116
 
 Minimum period of exposure for cohort studies.  
Prevalent user bias 
Prevalent users of statins may differ compared to incident statin use (new users). Differences between the two 
groups of patients may occur due to various factors such as adherence and tolerance to medications; attendance to 
health utilisation services and cancer screening/prevention programs, which may bias risk downward if prevalent 
users are included in study design. 
Upward or 
downward 
 New user design.
70
 
Healthy user bias 
Users of preventative therapy such as statins or antihypertensive medications may exercise more, have a healthier 
diet, and may adhere to health services directed at preventing related diseases compared to the general 
population.
117
   
 
Healthy user bias may increase the likelihood of cancer detection among statin users, and can increase the 
incidence rate of particular cancers, and hence bias risk estimates upward among statin users compared to non-
statin users from the general population. 
 
Healthy user bias may bias results downward if confounders such as diet, physical activity, or adherence are not 
adjusted within statistical analysis. 
 
Upward or 
downward 
 Comparison group consisting of patients 
prescribed a preventative therapy. This group of 
patients may be similar to statin users in terms of 
adherence to medications and healthy 
behaviour.
118
 
 Adjustment for lifestyle factors and access to 
health utilisation services.
118
 
Time-window bias 
Time-window bias arises when the time-period used to assess exposure status between cases and controls is not 
equal, and the sampling of controls is biased.
119
 If sampled at their last point of contact, controls may have a longer 
follow-up period and hence a higher likelihood of exposure being observed compared to cases, resulting in a 
spurious appearance of a benefit of exposure. 
Downward 
 
 Matching on duration of follow-up.
119
 
 Risk-set sampling.
119
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Figure 3.1: Diagrammatic illustration of biases examined 
(a) Diagram of immortal time bias (b) Diagram of protopathic bias (c) Diagram of prevalent user bias 
  
 
 
(d) Diagram of healthy user bias  (e) Diagram of time-window bias 
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3.3.4 Procedure 
All publications were reviewed; extracted data included: source population, data 
sources, primary and secondary analysis results. Methodological features were also 
recorded and included: case and exposure definitions; comparison groups; control 
selection; adjustment for confounders; and statistical methods used.  
3.3.5 Bias selection 
Five biases were assessed, including: immortal time, protopathic, prevalent user, 
healthy user, and time-window bias. Selection of these biases were based on 
discussion within the advisory group about key suspected biases in 
pharmacoepidemiology, as well as reviewing the literature on statin use and cancer 
risk which suggested that these particular biases may be important. Although, not all 
biases were shown to systematically impact across studies of different drug-disease 
associations69, 70, 116, 117, 119-122, 123, 124  
Each bias is described in Table 3.1 and illustrated in Figure 3.1. Each paper was 
assessed for the possibility of these biases, as follows: 
Immortal time bias was considered avoided if (i) a time-dependent analysis of statin 
treatment was implemented; or if (ii) immortal time periods were excluded from both 
exposure and referent groups. Assessment of this bias was restricted to cohort studies. 
Protopathic bias was considered mitigated if minimum periods of exposure or lag time 
periods were implemented within primary, secondary or sensitivity analyses. 
Prevalent user bias was considered minimised if a new user design was implemented. 
Healthy user bias was considered minimised if (i) a comparison group consisting of 
patients prescribed preventative therapy medications was used; or (ii) there was an 
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adjustment for uptake of preventative health services such as GP/physician 
consultations, hospitalisations; cancer related examinations such as screening, 
prostate specific antigen (PSA) testing, colonoscopy, stool occult blood test, digital 
rectal examination, mammogram. 
Time-window bias was minimised if the study authors implemented a case-control 
design in which controls were selected by risk-set sampling or if they were matched on 
follow-up or date of diagnosis. Assessment of this bias was restricted to case-control 
studies. 
Figure 3.2: Flow diagram of search strategy: inclusion/exclusion criteria. 
964 non-duplicate abstracts identified 
from Medline, EMBASE for initial 
screening
61 publications included for full-text retrieval
903 abstracts excluded as 
they did not meet the 
inclusion criteria
31 manuscripts excluded after full text retrieval because 
they did not meet the inclusion criteria
30 publications included in final review
 
 
3.3.6 Meta-analysis 
Firstly, a meta-analysis to compare the risk of breast, colorectal, lung and prostate 
cancer risk among statin users compared to non-users was conducted by using a 
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DerSimonian-Laird random effects model,125 accounting for heterogeneity among 
studies, was used to calculate summary relative risk (SRR) and 95%CIs. The possible 
heterogeneity among studies was examined by using the I2, the percentage pf total 
variation across studies that is due to heterogeneity.126  
Sources of heterogeneity were assessed by subgroup analyses according to study 
design (cohort vs case-control); comparison group (non-user vs other); new user vs any 
user; adjustment for smoking status; geographical location (European and Asian 
studies). If no more than 3 studies reported the association between a specific cancer 
type and exposure/referent, the overall effect was not summarised. For studies that 
only reported results for men and women, statin type separately, they were 
considered as independent data obtained from different studies. 
3.4 Results 
An overview of overall results is first presented; methodological considerations are 
then described. Second, results by cancer type are described, and then an assessment 
of bias in the context of these results are given. 
3.4.1 Overview 
A total of 30 relevant studies were identified for this review (Figure 3.2). Of the 30 
observational studies investigating the effect of statin use on breast, colorectal, lung or 
prostate cancer, 11 examined >1 cancer type: breast (n=14), colorectal (n=17), lung 
(n=11), and prostate (n=17) (Table 3.2 and Figure 3.3). 16 studies considered a cohort 
design and 14 a case-control design. There were variations in design methodology 
applied particularly in terms of treatment definitions, and adjustment for potential 
confounders.    
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3.4.2 Methodological considerations 
Variations in methodological aspects between studies occurred in several areas: 
populations, outcome ascertainment, outcome definition, exposure definition, 
comparison groups, and confounder adjustment (Table 3.3 and Table 3.4). 
3.4.2.1 Populations 
Studies included in this review were conducted in a broad range of populations and 
electronic health data sources (Table 3.3). Thirteen studies utilised administrative 
healthcare data from various healthcare programs in the US, including: Kaiser 
Permanente (KP), California (n=4); Veterans affairs (VA) healthcare system (n=4); 
Group Health, Washington healthcare system (n=3); and resident patients ≥65 years 
from Pennsylvania state (n=1); resident patients attending Cleveland Clinic (n=1). 
Seven studies utilised data from three UK primary databases: The CPRD,127-129 
QRESEARCH,90, 130, 131; and THIN.56 The remaining 10 studies were conducted in various 
populations including Finnish population registry (n=3); Canada: Quebec (n=1), the 
provinces of Saskatchewan insurance claim (n=1) and Manitoba (n=1); Danish registries 
(n=2); The Netherlands (n=1); and the Taiwanese National Health Insurance 
programme (TNIH; n=1).  
 Table 3.2: Frequency (%) of findings by cancer type 
 Any statin use  
Cancer 
No significant 
association 
Reduced risk Increased risk Total 
Prostate n (%) 10 (59) 4 (24) 3 (18) 17 (100) 
Colorectal n (%) 13 (76) 3 (18) 1 (6) 17 (100) 
Breast n (%) 14 (100) 0 (0) 0 (0) 14 (100) 
Lung n (%) 6 (55) 3 (27) 2 (18) 11 (100) 
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Table 3.3: Statin use associated with cancer risk - study details 
Author & Year 
Cancer(s) 
examined 
Study Population 
Data source for 
outcomes 
Invasive or 
non-
invasive 
cancer 
Data source 
for statin use 
Time 
period 
Study 
design 
Comparison 
group 
Statin exposure definition 
No. of cases 
(cases 
exposed) 
Total cancer or site-
specific cancer: point 
estimate (95% CI) 
Chang 2011
68
 Prostate 
Taiwan, National Health 
Insurance program 
National Health 
Insurance database 
Invasive 
Prescription 
database 
1996-2008 
Case-
control 
Non-Statin users 
≥1 statin prescription at any time 
during the study period 
388 (83) 1.55 (1.09-2.19) 
Farwell 2011
132
 Prostate 
Veterans Affairs New England 
Healthcare system 
VA database Invasive 
Prescription 
database  
1997-2007 Cohort 
Antihypertensive 
drug  users 
≥1 statin prescription; 2-year from 
date of first statin 
546 (359) 0.69 (0.52-0.90) 
Tan 2011
133
 Prostate 
Patients who underwent a 
prostate biopsy at Cleveland 
clinic 
Clinic electronic 
records 
Uncertain 
Prescription 
database 
2000-2010 
Case-
control 
Non-Statin users 
≥1 statin prescription prior to follow-
up 
2407 (565) 0.92 (0.85-0.98) 
Vinogradova 
2011
130
 
Prostate 
Colorectal 
Breast 
Lung 
UK general practices 
(QRESEARCH database) 
GP Records Invasive 
GP 
Prescription 
records 
1998-2008 
Nested 
Case-
control 
Non-Statin users 
≥2 prescriptions at any time during 
the study; 1-year lag from date of 
diagnosis 
88125 (13621) 1.01 (0.99-1.04) 
Hippisley-Cox 
2010
131
 
Prostate 
Colon 
Breast 
Lung 
UK general practices 
(QRESEARCH database) 
GP Records Uncertain 
GP 
Prescription 
records 
2002-2008 Cohort Non-Statin users New user: ≥1 prescription at any time 
during the study period 
-* No association* 
Murtola 
2010
134
 
Prostate 
Screening arm of the Finish 
prostate cancer screening trial 
Finnish cancer 
registry 
Yes 
Prescription 
database 
1996-2004 Cohort Non-Statin users ≥1 statin prescription at any time 
during the study period 
1594 (268) 0.75 (0.63-0.89) 
Robertson 
2010
135
 
Colorectal 
Counties of Aarhus and North 
Jutland, Denmark National 
Health Service 
Danish National 
Registry (hospital 
records) 
Invasive 
Prescription 
database 
1991-2008 
Case-
control 
Non-statin users 
≥2 prescriptions at any time during 
the study 
9979 (711) 0.87 (0.80-0.96) 
Wooditschka 
2010
136
 
Breast 
Kaiser Permanente (KP) 
Northern California members 
KP cancer registry Invasive 
Prescription 
database  
1997-2007 
Case-
control 
Non-Statin users ≥2 prescriptions and ≥2 years of 
statin use 
22488 (509) 1.02 (0.97-1.08) 
Flick 2009
137
 Colorectal 
KP Northern and Southern 
California members 
KP cancer registry Invasive 
Prescription 
database 
2002-2003 Cohort Non-Statin users 
>100 day supply of one or more 
statins 
171 (56) 0.89 (0.61-1.30) 
Hachem 
2009
138
 
Colorectal 
Diabetic Veterans (VA 
database with linkage to 
Medicare patient files)  
VA and Medicare 
database 
Invasive 
and non-
invasive 
Prescription 
database 
1997-2002 
Nested 
case-control 
Non-Statin users 
≥1 statin prescription at any time 
during the study period 
6080 (2987) 0.88 (0.83-0.93) 
Haukka 2009
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Prostate 
Colorectal 
Breast 
Lung 
Finish cancer registry and 
social insurance institution 
Finnish cancer 
registry  
Uncertain 
Prescription 
database  
1996-2005 Cohort Non-Statin users ≥1 prescription at any time during 
the study period  
50294 (25445) 1.00 (0.98-1.02) 
Singh 2009
64
 Colorectal 
Manitoba Health and Healthy 
Living insurance provider 
Manitoba cancer 
registry 
Uncertain 
Prescription 
database 
1995-2005 Cohort Non-Statin users 
≥2 prescriptions at any time during 
the study with no gaps >90 days 
6637 (402) 1.13 (1.02-1.25) 
[continued over] 
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[Table 3.3 continued] 
Author & Year 
Cancer(s) 
examined 
Study Population 
Data source for 
outcomes 
Outcome 
definition 
Data source 
for statin use 
Time-
period 
Study 
design 
Comparison 
group 
Statin exposure definition 
No. of cases 
(cases 
exposed) 
Total cancer or site-
specific cancer: point 
estimate (95% CI) 
Boudreau 
2008
139
 
Colorectal 
Group health (health care 
system) Washington 
Washington cancer 
registry 
Invasive 
and non-
invasive  
Prescription 
database  
2000-2003 
Case-
control 
Non-Statin users 
≥2 prescriptions within any 6-month 
period and statin use for >1 year 
357 (60) 1.02 (0.65-1.59) 
Boudreau 
2008
140
 
Prostate 
Group health (health care 
system) Washington 
Washington cancer 
registry 
Invasive 
Prescription 
database  
1990-2005 Cohort Non-Statin users ≥2 prescriptions within any 6-month 
period and statin use for >1 year 
2532 (246) 0.88 (0.76-1.02) 
Farwell 2008
141
 
Prostate 
Colorectal 
Lung 
VA New England Healthcare 
system 
VA database Invasive 
Prescription 
database  
1997-2005 Cohort 
Antihypertensive 
drug users 
≥1 statin prescription; 2-year from 
date of first statin 
6896 (2515) 0.74 (0.70-0.78) 
Friedman 
2008
142
 
Prostate 
Colorectal 
Breast 
Lung 
Kaiser Permanente Medical 
care program Northern 
California 
KP cancer registry Invasive 
Prescription 
database  
1994-2003 Cohort Non-Statin users ≥1 prescription at any time during 
the study period 
Women: 2694 
(-) 
Men: 4195  (-) 
1.03  (0.99-1.07) 
Smeeth 2008
56
 
Prostate 
Breast 
UK general practices (THIN 
database) 
GP Records Uncertain 
GP 
Prescription 
records 
1995-2006 Cohort Non-Statin users 
New user: First prescription on or 
after Jan 1995 and >12 months 
continuous registration with a 
general practice 
26484 (2471) 1.03 (0.96-1.11) 
Yang 2008
127
 Colorectal 
UK general practices (CPRD 
database) 
GP Records Uncertain 
GP 
Prescription 
records 
1987-2002 
Nested 
case-control 
Non-Statin users ≥5 years continuous statin use 4432 (-) 1.1 (0.5-2.2) 
Boudreau 
2007
143
 
Breast 
Group health (health care 
system) Washington 
Washington cancer 
registry 
Invasive 
Prescription 
database 
1990-2004 Cohort Non-Statin users ≥2 prescriptions within any 6-month 
period and statin use for >1 year 
861 (-) 0.90 (0.7-1.2) 
Flick 2007
144
 Prostate 
KP Northern and Southern 
California 
KP cancer registry Invasive 
Prescription 
database  
California, 
2002-2003 
Cohort Non-Statin users >100 day supply of one or more 
statins 
888 (270) 0.92 (0.79-1.07) 
Murtola 
2007
145
 
Prostate Finland cancer registry 
Finnish Cancer 
registry 
Uncertain 
Prescription 
database  
1995-2002 
Case-
control 
Non-Statin users ≥1 statin prescription 24723 (2622) 1.07 (1.00-1.16) 
Khurana 2007
27
 Lung 
Eight states of South Central 
USA 
VA database Uncertain 
Prescription 
database 
1998-2004 
Case-
control 
Non-Statin users ≥1 statin prescription 7280 (1994)  
Vinogradova 
2007
90
 
Colorectal 
UK general practices 
(QRESEARCH database) 
GP Records Invasive 
GP 
Prescription 
records 
1995-2005 
Nested 
Case-
control 
Non-Statin users ≥1 statin prescription 5686 (538) 0.93 (0.83-1.04) 
Setoguchi 
2006
146
 
Colorectal 
Breast 
Lung 
Elderly resident of 
Pennsylvania, ≥65 years with 
annual income <$16,200) 
Pennsylvania State 
Cancer 
Registry data 
Invasive 
Prescription 
database 
1994-2003 Cohort 
Glaucoma 
medication users 
New user: ≥ 3 prescriptions during 
the first 180 days after the first 
prescription. 
-* No association* 
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[Table 3.3 continued] 
Author & Year 
Cancer(s) 
examined 
Study Population 
Data source for 
outcomes 
Outcome 
definition 
Data source 
for statin use 
Time-
period 
Study 
design 
Comparison 
group 
Statin exposure definition 
No. of cases 
(cases 
exposed) 
Total cancer or site-
specific cancer: point 
estimate (95% CI) 
Friis 2004
147
 
Prostate 
Colorectal 
Breast 
Lung 
Residents of the county of 
North Jutland, Denmark 
Danish cancer 
registry 
Uncertain 
Prescription 
database 
1989-2002 Cohort 
Other lipid-
lowering drugs 
≥2 prescriptions during the study 
period - person time counted from 
the second prescription 
22512 (398) 0.73 (0.55-0.98) 
Graaf 2004
148
 
Prostate 
Colorectal 
Breast 
Lung 
PHARMO record linkage 
system - 8 Dutch cities 
Hospital linked 
discharge records 
Invasive 
Prescription 
database 
1985-1998 
Nested 
case-control 
Cardiovascular 
drugs ≥6 months of statin use 3080 (144) 0.80  (0.66-0.96) 
Kaye 2004
128
 
Prostate 
Colorectal 
Breast 
Lung 
UK general practices (CPRD 
database) 
GP Records Uncertain 
GP 
Prescription 
records 
 
Nested 
case-control 
Non-Statin users 
(untreated 
hyperlipidaemia) 
≥1 prescription 1 year prior to 
diagnosis and statin use within a year 
of diagnosis 
3244 (-) 1.0 (0.9-1.2) 
Beck 2003
149
 Breast 
Saskatchewan health services 
database 
Saskatchewan 
cancer registry 
Uncertain 
Prescription 
database 
1989-1997  Cohort Non-Statin users ≥1 statin at any time during the study 
period 
879 (188) 1.09 (0.93-1.28) 
Kaye 2002
129
 Breast 
UK general practices (CPRD 
database) 
GP Records 
Invasive 
and non-
invasive 
GP 
Prescription 
records 
1992-1998 
Nested 
case-control 
Non-Statin users 
(untreated 
hyperlipidaemia) 
≥1 prescription prior date of 
diagnosis 
200 (31) 1.00 (0.6-1.6) 
Blais 2000
150
 
Prostate 
Colorectal 
Breast 
Lung 
10% random sample of 
individuals ≥65 from Regie de 
L'assurance-Maladie du 
Quebec (RAMQ) database 
RAMQ Medical 
services records 
Invasive 
Prescription 
database 
1988-1994  
Nested 
case-control 
Bile acid-binding 
resins 
≥1 prescription at any time during 
the study period 
65 (-) 0.72 (0.57-0.092) 
GP: General Practice; CPRD: Clinical Practice Research Datalink; KP: Kaiser Permanente; VA: Veterans Affairs; 
*Hippisley-Cox et al. 
131
 and Setoguchi et al. 
146
  did not examine overall cancer, site-specific relative risk estimates are presented in Table 3.4 
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3.4.2.2 Outcome ascertainment  
A variety of electronic data sources were used to ascertain cancer events (Table 3.3): 
cancer registries (n=14), GP records (n=7), US administrative records (n=7), and 
hospital records (n=2). Only one study, which utilised the VA database141 compared 
cancer outcomes ascertained from computerised records to medical charts in which 
70% of cancer cases were verified. Vinogradova et al.90 reported lower incidence rates 
of colorectal cancer from the QRESEARCH database compared to 2003 ONS incidence 
rates (rate difference: 6.2 (men), and 5.9 (women) per 100k PY). 
3.4.2.3 Outcome definitions 
Studies defined incident cancer by either including or excluding non-invasive 
(carcinoma in-situ) cancers (Table 3.3). Of the 30 studies: 15 excluded non-invasive 
cancers; while 4 studies included them. From reported case definitions, neither 
inclusion nor exclusion of these cancer sub-types could be ascertained for the 
remaining 11 studies. Statin users may be under closer monitoring compared to non-
users and therefore diagnosis of early detection of non-invasive cancers may be more 
likely among statin users compared to their counterpart non-users.  
3.4.2.4 Exposure ascertainment and definitions 
Two main criteria were assessed by the 30 studies before classifying statin exposure 
status (Table 3.3): (i) a minimum number of statin prescriptions written or dispensed; 
and (ii) a minimum period of exposure. The most common requirement among 28 of 
the 30 studies was a minimum of 1 statin prescription only (n=19); ≥2 statin 
prescriptions only (n=4); and ≥3 statin prescriptions only (n=4).  
Minimum periods of statin use or lag-time periods were considered by 18 studies, 
which ranged from 3 months to 5 years: ≥3 months (~100 days’ supply of statins; n=2); 
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≥6 months (n=3); ≥1 year (n=7); ≥2 years (n=5); and ≥5 years (n=1). Minimum periods 
of exposure may be considered for two reasons: firstly, to ensure only adherent statin 
users are included, and secondly, to guard against protopathic bias (or reverse 
causality), where patients are diagnosed with cancer after a short period of statin use, 
but had a pre-existing cancer prior to commencing statin therapy.  
3.4.2.4.1 New user design 
Four studies considered a new user design;56, 64, 131, 146 only incident users of statins 
relative to the study period under consideration were included in the statin group. 
When a new user design is implemented the exclusion of prevalent statin users may 
minimise prevalent user bias (Prevalent user bias; Table 3.1). Importantly, Farwell et 
al.25, 141 noted that not all statin users could be confirmed as first time users within 
their study (proportions not given). Neither prevalent nor incident statin use was 
described in reported exposure methods; therefore the assumption was that both 
incident and prevalent statin users were included in both published analyses. Of note, 
all case-control studies did not specify whether statin users were incident or prevalent 
– the base cohort from which cases and controls are sampled could include only 
incident statin users as recommended by Ray et al.70 This review assumed that the 
cohort from which case-control studies sampled from included both new and 
prevalent statin users.  
3.4.2.5 Comparison groups 
Five different comparator groups were considered (Table 3.3): the primary comparison 
group consisted of non-statin users (n=24); antihypertensive drug users (n=3);141, 148 132 
other lipid lowering drugs (n=3);128, 129, 147 bile-acid binding resin drug users (n=1);150 
and glaucoma medication users (n=1).146  
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Table 3.4: Summary of findings and biases - risk of breast, prostate, and colorectal and lung cancer associated with statin use 
   
a
 Did the study potentially suffer 
from the following biases? 
   
Author + Year Cancer 
No. of cases (no. 
of cases in statin 
user group) Im
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b
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Confounders adjusted for in analysis Analysis method Ever use: Relative risk (95% CI) 
Cohort Studies 
Farwell 
2011
132
 
Prostate 546 (359) No No Yes No - 
Age, weight, co-morbidities, aspirin use, mental 
illness, alcoholism, lung disease, history of 
colonoscopy or sigmoidoscopy, smoking history, and 
total cholesterol. 
Cox proportional 
hazards 
HR=0.69 (0.52-0.90) 
Tan 2011
133
 Prostate 2407 (565) No Yes Yes No - 
Age, BMI, race, DRE positivity, prostate volume, and 
number of cores surveyed. 
Logistic Regression OR=0.92 (0.85-0.98) 
Hippisley-Cox 
2010
131
 
 
Breast 
Prostate 
Colon 
 
Lung 
 
 
9,823 (-) 
7,129 (-) 
Men: 2,182 (-) 
Women: 1,970 (-) 
Men: 3600 (-) 
Women: 2401(-) 
U Yes No Yes - 
All cancer types: Age, BMI,  
Breast Cancer: Townsend score, HRT, family history 
breast cancer, benign breast disease, oral 
contraceptive use, any other cancer. 
 
Prostate Cancer: smoking status. 
 
Colorectal Cancer: Townsend score, smoking status, 
colorectal polyps, type 2 diabetes. 
 
Lung Cancer: Townsend score, smoking status, any 
other cancer, corticosteroids, asthma 
Cox proportional 
hazards 
Breast: HR=1.09 (1.00 -1.18) 
Prostate: HR=1.05 (0.98 -1.13) 
Colon: Women HR= 0.89 (0.76- 1.05) 
Colon: Men HR= 0.89 (0.76-1.05) 
Lung: Women HR=1.10 (0.96-1.25) 
Lung: Men: HR=1.11 (1.01-1.23) 
Murtola  
2010
134
 
Prostate 1,594 (268) No Yes Yes No - 
Age, family history of prostate cancer, use of aspirin, 
diabetic drugs, antihypertensives, no. of PSA screens, 
and calendar period of screening. 
Cox proportional 
hazards with time-
dependent exposure 
HR=0.75 (0.63-0.89) 
Flick 2009
137
 Colorectal 171 (56) No No Yes No - 
Family history of colorectal cancer, history of 
colorectal polyps, history of sigmoidoscopy, BMI, 
cardiovascular disease, hyperlipidaemia, physical 
activity, smoking, alcohol use, NSAID use, 
multivitamin use, red meat intake, calcium, folate 
intake, and ethnicity. 
Cox proportional 
hazards 
Colorectal: HR=0.89 (0.61-1.30) 
Colon: HR=0.90 (0.58-1.40); N=42 
Rectum: HR=0.86 (0.41-1.78); N=14 
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[Table 3.4 continued] 
   
a
 Did the study potentially suffer 
from the following biases? 
   
Author + Year Cancer 
No. of cases (no. 
of cases in statin 
user group) Im
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b
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s 
Confounders adjusted for in analysis Analysis method Ever use: Relative risk (95% CI) 
Haukka  
2009
67
 
Breast 
Prostate 
Colon 
Rectum 
Lung 
6,046 (3048) 
10,928 (5871) 
2,950 (1486) 
2,066 (1080) 
5129 (2333) 
U* No Yes Yes - 
Age, sex, and follow-up period. 
 
Note: Also performed a sensitivity analysis for 
unmeasured confounders. 
Poisson regression 
Breast: IRR =1.01 (0.96-1.06) 
Prostate: IRR =1.12 (1.08-1.17) 
Colon: IRR =0.99 (0.92-1.06) 
Rectum: IRR =1.07 (0.98-1.17) 
Lung: IRR =0.81 (0.77-0.86) 
Singh 2009
64
 Colorectal 6,637 (402) Yes Yes No No - 
Age, sex, history of IBD, diabetes, CHD, resective 
colorectal surgery, lower GI endoscopy, level of 
morbidity (three categories), SES, NSAID use, and 
HRT use. 
Poisson regression IRR: 1.13 (1.02-1.25) 
Boudreau 
2008
139
 
Prostate 2,532 (246) No No Yes No - 
Age, diabetes, hypercholesterolemia, other lipid-
lowering drug use, and NSAID use. 
Cox proportional 
hazards with time-
dependent exposure 
HR=0.88 (0.76-1.02) 
Smeeth  
2008
56
 
Breast 
Prostate 
3,204 (324) 
3,213 (312) 
No No No Yes - 
Age, sex, propensity score, year of index date, co-
morbidities, co-medication 
Cox proportional 
hazards 
Breast: HR=1.17 (0.95-1.43) 
Prostate: HR=1.06 (0.86-1.30) 
Farwell 
2008
141
 
Prostate 
Colorectal 
Lung 
2,165 (1164) 
687 (316) 
867 (436) 
No No Yes No - 
Age, weight, co-morbidities, aspirin use, alcoholism, 
history of colonoscopy or sigmoidoscopy, smoking 
history, and total cholesterol. 
Cox proportional 
hazards 
Prostate: HR=0.90 (0.81-0.99) 
Colorectal: HR=0.65 (0.55-0.78) 
Lung: HR=0.70 (0.60-0.81) 
Friedman  
2008
142
 
Breast 
Colorectal 
 
Lung 
881 (-) 
Men:421 (-) 
Women: 312 (-) 
Men: 614 (-) 
Women: 482 (-) 
No No Yes Yes - 
Calendar year, hormone use, NSAID use (only for 
colorectal cancer). 
 
Note: Also performed external adjustment for 
smoking. 
Cox proportional 
hazards with time-
dependent exposure 
Women: 
Breast: HR=0.99 (0.92-1.06) 
Colon: HR=0.97 (0.85-1.11) 
Rectum: HR=0.97 (0.76-1.25) 
Lung: HR=1.16 (1.06-1.28) 
 
Men: 
Colon: HR=0.88 (0.78-1.00) 
Rectum: HR=0.93 (0.77-1.12) 
Prostate: HR=1.03 (0.98-1.08) 
Lung: HR=1.02 (0.94-1.11) 
 
Prostate 1,706 (-) No No Yes No - 
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[Table 3.4 continued] 
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 Did the study potentially suffer 
from the following biases? 
   
Author + Year Cancer 
No. of cases (no. 
of cases in statin 
user group) Im
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Confounders adjusted for in analysis Analysis method Ever use: Relative risk (95% CI) 
Boudreau  
2007
143
 
Breast 2,707 (130) No No Yes No - 
Age, HRT, diabetes, other lipid-lowering drugs, and 
BMI. 
Cox proportional 
hazards with time-
dependent exposure 
HR=1.07 (0.88-1.29) 
Flick 2007
144
 Prostate 888 (270) No No Yes No - Race, diabetes, KP California region. 
Cox proportional 
hazards 
HR=0.92 (0.79-1.07) 
Setoguchi  
2006
146
 
Breast 
Colorectal 
Lung 
300 (227) 
233 (178) 
216 (179) 
No No No No - 
Age, race, sex, health service utilisation, prevention-
related activities, co-morbidities, GI drug use, HRT, 
NSAID use, Tobacco abuse. 
Cox proportional 
hazards 
Breast: HR=0.99 (0.74-1.33) 
Colorectal: HR=0.96 (0.70-1.31) 
Lung: HR=1.11 (0.77-1.60) 
Friis 2004
147
 
Breast 
Prostate 
Colorectal 
Lung 
227 (48) 
1,407 (34) 
3,006 (55) 
3399 (73) 
U* Yes Yes No - 
Age, gender, calendar period, NSAID use, HRT, 
cardiovascular drugs. 
Poisson regression 
Breast: IRR=1.02 (0.76-1.36) 
Prostate: IRR=0.87 (0.61-1.23) 
Colorectal: IRR=0.85 (0.65-1.11) 
Lung: IRR=0.92  (0.72-1.16) 
Beck 2003
149
 Breast 879 (188) No Yes Yes Yes - Age, HRT, and oral contraceptive use. 
Mantel-Haenszel 
relative risk 
IRR=1.09 (0.93-1.28) 
Case-Control studies 
Chang 2011
68
 Prostate 388 (83) - No Yes No No 
Sex, year of birth, index date, diabetes, hypertension, 
CHD, Benign prostatic hyperplasia, NSAID use, use of 
other lipid lowering drugs, number of physician visits, 
and number of hospitalisations 
Conditional logistic 
regression 
OR=1.55 (1.09-2.19) 
Vinogradova  
2011
130
 
Breast 
Prostate 
Colorectal 
Lung 
15,666 (1481) 
14,764 (2774) 
11,749 (2000) 
10,163 (1998
67
) 
- No Yes Yes No 
Age, Sex, Practice, Calendar time, co-morbidities, 
BMI, smoking status, Townsend deprivation score, 
family history of breast cancer, co-medications. 
Conditional logistic 
regression 
Breast: OR=1.00 (0.93-1.08) 
Prostate: OR=1.08 (1.01-1.14) 
Colorectal: OR=1.07 (1.00-1.15)  
Lung: OR=1.07 (0.99-1.16) 
Robertson 
2010
135
 
Colorectal 9,979 (711) - No Yes Yes No Age, sex, NSAID use, diabetes, cholecystectomy, 
alcoholism, MI, stroke, Atherosclerosis 
Conditional logistic 
regression 
IRR =0.87 (0.80-0.96) 
Wooditschka  
2010
136
 
Breast 22,488 (5409) - No Yes Yes No Oral contraceptive use and HRT use. Unconditional 
logistic regression 
OR=1.02 (0.97-1.08) 
Hachem 
2008
138
 
Colorectal 
Rectal 
6,080 (2,987) 
 
- Yes Yes No  No 
Inflammatory bowel disease, diabetic nephropathy, 
colorectal evaluation, cholecystectomy, sulfonylurea 
prescription, NSAID, and liver disease 
Conditional logistic 
regression 
OR=0.88 (0.83 – 0.93) 
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[Table 3.4 continued] 
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 Did the study potentially suffer 
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Author + Year Cancer 
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Confounders adjusted for in analysis Analysis method Ever use: Relative risk (95% CI) 
Boudreau 
2008
140
 
Colorectal 357 (60) - Yes Yes Yes No Age, BMI, diabetes, smoking status, hormone 
therapy use, and NSAID use 
Conditional logistic 
regression 
Colorectal: OR=1.02 (0.65-1.59) 
Colon: OR=0.91 (0.55-1.50) 
Rectal: OR=1.47 (0.50-4.29) 
Yang 2008
127
 Colorectal  4,432 (-) - No Yes No No 
General practice site, calendar periods and duration 
of follow-up, BMI, Smoking status, alcohol use, HRT, 
NSAID use, colonoscopy, or flexible sigmoidoscopy. 
Conditional logistic 
regression 
≥5 yrs: OR=1.1 (0.5-2.2) 
≥10 yrs: OR=1.3 (0.6-2.7) 
Murtola 
2007
145
 
Prostate 22,101 (2622) - Yes Yes Yes No Age, antihypertensives and diabetic medications Conditional logistic 
regression 
OR=1.07 (1.00-1.16) 
Vinogradova 
2007
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Colorectal 5686 (538) - No Yes Yes No Smoking, obesity, deprivation, co-morbidities, use of 
the other medications 
Conditional logistic 
regression 
OR=0.93 (0.83-1.04) 
Khurana 
2007
27
 
Lung 7820 - Yes Yes Yes Yes BMI, age, race, sex, alcohol use, diabetes Logistic regression OR=0.55 (0.52-0.59) 
Graaf 2004
148
 
Breast 
Prostate 
Colorectal 
Lung 
467 (-) 
186 (-) 
486 (-) 
449 (-) 
- No Yes No No 
Diabetes mellitus, prior hospitalisations, chronic 
disease score, antihypertensives, hormone use, 
NSAIDs, other lipid-lowering therapy. 
Conditional logistic 
regression 
Breast: OR=1.07 (0.65-1.74) 
Prostate: OR=0.37 (0.11-1.25) 
Colon: OR=0.87 (0.48-1.57) 
Rectum: OR=0.48 (0.16-1.48) 
Lung: OR=0.89 (0.56-1.42) 
Kaye 2004
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Breast 
Prostate 
Colon 
Rectum 
Lung 
40 (-) 
62 (-) 
25 (-) 
23 (-) 
43 (-) 
- Yes Yes No No Age, sex, general practice BMI, smoking status, GP 
visit frequency 
Conditional logistic 
regression 
Breast: OR=0.9 (0.6-1.3) 
Prostate: OR =1.3 (1.0-1.9) 
Colon: OR =1.0 (0.6-1.7) 
Rectum: OR =1.6 (0.9-2.8) 
Lung: OR =0.9I (0.6-1.3) 
Kaye 2002
129
 Breast 66 (41) - Yes Yes No No Hyperlipidaemia, HRT use, BMI, history of benign 
breast disease. 
Conditional logistic 
regression 
OR =1.0 (0.6-1.6) 
Blais 2000
150
 
Breast 
Prostate 
Colon 
Lung 
65 (-) 
78 (-) 
56 (-) 
70 (-) 
- No Yes No No 
Age at index date, previous neoplasm, year of cohort 
entry, use of fibric acids, use of other lipid-lowering 
drugs and comorbidity score. 
Logistic regression 
Breast: IRR=0.67 (0.33-1.38) 
Prostate: IRR =0.74 (0.36-1.51) 
Colon: IRR =0.83 (0.37-1.89) 
Lung: IRR =0.94 (0.43-2.05) 
a
 Detailed assessment of bias described in Appendix B, Table 9.1; *U: Uncertain if study was potentially affected by potential biased based on lack of reported methods  
BMI: Body Mass Index; CHD: Coronary Heart Disease; DRE: Digital Rectal Examination; GI: Gastro-Intestinal; GP: General Practice; HRT: Hormone Replacement Therapy; IBD: Inflammatory Bowel Disease; 
KP: Kaiser Permanente; MI: Myocardial Infarction; NSAID: Non-steroidal anti-inflammatory drug; PSA: Prostate-specific antigen; SES: Socio-economic status 
IRR: Incidence rate ratio; HR: Hazard Ratio; OR: Odds Ratio; 
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3.4.2.6 Adjustment for potential confounding factors 
Adjustment for potential confounding factors was performed to varying degrees 
among the 30 studies (Table 3.4). Established risk factors such as age and sex were 
included in statistical adjustments by the majority of studies. However, adjustment for 
clinically relevant lifestyle factors and ethnicity were less frequent: smoking status 
(n=13), BMI (n=13); alcohol use (n=6); socioeconomic status (n=5); and ethnicity (n=5). 
This could be explained by studies utilising US claims databases, which do not collect 
lifestyle factors as part of routine practice. Co-medications (n=26) and co-morbidities 
(n=18) were included to varying degrees in statistical models. Three studies included 
propensity scores estimates as an adjustment factor within their statistical analysis.56, 
132, 141 A propensity score is a summary measure of how likely an individual is to be 
prescribed a particular drug. Use of a propensity score offers a method of reducing 
bias and confounding in pharmacoepidemiological studies.151 Of note, Farwell et al.141 
found no difference in effect estimates on overall cancer risk when comparing risk 
estimates from propensity score adjusted analyses to traditional statistical adjustment. 
3.4.3 Detailed consideration of site-specific associations 
The risk of prostate cancer associated with statin use had the most variability among 
the four cancer types examined (Figure 3.3): 4 studies reported a reduced risk; 3 
observed an increased risk; and 10 found no significant association. Variation in 
findings from studies examining the risk of colorectal cancer was also observed: 1 
found an increased risk, 3 observed a reduced risk, and 13 reported no association. 
Fourteen studies examined the association between statin use and risk of breast 
cancer; all 14 studies reported a null association between statin use and breast cancer 
72 
 
risk. Eleven studies examined the risk of lung cancer associated with statin use. Of the 
11 studies, 3 reported a reduced risk and 8 a null association.  
 
3.4.3.1 Prostate cancer 
Overview 
Seventeen studies examined the risk of prostate cancer associated with any statin use: 
3 observed an increased risk; 4 reported a reduced risk; and 10 found no association 
(Table 3.2 and 3.4).  
The majority of seventeen prostate cancer studies reported a null association (n=8) 
between statin use and the risk of prostate cancer. Point estimates varied among the 8 
studies, the majority of the variation was from three small studies published between 
2000-2004.128, 148, 150 Relative risk (RR) point estimates ranged from 0.37150 to 1.30.128 
Moreover, these three studies compared statin users to comparison drug groups, in 
contrast to most of the recent studies (post-2004) who compared statin users to non-
users.  
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Figure 3.3: Forest plots of studies examining statin use and breast, colorectal, lung, and prostate cancer risk 
(a) Studies examining breast cancer risk associated with statin use (b) Studies examining colorectal cancer risk associated with statin use 
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Figure 3.3 (continued): Forest plots of studies examining statin use and breast, colorectal, lung, and prostate cancer risk 
(c) Studies examining lung cancer risk associated with statin use (d) Studies examining prostate cancer risk associated with statin use 
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Two case-control studies and one cohort study observed an increased risk;68, 130 in both 
cases, the lower bounds of reported confidence intervals were close to 1 (Table 3.4). 
Chang et al.68 reported a 55% increased risk of prostate cancer among statin users 
compared to non-users (OR=1.55; 95% CI, 1.09, 2.19). Cases were identified over a 
relatively short time-window (2005-2008) relative to the entire study period (1996-
2008). In addition, a small number of cases (n=388) were included, generating 
relatively large confidence intervals. Of note, the pool of potential controls from the 
study conducted by Chang et al.68 comprised of subjects who did not have a history of 
wrist or hip fractures - the same exclusions did not apply to potential cases. 
Vinogradova et al.130 reported a borderline increased risk (OR=1.08; 95% CI, 1.01, 
1.14), in contrast to Chang et al.68, Vinogradova et al.130 identified a fairly large number 
of cases of prostate cancer (n=14,764) over the study period (1998-2008). Haukka et 
al.67 also reported an increased risk of prostate cancer (RR=1.12; 95% CI; 1.08, 1.17), 
however the study only adjusted for age, sex and duration of follow-up.  
Of the seventeen prostate cancer studies, four cohort studies observed a reduced risk 
of prostate cancer associated with statin use. Two studies were conducted by Farwell 
et al.25, 141 in the same population of VA veterans. In an attempt to minimise healthy 
user bias, a group of antihypertensive drug users were compared to statin users, which 
may have influenced the observed decrease in risk as there have been suggestions of 
an elevated risk of cancer among patients prescribed antihypertensives.152 Tan et al.153 
conducted a cohort study consisting of men who had undergone consecutive prostate 
biopsies to circumvent healthy user bias. A reduced risk was observed (OR=0.92; 95% 
CI; 0.85, 0.98) among 565 prostate cancer cases (2407 cases overall) who had 
previously been prescribed statins. Similarly, a cohort study by Murtola et al.134 also 
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observed a reduced risk (HR=0.75; 95% CI; 0.63, 0.89) sampled statin and non-statin 
users from the PSA screening arm of a Finnish clinical trial. All men from the trial had a 
PSA test every 4 years, which circumvented the issue of healthy user bias (differential 
PSA testing rates between treatment groups). 
Duration of statin use 
Eight studies evaluated the relationship between duration of statin use and prostate 
cancer risk, three studies observed a reduced risk, four an increased risk, and one 
found no association (Table 3.5).  
The short term effect of statin use were examined by four studies.67, 130, 134, 139 A large 
nested case-control study conducted in the UK QRESEARCH database 130 observed a 
null association related to 13-24 months of statin use (OR=0.93; 95% CI; 0.81, 1.07) but 
this association did not hold when increasing duration to >25 months. Similarly, a 
study conducted in Finland67 observed an increased risk of prostate cancer associated 
with less than 6 months (RR=1.27; 95% CI; 1.16, 1.38), however this relationship 
tended towards the null with 1 year of statin use. Furthermore, Murtola et al.134 
reported statistically significant effects associated with <3 years of statin use, although 
this association was much stronger within shorter periods of follow-up (1 year: 
HR=0.73; 95% CI; 0.54, 0.98; and 2-3 years: HR=0.67; 95% CI, 0.50, 0.90) compared to 
later durations of 4-5 years and ≥6 years (4-5 years; HR=0.85; 95% CI; 0.62, 1.11; ≥6 
years: HR=0.70; 95% CI; 0.45, 1.08); ptrend=0.007). Similar findings were observed by 
Boudreau et al.139, statin use for 1 - 2.9 years was associated with a reduced risk of 
prostate cancer (HR=0.75; 95% CI, 0.59, 0.95), however no association was found for 3-
4.9 years (HR=0.92; 95% CI; 0.71, 1.19) and 5+ years (HR=1.06; 95% CI; 0.83, 1.34).  
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Three studies examined long-term statin use (>5 years).133, 142, 144  Tan et al.133 reported 
no association between long-term statin use and prostate cancer risk (OR=0.95; 95% 
CI; 0.79, 1.09) and similar findings were observed by Friedman et al.142 In contrast, Flick 
et al.144 examined whether NSAID use modified the effect of statins on the risk of 
prostate cancer because of previous evidence suggesting that NSAIDs have a 
protective effect among different cancers and hence may be considered a possible 
confounder when examining the association between statin use and cancer risk.90, 93, 
154, 155 Flick et al. observed a lower risk of prostate cancer among long-term statin users 
who were also regular NSAID users (HR=0.64; 95% CI; 0.44, 0.93). However, long-term 
statin use alone was not associated with prostate cancer (HR =1.05; 95% CI; 0.55, 
1.98). Of note, a sensitivity analysis by Flick et al. compared analyses with and without 
a 1-year lag period; differences in results were negligible (For short term analysis: 
HR=0.94 with lag vs. OR=0.97 without lag and long-term analysis: 0.71 with lag vs. 0.72 
without lag).  
3.4.3.2 Colorectal cancer 
Overview 
Overall, 17 studies examined the association between statin use and risk of colorectal 
cancer: 1 found an increased risk, 3 observed a reduced risk, and 13 found no 
association (Figure 3.3 (b)). Among the 17 colorectal cancer studies, eight investigated 
colon and rectal cancer as separate outcomes (4/8 studies also examined colorectal 
cancer), two studies investigated colon cancer alone, and seven studies examined 
colorectal cancer only.  
Of the 17 colorectal cancer studies, 13 reported null associations in relation to statin 
use. Point estimates ranged from 0.83150 to 1.1.127 Six of the thirteen studies were 
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underpowered yielding wide confidence intervals. Similar to prostate and breast 
cancer studies these were undertaken in the years 2000-2004 (Figure 3.3 (b)). 
However, several large studies were conducted post-2004 that observed a null 
association. A large nested case-control study utilising the QRESEARCH database130 
observed a null association (OR=1.07, 95% CI; 1.00, 1.15). Similar results were 
observed by Hippisley-Cox et al.131 who also used the QRESEARCH database – primary 
results were stratified by sex and statin type. Haukka et al.67 conducted a large cohort 
study among all Finnish residents and reported a null association between statin use 
and colon cancer risk (RR=0.99; 95% CI; 0.92, 1.06); however, only a limited number of 
potential confounding factors were included for adjustment (age, sex, and follow-up).  
A cohort study conducted in a population of residents from Manitoba, Canada64 
reported a borderline increased risk of colorectal cancer associated with statin use 
(RR=1.13; 95% CI; 1.02, 1.25). Of note, Singh et al.64 observed statistically significant 
higher rates of lower gastro-intestinal endoscopy examinations among regular statin 
users compared to non-statin users: 28% vs 20%, similar differential rates were 
observed by Flick et al.137 for sigmoidoscopies. 
Three studies reported protective effects of statin use on colorectal cancer risk: two 
studies were conducted in the US138, 141 and one study among two counties of 
Denmark.135 A study utilising the VA healthcare database141 found a reduced risk of 
colorectal cancer (HR=0.65; 95% CI; 0.55, 0.78) among statin users compared to 
antihypertensive drug users. Similarly, Hachem et al.138 conducted a nested case-
control study among diabetic veterans from the VA healthcare system and found a 
12% reduction in colorectal cancer among statin users when compared to non-statin 
users (OR=0.88; 95% CI; 0.83, 0.93). Furthermore, Hachem et al.138 stratified on 
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previous colon polyps and found no significant association in patients with previous 
polyps, however a protective effect was observed when analyses were restricted to 
patients without colon polyps (OR=0.86; 95% CI; 0.80, 0.93). Robertson et al.135 
examined the risk of colorectal cancer among statin users compared to non-users 
residing in two counties of Denmark and reported a 13% reduction in colorectal cancer 
risk in statin users compared to non-users (OR=0.87; 95% CI; 0.80, 0.96). 
Of note, three studies utilised active comparator groups with contrasting findings. In 
contrast to Farwell et al.141, Graaf et al.148 reported a null association (OR=0.87; 95% 
CI; 0.48, 1.57) of colon cancer risk when comparing statin users to antihypertensive 
drug users. However, based on the wide confidence interval reported the study lacked 
power. Setoguchi et al.146 implemented an active comparator group of patients 
prescribed glaucoma medications and did not find any evidence of a difference in 
colorectal cancer incidence rates between the two groups (HR=0.96; 95% CI; 0.70, 
1.31). Of note, both Setoguchi et al.146 and Farwell et al.141 observed comparable rates 
of colorectal examinations between the statin group and the respective comparator 
drug group. 
Duration of statin use 
Six studies reported results relating to short term statin use (0-3 years)90, 130, 135, 138, 140, 
146 (Table 3.5). Three studies observed a reduced risk90, 135, 138.  Vinogradova et al.90 
reported a marginal reduced risk associated with less than 1 year of statin use. 
Hachem et al.138 reported a reduced risk associated with less than 6 months of statin 
use (OR=0.86; 95% CI; 0.77, 0.95), similarly Robertson et al.135 also observed a reduced 
risk associated with 0-3 years of statin use (OR=0.84; 95% CI; 0.75, 0.95). Of note, 
when Hachem et al. restricted analyses to patients with no history of colorectal polyps 
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the protective association remained (OR=0.86; 95% CI; 0.75, 0.99). The remaining 
three studies did not observe an association between short term statin use and 
colorectal cancer risk. 
Six studies assessed the effects of long term statin use on the risk of colorectal 
cancer:64, 127, 130, 135, 137, 142 prolonged durations of >5 years were consistently shown to 
have no association with the risk of colorectal cancer among five of the six studies 
(Table 3.5). However, Vinogradova et al.130 reported statistically significant increased 
risk associated with ≥49 months (~4 years) of statin use, and the corresponding test for 
trend was significant across stratified 1-year time periods over the 4-year period 
(p=0.002). 
3.4.3.3 Breast cancer 
Overview 
Fourteen studies examined the association between statin use and risk of breast 
cancer; all 14 studies found no relationship between breast cancer risk and statin use 
However, there were a range of point estimates reported (Relative risk range, 0.33150 
to RR=1.1756). Earlier studies reported wide confidence interval estimates around 
observed effect estimates demonstrating a lack of power. However, from 2004 
onwards effect estimates were closer to the null with narrowing confidence intervals 
(Figure 2.3 (a)).  Adjustment for potential confounders varied by study. The majority of 
studies adjusted for HRT (n=10), which may have increased the risk of breast cancer; in 
contrast, oral contraceptive use was only included for adjustment by 4 studies.   
Duration of statin use 
Six studies investigated the effects of statin duration on breast cancer risk (Table 3.5). 
Only one study reported an increased risk associated with short term statin use (<6 
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months). Short durations were investigated by 4 studies.130, 143, 146, 149 Beck et al.149 
observed an increase in breast cancer risk associated with <6 months of statin use. 
Setoguchi et al.146 and Vinogradova et al.130 did not observe any significant effects on 
breast cancer associated with <3 years and <2 years respectively. 
Similarly, long-term durations of statin use did not show any significant associations in 
five studies.130, 142, 143, 146, 149 Friedman et al. looked at >5 years of statin use (HR=1.06; 
95% CI; 0.86, 1.21); estimates from the other four studies were similar (Table 3.5).  
3.4.3.4 Lung cancer 
Overview 
Overall, eleven studies examined lung cancer risk associated with statin use, two 
reporting an increased risk, and three a decreased risk, and six a null association (Table 
3.2). 
Two studies reported an increased risk of lung cancer (Table 3.4, Figure 3.3).131, 142 
Friedman et al. observed an elevated risk among women (HR=1.16; 95% CI, 1.06, 1.28). 
In contrast, Hippisley-Cox et al.131 observed a marginal increased risk among men 
(HR=1.11; 95% CI; 1.01, 1.23). In both cases, results were borderline and may have 
been a result of unmeasured confounding or chance findings. 
Of the 11 studies, 3 reported a reduced risk (Table 3.4). Among the three studies,27, 67, 
141 none adjusted for smoking status – Farwell et al.141 extracted smoking status; 
however, over 50% of statin users and >60% of antihypertensive drug users (referent 
group) had an unknown smoking status. Although 6 studies observed a null 
association, most of these studies were underpowered, reporting relatively large 
confidence intervals and adjustment for smoking status varied by study. The exception 
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being Vinogradova et al. a large case-control study conducted in the QRESEARCH 
database, adjusting for several important confounding factors including smoking 
status. Vinogradova et al.63 reported a null association (OR=1.07; 95% CI; 0.99, 1.16). 
Duration of statin use 
Three studies examined the risk of cancer associated with short term statin use (0-
3years). Vinogradova et al.63 did not find a significant association between short term 
statin use. Similar findings were reported by Setoguchi et al.146 (<3 years: HR=1.18; 
95% CI; 0.72, 1.92). In contrast, Khurana et al.27 reported an elevated risk associated 
with less than 6 months of statin use (OR=2.32; 95% CI; 2.05, 2.63). However, an 
inverse association was reported with increasing duration of statin use >6 months (1-2 
years: OR=0.70; 95% CI; 0.61, 0.79).  
Four studies examined the risk of lung cancer associated with long term statin use, two 
of which observed a null association.142, 146 In contrast, Vinogradova et al.63 reported 
an increased risk (>4 years: OR=1.18; 95% CI; 1.05, 1.34), while Khurana et al.27 
reported a reduced risk of cancer (>4 years: OR=0.23; 95% CI; 0.20, 0.26).  
3.4.4 Assessment of bias 
For each study, summarised assessments of five pre-selected biases are presented in 
Table 3.4; detailed assessments of each bias are provided in Appendix B, Table 9.1. 
Overall, many of the studies included in this review may have been potentially affected 
by at least one of the biases considered: 1/16 cohort studies by immortal time bias; 
26/30 by prevalent user bias; 10/30 by healthy user bias; 1/14 case-control studies by 
time-window bias; and 12/30 from protopathic bias. Varied methodology and 
populations between the studies made it difficult to un-tangle specific bias effects.  
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3.4.4.1 Immortal time bias 
Only one of the 16 cohort studies potentially suffered from immortal time bias (Table 
3.4). Singh et al.64 reported a borderline increased risk of colorectal cancer associated 
with statin use, statin use was defined as a minimum of two statin prescription during 
follow-up. However, observation for cancer events began at the first statin 
prescription rather than second potentially inducing immortal time bias. Immortal time 
bias would have biased the rate ratio downward, suggesting an underestimate of the 
risk reported. That being said, protopathic bias could have also affected findings of this 
study. Hippisley-Cox et al.156 and Friis et al.147 were also identified as studies 
potentially affected by immortal time bias; however, based on described methods 
from both studies, immortal time bias could not be assessed with certainty. The 
remaining 13 cohort studies avoided immortal time bias by incorporating either a time-
dependent exposure of statin use or excluded immortal time bias. 
3.4.4.2 Protopathic bias 
Overall, 12 studies did not implement a lag period or minimum period of exposure, 
which could have made them susceptible to protopathic bias (Table 3.4). Of the 12 
studies, 4 examined short term statin use (≤12 months) associated with cancer risk: 2 
observed an increased risk of cancer (1 lung cancer27 and 1 breast cancer149), and 2 a 
reduced risk of cancer (1 colorectal cancer138 and 1 prostate cancer29). Relative risk 
estimates incorporating all periods of follow-up time were similar for the two studies 
initially observing a reduction in cancer risk.29, 138 However, the 2 studies initially 
reporting an increased risk of lung and breast cancer associated with short term statin 
use observed a reduced risk and null association when examining all time periods of 
follow-up respectively.  
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In comparison, 18 studies implemented a lag-period, of which 5 examined short term 
statin use (≤12 months) associated with cancer risk: 4 observed a null association90, 127, 
130, 137 and 1 an increased risk of prostate cancer.67 Short term statin-cancer 
associations observed remained for 4 of the 5 studies when examining all periods of 
statin follow-up. Vinogradova et al.130 observed a borderline increased risk of prostate 
cancer when considering all follow-up time (OR=1.08; 95% CI; 1.01-1.14). Of note, 
none of the 9 studies that examined short term statin use associated with cancer risk 
implemented a new user design. 
3.4.4.3 Prevalent user bias 
The majority of studies included in this review (26/30) included prevalent statin users 
within their study. Four cohort studies restricted exposure to incident statin use,56, 64, 
131, 146, 156 3 utilised a comparator group of non-statin users, while one compared new 
statin users to glaucoma medication users.146 Of the 4 studies, 3 reported a null 
association between statin use and cancer risk. Of note, Singh et al.64 performed two 
sets of exposure analyses: (i) examining the dose effect of statin use among new and 
prevalent statin users; and (ii) the same dose-response analysis restricted to new statin 
users. Interestingly, compared to the any user analysis, new user risk estimates were 
marginally reduced (rate ratio=1.35 any use vs 1.28) when low doses (≤1 daily defined 
dose, DDD) were considered; however, risk estimates (rate ratio = 0.79 any vs 0.82 
new) increased when high doses (>1 DDD) were examined. Marginally higher relative 
risk point estimates were reported by Smeeth et al.56 and Hippisley-Cox et al.131 in 
comparison to their counterpart studies (cohort design of any statin users and non-
users) (Figure 3.3), suggesting a marginal downward biasing effect from the inclusion 
of prevalent statin users.    
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3.4.4.4 Healthy user bias 
Eight studies compared statin users to an active comparator group to minimise healthy 
user bias (Section 3.4.2.5). Setoguchi et al.146 observed a null association when 
comparing statin users to glaucoma medication users. Of note, physician visits at 
treatment start date were similar between treatment groups (mean no of physician 
visits – statin users 9.1 vs glaucoma medication users 9.6).  Similarly, null associations 
were observed from studies comparing statin users to non-statin lipid lowering 
drugs128, 129, 147 and bile-acid binding drugs.150 However, most of these studies were 
generally underpowered due to the high prevalence of statin use and low number of 
patients in the respective comparator groups. Farwell et al.25, 141 reported a reduced 
risk of colorectal, lung, and prostate cancer among statin users compared to 
antihypertensive drug users (Table 3.4). Although there is some evidence of an 
association between antihypertensive drug use and cancer risk, which may have 
influenced findings.96, 157 
The majority of studies in this review compared statin users to non-users; however, 
some studies (n=12) adjusted for potential factors that could contribute to healthy 
user bias; for example, PSA testing, GP/physician visits, no. of hospitalisations, or 
cancer related testing. Of particular note is the adjustment of PSA testing in prostate 
cancer studies. Larger proportions of statin users have been shown to have had a PSA 
test compared to non-users, which could increase detection of prostate cancer. 
Murtola et al.134, 145 conducted two studies, one adjusting for PSA testing, the other 
not. The study that did not adjust for PSA testing reported a null association (1.07; 95% 
CI; 1.00-1.16) between statin use and prostate cancer risk.145 In contrast, once 
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adjusting for PSA testing, a reduced risk of prostate cancer was observed (HR=0.75; 
95% CI, 0.63, 0.89). 
Studies accounting for healthy user bias brought about the most variability in terms of 
relative risk estimates compared to studies that apparently did not adjust for healthy 
user bias. However, this may be due to a lack of power in studies utilising comparator 
groups or an association existing between the comparator drug group and the cancer 
of interest, or unmeasured confounding. 
3.4.4.5 Time-window bias 
Only one of the 14 case-control studies was potentially affected by time-window 
bias.27 Khurana et al.27 sampled controls from their last observation point during study 
follow-up; which potentially overestimated the proportion of exposed controls relative 
to exposed cases (statin exposure – controls (34%), cases (27%)). Of note, no lag period 
was implemented which may have made the study susceptible to protopathic bias. The 
remaining 13 case-control studies minimised time-window bias by either incorporating 
risk-set sampling of controls or matching controls on case date of diagnosis. However, 
12 of the remaining 13 studies reported higher relative risk estimates (except Graaf et 
al.148 – although an alternative drug group of antihypertensive drug users were 
considered as a comparator group) compared to Khurana et al.27 suggesting a 
downward biasing effect of time-window bias. 
3.4.5 Meta-analysis 
Four main meta-analyses (random effects models) were undertaken for each cancer 
type. All 95% confidence intervals for the summary relative risk estimates spanned 1 
(Figure 3.3). Among the breast cancer studies there was low heterogeneity (I2=0.0%, 
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p=0.0843); however, high heterogeneity was observed for colorectal (I2=83.2%, 
p=0.000), lung (I2=96.4%, p=0.000), and prostate cancer (I2=79.0%, p=0.000). 
Subgroup analyses were conducted to examine the stability of the pooled relative risk 
estimates. Choice of any user or new user as the exposure group yielded the most 
variability: among studies of breast cancer that focussed on new users vs any users, 
the SRR was 1.09, 95% CI (1.01, 1.18); for colorectal cancer any user vs non-user 
yielded SRR=0.91, 95% CI (0.38, 0.99), and for lung cancer, new user vs non-user 
yielded SRR=1.11, 95% CI (1.02, 1.20). Other comparisons with non-users all resulted in 
non-significant effects for breast, colorectal, and prostate cancer; however, a pooled 
protective effect of lung cancer among statin users compared to active comparison 
drug groups  was observed SRR=0.7, 95% CI(0.71, 0.79). There was no variation by 
geographical location in the associations between statin use and breast, colorectal, or 
lung cancer, but a non-significant protective effect of statin use was observed for 
North American studies examining prostate cancer  SRR=0.93, 95% CI(0.86, 1.00).
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Table 3.5: Association between duration of statin use and cancer risk – secondary analysis results 
 Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer 
Author & Year 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Chang 2011
68
 Cancer type not investigated - Cancer type not investigated N/A Cancer type not investigated N/A 
0-5 years: 0.92 (0.85-0.99) 
>5 years: 0.95 (0.79-1.09) 
495 
70 
Farwell 2011
132
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A No analysis - 
Tan 2011
133
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A No analysis - 
Vinogradova 2011
130
 
<12 months: 1.01 (0.90-1.13) 
13-24 months: 0.93 (0.81-1.07) 
25-48 months: 1.07 (0.95-1.21) 
≥49 months: 0.95 (0.83-1.09) 
Ptrend=0.719 
433 
289 
430 
329 
 
<12 months: 1.05 (0.95-1.17) 
13-24 months: 1.04 (0.92-1.17) 
25-48 months: 1.02 (0.92-1.14) 
≥49 months: 1.23 (1.10-1.38) 
Ptrend=0.002 
525 
400 
539 
536 
<12 months: 1.02 (0.90-1.15) 
13-24 months: 1.11 (0.97-1.27) 
25-48 months: 1.01 (0.90-1.14) 
≥49 months: 1.18 (1.05-1.34) 
Ptrend=0.013 
485 
406 
549 
558 
<12 months: 1.05 (0.95-1.15) 
13-24 months: 1.14 (1.03-1.26) 
25-48 months: 1.09 (0.99-1.19) 
≥49 months: 1.05 (0.95-1.16) 
Ptrend=0.084 
668 
560 
796 
750 
Murtola 2010
134
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
1 year : 0.73 (0.54-0.98) 
2-3 years: 0.67 (0.50-0.90) 
4-5 years: 0.85 (0.62-1.11) 
≥6 years: 0.70 (0.45-1.08) 
Ptrend=0.007 
60 
95 
60 
53 
 
Robertson 2010
135
 Cancer type not investigated N/A 
0-3 years: 0.84 (0.75-0.95) 
3-5 years: 0.88 (0.74-1.04) 
>5 years: 0.95 (0.80-1.12) 
370 
162 
179 
Cancer type not investigated N/A Cancer type not investigated N/A 
Wooditschka 2010
136
 No analysis - Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
Hippisley-Cox 2010
131
 No analysis - No analysis - No analysis - No analysis - 
Flick 2009
137
 Cancer type not investigated N/A 
Colorectal cancer: 
101 days-<5 years: 0.91 (0.61-1.34) 
≥5 years: 0.83 (0.43-1.63) 
 
45 
11 
Cancer type not investigated N/A Cancer type not investigated N/A 
Haukka 2009
67
 No analysis - No analysis - No analysis - 
<0.5 year: 1.27 (1.16-1.38) 
1 year: 0.98 (0.97-1.00) 
Unspecified 
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[Table 3.5 continued] 
 Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer 
Author & Year 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Singh 2009
64
 Cancer type not investigated N/A 
≥5 years (New & prevalent users) 
<1.14 DDD: 1.01 (0.75-1.37) 
≥1.14 DDD: 0.75 (0.51-1.10) 
 
≥5 years (New users) 
<1.18 DDD: 0.90 (0.54-1.49) 
≥1.18 DDD: 0.69 (0.37-1.28) 
 
43 
27 
 
 
15 
10 
Cancer type not investigated N/A Cancer type not investigated N/A 
Boudreau 2008
140
 Cancer type not investigated N/A 
Colorectal: 
<2 years:  0.80 (0.40-1.59) 
≥2 years: 1.22 (0.70-2.12) 
20 
40 
Cancer type not investigated N/A Cancer type not investigated N/A 
Boudreau 2008
139
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
1 - <3 years: 0.75 (0.59-0.95) 
3 - <5 years: 0.92 (0.71-1.19) 
≥5 years: 1.06 (0.83-1.34) 
79 
66 
87 
Farwell 2008
141
 Cancer type not investigated N/A No analysis - No analysis - No analysis - 
Friedman 2008
142
 
>5 years statin use 
1.02 (0.86-1.21) 
 
136 
>5 years statin use 
Women: 1.02 (0.75-1.38) 
Men: 1.00 (0.78-1.30) 
 
42 
62 
>5 years statin use 
Women: 1.17 (0.93-1.46) 
Men: 1.06 (0.88-1.28) 
78 
119 
>5 years statin use 
1.04( 0.93-1.17) 
 
322 
Hachem 2008
138
 Cancer type not investigated N/A 
<6 months: 0.86 (0.77-0.95) 
6-12 months: 0.98 (0.89-1.09) 
12-18 months: 0.91 (0.82-1.02) 
18-24 months: 0.93 (0.84-1.04) 
>24 months: 0.87 (0.80-0.95) 
144 
225 
180 
201 
366 
Cancer type not investigated N/A Cancer type not investigated N/A 
Smeeth 2008
56
 No association: data not shown Unspecified Cancer type not investigated N/A Cancer type not investigated N/A No association: data not shown Unspecified 
Yang 2008
127
 Cancer type not investigated N/A 
5 years: 1.1 (0.8-1.6) 
6 years: 1.2 (0.8-1.8) 
7 years: 1.2 (0.7-2.0) 
8 years: 1.2 (0.7-2.2) 
9 years: 1.3 (0.7-2.4) 
10 years: 1.3 (0.6-2.7) 
Unspecified 
Unspecified 
Unspecified 
Unspecified 
Unspecified 
Unspecified 
Cancer type not investigated N/A Cancer type not investigated N/A 
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[Table 3.5 continued] 
 Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer 
Author & Year 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Duration, point estimate  
(95 % CI) 
No of cases: 
statin users 
Boudreau 2007
143
 
1 - <3: 0.96 (0.71-1.31) 
3 - <5: 1.04 (0.72-1.51) 
≥5: 1.27 (0.89-1.81) 
Ptrend=0.2 
~4541 
~30 
~35 
 
Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
Flick 2007
144
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
101 days - <5 yrs: 0.97 (0.83-1.13) 
≥5 years: 0.72 (0.53-0.99) 
228 
42 
Murtola 2007
145
 Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A No analysis - 
Khurana 2007 Cancer type not investigated N/A Cancer type not investigated N/A 
0-0.5 yrs: 2.32 (2.05-2.63) 
0.5-1.0 yrs: 0.75 (0.63-0.89) 
1.0-2.0 yrs: 0.70 (0.61-0.79) 
2.0-4.0 yrs: 0.49 (0.44-0.55) 
>4.0 yrs: 0.23 (0.20-0.26) 
446 
214 
416 
649 
269 
Cancer type not investigated N/A 
Vinogradova 2007
90
 Cancer type not investigated N/A 
1-12 months: 0.84 (0.71-1.00) 
13-24 months: 0.99 (0.80-1.22) 
>24 months: 0.99 (0.84-1.16) 
183 
122 
233 
Cancer type not investigated N/A Cancer type not investigated N/A 
Setoguchi 2006
146
 
<3 years: 0.66 (0.42-1.05) 
≥3 years: 1.28 (0.90-1.84) 
47 
156 
<3 years: 0.93 (0.57-1.51) 
≥3 years: 0.97 (0.65-1.46) 
74 
104 
<3 years: 1.18 (0.72-1.92) 
≥3 years: 1.02 (0.59-1.74) 
99 
80 
Cancer type not investigated N/A 
Friis 2004
147
 No analysis - No analysis - No analysis - No analysis - 
Graaf 2004
148
 No analysis - No analysis - No analysis - No analysis - 
Kaye 2004
128
 No analysis - No analysis - No analysis - No analysis - 
Beck 2003
149
 
1-90 days: 1.59 (1.14-2.20) 
91-180 days: 2.02 (1.42-2.89) 
181-365 days: 0.92 (0.57-1.49) 
1-2 years: 1.48 (1.06-2.07) 
2-3 years : 1.07 (0.68-1.69) 
3-4 years: 0.95 (0.55-1.65) 
≥4 years: 0.26 (0.12-0.55) 
38 
32 
17 
37 
19 
13 
7 
Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
Kaye 2002
129
 No analysis - Cancer type not investigated N/A Cancer type not investigated N/A Cancer type not investigated N/A 
Blais 2000
150
 No analysis - No analysis - No analysis - No analysis - 
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3.5 Discussion 
3.5.1 Overview 
A total of 30 relevant studies were identified for this review. Overall, most early 
studies (pre 2004) observed a null association between statin use and the risk of 
breast, colorectal, lung, and prostate cancer; but most lacked power to detect a 
true association. Importantly, recent and large observational studies reported 
conflicting findings, particularly for the risk of colorectal, lung, and prostate cancer 
among statin users. Among the 30 studies, there was variability in terms of applied 
design methods, adjustment for potential confounders, as well as range of differing 
populations in which the studies were undertaken.   
3.5.2 Meta-analysis 
The meta-analysis of 30 observational studies examining the risk of breast, 
colorectal, lung, and prostate cancer among patients prescribe statins support no 
evidence of an association. Studies examining colorectal, lung, and prostate cancer 
showed the most variability in relative risk estimates. In subgroup analyses, new 
users of statins compared to non-users showed marginal increased risks of breast 
and lung cancer. A protective effect of lung cancer was observed when comparing 
statin users to active drug comparator groups. Studies conducted among North 
American patients yielded a non-significant protective effect of prostate cancer 
among statin users compared to non-users. Although subgroup analyses showed 
significant pooled effects among studies implementing a new user design or an 
alternative drug comparator group, their effects may have been intertwined (4 new 
user design studies in which 3 incorporated a comparator drug group). In addition, 
studies incorporating comparison drug groups were underpowered due to the high 
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prevalence of statin use (other lipid lowering drugs and glaucoma medication 
drugs).   
3.5.3 Assessment of bias 
Among the 30 studies, several common biases were examined which could explain 
part of the variation in findings between observational studies examining the risk of 
cancer associated with statin use. The biases included immortal time, protopathic, 
prevalent user, healthy user, and time-window bias. Prevalence of the different 
biases varied between the 30 studies: 1/16 cohort studies may have potentially 
suffered from immortal time bias; 12/30 from protopathic bias; 26/30 from 
prevalent user bias; 10/30 from healthy user bias; and 1/14 cases-control studies 
from time-window bias. 
3.5.3.1 Immortal time bias 
Immortal time bias could have potentially affected findings reported by one cohort 
study. However, the impact of immortal time bias may have been minimal due to 
the conservative exposure definition (statin user: minimum of 2 statin 
prescriptions) implemented by Singh et al64. That being said, the study conducted 
by Singh et al. might have also been affected by protopathic bias which could have 
influenced the rate ratio upward or downward. In the former situation, this may 
have diluted or negated any effects of immortal time bias.  
3.5.3.2 Protopathic bias 
In general, most cancer types typically have a long latency period. Statin exposure 
shortly before diagnosis may have little effect on the development of cancer. In 
comparison to studies that did implement a lag period minimising protopathic bias, 
short term risk estimates from studies that did not implement varied in terms of 
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direction (2 reduced and 2 increased risk of cancer). Importantly, although studies 
examined the risk of cancer among short term statin users, a new user analysis was 
not implemented in any of the study designs, making it difficult to assess the 
relationship between statin duration and cancer risk and also potentially inducing 
prevalent user bias. 
There is no general consensus on how to define exposure optimally to firstly 
mitigate protopathic bias, and secondly to ensure a cohort of adherent statin 
users.158-161 However, there are several important issues that need to be considered 
before defining exposure status. Firstly, studies investigating more than one cancer 
type implemented minimum periods of exposure in a global fashion. Optimal lag-
periods may vary depending on the drug and cancer type under investigation.116, 130 
Secondly, time related selection bias must be kept in mind when decisions about 
periods of follow-up between treatment groups are made.69, 119 Lastly, the adoption 
of minimum periods of exposure may be more appropriate when implemented 
alongside a new user design, rather than implemented arbitrarily among prevalent 
users, where cohort entry is a time point unrelated to exposure. This allows for the 
duration of statin use to be investigated with greater precision. 
3.5.3.3 Prevalent user bias 
In relation to the previous subsection, new user designs were implemented by four 
studies; however, all studies utilised a prescription database which could have 
made it easier to implement a new user design.56, 64, 131, 132, 141, 146 All new user 
studies reported a null association between statin use and the risk of any of the 
cancer types of interest. The effect of utilising a new user design was examined by 
only one study.64 Singh et al.64 performed two sets of dose-response analyses on 
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colorectal cancer risk: with and without prevalent statin users. Interestingly, when 
comparing the two analyses the exclusion of prevalent users reduced the relative 
risk of colorectal cancer at low doses and drove the estimate upward at high doses.  
Higher relative risk estimates of cancer were observed from the two cohort studies 
that compared new statin users to non-users compared to cohort studies that 
utilised a prevalent statin cohort. This protective effect is consistent with prevalent 
user bias discussed by Ray et al.70 However, caution is needed in making this 
assertion due to competing biases and potential unmeasured confounding from the 
observational studies included in this review.   
The new user design has two practical benefits: it allows for the mitigation of 
prevalent user bias and depletion of susceptible patients; as well as accurate 
assessment of statin duration. However, the utilisation of an inception cohort with 
a comparable drug group may be problematic due to the high prevalence of statin 
use among elderly patients. For example, the study by Setoguchi et al.146 was 
underpowered, when considering a comparison drug group of new glaucoma 
medication users. In addition, statins are the primary drug of choice when treating 
hyperlipidaemia: the prevalence of other lipid lowering drugs such as bile acid-
binding resins, and fibrates have declined since statins were first licensed in the 
early 1990s. 
3.5.3.4 Healthy user bias 
It has been shown that compared with the general population, statin users have 
good adherence to medications. In addition, they may also receive more 
counselling regarding a healthy lifestyle. Both of these factors are predictors of 
good health which may lead to an increased detection or prevention of early 
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cancers.162 Furthermore, statin users may also be more likely to receive or be 
adherent to cancer screening,117 for example PSA testing, and therefore may have 
higher cancer incidence rates compared to the untested general population. These 
healthy user and detection biases can be mitigated by implementing a new user 
design and/or comparing statin users to a group with similar healthy characteristics. 
Comparison groups 
The majority of the reviewed studies compared statin users to non-statin users 
when assessing cancer risk; four studies compared statin users to other drug 
groups: antihypertensive drug groups; glaucoma medication users; and other non-
statin lipid lowering drugs. Farwell et al.132, 141 reported a reduced risk of prostate, 
and colorectal cancer among statin users compared to men prescribed 
antihypertensive medications. However, there is some evidence of an increased risk 
of cancer associated with antihypertensive drug use,157, 163 hence the selection of 
antihypertensive drug users as a comparator group may lead to a spurious reduced 
risk among statin users. Setoguchi et al.146 compared new statin users to new users 
of glaucoma medications. However, no significant effects of statin use associated 
with colorectal or breast cancer were observed when compared to glaucoma 
medication users. Importantly, there have been no previous reports of an 
association between glaucoma medications and cancer risk.  
Non-statin lipid-lowering drug groups were utilised by two studies.147, 150 Although 
non-statin lipid-lowering drug users are a relatively rare group due to the increasing 
number of patients prescribed statins in preference over non-statin drugs. 
Characteristics of statin and non-statin lipid lowering drugs may be similar in terms 
of healthy behaviour. Both studies found a significant reduction in risk of overall 
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cancer, however when individual cancers were examined non-significant reduced 
risks were observed.  
The utilisation of a non-statin group from the general population has been 
considered a limitation by some.123, 146 However, the utilisation of comparators 
from another drug-class has several disadvantages: (i) different co-morbidities from 
statin users may influence results; (ii) the comparator drug chosen may be 
associated with the disease of interest, and (iii) there may be a possible reduction in 
precision due to a smaller number of patients available in the comparator group. 
Adjustment for health utilisation services 
Several studies included in this review showed that statin users have a higher 
likelihood of PSA testing compared to non-statin users from the general 
population.139, 144, 145 This could explain the increased risk of prostate cancer found 
in four of the studies included in this review,67, 68, 130, 145 - none of which avoided 
potential detection bias by PSA testing. Conversely, there is evidence suggesting 
that statin use is associated with decreased PSA levels,139, 164 hence PSA testing may 
lead to missed cases of prostate cancer and a false reduced risk associated with 
statin use.165 All the studies in this review that observed a reduced risk of prostate 
cancer associated with any statin use also attempted to minimize detection bias by 
either study design or through a subset analysis. However, the rate of PSA testing 
has been shown to vary by country and healthcare system:166 in parts of the US, the 
rate of PSA testing among men is higher compared to that of the UK, where no 
recommendations for prostate cancer screening have been made. This would imply 
that the impact of detection bias via PSA testing may also differ from country to 
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country – and would possibly be less of a biasing factor in UK studies compared to 
studies conducted in the US. 
3.5.3.5 Time-window bias 
Based on reported methods, one of the 14 case-control studies included in this 
review was susceptible to time-window bias.27 Khurana et al.27 reported a 45% 
reduction of lung cancer risk associated with statin use compared to non-users. 
Controls were sampled independently of time from their last point of contact, 
leading to a higher proportion of exposed controls due to their longer treatment 
observation period. Suissa et al.35, 119 identified this potentially biased study and 
others that may have also been affected by time-window bias. The other 12 case-
control studies avoided time-window bias by either matching controls to case date 
of diagnosis or risk-set sampling. Notably, all 12 case-control studies comparing 
statin users to non-users reported overall higher relative risk estimates compared 
to the potentially biased study conducted by Khurana et al.,27 suggesting a 
consistent effect of time-window bias. 
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3.5.4 Updated review studies 
An update of the systematic review was conducted to examine the current findings 
from studies undertaken after the original systematic review. Overall, ten studies 
were identified from a re-run of the original literature search in July 2015 
(Appendix Table B, Table 9.2).  
Overall, 2 studies examined the effects of statin use on breast cancer risk,167, 168 5 
on colorectal cancer risk,168-172 2 on lung cancer risk,168, 173 and 4 on prostate cancer 
risk168, 174-176 – one study examined all four cancer types168 (Appendix C, Table 9.3). 
Both breast cancer studies observed a null association. For colorectal cancer, four 
studies observed a null association. In contrast, one study observed a reduced risk 
(HR=0.84; 95% CI; 0.76, 0.92) of colorectal cancer when comparing new statin users 
to new glaucoma medication users. Two studies reported no association of lung 
cancer risk associated with statin use compared to non-users. Two prostate cancer 
studies reported a reduced risk, while the remaining study reported an increased 
risk (OR=1.24; 95% CI; 1.10, 1.42). 
Some of the studies may have been potentially affected by at least one bias: 1/10 
cohort studies by immortal time bias; 8/10 by prevalent user bias; 5/10 by Healthy 
user bias; 1(uncertain)/10 case-control studies by time-window bias; and 6/9 from 
protopathic bias (Appendix B, Table 9.3). 
Only two studies examined duration of statin use associated with cancer risk, both 
for prostate cancer. Jesperson et al.174 reported null associations for 0-4 years of 
statin use, and a marginal reduction in risk for statin use between 5-9 years 
(OR=0.93; 95% CI; 0.88, 0.98). In contrast, Lustman et al.175 reported consistent 
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reduced risks of prostate cancer associated with short (0-12 months: HR=0.68; 95% 
CI; 0.60, 0.79) and long term statin use (5+ years: HR=0.22; 95% CI; 0.17, 0.26). 
Findings from the updated review studies were generally consistent with the 
original systematic review: (i) variation in reported relative risk estimates by cancer 
type; (ii) wide range of populations and design methods utilised; and (iii) the low 
prevalence of immortal and time-window bias and relatively high prevalence of 
protopahic, prevalent user, and healthy user bias.   
3.5.5 Future research 
There are a number of suggestions for future research.  Overall, only four studies 
examined the effects of statin use on cancer risk using a new user design, and two 
of the six studies conducted analysis relating to statin dose. Further research into 
the effects of new user designs in combination with dose-response analysis would 
be helpful in assessing prevalent user bias. Additionally, similar comparison groups 
relative to the exposure groups could also be identified, although this may be 
difficult due to the high prevalence of statin use among many populations. 
Furthermore, the assessment of optimal lag times among different cancer types 
could be addressed in more detail. In the majority of cases, lag times were based on 
the investigators’ subject knowledge and are not necessarily consistent between 
studies or transparently justified.  
3.6 Conclusion 
Overall, there was no strong evidence of an association between statin use and risk 
of breast, colorectal, lung, or prostate cancer from the reviewed observational 
studies. However, there were conflicting findings from some studies, which might 
have been affected by potential biases. Whether these findings were driven by 
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particular biases is difficult to ascertain due to the varying methodology applied, 
various adjustment for potential confounder, and differing populations from which 
these studies were undertaken. The impact of the potential biases considered in 
this review will be further examined in the context of the statin-cancer association, 
Chapter 6.  
3.7 Summary 
 A systematic review of statin use and the risk of breast, colorectal, lung, and 
prostate cancer among studies utilising routinely collected electronic patient 
records was conducted with an emphasis on methodological considerations. 
 30 studies were identified, 14 case-control and 16 cohort studies. Studies 
were conducted in a variety of populations and various routinely collected 
electronic health data sources. 
 All studies were assessed for potential biases including: immortal time, 
protopathic, prevalent use, healthy user, and time-window bias. 
 Overall, there were conflicting findings between studies, particularly for 
cancers of the colorectum, lung, and prostate. 
 Prevalence of immortal time and time window-bias was low. However, 
greater than a third of all studies were potentially affected by either 
protopathic, prevalent user, or healthy user bias.  
 The impact of biases examined in this review was difficult to assess due to 
competing biases, different populations, and varying methodology between 
studies. However, there was some evidence of healthy user, prevalent user 
and time-window bias influencing overall findings.
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4 Data Sources and Methods 
4.1 Introduction 
This chapter describes the main data sources utilised and methods applied to both 
main analysis chapters (Chapters 5 and 6) of this thesis. 
4.2 Data Sources 
4.2.1 The Clinical Practice Research Datalink (CPRD) 
4.2.1.1 Overview 
The Clinical Practice Research Datalink is a primary care database containing 
anonymised patient records from computer systems used by general practitioners 
in the UK. The CPRD began data collection from general practices in 1987. 
Currently, the CPRD hold medical records for about 8% of the UK population with 
around 12 million patient records.177, 178 
A typical dataset provided by the CPRD (CPRD GOLD, GP OnLine Database) contains 
patient information such as date of birth, sex, and details of registration with the 
practice. In addition, longitudinal data on clinically relevant lifestyle factors such as 
body mass index (BMI), smoking status, and alcohol status are also recorded. 
Detailed information on prescriptions, clinical events, specialist referrals, and 
hospital admissions are also recorded. General practitioners enter all the medical 
information through a computerised system which codes clinical events using a 
Read coding system.177 
Read codes are the standard hierarchical classification system used to record 
medical information in UK primary care settings. They were specifically developed 
for use in primary care by Dr James Read during the 1980s. There are approximately 
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250,000 Read codes used to record patient diagnoses, symptoms, and processes of 
care (e.g. referrals to secondary care).179 Currently, the CPRD uses the 5-byte Read 
(or Read version 2) dictionary to code medical events; codes are continually added 
to the dictionary over time, though never removed. Each Read code is linked to a 
specific phrase of text, which indicates a single diagnosis or symptom. Diagnostic 
codes start with a letter whereas symptoms, signs, investigations, procedures and 
administration tasks start with a number. Previously, the OXford Management 
Information Systems (OXMIS) coding system was used by the CPRD to code all 
clinical data. All practices transferred to the Read dictionary at varying dates in the 
1990s.180 Once data have been collected from the general practices, the CPRD 
perform a series of assessments at both practice and patient level to ensure a high 
quality standard of data.177 
4.2.1.2 Data access and extraction 
Studies that plan to access data from the CPRD require approval from the 
Independent Scientific Advisory Committee for MHRA database research (ISAC) 
(Appendix C.1). 
The LSHTM hold flat data files (CPRD GOLD datasets) provided by the CPRD 
(updated every 6 months). The flat files were processed and formatted (Stata 
format) by the Electronic Health Records (EHR) group at LSHTM; bespoke data 
extraction from the flat files is available on ISAC approval. All CPRD GOLD data used 
for purposes of this thesis were extracted from the July 2012 version of the CPRD. 
In order to address Aims 1-4 of this thesis (Chapter 1, Section 1.7), several samples 
of the CPRD database were used to conduct analyses, detailed methods are 
described in each chapter (Chapter 5, Section 5.3 and Chapter 6, Section 6.3). Case 
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identification methods applicable to Chapters 5 and 6 are described in Sections 
4.2.2-4.2.4. Further case identification methods specific to each main analysis are 
described in each respective chapter.   
4.2.1.3 Included events 
Four specific cancer types were elected as primary events for this study: breast, 
colorectal, lung, and prostate. These were selected because of their importance to 
pharmacoepidemiological research and because they among the most common 
cancer types diagnosed in men and women in the UK.181  
4.2.2 Cancer diagnostic groups 
A cancer diagnosis code list used in past studies30, 97, 102 to identify cancer outcomes 
was modified for the purposes of this study (Appendix C, Table 10.1-10.5). Cancer 
diagnosis codes were classified into six groups: (1) malignant neoplasms; (2) in-situ 
cancers; (3) history of cancer; (4) borderline (uncertain whether malignant or 
benign); (5) suspected (suspected cancer, abnormal screening test, or fast track 
referral); and (6) general malignant neoplasms (site unspecified). In addition, Read 
codes were mapped to equivalent International Statistical Classification of Diseases 
and Related Health Problems, 10th Revision (ICD-10) diagnosis codes in order to be 
consistent with case definitions used by the ONS. All codes were reviewed and 
classified by KB, MR, and LS; any disagreements were reviewed again until resolved. 
Three diagnostic groups were developed; Figure 4.1 depicts the algorithm used to 
classify patients into certain groups. A hierarchical approach was used. First, 
patients with a recorded malignant diagnosis were grouped into the “definite” 
diagnostic group. Second, further searches of patient records grouped patients into 
a “probable” diagnostic group if they had a borderline diagnosis code. Lastly, 
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patients were grouped into a “possible” group if they had a suspected or general 
diagnosis code recorded within their computerised records. 
Evidence of diagnosis such as cancer related surgery, chemotherapy, visits to an 
oncologist assisted in confirming potential cases that did not have a recorded 
malignant diagnosis code within their patient records. Evidence of diagnosis used as 
supporting evidence of diagnosis is listed in Appendix C, Table 10.6. 
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Figure 4.1: CPRD diagnostic algorithm 
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4.2.3 Cancer case definitions 
Two case definitions were implemented (Table 4.1):  
(i) (i) A “standard” definition included patients from the definite diagnostic 
group. At least one definite diagnosis of a cancer of interest was required;  
(ii) (ii) A “broad” definition included patients from all three diagnostic groups 
(i.e. definite, probable, and possible). 
These definitions were developed for the following reasons: (i) they reflect how 
researchers typically defined cancer in UK primary care databases (Chapter 2); (ii) 
inclusion of cases with non-specific diagnoses, such as borderline or suspected 
diagnoses, may have been misclassified in the “standard” definition as non-cases, 
which may influence primary care estimated incidence rates (Chapter 2); (iii) earlier 
non-specific diagnoses may be detected differentially between patients prescribed 
a preventative medication compared to non-users from the general population.
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Table 4.1: Case definitions 
Case definition Diagnostic group* Description 
Standard Definite 
≥1 site-specific malignant neoplasm diagnosis code corresponding to ICD-10: C18-
C20 (colorectum); C34 (lung); C50 (breast); C61( prostate) 
   
Broad: Definite + 
probable + 
possible 
Definite 
≥1 malignant neoplasm diagnosis code corresponding to ICD-10: C18-C20 
(colorectum); C34 (lung); C50 (breast); C61( prostate) 
Probable 
≥1 borderline diagnosis code with supportive evidence of diagnosis (site known) 
during UTS follow-up 
Possible  
≥1 Malignant neoplasm diagnosis code (site unspecified) with supportive 
evidence of diagnosis (site known) during UTS follow-up 
 
≥1 suspected diagnosis code and further evidence of diagnosis 
Detailed algorithm depicting the classification of “definite”, “probable”, and “possible” diagnostic groups is given in Figure 4.1 
ICD: International Classification of Diseases; UTS: Up-to-standard 
108 
 
4.2.4 Externally linked data sources 
Two external data sources were linked to the CPRD: cancer registry and ONS 
mortality. Overview of the individual data sources and linkage coverage are 
described in the following sections. 
4.2.4.1 National Cancer Data Repository (NCDR) 
In England, there are 8 regional population based cancer registries; English cancer 
registrations are collated by the NCDR and are individually linked to primary care 
records for patients in the CPRD linkage scheme.178, 182 Since 1993, it has been 
mandatory for the NHS, including trusts, to provide key items on demographics and 
diagnosis to regional cancer registries. Clinical information on new cancer 
registrations typically include date of diagnosis, site, death certificate indicator 
(indicating if a diagnosis was confirmed by death certificate only), treatments, stage 
and grade of diagnosis, and diagnosis by a screening process.182  
Cancer registrations held by the 8 regional registries are received from a range of 
NHS sources (e.g. GPs, hospitals, coroners, radiotherapy) and are centrally stored 
by the ONS cancer registration computer system. Cases with either duplicated 
records or true multiple primary records are linked together by a probability 
matching process and are queried back to the regional registries until resolved 
(Figure 4.2).182  
Once all data have been received by the ONS and checks have been made, the ONS 
compiles detailed statistical tables on mortality, survival, prevalence, and incidence 
rates of different cancer types by age, sex, and geographical location.182 The ICD 
coding dictionary is currently adopted by the ONS to code all cancer registrations. 
The ICD classifies diseases into broad groups known as chapters, and its worldwide 
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use enables numbers of deaths from different causes to be compared both 
between countries and over time. The World Health Organisation (WHO) has co-
ordinated these revisions for many years. 
Figure 4.2: Flow diagram illustrating sources of cancer registrations [reproduced 
from Cancer Statistics registrations Series MB1182] 
 
 
 
4.2.5 ONS Mortality (Death Registry) 
In the UK, the ONS collects information on cause of death from civil registration 
records. Since 1837, it has been mandatory for all deaths in the UK to be 
registered.183 The legal requirement to certify and register all deaths occurring in 
England and Wales means that death registrations provide the most complete data 
source for mortality statistics. 
Currently, the ONS holds two databases on death related data: (i) a registration 
database which contains textual information derived from the death certificate; 
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and (ii) a statistical database which contains coded details on each death.183 Once 
on the ONS database, data are passed through a series of automated validation 
processes which highlight any inconsistencies. Validation checks include consistency 
between dates of birth, death and registration, as well as consistency between date 
of death and employment status. Inconsistencies are checked through regular 
contact with the identified registrars to resolve any issues identified.183 Cause of 
death is coded using the ICD-9/10. For the majority of deaths (around 80%), ONS 
codes the underlying cause of death using automated cause coding software. 
Remaining deaths are processed manually by experienced coders, mainly from 
deaths that have received a coroner’s inquest.183 A typical death registry dataset 
includes date of death, underlying cause of death, and other contributing diseases 
or conditions leading to the underlying cause of death.   
4.2.6 Linkage to the CPRD: cancer and death registry 
Patients in the CPRD were linked to the NCDR and death registry (ONS Mortality) 
data. The linkage was carried out in December 2014 by a trusted third party (The 
Health and Social Care Information Centre, HSCIC), using a deterministic match 
between NHS number, date of birth, and sex.184 Currently, only a subset of English 
practices are part of the linkage scheme, some individual patients are excluded due 
to opting out or lack of a valid NHS identifier. NCDR and death registry linkage cover 
approximately 70% of the contributing CPRD English practices, or about 55% of 
contributing CPRD UK practices. 
All analyses that incorporated linked data were restricted to patients who were 
eligible and consented to participate in the linkage scheme. Set 9 of the CPRD 
linked dataset was used, which covered the following time periods: Cancer registry, 
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from January 1, 1990 to December 31, 2010; and ONS death registrations, from 
January 1, 1998 to January 10, 2012.  
Deaths registered after January 1, 2001 were coded using ICD-10. Prior to this date, 
ICD-9 had been in use across the UK since 1979. All ICD-9 codes were mapped to 
ICD-10 to accommodate the overall coding used in this thesis. 
When patient data was linked by the HSCIC, several variables were used to judge 
the certainty of patient-level linkage, such as NHS number, date of birth, and sex. 
Each CPRD patient linked to ONS mortality data was given a “match rank” score 
based on how many variables were used to link patient records.185 For analyses 
presented in this thesis (Chapter 5 and 6), if multiple death dates were observed 
for a patient, records with the highest match rank were retained. When a patient 
had >1 record with the same “match rank” score, the earliest date of death record 
was used for all analyses. 
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5 Validity of cancer diagnosis in the CPRD: comparison of 
observed and expected cancer incidence rates and 
concordance with national cancer registrations 
5.1 Introduction 
This chapter describes a series of analyses comparing CPRD estimated cancer 
incidence rates to UK ONS reported rates. In addition, this chapter also measures 
the concordance of recorded cancer diagnoses between the CPRD (primary care), 
NCDR (cancer registry), and ONS mortality (death registry).  
5.2 Objectives 
For the four most common cancers, breast, colorectal, lung, and prostate cancer, 
this chapter aimed to: 
1.  Compare incidence rates calculated from primary care data (CPRD) with 
published national incidence rates based on cancer registrations (ONS).  
2. Measure concordance of recorded diagnoses between the CPRD, NCDR, and 
ONS mortality. 
3. Assess the impact of incorporating cancer registry data linked to the CPRD 
when estimating incidence rates. 
5.3 Methods 
5.3.1 Patients 
For computational reasons, a random sample of 2 million eligible patients was 
selected from the CPRD. Eligible patients had to meet the following criteria: 
acceptable record flag (e.g. consistent recording of age, sex, registration details and 
event recording);177 subjects with acceptable registration status (e.g. permanently 
registered with a practice; no out of sequence year of birth or registration date; no 
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missing or invalid transfer out date; valid and non-missing year of birth; no missing 
sex information). In addition, subjects were excluded if they had a diagnosis or 
history of the cancer of interest prior to the start of follow-up.   
5.3.2 Outcomes 
Four specific cancers were elected as outcomes for this study: breast, colorectal, 
lung, and prostate. These were selected because of their importance to 
pharmacoepidemiological research and for being the most common cancers 
diagnosed among men and women in the UK.186 
5.3.3 Follow-up time 
The start of follow-up for each subject was the latest of the following dates: January 
1, 2000, or 6 months after UTS registration with a practice. The end of follow-up 
was defined as the earliest of the following: December 31, 2010 (end of study 
period), a diagnosis of the cancer of interest; the date that the patient transferred 
out of the practice; date of death, or the last date for data collection by the 
practice. Follow-up was limited to the end of 2010 because published ONS 
incidence rates were only available up to 2010 at the time of conducting this study.  
5.3.4 CPRD diagnostic groups and case definitions 
Diagnostic groups and case definitions for the four cancer types examined in this 
thesis are described in Chapter 4, Section 4.2.2 and 4.2.3. 
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5.3.5 Concordance of recorded cancer diagnoses between primary care, 
linked cancer registry, and death registry data 
Details of the linkage are described in Chapter 4, Section 4.2.4. Cancer diagnoses in 
the NCDR and ONS death data were coded using ICD-10. Read codes were mapped 
to ICD-10 to enable consistency of recorded diagnoses between the CPRD and 
linked data sources (Chapter 4, Section 4.2.2). If a patient had an incident diagnosis 
of breast (C50), colorectal (C18, C19, C20), lung (C34), or prostate (C61) cancer in 
the CPRD and also had a corresponding diagnosis (same ICD-10 code) in the NCDR, 
then this would be classified as a concordant diagnosis.  
However, if a diagnosis of either of the cancers of interest was recorded in the 
NCDR and not in the CPRD, then a number of pre-determined factors were 
investigated to shed light on the discrepancy. In particular, the following were 
described: (i) any cancer diagnoses in the CPRD (e.g. different or non-specific cancer 
types), (ii) related cancer diagnoses in the CPRD (same site: in situ, borderline, 
suspected); (iii) NCDR age at diagnosis; (iv) time from NCDR diagnosis to CPRD 
defined end date (v) death recorded in the CPRD.   
In the other direction, if a diagnosis of any of the cancer types was recorded in the 
CPRD and not in the NCDR, then information on any malignant diagnoses in the 
NCDR was sought. Pre-determined factors included: (i) frequency of recorded 
diagnosis in the CPRD, (ii) time from CPRD recorded diagnosis to death, (iii) age at 
CPRD diagnosis, and (iv) time from registration to CPRD diagnosis (to assess 
inclusion of prevalent cases).  
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5.3.6 Linked ONS death certificates and cancer registry incidence rates 
Three combinations of linkages were considered when calculating incidence rates: 
(i) CPRD and ONS death registrations; (ii) CPRD and cancer registry data; and (iii) 
CPRD, ONS death registrations and cancer registry. For each of the combinations, 
two estimates were calculated: (1) incidence rates among the linkage population, 
but restricted to CPRD data only, and (2) supplemented rates from (1) incorporating 
additional cases from the respective linked data source (NCDR and/or ONS 
mortality).  
5.3.7 Statistical analysis 
5.3.7.1 Denominator 
Individuals were eligible to contribute to the denominator population if their 
records were UTS and they had been followed on the database for ≥6 months 
before the beginning of the year of interest. For each age and sex category, the 
denominator person-time was estimated by summing the number of days each 
eligible individual contributed to each category, by calendar year and dividing this 
sum by 365.25. 
5.3.7.2 Incidence rate estimates 
CPRD incidence rates initially calculated using primary care data only, were 
compared to reported UK ONS rates.182 For each cancer type, crude age- and sex-
specific incidence rates were estimated for each year over the study period with 
corresponding 95% confidence intervals according to a Poisson distribution. Age 
was categorised into 5-year age groups through to 80 years of age, and then a 
single age-group for 85 years and older.  
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5.3.7.4 Age-standardised incidence rate estimates 
Directly age-standardised incidence rates (ASIR) were estimated using the European 
Standard Population182 given by:  
ASIR = {∑AIRkPk}/∑Pk,       K= 0, 1-4, 5-9, ..., 80-84, and 85 and over 
AIRk = observed incidence rate in age group k 
Pk = European standard population in age group k 
Corresponding 95% confidence intervals were calculated using the following 
formula: 
ASIR ± ASIR/( √∑ nk), where nk is the number of events observed in sex/age group k 
5.3.7.5 Comparisons of incidence rates 
Several comparisons of incidence rates were made: first, directly standardised CPRD 
age-standardised incidence rates based on the European Standard population (pre-
2013) were caglculated (2000-2010) and compared to directly standardised rates 
published by the ONS.182 Overall ONS rates (2000-2010) were not made available to 
the public. Therefore, a static population over the whole study period (2000-2010) 
was assumed; derived ONS incidence rates were estimated for each age category by 
averaging denominator follow-up time. Second, crude age and sex specific rates 
were compared from the CPRD were compared to reported crude ONS rates. Last, 
estimated age-standardised incidence rates that incorporated linked data from the 
NCDR and ONS death registry to the CPRD were compared to national rates 
provided by the ONS.  
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Table 5.1: Distribution of age (at cohort entry) and sex for the random sample of 2 
million patients from the CPRD  
 Male Female 
Age N % N % 
0-4 144 426 (14.8) 136 103 (13.3) 
5-9 56 725 (5.8) 52 459 (5.1) 
10-14 49 768 (5.1) 44 929 (4.4) 
15-19 49 408 (5.1) 51 797 (5.1) 
20-24 72 664 (7.4) 94 079 (9.2) 
25-29 88 871 (9.1) 101 867 (10.0) 
30-34 91 902 (9.4) 91 202 (8.9) 
35-39 81 927 (8.4) 75 800 (7.4) 
40-44 69 408 (7.1) 63 199 (6.2) 
45-49 58 596 (6.0) 54 594 (5.3) 
50-54 51 327 (5.2) 50 170 (4.9) 
55-59 43 027 (4.4) 43 308 (4.2) 
60-64 36 116 (3.7) 38 547 (3.8) 
65-69 29 205 (3.0) 33 005 (3.2) 
70-74 22 113 (2.3) 28 212 (2.8) 
75-79 15 882 (1.6) 24 579 (2.4) 
80-84 9 268 (0.9) 18 175 (1.8) 
85+ 7 047 (0.7) 20 295 (2.0) 
Total 977 680 (100.0) 1 022 320 (100.0) 
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Figure 5.1: Flow diagram of cancer cohorts - inclusion and exclusion 
 
*Sampled from a pool of acceptable patients with at least 6 months up-to-standard (UTS) during the study period (2000-2010)
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previous diagnosis of lung 
cancer EXCLUDED
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5.4 Results 
5.4.1 Cohort 
The initial study population consisted of 2 million eligible patients (1,022,320 
female and 977,680 male) randomly sampled from all eligible CPRD patients (July 
2012 version). Table 5.1 shows the age (at cohort entry) and sex distribution of the 
2 million randomly sampled patients. In each 5-year age category, patients were 
similarly distributed by gender. A significantly larger proportion of patients aged 0-4 
years (14.8% male, and 13.3% female), relative to other ages, entered the cohort 
(latest of 6 months UTS or January 1, 2000). 
Four cohorts were formed, one for each individual outcome studied (Figure 5.1). Of 
the 2 million patients, 9,072 patients were excluded due to a previous diagnosis of 
breast cancer; 3,339 due to a previous diagnosis of colorectal cancer; 885 due to a 
previous diagnosis of lung cancer; and 2,992 due to a previous diagnosis of prostate 
cancer.  
5.4.2 Potential cases and evidence of diagnosis 
Figure 5.2 shows the number of potential cases identified based on the certainty of 
diagnosis and evidence of diagnosis found in their GP records. For all cancer types, 
the majority of potential cases were identified using definite codes: 8053/9942 
(81%) breast cancer; 5,415/7,103 (76%) colorectal cancer; 5,321/7,180 (74%) lung 
cancer; and 6,154/7,614 (81%) prostate cancer. Potential cases from “probable” 
and “possible” diagnostic groups required evidence of diagnosis to confirm case 
status based on the diagnostic algorithm described in Chapter 4; Figure 4.1. The 
exact forms of evidence of diagnosis varied by cancer type, surgery was most 
prominent among definite breast and colorectal cancer cases 54.6% and 50.3%, 
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respectively. In contrast, hormonal therapy (46.9%) was more common among 
prostate cancer cases, while non-surgical evidence (43.2%) such as oncology clinic 
visits was highest for lung cancer (Figure 5.2). 
Although cases from both “probable” and “possible” diagnostic groups represented 
about a quarter of all potential cases (proportion range: 19-24%), overall 
proportions with evidence of diagnosis (within a 1-year window) to confirm case 
status was low: breast cancer (42%); colorectal cancer (9%); lung cancer (13%); and 
prostate cancer (31%) (Figure 5.2).  
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Figure 5.2: Number of potential cases by diagnostic group and corresponding proportion of evidence of diagnosis 
(a) Breast Cancer (b) Colorectal Cancer 
  
(c) Lung Cancer (d) Prostate Cancer 
  
*Diagnostic groups - Definite: patients with a recorded malignant diagnosis; Probable: patients with a borderline diagnosis code and evidence of 
diagnosis; Possible: patients with a recorded suspected or general diagnosis code and evidence of diagnosis (Figure 4.1, Chapter 4) 
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Table 5.2: Comparison of CPRD age-standardised incidence rates (2000-2010) compared to published ONS age-standardised rates, by 
cancer type and case definition 
 
CPRD estimated age-standardised incidence rates (ASIR) 
 ONS estimated 
incidence ratesc 
Case definition 
Number of 
cases 
Patient-years 
ASIR per 
100 000 PY 
95% CI 
 ASIR per 
100 000 PY 
       
Breast (C50) Standard definition a 8,053 5,744,585 111.7 110.5, 113.0  122.9 
  Broad case definition b 8,459 5,742,335 119.1 117.8, 120.4   
  
Colorectal (C18, C19, C20) Standard 
definition a     
 
 
Male 3,022 5,712,070 42.9 42.1, 43.6  56.4 
Female 2,393 5,814,819 27.8 27.3, 28.4  35.7 
Broad case definition b       
Male 3,031 5,711,739 43.1 42.3, 43.8   
Female 2,400 5,814,459 28.5 27.9, 29.0   
       
Lung (C34) Standard definition a       
Male 3,010 5,724,253 39.6 38.9, 40.3  61.1 
Female 2,311 5,826,312 24.4 23.9, 24.9  36.4 
Broad case definition b       
Male 3,091 5,724,093 41.9 41.1, 42.6   
Female 2,362 5,826,182 26.7 26.1, 27.2   
       
Prostate (C61) Standard definition a 6,154 5,694,732 84.7 83.6, 85.8  99.7 
Broad case definition b 6,729 5,692,703 86.2 85.1, 87.3   
a Standard case definition: includes “definite” cases with a Read code indicating a malignant neoplasm of the cancer of interest 
b Broad case definition: includes cases from all diagnostic groups – “definite”, “probable”, and “possible” (Chapter 4, Section 4.2.2) 
c Office for National Statistics (ONS)
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5.4.3 Comparison of incidence rates using CPRD-only case definitions vs 
ONS published rates 
5.4.3.1 Age-standardised incidence rates  
Table 5.2 shows CPRD age-standardised cancer incidence rates compared to ONS 
reported rates between 2000-2010. Lower CPRD age-standardised incidence rates 
(standard case definition) were observed for each of the four cancers under 
investigation in comparison to ONS reported rates: breast cancer, 111.7 compared 
with 122.9 per 100k PY (9.1% difference); colorectal cancer, 42.9 compared with 
56.4 per 100k PY for men (23.9% difference), and 27.8 compared with 35.7 per 100k 
for women (22.1% difference); lung cancer, 39.6 compared with 61.1 per 100k PY 
for men (35.2% difference), and 24.4 compared with 36.4 per 100k PY for women 
(33.0% difference); prostate cancer, 84.7 compared with 99.7 per 100k PY (15.0% 
difference). In addition, upper limits of all CPRD age-standardised incidence rate 
confidence intervals were also lower compared to ONS reported rates. 
5.4.3.2 Case definitions 
Comparison of the “broad” case definition to that of the “standard” definition 
resulted in a marginal increase in CPRD incidence rates for all cancer types under 
study (Table 5.2), but yielded mixed results when compared to ONS reported age-
standardised rates. Percentage increase for age-standardised incidence rates from 
standard to broad case definition were slightly higher for breast (6.6%) and lung 
cancer (Female: 9.4%) were calculated. In contrast, “broad” case definitions yielded 
slightly lower percentage increase in incidence rates for colorectal (Male: 0.4%; 
Female: 2.5%) and lung (Male: 5.8%), and prostate cancer (1.7%). All broad case 
definition age-standardised incidence rates remained lower compared to ONS 
reported rates.   
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Figure 5.3: Comparison of CPRD and ONS age-standardised incidence rates by calendar year 
 
(a) Breast Cancer (c) Colorectal Cancer (Female) (e) Lung Cancer (Female) 
   
(b) Prostate Cancer (d) Colorectal Cancer (Male) (f) Lung Cancer (Male) 
   
CPRD: Clinical Practice Research Datalink; CI: Confidence Interval; ASIR: Age-Standardised Incidence Rate; ONS: UK Office for National Statistics 
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Figure 5.4: Comparison of primary care and ONS reported crude age-specific incidence rates (over the whole study period) by age at diagnosis 
 
(a) Breast Cancer (c) Colorectal Cancer (Female) (e) Lung Cancer (Female) 
   
(b) Prostate Cancer (d) Colorectal Cancer (Male) (f) Lung Cancer (Male) 
   
CPRD: Clinical Practice Research Datalink; CI: Confidence Interval; IR: Crude Incidence Rate; ONS: UK Office for National Statistics 
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5.4.3.3 Comparison of CPRD and ONS age-standardised incidence rates 
over time 
Figure 5.3 shows a comparison of CPRD estimated age-standardised incidence rates 
for breast, prostate, colorectal, and lung cancer across all ages compared to ONS 
reported age-standardised incidence rates for each year during the study period 
(2000-2010). Levels of disparity between CPRD and ONS rates varied by cancer type 
over time. Differences were particularly pronounced during earlier years of the 
study period. CPRD and ONS reported age-standardised incidence rates for breast 
and prostate cancer converged post-2002 and 2003, respectively. For women, 
colorectal cancer incidence rates converged from 2005 onwards, while a constant 
difference remained throughout the study period for colorectal cancer in men. This 
disparity was particularly prominent for lung cancer among both men and women - 
confidence intervals of estimated rates did not crossover with ONS reported rates 
over the entire study period.    
5.4.3.4 Comparison of CPRD and ONS incidence rates by age at diagnosis 
CPRD crude cancer incidence rates stratified by age were estimated over the study 
period (Figure 5.4). Differences between the CPRD and ONS were found for all 
cancers as age increased, however, the magnitude of disparity varied by cancer 
type. Breast cancer incidence rates estimated from the CPRD were similar to ONS 
reported rates across ages <80 years, although a slight disparity was observed for 
ages >80 years. Colorectal and lung cancer displayed larger differences compared to 
breast and prostate cancer, particularly for patients ≥70 years of age. CPRD 
prostate cancer incidence rates were lower for men aged 60-74 years, but were 
relatively similar to those reported by the ONS for men aged 80+ years.
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Figure 5.5: Flow diagram of eligible CPRD (primary care) patients linked to the cancer registry (NCDR) and death registry (ONS mortality) 
 
*Sampled from a pool of acceptable patients with at least 6 months UTS during the study period (2000-2010)
UK Office for National Statistics (ONS)
National Cancer Data Repository (NCDR)
2 Million Randomly Sampled Patients*
631 Practices 
(977,680 Men vs 1,022,320 Women)
1,206,070 patients ONS 
mortality linked
353 practices
1,247,849 NCDR linked
363 practices
1,206,006 ONS mortality & 
NCDR linked
353 practices
(a) ONS mortality
 linkage
(c) NCDR linkage(b) ONS mortality
 & NCDR linkage
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5.4.4 CPRD linkage to the NCDR and ONS mortality 
Of the 2 million CPRD patients, 1,247,849 were eligible for linkage to the cancer 
registry, 1,206,070 were eligible for linkage to the ONS death registration, and 
1,206,006 patients were eligible for linkage in both data sources (Figure 5.5). 
5.4.4.1 Concordance between CPRD and NCDR 
In total, 5,562, 4,337, 4,838, and 4,717 cases of breast, colorectal, lung, and 
prostate cancer were identified from all data sources: linkage of the CPRD to the 
cancer registry and ONS mortality data respectively (Figure 5.6). PPVs of CPRD 
recorded diagnoses against the NCDR was high: breast (89%), colorectal (90%), lung 
(86%), prostate (88%). In the other direction, sensitivity of CPRD for capturing NCDR 
recorded diagnosis was lower: breast (89%), colorectal (73%), lung (67%), prostate 
(81%). Notably, additional linkage to the death registry identified a relatively small 
number of additional cases for most cancer types not identified in the cancer 
registry; however, 321 (7%) lung cancer cases were identified in ONS mortality 
alone. Overall, a low number of patients from the death registry alone were 
identified, with percentages ranging from 0.4% for prostate cancer to 6.6% for lung 
cancer. 
Cases identified in the cancer registry or death registry but not in the CPRD also 
varied by cancer type (Figure 5.6). For colorectal and lung cancer, 1104/3233 (34%) 
and 1532/3155 (49%) additional cases were identified in the NCDR and ONS 
mortality data respectively, while lower proportions were observed for breast 
599/4963 (13%) and prostate cancer 827/3890 (21%).  
Greater than half of the cases that had a recorded diagnosis in the cancer registry 
alone had a cancer related diagnosis code in the CPRD (Table 5.3). Most of the 
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cases identified in the NCDR alone were elderly patients, median age at diagnosis 
ranged from 63-74 years across the four cancer types. Of note, 880 (31%) “NCDR 
only” lung cancer cases had a recorded death within 90 days of diagnosis, this 
proportion increased to 40% when extending the time-window to 1 year. 
Furthermore, timing of lung cancer diagnosis was near to the date of CPRD 
recorded end of follow-up for the majority of lung cancer cases identified in the 
NCDR alone: median 84 days, IQR (26, 836 days) (Table 5.3).  For all cancer types, 
few CPRD cases with no matching diagnosis in the NCDR had a cancer diagnosis 
record of any type in the NCDR (Table 5.4). For colorectal (13%) and lung cancer 
(29%) a substantial proportion of cases died within 1 year of CPRD diagnosis date, 
this proportion was lower for breast (3%) and prostate cancer (6%). 
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Figure 5.6: Agreement of recorded diagnosis between the CPRD, NCDR, and ONS 
mortality by cancer type 
  
  
CPRD: Clinical Practice Research Datalink 
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Table 5.3: Cases identified in the cancer registry alone 
  Breast   Colorectal   Lung   Prostate 
  N (%)   N (%)   N (%)   N (%) 
NCDR Only 417     621     301     603   
Any cancer related diagnosis code in CPRD 254 (60.9)   367 (59.1)   184 (61.1)   405 (67.2) 
  Cancer related diagnosis (same site) 138 (33.1)   71 (11.4)   35 (11.6)   200 (33.2) 
     In situ 121 (29.0)   67 (10.8)   8 (2.7)   178 (29.5) 
     Borderline 1 (0.2)   2 (0.3)   - -   - - 
     Suspected 16 (3.8)   2 (0.3)   27 (9.0)   22 (3.6) 
  Non-specific or Other (not cancer of interest)  
  diagnosis in CPRD 
116 (27.8)   296 (47.7)   149 (49.5)   205 (34.0) 
     Malignant related code in the CPRD 0 (0.0)   22 (3.5)   11 (3.7)   28 (4.6) 
Non-specific (No site - C80) 55 (13.2)   153 (24.6)   76 (25.2)   104 (17.2) 
Other 61 (14.6)   121 (19.5)   62 (20.6)   73 (12.1) 
No record of a cancer related code in the 
CPRD 
163 (39.1)   254 (60.9)   117 (28.1)   198 (47.5) 
                        
                        
Death in CPRD                        
  within 90 days of NCDR diagnosis 13 (3.1)   103 (16.6)   93 (30.9)   27 (4.5) 
  within 1 year of NCDR diagnosis 22 (5.3)   139 (22.4)   121 (40.2)   53 (8.8) 
                        
Time (days) from NCDR diagnosis to end of 
follow-up: median (IQR): 
1211 (533, 2477)   913 (112, 2124)   84 (26, 836)   1231 
(503, 
2371) 
                        
Age at NCDR diagnosis: median (IQR) 63 (54, 76)   74 (64, 82)   73 (64, 80)   71 (64, 78) 
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Table 5.4: Cases identified in the CPRD alone (potential CPRD false positive cases) 
  Breast   Colorectal   Lung   Prostate 
  N (%)   N (%)   N (%)   N (%) 
CPRD Only 532 
 
  273 
 
  345 
 
  456 
 
>1 code for same diagnosis within the 
CPRD 
112 (21.05)   46 (16.85)   39 (11.30)   96 (21.05) 
  2-4 codes 106 (19.92)   45 (16.48)   39 (11.30)   84 (18.42) 
  5-9 codes 6 (1.13)   1 (0.37)   0 (0.00)   10 (2.19) 
  >=10 codes 0 (0.00)   0 (0.00)   0 (0.00)   2 (0.44) 
  
  
  
  
  
  
  
  
Non-malignant* related code>=1 50 (9.40)   10 (3.66)   24 (6.96)   65 (14.25) 
  2-4 codes 7 (1.32)   1 (0.37)   5 (1.45)   11 (2.41) 
  5+ codes 0 (0.00)   0 (0.00)   0 (0.00)   1 (0.22) 
  
  
  
  
  
  
  
  
Any other cancer related diagnosis in 
CPRD 
38 (7.14)   59 (11.09)   94 (17.67)   61 (11.47) 
  
  
  
  
  
  
  
  
Death in CPRD  
  
  
  
  
  
  
  
  within 90 days of NCDR diagnosis 9 (1.69)   39 (7.33)   80 (15.04)   11 (2.07) 
  within 1 year of NCDR diagnosis 17 (3.20)   69 (12.97)   152 (28.57)   34 (6.39) 
  
  
  
  
  
  
  
  
Time (days) from NCDR diagnosis to 
start of follow-up, median (IQR) 
2680 1318-3962 3078 1740-4403 3018 1668-4515 2872 1546-4345 
  
  
  
  
  
  
  
  
Age at CPRD diagnosis, median (IQR) 62 (53, 72)   71 (61, 80)   72 (62, 79)   76 (68, 83) 
  
  
  
  
  
  
  
  
Year of diagnosis 2005 2003-2008 2006 2003-2008 2006 2003-2008 2006 2003-2008 
* Non-malignant: in-situ, borderline, or suspected diagnosis code 
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5.4.4.2 Overall Incidence rates – linkage to cancer registry and ONS 
mortality data 
Supplementing CPRD age-standardised incidence rates by the addition of patient 
level-data from the NCDR and ONS mortality yielded mixed results. In comparison 
to ONS reported age-standardised rates, supplemented age-standardised incidence 
rates that included all cases from the CPRD and NCDR were higher for breast (130.0 
per 100k PY, CPRD/NCDR vs 122.9 per 100k PY, ONS) and prostate cancer (105.6 per 
100k PY, CPRD/NCDR vs 99.7 per 100k PY, ONS). In contrast, incidence rates for 
colorectal (male: 57.6 per 100K PY, CPRD/NCDR vs 56.4 per 100k PY, ONS; female: 
36.1 per 100K PY, CPRD/NCDR vs 35.7 per 100K PY, ONS) and lung cancer (male: 
60.7 per 100K PY, CPRD/NCDR vs 61.1 per 100k PY, ONS; female: 37.0 per 100K PY, 
CPRD/NCDR vs 36.4 per 100K PY, ONS) were similar to ONS estimates (Figure 5.7). 
Of note, incidence rates were similar between linkage participating patients and 
overall CPRD rates from the 2 million sample (Figure 5.7). Linkage to ONS mortality 
data increased incidence rates, although not to the same degree as incorporating 
NCDR linkage. Incorporating all linked data sources (CPRD, NCDR, ONS Mortality) 
gave similar estimates to those from linkage analyses linking the CPRD to the NCDR 
(Figure 5.7).  
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Figure 5.7: Primary age-standardised incidence rates incorporating cancer and death registry linked data by cancer type and linkage 
 
(a) Breast Cancer (c) Colorectal Cancer (Female) (e) Lung Cancer (Female) 
   
(b) Prostate Cancer (d) Colorectal Cancer (Male) (f) Lung Cancer (Male) 
   
CPRD: Clinical Practice Research Datalink; NCDR: National Cancer Data Repository; ONS: Office for National Statistics  
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5.5 Discussion 
5.5.1 Overview 
Incidence rates for four of most common cancer types in the UK from primary care 
data (CPRD) were compared to national rates published by the ONS. Consistent 
with previous studies,187, 188 cancer incidence rates from the CPRD were lower 
compared to UK national estimates published by the ONS. This was no longer the 
case when linkage to cancer and death registry data were incorporated: compared 
to ONS estimates, breast, prostate, colorectal (women), and lung (women) cancer 
incidence rates were higher than expected, while similar rates were observed for 
colorectal and lung cancer in men. 
5.5.2 Comparison of cancer incidence: CPRD vs ONS 
Disparities of cancer incidence rates from the CPRD compared to the ONS varied by 
calendar period, sex, and age. These disparities remained when CPRD and ONS age-
standardised incidence rates were compared, which is consistent with the CPRD 
being representative of the UK population in terms of age and sex.98 For all four 
cancer types, the disparity between CPRD and ONS age-standardised incidence 
rates were particularly larger during the earlier periods of the study (2000-2004); 
however, estimates from the two data sources converged from 2005 onwards. This 
trend is consistent with findings from Haynes et al.188, a possible explanation for 
this trend could be the implementation of the Quality and Outcomes Framework 
(QOF) in the UK in 2004 - a programme which provides an incentive to GP surgeries 
by awarding them achievement points for measures such as: managing chronic 
diseases, implementing preventative measures, and an overall service of high 
quality and productivity.189, 190 
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Age at diagnosis contributed to the disparity in incidence rates between the CPRD 
and ONS, again consistent with findings from past studies.187, 188, 191 Notably, larger 
differences were observed for lung and colorectal cancer, particularly for the 
elderly. Misclassification of case status could have potentially driven this observed 
relationship: diagnosis of cancer, for some cases, would not have been recorded 
until death, which may not have been captured in GP records leading to 
misclassification of some cases as non-cases. Instances where cancer diagnoses are 
recorded on or near the date of death in CPRD patient records may reflect diseases 
related to death. Cause of death is not routinely coded in general practice data; 
however, linkage to the ONS death registry, which collects data from death 
certificates, does include this information, and can be used in conjunction with the 
CPRD. Furthermore, this age-related misclassification of case status may be 
magnified for cancers that are diagnosed at a late stage with low survival rates such 
as lung or pancreatic cancer.192 Compared to lung and colorectal cancer, which have 
higher mortality,183 disparities by age were not as pronounced for breast and 
prostate cancers which are typically detected at earlier stages and have higher 
survival rates.183 
The disparity observed by cancer type may also have been driven by regional 
variation in England. Higher incidence rates of breast and prostate cancer have 
been observed in the South of England (London, South East, and South West), while 
lower rates were observed in the Northern regions of England (North East & West, 
and Yorkshire and The Humber). Similarly, lung and colorectal cancer registrations 
are higher in the Northern regions of England compared to Southern regions.182 
Variations in regional cancer incidence rates coupled with a higher density of CPRD 
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GP practices located in the South of England, may have driven the disparity 
observed between CPRD and ONS published rates.193 
5.5.3 Alternative case definitions 
Whether the difference between primary care and registry reported rates would be 
reduced by using broader case definitions in the CPRD was evaluated. The broad 
case definition resulted in increased rates for all cancer types, lower rates were still 
observed for colorectal, lung, prostate cancer; however, similar rates were 
observed for breast cancer. Recent cancer incidence studies from Haynes et al.188 
and Tate et al.191 speculated on whether incidence rates were lower in their studies 
due to their employment of unambiguous Read codes (definite codes) to define 
cases. Results from this study and those of Charlton et al.187 suggest that this is not 
the case. Although additional cases were identified by adopting non-specific cancer 
codes as part of the case definition, their inclusion resulted in marginal differences 
to definite CPRD incidence rates for colorectal, lung, and prostate cancer. 
Moreover, inclusion of false-positive cases is a likely possibility if a broader case 
definition is employed. Verification of such cases would be important, for example 
by request of patient records, free-text, or cancer registry linkage. The last of these 
verification mediums, namely the cancer registry would be the most pragmatic due 
to its relative ease to apply to a large sample. Previous studies that have conducted 
validation studies have done so by requesting hard copies of patient records or 
accessed free-text, which is a stand-alone facet provided by the CPRD.  These 
methods are resource intensive and have been limited to relatively small case 
samples as described in the systematic review of cancer outcomes in UK primary 
care databases (Chapter 2). However, results from this study do support the point 
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that GPs may not always record an event (e.g. prostate cancer diagnosis) by using 
the most detailed Read code. Findings from this study show that a substantial 
proportion of cases with a malignant diagnosis in the NCDR have a less specific 
(borderline, suspected, or malignant diagnosis code with no site specified) recorded 
diagnosis in primary care records.  
In relation to non-specific diagnosis codes, over half of cases identified in the NCDR 
and not in the CPRD nevertheless had some form of cancer-related diagnosis code 
within their CPRD records. The proportion of diagnoses recorded in the cancer 
registry, but not in the CPRD ranged from 10-40% depending on cancer type. 
However, many of these cases had a record of unspecified malignant neoplasms, in-
situ diagnoses or suspected diagnoses.  
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5.5.4 Linkage to cancer registry and death registrations 
In comparison to ONS age-standardised rates, supplemented CPRD age-
standardised incidence rates incorporating linked NCDR and death registry data 
were similar for colorectal and lung cancer, but higher for breast and prostate 
cancer. It is inevitable that incorporating additional data sources would result in an 
increased incidence rate unless there was 100% concordance between datasets. 
Similar rates observed for colorectal/lung cancer and higher rates for 
breast/prostate cancer could be related to the proportion of potential false-positive 
(or not registered nationally) cases identified which was higher for breast/prostate 
(10%) compared to colorectal (6%) and lung (7%) cancer. Cases identified in primary 
care but not in the cancer registry would necessarily produce higher estimates to 
reported ONS rates (based on cancer registrations) because of the additional cases 
identified. However, the magnitude of disparity would depend on the proportion of 
potential false-negative cases.    
Consistent with past studies of CPRD and cancer registry linkage,80, 194 positive 
predictive values of CPRD cancer diagnosis were high, ranging from 83% to 89% 
across all four cancer types. In primary care records, a diagnosis may appear on 
more than one occasion; for example, a patient may transfer to another practice 
and the new GP may enter the diagnosis for reference as described by Lewis et 
al.195 Allowance for this was implemented by excluding any cases that were 
diagnosed with cancer within 6-months of start of follow-up, and most of the cases 
identified in the CPRD had been followed for a substantial amount of time before 
the date of recorded diagnosis in the NCDR.  
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A small proportion, ranging from 5-10%, of cases were identified in the CPRD but 
not in either the NCDR or ONS death data. Three possible reasons for cases being 
identified in the CPRD and not in the NCDR are (i) they are false-positive cases and 
wrongly recorded as having a cancer diagnosis in the CPRD; or (ii) they could be 
cases that are missed by the cancer registry; or (iii) were simply never notified of 
the case from primary care records. 80% of these cases were more likely to be 
false-positives because only 1 diagnosis code was identified within their CPRD 
records in comparison to 20% who had >1 definite diagnosis code (Read code 
mapped to cancer ICD-10) within their CPRD patient records. In addition, the 
median time from start date to diagnosis date was over 7 years for all cancer types. 
A short time period from start date to diagnosis date might suggest that the GP 
entered the diagnosis as a reference point rather than an incident diagnosis.195 In 
the other direction, the NCDR may have missed cases that were identified in 
primary care. Registries receive information on newly diagnosed cases from many 
sources in the NHS, one of them being general practices. A possibility could be that 
these primary cases failed ONS validation checks and were not included as 
registered cases.182 All coded records in the CPRD typically remain unchanged once 
recorded, and cases identified would remain as cases within the CPRD.  
The sensitivity of the CPRD in capturing nationally registered cancers was lower 
compared than previous studies reporting on CPRD and cancer registry.80, 194 
Sensitivities ranged from 73% to 89% for breast, colorectal and prostate cancer, 
while sensitivity for lung cancer was low (66%). The NCDR had a higher number of 
cases in comparison to cases identified in the CPRD, particularly for cancer types 
with a lower survival rate such as colorectal and lung cancer.  
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There are a few possible explanations for lower sensitivities observed in this study 
compared to previous studies.80, 194 First, both studies utilised a specific sample of 
patients from the CPRD: Boggon et al.194 a diabetes cohort, and Dregan et al.80 a 
cohort of patients with alarm symptoms for cancer. As a result, these groups may 
be under closer monitoring and therefore would have been more likely to have 
cancer diagnosed. In contrast, this study randomly sampled from all eligible 
patients from the CPRD. Second, an earlier version of the linkage set was used in 
both past studies. Third, Boggon et al. also utilised hospital episodes statistics (HES) 
and free-text data which would increase sensitivity estimates. Last, the CPRD and 
cancer registry record diagnoses using two different coding dictionaries, the code 
list used to define cases in both data sources will inevitably influence concordance 
measures.  
The cancer registry collects data on cancer diagnoses from a number of data 
sources including hospitals, GPs, and coroners, and as such was considered as the 
gold standard in terms of collection of cancer registrations in the UK. In 
comparison, the CPRD collects data based on a recording system of administrative 
physician recording and may not necessarily be complete without supplementation 
of linkage to external data sources such as the cancer registry. As such, linkage to 
the cancer registry, death certificates, or hospital data are needed to supplement 
the existing primary care data. A current disadvantage of the utilisation of linking 
primary care patient data to a disease specific registry is the trade-off between 
more comprehensive outcome data and a loss in overall sample size. Nonetheless, 
one of the main aims of some past epidemiological studies utilising UK primary care 
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databases on cancer outcomes (Chapter 2) was to avoid inclusion of false-positive 
cases. 
5.5.5 Cancer Type 
Findings from this study varied by cancer type, however, patterns of consistency 
emerged among the different cancers examined in this study. Fatality of cancer 
type, as observed in this study for lung/colorectal cancer compared to 
breast/prostate cancer, may be a strong predictor of disparity between primary 
care and ONS reported rates. Similar rates were observed by Haynes et al.95 for 
cancer types with high survival rates (>90% one year survival for lymphoma, breast, 
prostate, and melanoma).188 In comparison, lower primary care incidence rates 
were observed for pancreatic (21% 1-year survival), lung (32% 1-year survival), 
colorectal (76% 1-year survival), and ovarian cancer (72% 1-year survival). The 
exception to these was leukaemia and brain tumours, where similar rates were 
observed. 
5.5.6 Limitations 
This study has several limitations. First, findings were limited to the four types of 
cancer included in this study, which were chosen because they are the four most 
common cancers diagnosed among men and women in the UK. Second, reference 
ONS incidence rates over the entire study period (2000-2010) could not be 
estimated as longitudinal patient data were not available for each calendar year. As 
such, average overall and age-specific ONS rates across all years were estimated, 
assuming a static population - averaging reported ONS rates over all years. Year-
specific plots (data not shown) showed that there was no apparent change in trend 
for the individual years. Third, an alternative method to assess data quality could 
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have been conducted, namely verification of diagnosis through hard-copy requests 
of GP patient records. Such a validation was not conducted for the cancer diagnosis 
codes included in this study due to the resource intensive nature of such a process. 
Moreover, whether GPs that partake in this validation process refer to the same 
electronic data provided by the CPRD or access extra information is unclear. 
Optimistic estimates of validity would likely be observed if the former were true. 
Thus, some misclassification of case status may have been possible which would 
likely have resulted in an overestimate of incidence rates. However, incidence rates 
estimated in this study were consistent with past studies. Fourth, not all practices 
participate in validation or linkage studies, which may limit the generalisability of 
validity findings. The subgroup of practices included in this study may differ 
compared to non-participating practices in terms of case file organisation, clarity, or 
maintenance. Yet, rates were similar between eligible participating practices and 
overall CPRD rates including all acceptable GP practices. Last, HES and free-text 
data were not utilised in this study; future studies could incorporate these data 
sources to assess the impact on incidence rates in comparison to ONS reported 
rates.  
5.5.7 Future Research 
This study was limited to cancers of the breast, colorectum, lung and prostate; 
future research might investigate the extent to which incidence rates from other 
cancers vary or are consistent with expected ONS reported rates with the addition 
of linkages to the NCDR or ONS mortality data. In addition, cancer related 
epidemiological studies incorporating linkages to external sources could investigate 
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the impact of age-related biases that might impact study findings if primary care 
data is used either alone or with the addition of registry data. 
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5.6 Conclusion 
Consistent with recent studies, CPRD cancer incidence rates were generally lower 
compared to ONS reported rates. Incorporating linked data from the cancer registry 
yielded higher incidence rates for prostate and breast cancer, yet, similar rates, 
compared to ONS published rates, were observed for cancers of the lung and 
colorectum.  
Three possible permutations of linked data are possible for use in future analysis: (i) 
incorporating all identified events from all data sources (primary care OR cancer 
registry); (ii) events restricted to those identified from the cancer registry, as the 
cancer registry is considered the “gold standard”; and (iii) concordant diagnosis 
(primary care AND cancer registry) between data sources. Approaches (i) and (ii) 
capitalise on the gains from incorporating linked data as valid events supplement 
existing data, whereas approach (ii) limits events to those recorded in primary care. 
Between approaches (i) and (ii), approach (ii) may be considered the most valid in 
terms of case ascertainment, as cancer registries apply a stringent validation 
process to ensure true cases are registered.182 Moreover, the best approach may 
depend on the context of the study; in some settings identification of all possible 
cases is sufficient. In contrast, specificity may be an important property even at the 
expense of missing some true cases such as pharmacoepidemiological studies 
(Chapter 2).  
In line with previous studies,196 findings from this study have shown that sole use of 
primary care databases to identify particular cancer outcomes may be biased and 
lead to an underestimation of cancer incidence. Primary care data may misclassify 
case status without external linkage to the cancer registry, particularly among 
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elderly patients and for cancer types that are captured at a late stage of disease 
progression with low short-term survival. Failure to incorporate linked data from 
the cancer and death registry may result in the inclusion of false-negative cases. In 
the other direction, utilisation of linked data may generate higher cancer incidence 
either because cases in primary care data may be either false-positive outcomes or 
are simply not registered nationally. In any case, linkage of primary care data to 
secondary external data sources, such as the cancer registry and ONS mortality, has 
proven to be beneficial by allowing exploration of the limitations of primary care 
data in terms of cancer diagnosis recording. 
5.7 Summary 
 CPRD (primary care) incidence rates for breast, colorectal, lung, and 
prostate cancer were lower compared to ONS reported rates based, which 
were based on cancer registrations.  
 Disparities between primary care estimated incidence rates and ONS 
reported rates varied by cancer type, age at diagnosis, calendar year, and 
sex. 
 High positive predictive value estimates of CPRD recorded diagnoses across 
all cancer types examined was observed. However, the sensitivity of CPRD 
for capturing registered cancers was lower. 
 CPRD incidence rates incorporating linked cancer registry data yielded 
similar incidence rates for colorectal (men) and lung cancer (men). However, 
higher rates were observed for breast and prostate cancer.
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6 Systematic evaluation of the impact of potential 
methodological drivers of discrepant results in a 
pharmacoepidemiological study of statin use and cancer 
risk 
6.1 Introduction 
This chapter describes a series of analyses examining the impact of several 
methodological aspects of study design in the context of estimating the statin-
cancer association within the CPRD. 
6.2 Objective 
The main objective of this chapter is to measure and compare the individual impact 
of several potential drivers of discrepant results. 
6.3 Methods 
6.3.1 Primary methodological outcome measure: assessment of potential 
drivers of discrepant results 
Several potential drivers of discrepant results were examined in this chapter, which 
included study bias, alternative outcome definitions, and linkage to the cancer 
registry and ONS mortality. 
Five commonly cited biases that have been noted as potential drivers of discrepant 
results in previous pharmacoepidemiological studies were examined in this chapter, 
namely: immortal time,69 protopathic,116 prevalent user,70 healthy user,118 and 
time-window bias.119 In addition, potential factors related to the definition of cases 
in the CPRD were examined: (i) alternative case definitions and (ii) a comparison of 
the impact of linking primary care data (CPRD) to the cancer registry to define 
cancer outcomes. 
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To address the main objective, several potential drivers of discrepant results were 
investigated in the CPRD by using a variety of study design methods within the 
context of estimating the statin-cancer association. For each set of analyses, the 
relative risk of each cancer of interest was estimated for: (i) a design incorporating 
the potential driving factor (RRB), and (ii) a corresponding “corrected” analysis 
(RRC). The difference in log relative risk estimates (Δβ; representing change in the 
un-exponentiated model coefficient of the main treatment effect (statin use) on 
cancer risk), with corresponding 95% confidence intervals,197 was the main 
outcome of interest used to measure the impact of a particular driver within the 
statin-cancer association, and to give a basic standardised comparison across 
potential drivers. 
The statin-cancer association was selected as a basis for this study due to its 
importance to public health and additionally the large number of 
pharmacoepidemiological studies that have presented conflicting findings (Chapter 
3- Systematic Review). There was assumed to be no causal link between statin use 
and the risk of cancer based on previous literature and evidence from RCTs,40, 41, 50, 
78, 198 and therefore a valid analysis would yield a confidence interval estimate 
including 1. In addition, the direction of the risk estimate and consistency between 
“biased” and corrected analysis was assessed. 
A number of analyses and study designs were conducted to examine the impact of 
potential drivers of discrepant results on the statin-cancer association. Details of 
these methods are outlined in following sections of this chapter. 
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6.3.2 Outcomes 
The primary outcomes of interest include primary incident cancers of the breast, 
colorectum, lung, and prostate. Specific details of methods related to case 
identification and definitions are provided in Chapter 5. 
6.3.3 Treatment groups 
Overall, three treatment groups were considered for comparison in this chapter: (i) 
statin users; (ii) statin non-users; and (iii) glaucoma medication users (this was an 
alternative comparison group used to assess the impact of healthy user bias, 
Section 6.3.6.4). Several treatment definitions were used and are described in the 
following sections. 
6.3.3.1 Statin users 
Patients with any statin prescription (British National Formulary (BNF), Chapter 
2.12) prior to July 31, 2012 were identified in the CPRD (July 2012 version). 
New statin users were identified as any patient aged 30-90 years with a first 
recorded statin prescription during the study period (1995-2012); this time point 
was defined as the treatment start date. Patients prescribed statins prior to January 
1, 1995 were excluded. Furthermore, new statin users were required to have at 
least 12 months UTS registration with their GP before their treatment start date to 
minimise the likelihood of including prevalent cases of cancer.199 Statin users with 
missing date of birth, start date (maximum of either current registration or UTS 
practice date) or end date (minimum of either death, transfer out , or last collection 
date) were excluded. Furthermore, statin users with dates that did not agree over 
follow-up were excluded, for example: start date ≥ end date; date of birth ≥ end 
date. Patients were also excluded if they had a history of any cancer (malignant 
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neoplasm, malignant morphology, borderline, in-situ, suspected) prior to the first 
statin date. 
6.3.3.2 Potential statin non-users 
CPRD denominator data included all acceptable (e.g. consistent recording of age, 
sex, registration details and clinical events) patients registered to a GP before July 
31, 2012. A pool of eligible (follow-up during the period 1995-2012 and >12 months 
UTS follow-up) non-users were identified; excluding all patients with a record of a 
statin prescription. Non-users who went on to become a statin user were included 
in this pool, their end of follow-up date defined as the day before the first statin 
prescription. Non-users with dates that did not agree over follow-up were excluded, 
for example: start date ≥ end date, or date of birth ≥ end date. 
6.3.3.3 Glaucoma medication users 
Glaucoma medication users were considered as an alternative comparison group to 
assess the impact of healthy user bias (Section 6.3.6.4). Patients with a glaucoma 
medication prescription (BNF Chapter 11.6) prior to July 31, 2012 were identified in 
the CPRD (July 2012 version). 
New glaucoma medication users were identified as patients aged 30-90 years with 
no record of glaucoma medication prescription prior to the study period (1995-
2012), so that their first prescription (treatment start date) occurred during 1995-
2012. Furthermore, new glaucoma medication users were required to have at least 
12 months UTS registration with their GP before the equivalent glaucoma 
medication start date. Glaucoma medication users with dates that did not agree 
over follow-up were excluded, for example: start date ≥ end date; date of birth ≥ 
end date. 
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6.3.4 Study design 
Broad study design methods are described in this section, and specific designs 
related to the study bias are described in Section 6.3.6. 
In order to assess the impact of several potential drivers of discrepant results on 
the risk of cancer among statin users, several study designs were conducted to 
emulate studies that were conducted in past literature (Chapter 3 – Systematic 
review).  
6.3.4.1 Matched cohort of statin and non-users 
From the pool of potential non-users (Section 6.3.3.2), all potential matches for 
each statin user were identified based on the following matching criteria: treatment 
start date, age (±2.5), sex, GP, and >12 months UTS follow-up prior to the matched 
treatment start date with no history of cancer prior to this date. Sampling of non-
users was implemented with replacement, non-users were allowed to be matched 
to >1 statin user. Once a non-user was selected as a potential control for a user, 
they would be re-entered into the non-user pool and considered as a potential 
match for other statin users. Lastly, once a pool of potential non-user matches was 
selected for each statin user, five non-users (ratio of 5 non-users to 1 statin user) 
were selected based on closest age difference. 
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Figure 6.1: Diagrammatic representation of intention to treat analysis 
 
Patient 1: Statin user
Cohort entry = latest of 
1/1/1995 or >12m UTS 
Statin 
(Start date)
Patient 5: Statin user
Non-user person time
Patient 2: Non-user
Patient 3: Non-user
Patient 4: Non-user
Patient 1: Non-user
Patient 6: Non-user
Patient 7: Non-user
Patient 8: Non-user
Match Set 1
Match Set 2
Cohort entry = latest of 
1/1/1995 or >12m UTS 
Match Set 1:
Patient 1: New statin user
Match Set 2:
Patient 1: Non-user – potential match to Patient 5: statin user
Intention To Treat (ITT) Analysis
In Match Set 2, if non-user time from Patient 1 is matched as a non-
user control for Patient 5, then the initial treatment group to which 
Patient 1 belonged will define treatment status.
Furthermore, since Patient 1 is a matched non-user for Patient 5, 
Match set 1 is excluded from further analyses. 
Follow-up time for Patient 1 (Match Set 2) will start at cohort entry 
and end at last observed point of contact, ignoring subsequent statin 
use as depicted in Match Set 1
Statin
(Start date)
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Tim Collier, Krishnan Bhaskaran and Harriet Forbes wrote the original program to 
implement matching. 
Cohort analysis was conducted on an intention to treat (ITT) basis. This design 
feature is analogous to a randomised design where treatment assignment is based 
on initial randomisation and not the treatment eventually received.56 As illustrated 
in Figure 6.1, the initial treatment status of a patient would determine their 
classification, hence anyone selected as a matched non-user would be excluded as 
a later statin user. 
Observation period: matched cohort 
Matched cohort (6.3.4.1): The period of observation for cancer events began at the 
treatment start date for statin users or corresponding matched treatment start 
date for non-users up to either the end date or first date of diagnosis for a cancer of 
interest or censored at a malignant diagnosis of another cancer. 
6.3.4.2 Nested case-control study 
6.3.4.2.1 Base cohort 
A cohort of new statin users and non-users aged between 30-90 years at cohort 
entry was identified in the CPRD. Patients were excluded if they had a previous 
history of cancer prior to cohort entry: latest of January 1, 1995 or start of 
registration with their GP. 
6.3.4.2.2 Case-control: time independent sampling 
Cases of breast, colorectal, lung, and prostate cancer were identified among the 
cohort of patients. The date corresponding to the first medical record of a definite 
diagnosis of breast, colorectal, lung or prostate cancer was assigned as the index 
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date for cases. Controls were defined as patients with no record of cancer prior to 
their end date (minimum of either death, transfer out date, or last collection date).  
6.3.4.2.3 Nested case-control: risk-set sampling 
For the case-control design, patients with no record of a cancer of interest were 
selected as potential controls. However, the time before diagnosis for an identified 
case was considered as potential control person time, and therefore cases were 
eligible to be controls for other cases. 
Matching of controls to cases 
Firstly, controls were matched according to index date, age (±2.5 years), sex, GP 
and >12m UTS follow-up before the index date. Secondly, as controls were matched 
on index date, all eligible controls with UTS follow-up prior to the matched index 
date were considered as potential controls for that particular case (risk-set 
sampling). Controls were allowed to be matched to >1 case (replacement of 
controls). 
Treatment definition and observation period 
A patient was defined as a statin user if they had a recorded prescription 12 months 
prior to their observed end of follow-up: end date or event of interest. 
The period of observation for exposure began 12 months prior to the index date for 
a case or matched index date for controls, back to the earliest occurrence of follow-
up, defined by either the start date or a statin prescription. 
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6.3.5 Statistical analysis 
6.3.5.1 Statistical models 
To model the risk of cancer associated with statin use, three statistical models were 
used: (i) Cox regression for the matched cohort design (6.3.4.1); (ii) conditional 
logistic regression for the nested case-control design (6.3.4.2.3); and (iii) 
unconditional logistic regression for the case-control design with time-independent 
sampling (6.3.4.2.2). Hazard and odds ratios with corresponding 95% confidence 
intervals were estimated as appropriate. 
In addition, the Cox regression model (6.3.4.1) was stratified by “match set” (Figure 
6.1) enabling equal coefficient estimates across “match set” with individual baseline 
hazard estimates unique to each stratum.200 
6.3.5.2 Confounders 
Age at first statin (cohort) or diagnosis (case-control), sex, calendar year, and 
general practice were matching variables in both the matched cohort and nested 
case control design. Calendar year was included in the statistical adjustment of the 
new statin and new glaucoma medication cohort. Lifestyle factors included: 
smoking status (non-smoker, current smoker, ex-smoker, and unknown), body mass 
index (BMI) (<20, 20-25,>25, unknown), alcohol status (non, ex, current, rare <2u/d, 
moderate 3-6u/d, excessive >6u/d, unknown), and rate of GP consultation visit rate. 
Code lists available from the EHR group at LSHTM were updated and utilised to 
search CPRD patient records for the following co-morbidities: diabetes, coronary 
heart disease (CHD), heart failure, hypertension, and hyperlipidaemia. Co-
medications included non-steroidal anti-inflammatory drugs (NSAID) or aspirin use 
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(BNF: 10.1.1). antihypertensive medications: thiazides and diuretics (BNF: 2.2.1), 
beta-blockers (BNF: 2.4), angiotensin-II receptor blockers and angiotensin-
converting enzyme inhibitors (BNF: 2.5.5), calcium channel blockers (BNF: 2.6.2); 
oral contraceptives (BNF: 7.3.1) and hormone replacement therapy (HRT) (BNF: 
6.4.1.1). All co-morbidities and co-medications were formatted as binary variables 
(No/Yes). All potentials confounder were identified within a (±) 1-year window to 
the treatment start date (matched date for non-users) for the matched cohort and 
index date (date of diagnosis) for the nested case-control design. All potential 
confounders were compared and tested for differences between treatment groups 
(case status for nested case-control design) by a Chi-squared test for categorical 
variables and a t-test for continuous variables. Corresponding p-values were two-
sided.  
6.3.5.3 Sensitivity analysis 
6.3.5.3.1 Matching with replacement: weighting of non-users 
Non-statin users were matched to ≥1 statin user. In the statistical models utilised, 
all non-users were considered independent, however potential non-users could be 
included in the analysis on more than one occasion and the independence 
assumption of the statistical models may be violated.  
In order to account for the non-independence, inverse frequency weights were 
included in all statistical models that incorporated matching with replacement. 
Inverse frequency weights were based on the inverse number of times a non-user 
was matched to different statin users.201 
6.3.5.3.2 Missing data 
157 
 
Complete case analysis was conducted in all primary analyses.202 Patients with 
missing data (unknown) on smoking status, BMI, or alcohol status were excluded 
from further analysis. For the complete case analysis, the probability of missingness 
in BMI, smoking status, and alcohol status was assumed to be independent of the 
cancer events conditional on observed covariates measured.202 Sensitivity analyses 
were conducted to assess the impact of missing BMI, smoking status, and alcohol 
data: (i) inclusion of a separate missing data category for each of the incomplete 
variables; (ii) multiple imputation. 
Multiple imputation of missing BMI, smoking status, and alcohol status was 
implemented using chained equations. The imputation model included all potential 
confounders included in the main model listed in Section 6.3.5.2 as well as the 
cancer event of interest; five imputed datasets were created and the results were 
combined using Rubin’s rules.203, 204  
6.3.5.3.3 Censoring at treatment change 
All analyses that were conducted on the matched cohort were conducted on an 
intention to treat basis. As a sensitivity analysis, the effect of censoring follow-up 
was conducted. For each patient, censoring of follow-up was implemented if a 
patient’s exposure status changed. For example, statin users were censored if they 
stopped statin use for a collective period of 6 months. Similarly, a non-user would 
be censored if they initiated statin use. 
6.3.6 Impact of potential drivers of discrepant results 
6.3.6.1 Immortal time bias: biased and corrected designs 
 
Description 
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Immortal time bias is introduced when a wait period in which an event cannot 
occur is implemented within the design of a study. For example, an exposure 
definition requiring 6-months follow-up from therapy initiation before observation 
for outcome events can commence. This wait period gives a survival advantage to 
the exposed group until the treatment definition is met, leading to a spurious 
protective bias on the risk estimate.69 
Study design utilised 
From the matched cohort of new statin users and non-users (6.3.4.1) treatment 
status was defined in two ways: 
(i) Requirement of 2 recorded statin prescriptions during follow-up. 
(ii) Requirement of 2 recorded statin prescriptions within the first 6 
months of treatment start date, and a minimum of 6-months follow-
up duration after the first statin date. 
Statin users (and corresponding matched non-users) who did not meet the 
treatment definition were excluded from further analyses. 
Potentially biased design 
For both treatment definitions, the start of follow-up began at the first statin 
prescription during follow-up (and corresponding matched treatment start date for 
non-users). However, statin users still needed to satisfy the treatment definition 
which included the period of immortal time where an event could not occur (Figure 
6.2 (i)). 
Correction of immortal time bias 
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For the corrected design, immortal time was excluded by starting follow-up at the 
time point where the treatment definition was satisfied: (i) follow-up began at the 
second consecutive statin prescription in cohort 1; (ii) follow-up began after a 
minimum of 6-months follow-up from the first recorded statin prescription (Figure 
6.2 (ii)). 
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6.3.6.2 Protopathic bias: biased and corrected designs 
 
Description 
Protopathic bias occurs when patients with latent cancer which has not been 
diagnosed may present with symptoms that lead to a statin being initiated. For 
example, due to a pre-existing cancer, changes in diet or physical activity may lead 
to changes in patient lipid profiles, which in turn may lead to a statin being 
prescribed. As these individuals are subsequently diagnosed with cancer, statin use 
may mistakenly be associated as the cause of cancer, when in fact the pre-diagnosis 
cancer symptoms caused the statin initiation.116 
Study Design utilised 
Protopathic bias was examined by utilising the new statin user matched cohort 
described in Section 6.3.4.1. 
Potentially biased design 
The potentially biased analysis did not implement a minimum period of exposure, 
any events occurring early on during initiation of statin use were included in the 
relative risk estimate. Start of follow-up began at the date of first statin prescription 
(Figure 6.3 (i)). 
Correction of protopathic bias 
For each cancer type, the relative risk of cancer among statin users from multiple 
analyses incorporating sequentially increasing minimum periods of exposure (30 
day increments) was estimated. The corrected analysis was set at 360-day lag  
(Figure 6.1.3 (ii)). 
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Figure 6.2: Immortal time bias: biased and corrected designs 
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Figure 6.3: Protopathic bias: biased and corrected designs 
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Figure 6.4: Prevalent User bias: biased and corrected designs 
 
Statin User
Matched non-user
Statin
(Start date)
Matched 
Start date
Statin and non-statin 
follow-up
First Statin 
ever after 
12m UTS
No previous record of statin use
Statin User
Matched non-user
Statin
(Start date)
Matched 
Start date
Statin and nonstatin 
follow-up
First Statin 
during study 
period
(i). Biased analysis: prevalent user
(ii). Corrected analysis: new user
Cohort entry a
Cohort entry a
Cohort entry a
Cohort entry a
a
 Cohort entry = latest of 1/1/1995 or >12m Up-to-standard follow-up (UTS)  
 
Figure 6.5: Time-window bias: biased and corrected designs 
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6.3.6.3 Prevalent user bias: biased and corrected designs 
Description 
Prevalent users of statin therapy may be different from initiators of statins. 
Prevalent statin users have remained on therapy for a longer period of time 
compared to new statin users which potentially introduces a number of protective 
biases. Firstly, depletion of susceptible patients, in which prevalent users would 
include patients that have persisted with statin therapy, and remained tolerant of 
any potential side effects from the drug. Secondly, prevalent users of medications 
are associated with better adherence and outcomes overall compared to new 
users.70 
Study designs utilised 
Two sets of analyses were used to assess the impact of prevalent user bias: (i) a 
matched cohort of new statin users and non-users (Section 6.3.4.1); and (ii) a 
matched cohort of statin users (incident and prevalent) and non-users. 
The cohort of any statin users (incident and prevalent) matched to non-users was 
formed to assess the impact of prevalent user bias. The main differences between 
the any statin cohort and the new statin cohort included the following: 
1. Requirement for >12 months UTS follow-up 
2. Inclusion of prevalent statin users: defined as any statin use prior to the 
start of cohort entry (January 1, 1995) 
The period of observation for cancer events began at the treatment start date for 
statin users or corresponding matched treatment start date for non-users up to 
either the end date or first date of diagnosis for a cancer of interest or censored at 
a malignant diagnosis of another cancer. 
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Potentially biased design 
The relative risk of cancer among patients with any record of statin use (incident 
and prevalent) was estimated. 
Correction of Prevalent user bias 
To correct prevalent user bias, an analysis of new statin users was conducted and 
compared to findings from the prevalent user analysis (Figure 6.4 (ii)). 
6.3.6.4 Healthy user bias: corrected and biased designs 
 
Description 
Statins are a widely used class of drug prescribed to lower cholesterol levels, and 
aid in the management and prevention of stroke. Similarly, glaucoma medications 
are used to prevent progression of glaucoma. Compared to non-users, patients 
prescribed preventative therapy may be more likely to have better health-seeking 
behaviour, such as exercise, healthier diet, and may adhere to health services 
directed at preventing related diseases, which may influence study findings.205 
Study design 
In order to assess the impact of healthy user bias two cohorts were compared (i) a 
matched cohort of new statin users and non-users (Section 6.3.4.1); and (ii) an 
unmatched cohort of new statin users compared to new glaucoma medication 
users (Section 6.3.3.3). The two treatment groups were joined; new statin users 
with a prior record of glaucoma medication use were excluded and vice-versa. 
Observation for events began at the treatment start date for new statin users and 
equivalent start date for new glaucoma medication users up to either the end date 
or first date of diagnosis for a cancer of interest or censored at a malignant 
diagnosis of another cancer. 
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Potentially biased design 
New statin users compared to non-users as described in Section 6.3.4.1. 
Correction of Healthy user bias 
To assess the effect of healthy user bias the corrected analysis consisted of new 
statin users compared to initiators of another preventative medication, namely: 
glaucoma medications. New users of both medications were defined as patients 
with a first ever recorded prescription of the drug of interest after cohort entry. 
Additionally, this was the time-point at which follow-up commenced for both 
cohorts. 
6.3.6.5 Time-window bias (nested case-control): corrected and biased 
designs 
 
Description 
The time-window used to assess exposure status between cases and controls may 
not necessarily be fairly distributed if a time-independent sampling strategy of 
controls is utilised. Cases in general may have a shorter period of observation 
compared to their counterpart controls. Compared to controls, this would like lead 
to a shorter observation period to classify treatment status for cases, which would 
likely lead to an overrepresentation of both exposed controls and unexposed cases 
leading to a downward bias.119 
Study designs 
A case-control design which sampled controls independently of time (Section 
6.3.4.2.2) was used to implement the biased analysis and a nested case-control 
design (risk-set sampling of controls) was utilised for the corrected analysis (Section 
6.3.4.2.3). 
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Potentially biased design 
From the case-control design (Section 6.3.4.2.2), controls were sampled from their 
last point of contact in the CPRD independently of time (end of follow-up: end of 
CPRD follow-up; or death from any other cause). Exposure history was also 
ascertained up to this time point. 
Correction of Exposure Time-Window Bias 
Risk-set sampling was implemented to sample and select controls in the corrected 
design. This allowed a fair observation period between cases and controls to classify 
treatment status. Controls were sampled from those that were eligible and under 
follow-up on the day the case was diagnosed (Figure 6.5 (ii)). 
6.3.6.6 Alternative outcome definitions 
 
Description 
As shown in the systematic review conducted in Chapter 2, there has been a divide 
between research groups that have conducted cancer outcome studies in UK 
primary care databases. Findings from the systematic review in Chapter 2 show 
that the majority of studies have implemented case definitions requiring only a 
malignant diagnosis code for the cancer of interest. In contrast, other studies have 
implemented case definitions that have been based on a broader set of diagnosis 
codes including malignant and non-malignant codes with the requirement of 
evidence of diagnosis such as cancer related surgery or chemotherapy to confirm 
case status. Whether alternative case definitions that include non-malignant 
diagnoses may impact study findings is unknown. 
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Study design 
For both case definitions, the matched cohort of new statin users and non-users 
(Section 6.3.4.1) was used to examine the impact of alternative case definitions on 
the relative risk of cancer. 
Standard case definition 
All previous analyses described in this chapter have been based on a “standard” 
case definition (Chapter 4, Section 4.2.3) which required at least one definite 
malignant diagnosis code during follow-up and no previous history of cancer. Here, 
the impact of using a broader definition was investigated. 
Broad case definition 
The broad case definition included patients from three diagnostic groups (i) cases 
with a definite malignant  diagnosis of the cancer of interest; (ii) probable and (iii) 
possible cases. Probable and possible cases required supporting evidence of 
diagnosis such as cancer related surgery or chemotherapy to confirm case status 
(Chapter 4, Section 4.2.2). Early detection of cancers may be differential between 
treatment groups particularly for patients prescribed statins (disease prevention 
drug). As demonstrated in Chapter 5, some cases identified in the cancer registry 
alone had a related code entered in their CPRD records i.e. carcinoma in-situ, 
suspected diagnosis, or a malignant diagnosis (site unspecified). Reasons for these 
recordings are unclear, whether these diagnoses were entered retrospectively by 
the GP (prevalent diagnosis) or were a detailed account of disease progression.     
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6.3.6.7 Linkage to the cancer and death registry 
 
Description 
The impact of incorporating cancer outcomes from cancer registry data within a 
pharmacoepidemiological setting is unknown. Linkage of primary care data (CPRD) 
to the cancer registry provides several challenges. Firstly, not all general practices in 
the CPRD consented to linkage studies, which may imply a difference between 
analyses utilising all of the CPRD, compared to a subset of the CPRD which was 
eligible or consented to linkage research. Secondly, the extent of concordance may 
also affect results: Boggon et al.194 and Dregan et al.80 have shown that all cancers 
are not equal in terms of concordance. Cancers with high mortality rates such as 
lung and pancreatic cancer have lower levels of concordance. 
Study design 
Three linkage analyses were conducted: (i) cancer outcomes identified from the 
CPRD alone; (ii) incorporation of all outcomes from both the CPRD OR NCDR; and 
(iii) restricting cancer events to concordant diagnosis only (CPRD AND NCDR). For all 
analyses, the matched cohort of new statin users and non-users (Section 6.3.4.1) 
was used to examine the impact of linking primary care data (CPRD) to the cancer 
registry (NCDR) and ONS mortality on the relative risk of cancer. 
CPRD data only  
The matched cohort described in Section 6.3.4.1 was restricted to patients eligible 
to participate in the linkage scheme. No updates of cancer events were applied; all 
cancer events were identified from the CPRD. 
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Incorporation of linked data: diagnosis identified in the CPRD OR cancer 
registry (concordant and discordant)   
Similarly to the CPRD only data analysis, the matched cohort described in Section 
6.3.4.1 was restricted to patients eligible to participate in the linkage scheme. 
However, cancer outcomes identified in both the CPRD OR NCDR were included as 
events. For a concordant diagnosis recorded on different dates, the earlier of the 
two dates was assigned as the date of diagnosis. In addition, if the assigned NCDR 
date of diagnosis occurred before the statin treatment start date the statin user 
(and matched non-users) was excluded from further analyses. 
Incorporation of linked data: diagnosis identified in the CPRD AND cancer 
registry (concordant)   
For the concordant analysis, only concordant diagnoses were included as cancer 
events. Diagnoses identified in the CPRD alone and not in the NCDR were censored 
at the date of CPRD diagnosis and vice-versa. 
170 
 
Figure 6.6: Flow diagram of inclusion exclusion of new statin users matched to non-users 
 
8 261 204 Non-users
12 099 330 All Acceptable patients
(July 2012 version)
a
Matched on treatment start date, age (±2.5), sex, general practice; 1:5 ratio of statin users to non-users.
b
Intention to treat analysis: If a non-user went on to become a statin user, the matched set in which he/she was classified as a statin user was excluded, but the set in which he/she was classified as a non-user was included.
  UTS: Up-to-standard
1 023 812 Statin users (prevalent 
and incident)
630 827 New statin users
(During 1995-2012)
5 Non-users matched (with replacement) to 1 new statin user
a
630 814 New statin users
3 153 379 Non-users (Non-users can be matched to >1 statin user)
1 526 104 Unique non-users
307 646 New statin users
1 538 020 Non-users
323 168 Statin user sets excluded
b
13 Statin users with no matches
Exclusions
 - 145 989 Follow up outside study period
 - 357 Out of sync start and end dates
 - 11 209 Aged <30 or >90 at first statin during study period
 - 74 938 History of cancer prior to first statin
 - 155 937 <12 months UTS prior to first statin
 - 4 555 Prevalent statin user
Non-user Exclusions
 - 1 023 812 Statin users
 - 1 042 349 Follow-up outside study period
 - 1 038 780 Out of start and end dates
 - 1 364 012 <12 months UTS follow-up 
Non-user Inclusions
630 827 Nonuser time of new statin users
Pool of 630 827 New statin users and 
 8 261 2014 potential non-user for 
matching
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Figure 6.7: Flow diagram of inclusion exclusion of new statin and new glaucoma medication users 
162 709 Glaucoma medication 
users
64 021 New glaucoma medication 
users
(During 1995-2012)
630 827 New statin users
(During 1995-2012)
Cohort of 
610 121 New statin and 
48 310 New Glaucoma medication users
Exclusions
 - 47 228 Follow up outside study period
 - 2 799 Out of sync start end dates 
 - 6 771 Age <30 or >90 at first statin
 - 11 465 History of cancer prior to first glaucoma medication prescription
 - 20 944 <12 months UTS prior to first glaucoma medication prescription
 - 9 481 Prevalent glaucoma medication user
15 711 Statin medication prior to 
first glaucoma medication 
prescription
20 706 Glaucoma medication prior 
to first statin
12 099 330 All Acceptable patients
(July 2012 version)
UTS: Up-to-standard
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Figure 6.8: Flow diagram of inclusion exclusion of statin users (incident and prevalent) matched to non-users 
 
9 785 808 Non-users
12 099 330 All Acceptable patients
(July 2012 version)
a
Matched on treatment start date, age (±2.5), sex, general practice; 1:5 Ratio of statin users to non-users.
b
Intention to treat analysis: If a non-user went on to become a statin user, the matched set in which he/she was classified as a statin user was excluded, but the set in which he/she was classified as a non-user was included.
UTS: Up-to-standard
1 023 812 Statin users (prevalent 
and incident)
791 319 Ever statin users
(During 1995-2012)
5 Non-users matched (with replacement) to 1 new statin user
a
791 295 New statin users
3 955 498 Non-users (Non-users can be matched to >1 statin user)
1 784 038 Unique non-users
418 188 New statin users
2 090 482 Non-users
373 107 Statin user sets excluded
b
24 Statin users with no matches
Exclusions
 - 145 989 Follow up outside study period
 - 357 Out of sync start and end dates
 - 11 209 Aged <30 or >90 at first statin during study period
 - 74 938 History of cancer prior to first statin
Non-user Exclusions
 - 1 023 812 Statin users
 - 1 042 349 Follow-up outside study period
 - 1 038 780 Out of start and end dates
Non-user Inclusions
791 319 Nonuser time of new statin users
Pool of 791 319 Ever statin users and 
 9 785 808 potential non-users for matching
 
173 
 
Figure 6.9: Flow diagram of the cohort of new statin users and non-users and a case-control design nested within the cohort 
 
4 093 800 Non-users
12 099 330 All acceptable patients
(July 2012 version)
1 023 812 Statin Users
786 331 New statin users
(During 1995-2012)
Corrected Analysis: risk set sampling of 
controls
 Cohort 4 880 131 Patients
106 244 Potential cases 
4 773 887 Potential controls 
Case-Control: Corrected Anlaysis
5 Controls matched (with replacement) to 1 Case
a
97 657 Cases (Breast 32 996; Colorectum 20 327; Lung 21 084; Prostate 23 270)
487 883 Controls (Controls can be matched to >1 Case)
417 623 Unique Controls
Statin user exclusions
 - 145 989 Follow-up outside of study period
 - 357 Out-of sync dates
 - 11 209 Age <30 or >90 years at cohort entry
 - 74 938 History of cancer prior to cohort entry
 - 4 988 Prevalent statin user 
Non-user Exclusions
- 1 023 812 Statin User
- 1 042 349 Follow-up outside of study period
- 1 038 780 Out-of-sync dates
- 4 761 634 <30 or >90 years at cohort entry
- 138 955 History of cancer prior to cohort entry
97 677 Controls that go on to be cases
4 969 241 Patients
97 677 Cases 
4 871 564 Controls
8 567 Cases excluded <12 months UTS
20 Cases excluded no matches
Cohort pool
Cohort: 4 880 131 Patients
106 244 Cases 
4 773 887 Controls
Biased analysis: time independent sampling 
of controls
Cohort: 4 880 131 Patients
106 244 Cases 
4 773 887 Controls
a 
Matched on index date, age (±2.5), sex, general practice; 5:1 ratio of controls to cases.
UTS: Up-to-standard
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6.4 Results: Descriptive Analysis 
Overall, three cohort designs and one case-control design was used in this thesis, all 
of which comprised of statin users as the main treatment group. 
6.4.1 New statin and non-user cohort 
The matched cohort of new statin users and non-users consisted of 630,814 new 
statin users and 3,153,379 non-users. Overall, 630,484 (99.95%) statin users were 
matched to 5 non-users. All further analyses on this cohort were conducted on an 
intention-to-treat basis, which excluded 323,168 of the 630,814 statin users (as well 
as their non-user matches) leaving a total of 307,646 new statin users matched to 
1,538,020 non-users (Figure 6.6). Overall, the majority of non-users were selected 
once as a match (837,025 non-users, 54.4%), while 478,776 non-users were 
matched on two occasions (31.1%), 169,671 non-users matched to three statin 
users (11.0%), and 52,548 (3.4%) non-users matched to 4-8 statin users.  
Table 6.1 (a) presents the overall distribution of demographics between the two 
groups. Distributions of age and sex (matching factors) were identical between the 
two groups (p=1.000). In terms of lifestyle factors, new statin users were more 
likely to be current or ex-smokers and have a higher BMI (>25) compared to their 
counterpart non-users (p<0.001). In addition, statin users were more likely to have 
a diagnosis of diabetes, coronary heart disease, hypertension, and hyperlipidaemia 
compared to non-users (p<0.001). In terms of medications, statin users were also 
more likely to have been taking NSAIDs and antihypertensive medications 
(p<0.001). Consultation visits to the GP were slightly higher (within 1 year of 
treatment start date) among statin users compared to non-users: mean 
consultation rate per year was 11 for statin users vs 6 for non-users (p<0.001).
175 
 
Table 6.1: Demographics for the matched new statin cohort and nested case-control design (risk-set sampling) 
 
(a) New statin vs matched non-users cohort 
 
(b) Nested case-control 
 
New statin 
 
Non-Statin P-value
a
  Control Case
b
 P-value
a
 
All Patients 307646   
1538020 
 
  487883  97657   
Age 
     
1.000      0.999 
30-39 14368 (4.7)  
71841 (4.7)   5680 (1.2) 1136 (1.2)  
40-49 53773 (17.5)  
268869 (17.5)   33565 (6.9) 6713 (6.9)  
50-59 91622 (29.8)  
458113 (29.8)   78097 (16.0) 15619 (16.0)  
60-69 80903 (26.3)  
404517 (26.3)   127639 (26.2) 25530 (26.1)  
70-79 46576 (15.1)  
232884 (15.1)   142428 (29.2) 28479 (29.2)  
80+ 20404 (6.6)  
101796 (6.6)   100474 (20.6) 20180 (20.7)  
Sex 
     
0.970      0.873 
Male 163667 (53.2)  
818167 (53.2)   233391 (47.8) 46744 (47.9)  
Female 143979 (46.8)  
719853 (46.8)   254492 (52.2) 50913 (52.1)  
Smoking status 
     
<0.001      <0.001 
Non 115053 (37.4)  
689504 (44.8)   200898 (41.2) 37450 (38.3)  
Current 75132 (24.4)  
333811 (21.7)   86533 (17.7) 20270 (20.8)  
Ex 115704 (37.6)  
439600 (28.6)   166986 (34.2) 36894 (37.8)  
Unknown 1757 (0.6)  
75105 (4.9)   33466 (6.9) 3043 (3.1)  
BMI 
     
<0.001      <0.001 
<20 6494 (2.1)  
63518 (4.1)   22965 (4.7) 5986 (6.1)  
20-25 65977 (21.4)  
447459 (29.1)   146544 (30.0) 31148 (31.9)  
>25 218815 (71.1)  
804975 (52.3)   259904 (53.3) 48307 (49.5)  
Unknown 16360 (5.3)  
222068 (14.4)   58470 (12.0) 12216 (12.5)  
[Table 6.1 continued over] 
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[Table 6.1 continued] 
 
(a) New statin vs matched non-users cohort 
 
(b) Nested case-control 
 
New statin 
 
Non-Statin P-value
a
  Control Case
b P-valuea 
Alcohol status      
<0.001      <0.001 
Non 38768 (12.6)  
167407 (10.9)   55058 (11.3) 9944 (10.2)  
Ex 12350 (4.0)  
36426 (2.4)   21140 (4.3) 4674 (4.8)  
Current 8096 (2.6)  
39943 (2.6)   11352 (2.3) 2276 (2.3)  
rare<2u/d 56488 (18.4)  
245204 (15.9)   92587 (19.0) 17844 (18.3)  
moderate3-6u/d 146339 (47.6)  
709770 (46.1)   220934 (45.3) 44250 (45.3)  
excessive >6u/d 29005 (9.4)  
127556 (8.3)   32302 (6.6) 7601 (7.8)  
Unknown 16600 (5.4)  
211714 (13.8)   54510 (11.2) 11068 (11.3)  
Diabetes 88714 (28.8)  
105621 (6.9) <0.001  74658 (15.3) 15420 (15.8) <0.001 
CHD 69974 (22.7)  
58168 (3.8) <0.001  58055 (11.9) 12011 (12.3) <0.001 
Heart Failure 11877 (3.9)  
22732 (1.5) <0.001  21111 (4.3) 5167 (5.3) <0.001 
Hypertension 148318 (48.2)  
325190 (21.1) <0.001  173647 (35.6) 34454 (35.3) 0.064 
Hyperlipidaemia 99255 (32.3)  
65564 (4.3) <0.001  56159 (11.5) 10985 (11.2) 0.019 
NSAIDs/Aspirin 124978 (40.6)  
342029 (22.2) <0.001  168153 (34.5) 37663 (38.6) <0.001 
Antihypertensives 168613 (54.8)  
353061 (23.0) <0.001  208667 (42.8) 44210 (45.3) <0.001 
OC 2484 (0.8)  
16837 (1.1) <0.001  4500 (0.9) 1123 (1.1) <0.001 
HRT 16550 (5.4)  
78697 (5.1) <0.001  20794 (4.3) 5078 (5.2) <0.001 
Consultations      
       
Mean (SD) 10.6 (8.9)  
5.8 (7.3) <0.001  7 (8.5) 11.8 (11.9) <0.001 
a P-values (two-sided) were from t tests (continuous factor) or chi-square test (categorical factor). 
b Includes all cases of breast, colorectal, lung, and prostate cancer 
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6.4.2 New statin users vs new glaucoma medication users 
Overall, 630,827 new statin users were identified, of which 20,706 had a recorded 
prescription for glaucoma medications prior to the first statin prescription (Figure 
6.7). In total, 162,709 patients with a recorded prescription for glaucoma related 
medications were identified; 98,688 patients were excluded as they did not meet 
the inclusion criteria leaving 64,021 new glaucoma medication users. Of the 
remaining 64,021 new glaucoma medication users, 15,711 had a previous statin 
prescription. Leaving a cohort of 48,310 glaucoma medication users and 610,121 
new statin users (Figure 6.7). 
Figure 6.10: Distribution of treatment start date by age and treatment group 
 
(a) Statin Initiation (b) Glaucoma Initiation 
  
 
 
Appendix D, Table 11.1 (c) shows the distribution of demographics between new 
statin users and new glaucoma medication users. Overall age at treatment start 
date differed between the two groups (p<0.001). Higher proportions of statin 
initiators compared to glaucoma medication initiators were seen among ages 50-
79. In contrast, a slightly higher proportion of glaucoma medication users were ≥80 
years (statin 8.8% vs glaucoma 20.4%). Glaucoma medication users were less likely 
to smoke; lower proportions of non-smokers compared to statin users, in addition 
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to a lower proportion of current and ex-smokers (p<0.001).  BMI measures between 
20-25 were higher among new glaucoma medication users compared to new statin 
users (32% vs 23%), However, a higher proportion of statin users had a BMI>25 
compared to glaucoma medication users (70% vs 51%, overall p<0.001). Glaucoma 
medication users were also less likely, compared to statin users, to have been 
diagnosed with diabetes, CHD, hypertension, or hyperlipidaemia. Use of NSAIDs or 
antihypertensive medications was also lower among glaucoma medication users. 
Consultation rates in the year prior to drug initiation was similar between the two 
groups (statin users, rate=10.7; glaucoma medication users, rate=9.2). 
Figure 6.10 depicts initiation of the two treatment groups (statin and glaucoma 
medication use) by calendar year. Figure 6.10 (a) shows the uptake of statin use 
from 1995-2012. A sharp increase in statin initiation can be seen between 1995 and 
2004, a trend which later declines after 2004. Similarly, glaucoma medication users 
also show an increase in uptake from 1995 to 2004. Although not as sharp as with 
statin users, a small decline can be observed post-2004; however, uptake of 
glaucoma medications remained relatively constant from 2005 onwards. 
6.4.3 Ever statin user matched cohort 
Of the initial 1,023,812 patients identified as having a recorded prescription for a 
statin during the study period (1995-2012), 231,493 patients were excluded for 
failing to meet exclusion criteria (Figure 6.8). In total, 3,955,498 non-users were 
matched to 791,295 statin users (prevalent and incident). The final cohort included 
2,090,482 non-users matched to 418,188 statin users – 111,172 extra prevalent 
statin users were added to the new statin cohort (Figure 6.8). 
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Appendix D, Table 11.1 (a) shows the demographics at treatment start date of the 
ever statin user cohort. Overall, similar distributions of most potential confounding 
factors were observed between ever statin users and new statin users (Appendix D, 
Table 11.1 (b)) Antihypertensive use was slightly higher among new statin users 
compared to prevalent users (new statin, 55%; prevalent statin, 44%). Similarly, the 
proportion for NSAID use was slightly higher among new statin users compared to 
prevalent statin users (new statin, 41%; prevalent statin, 32%). 
6.4.4 Nested case-control design 
A cohort of new statin users (N=786,331) and non-users (N=4,093,800) aged 30-90 
years at cohort entry was identified. From this cohort a total of 106,244 incident 
cancer (breast, colorectal, lung, and prostate) cases and 4,773,887 non-cases 
(controls) were identified (Figure 6.9). A matched case control design nested within 
this cohort was conducted. From the initial 106,244 cases identified, 8,567 cases 
were excluded because they had <12 months UTS follow-up prior to the index date. 
Control-time of the remaining 97,677 cases were included in the cohort for further 
consideration as potential controls. The final cohort consisted of 97,657 cases 
matched to 417,623 controls. 
Appendix D, Table 11.2 shows the demographics of the case-control (time-
independent sampling) of new statin users and non-users. Cases in general were 
older compared to controls (p<0.001). Lifestyle factors including smoking status, 
BMI, and alcohol status were similarly distributed between cases and controls 
(p<0.001). Demographics from the matched nested case-control (risk-set sampling) 
showed an even distribution of age and sex compared to the time-independent 
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case-control design (Table 6.1 (b)). However, differences were observed between 
cases and controls in terms of lifestyle factors, co-morbidities and co-medications. 
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Figure 6.11: Relative risk estimates and corresponding 95% confidence intervals for each bias analysis by cancer type 
 
(a) Immortal time bias (treatment definition: 2 statins) (b) Protopathic bias (c) Prevalent user bias 
   
(d) Healthy user bias (e) Time-window bias  
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6.5 Results: Impact of bias 
6.5.1 Overview 
Overall, the impact of four of the five biases in the context of the statin-cancer 
association was minimal. Only time-window bias showed a consistent and 
substantial impact, biasing the relative risk of cancer among statin users toward a 
protective effect.  
6.5.2 Immortal time bias 
Table 6.2 and Figure 6.11 (a) present relative risk estimates, Δβ estimates, and 
corresponding 95% confidence intervals for both the biased and correct analyses of 
immortal time bias. Analyses that required two consecutive recorded statin 
prescriptions (Table 6.2 (a)) yielded Δβ =-0.01 (95% CI; ranging from  -0.11, 0.09) 
across all four cancer types. Compared to the biased analysis, the corrected analysis 
excluded on average 0.12 PY (~44 days) of immortal time. Further analysis that 
extended the minimum period of follow-up to six months (Table 6.2 (b)) yielded 
lower relative risk estimates tending toward the null compared to the less 
restrictive 2-statin definition. More variability between the biased and corrected 
analysis was observed, Δβ for the 6-month follow-up analysis ranging from -0.07 
(95% CI; -0.15, 0.02) for breast cancer to -0.05 (95% CI; -0.13, 0.03) for prostate 
cancer.  
For the 2-statin treatment definition, only corrected confidence interval estimates 
for lung cancer included 1. Breast cancer corrected analysis showed a marginal 
increased risk (RR=1.09; 95% CI; 1.03, 1.16). Prostate and colorectal cancer showed 
borderline increased risk in both biased and corrected analyses. For the 6-month 
treatment definition, confidence intervals from the corrected analyses included 1 
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for prostate cancer. For colorectal, lung, and prostate cancer, increased risks 
associated with the corrected design were observed (colorectal: RR=1.10; 95% CI; 
1.03, 1.18; lung: RR=1.08; 95% CI; 1.01, 1.17; prostate: RR=1.11; 95% CI; 1.05, 1.18).  
Furthermore, risk estimates were marginally different between the biased (lower 
relative risk estimate) and corrected analysis (higher relative risk estimate). Biased 
and corrected risk estimates were generally consistent in terms of direction. 
6.5.3 Protopathic bias 
The impact of protopathic bias on the statin-cancer association was minimal. Table 
6.3 and Figure 6.11 (b) show relative risk estimates, Δβ estimates, and 
corresponding 95% confidence intervals for both the biased and corrected analysis. 
Biased analyses incorporated a 0-lag period, in contrast to the corrected analysis 
which included a 360-day lag period. Protopathic bias Δβ ranged from 0.00 (95% CI; 
-0.10, 0.09) for colorectal cancer to 0.03 (95% CI; -0.06, 0.12) for breast cancer.  
Relative risk point estimates showed little or no change from biased to corrected 
analysis. Of note, confidence intervals for corrected protopathic bias analyses 
spanned 1 for breast and lung cancer. 
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Table 6.2: Immortal time bias relative risk estimates, Δβ estimates and 
corresponding 95% confidence intervals 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Relative Riska 
(95% CI)
Δβb
(95% CI)
(a) Minimum of 2 statin 
prescriptions 
Breast Cancer
Unexposed 505 031 5.94 8254 (1.6) 1.08 -0.01
Exposed 117 691 5.88 2154 (1.8) (1.02, 1.15) (-0.10, 0.08)
Unexposed 502 829 5.85 8149 (1.6) 1.09
Exposed 117 691 5.77 2154 (1.8) (1.03, 1.16)
Colorectal Cancer
Unexposed 1 035 532 5.94 7061 (0.7) 1.08 -0.01
Exposed 251 556 5.83 1787 (0.7) (1.01, 1.16) (-0.11, 0.08)
Unexposed 1 030 623 5.85 6980 (0.7) 1.10
Exposed 251 556 5.71 1787 (0.7) (1.03, 1.17)
Lung Cancer
Unexposed 1 035 532 5.94 7145 (0.7) 1.06 -0.01
Exposed 251 556 5.83 1931 (0.8) (0.99, 1.14) (-0.11, 0.09)
Unexposed 1 030 623 5.85 7082 (0.7) 1.07
Exposed 251 556 5.71 1931 (0.8) (1.00, 1.16)
Prostate Cancer
Unexposed 530 501 5.94 9686 (1.8) 1.12 -0.01
Exposed 133 865 5.78 2517 (1.9) (1.06, 1.19) (-0.09, 0.07)
Unexposed 527 794 5.85 9606 (1.8) 1.13
Exposed 133 865 5.66 2517 (1.9) (1.07, 1.20)
(b) Minimum of 6 months 
follow-up
Breast Cancer
Unexposed 488 154 6.04 8134 (1.7) 1.01 -0.07
Exposed 113 735 6.06 2019 (1.8) (0.95, 1.07) (-0.15, 0.02)
Unexposed 478 769 5.65 7644 (1.6) 1.08
Exposed 113 735 5.56 2019 (1.8) (1.01, 1.15)
Colorectal Cancer
Unexposed 1 000 777 6.05 6929 (0.7) 1.04 -0.06
Exposed 242 986 6.02 1725 (0.7) (0.97, 1.11) (-0.15, 0.04)
Unexposed 980 554 5.65 6606 (0.7) 1.10
Exposed 242 986 5.52 1725 (0.7) (1.03, 1.18)
Lung Cancer
Unexposed 1 000 777 6.05 7040 (0.7) 1.02 -0.06
Exposed 242 986 6.02 1869 (0.8) (0.95, 1.10) (-0.16, 0.04)
Unexposed 980 554 5.65 6735 (0.7) 1.08
Exposed 242 986 5.52 1869 (0.8) (1.01, 1.17)
Prostate Cancer
Unexposed 512 623 6.05 9496 (1.9) 1.06 -0.05
Exposed 129 251 5.98 2403 (1.9) (1.00, 1.12) (-0.13, 0.03)
Unexposed 501 785 5.66 9102 (1.8) 1.11
Exposed 129 251 5.48 2403 (1.9) (1.05, 1.18)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
No. of 
outcomes (%)
Biased
Corrected
Biased
Corrected
Biased
Corrected
Corrected
Biased
Corrected
Biased
Corrected
Biased
Corrected
Biased
Corrected
Biased
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Table 6.3: Protopathic bias relative risk estimates, Δβ estimates and 
corresponding 95% confidence intervals 
 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Relative Riska
(95% CI)
Δβb
(95% CI)
Breast Cancer
Unexposed 553 656 5.81 9 000 (1.6) 1.08 0.03
Exposed 131 581 5.74 2 377 (1.8) (1.02, 1.14) (-0.06, 0.12)
Unexposed 434 616 5.52 6 932 (1.6) 1.05
Exposed 107 399 5.50 1 888 (1.8) (0.98, 1.12)
Colorectal Cancer
Unexposed 1 131 970 5.79 7 641 (0.7) 1.08 0.00
Exposed 281 347 5.67 1 948 (0.7) (1.01, 1.15) (-0.10, 0.09)
Unexposed 895 020 5.51 6 136 (0.7) 1.08
Exposed 231 466 5.45 1 679 (0.7) (1.01, 1.16)
Lung Cancer
Unexposed 1 131 970 5.79 7 743 (0.7) 1.07 0.01
Exposed 281 347 5.67 2 119 (0.8) (0.99, 1.14) (-0.09, 0.11)
Unexposed 895 020 5.51 6 325 (0.7) 1.05
Exposed 231 466 5.45 1 797 (0.8) (0.98, 1.14)
Prostate Cancer
Unexposed 578 314 5.77 10 417 (1.8) 1.12 0.02
Exposed 149 766 5.60 2 726 (1.8) (1.06, 1.18) (-0.06, 0.10)
Unexposed 460 404 5.51 8 537 (1.9) 1.10
Exposed 124 067 5.41 2 336 (1.9) (1.04, 1.17)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
(360-day lag)
Corrected
(360-day lag)
No. of 
outcomes (%)
Biased 
(0-day lag)
Biased
(0-day lag)
Biased
(0-day lag)
Biased
(0-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
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6.5.4 Prevalent user bias 
Table 6.4 and Figure 6.11 (c) present relative risk estimates, Δβ estimates, and 
corresponding 95% confidence intervals for prevalent user bias. Prevalent user Δβ 
ranged from -0.09 (95% CI; -0.17, -0.01) for breast cancer to -0.05 (95% CI; -0.12, 
0.03) for prostate cancer.  
For all four cancer types, the biased analysis, which included prevalent statin users, 
yielded relative risk estimates that were consistently lower compared to the new 
user analysis (Table 6.4 and Figure 6.11 (c)). Confidence intervals for the corrected 
analysis included 1 only for lung cancer. Of note, prevalent users of statins 
represented more than a third of total statin use during the study period (1995-
2012): women only (36%), men and women (38%), and men (46%). 
6.5.5 Healthy user bias 
Table 6.5 and Figure 6.11 (d) present relative risk estimates, Δβ estimates, and 
corresponding 95% confidence intervals for the biased and corrected analysis of 
healthy user bias. The impact of healthy user bias varied by cancer type: Δβ ranged 
from -0.05 (95% CI; -0.18, 0.09) for colorectal cancer to 0.07 (95% CI; -0.06, 0.19) for 
breast cancer.  
No consistent pattern was observed in terms of direction of relative risk estimates 
between biased and corrected analysis among the four cancer types. Breast 
(RR=1.02; 95% CI; 0.91, 1.14) and prostate (RR=1.07; 95% CI; 0.97, 1.18) cancer 
yielded the lowest corrected relative risk estimates, while higher corrected relative 
risk estimates were observed for colorectal (RR=1.15; 95% CI; 1.02, 1.29) and lung 
cancer (RR=1.07; 95% CI; 0.97, 1.18). All corrected analyses confidence intervals 
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included 1 except for colorectal cancer. However, confidence intervals in the 
corrected analysis which compared statin users and glaucoma medication users 
were slightly larger due to the relatively smaller sample size. 
6.5.6 Time-window bias 
Table 6.6 and Figure 6.11 (e) show relative risk estimates, Δβ estimates, and 
corresponding 95% confidence intervals for both the biased and corrected analysis 
of time-window bias. Time-window bias yielded the most variability in terms of Δβ, 
which ranged from -0.34 (95% CI; -0.41, -0.27) for lung cancer to -0.13 (95% CI; -
0.19, -0.08) for prostate cancer.  
Biased analyses yielded statistically significant protective effects across all four 
cancer types: relative risk estimates ranging from RR=0.69 (95% CI, 0.66, 0.72) for 
lung cancer to RR=0.87 (95% CI, 0.84, 0.91) for prostate cancer. Corrected analyses 
showed no association for all four cancer types: relative risk estimates ranged from 
RR=0.97 (95% CI, 0.92, 1.02) for lung cancer to RR=1.05 (95% CI, 1.00, 1.10) for 
breast cancer. 
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Table 6.4: Prevalent user bias relative risk estimates, Δβ estimates and 
corresponding 95% confidence intervals 
Analysis
Statin 
Exposure
N
Median 
Folow-up 
(years)
Relative Riska 
(95% CI)
Δβb
(95% CI)
Breast Cancer
Unexposed 812 670 5.31 12 520 (1.5) 1.00 -0.09
Exposed 169 619 5.28 2 837 (1.7) (0.95, 1.06) (-0.17, -0.01)
Unexposed 502 829 5.85 8 149 (1.6) 1.09
Exposed 117 691 5.77 2 154 (1.8) (1.03, 1.16)
Colorectal Cancer
Unexposed 1 690 276 5.28 10 813 (0.6) 1.03 -0.06
Exposed 369 963 5.17 2 475 (0.7) (0.97, 1.09) (-0.15, 0.03)
Unexposed 1 030 623 5.85 6 980 (0.7) 1.10
Exposed 251 556 5.71 1 787 (0.7) (1.03, 1.17)
Lung Cancer
Unexposed 1 690 276 5.28 10 709 (0.6) 1.01 -0.07
Exposed 369 963 5.17 2 636 (0.7) (0.95, 1.07) (-0.16, 0.03)
Unexposed 1 030 623 5.85 7 082 (0.7) 1.07
Exposed 251 556 5.71 1 931 (0.8) (1.00, 1.16)
Prostate Cancer
Unexposed 877 606 5.26 14 579 (1.7) 1.08 -0.05
Exposed 200 344 5.07 3 380 (1.7) (1.03, 1.14) (-0.12, 0.03)
Unexposed 527 794 5.85 9 606 (1.8) 1.13
Exposed 133 865 5.66 2 517 (1.9) (1.07, 1.20)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Biased
(Prevalent user)
Corrected
(New user)
No. of 
outcomes (%)
Biased
(Prevalent user)
Corrected
(New user)
Biased
(Prevalent user)
Corrected
(New user)
Biased
(Prevalent user)
Corrected
(New user)
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Table 6.5: Healthy user bias relative risk estimates, Δβ estimates and 
corresponding 95% confidence intervals 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Relative Riska
(95% CI)
Δβb
(95% CI)
Breast Cancer
Unexposed 502 829 5.85 8 149 (1.6) 1.09 0.07
Exposed 117 691 5.77 2 154 (1.8) (1.03, 1.16) (-0.06, 0.19)
Unexposed 21 634 4.96 381 (1.8) 1.02
Exposed 254 826 4.95 4 210 (1.7) (0.91, 1.14)
Colorectal Cancer
Unexposed 1 030 623 5.85 6 980 (0.7) 1.10 -0.05
Exposed 251 556 5.71 1 787 (0.7) (1.03, 1.17) (-0.18, 0.09)
Unexposed 40 538 4.90 354 (0.9) 1.15
Exposed 561 295 4.83 4 249 (0.8) (1.02, 1.29)
Lung Cancer
Unexposed 1 030 623 5.85 7 082 (0.7) 1.07 -0.02
Exposed 251 556 5.71 1 931 (0.8) (1.00, 1.16) (-0.15, 0.12)
Unexposed 40 538 4.90 331 (0.8) 1.09
Exposed 561 295 4.83 4 414 (0.8) (0.97, 1.23)
Prostate Cancer
Unexposed 530 501 5.94 9 686 (1.8) 1.12 0.06
Exposed 133 865 5.78 2 517 (1.9) (1.06, 1.19) (-0.05, 0.17)
Unexposed 18 904 4.82 525 (2.8) 1.07
Exposed 306 469 4.73 5 984 (2.0) (0.97, 1.18)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Biased
(non-user comparison group)
Corrected
(glaucoma medication 
comparison group)
No. of 
outcomes (%)
Biased 
(non-user comparison group)
Corrected 
(glaucoma medication 
comparison group)
Biased
(non-user comparison group)
Corrected
(glaucoma medication 
comparison group)
Biased
(non-user comparison group)
Corrected
(glaucoma medication 
comparison group)
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Table 6.6: Time-window bias relative risk estimates, Δβ estimates and 
corresponding 95% confidence intervals  
 
Analysis Case status N
Median 
Follow-up 
(years)
Relative Risk 
(95% CI)
Δβb
(95% CI)
Breast Cancer
Control 1 859 617 6.65 313 766 (16.9) 0.77 -0.31
Case 30 283 5.46 5 096 (16.8) (0.74, .80) (-0.37, -0.25)
Control 122 015 6.10 20 400 (16.7) 1.05
Case 27 965 6.00 4 955 (17.7) (1.00, 1.09)
Colorectal Cancer
Control 3 602 729 6.43 703 478 (19.5) 0.84 -0.21
Case 17 753 6.20 5 195 (29.3) (0.81, 0.88) (-0.28, -0.15)
Control 71 522 6.78 20 641 (28.9) 1.04
Case 16 689 6.64 5 111 (30.6) (0.99, 1.09)
Lung Cancer
Control 3 603 001 6.43 703 351 (19.5) 0.69 -0.34
Case 17 481 6.01 5 322 (30.4) (0.66, 0.72) (-0.41, -0.27)
Control 71 458 6.64 21 139 (29.6) 0.97
Case 16 459 6.40 5 221 (31.7) (0.92, 1.02)
Prostate Cancer
Control 1 709 268 6.23 382 437 (22.4) 0.87 -0.13
Case 21 314 6.59 7 374 (34.6) (0.84, 0.91) (-0.19, -0.08)
Control 85 660 7.20 29 489 (34.4) 1.00
Case 20 064 7.03 7 224 (36.0) (0.96, 1.04)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected 
(Risk-set sampling)
Statin user (%)
Biased
 (Time independent 
sampling)
Biased
 (Time independent 
sampling)
Biased
 (Time independent 
sampling)
Biased
 (Time independent 
sampling)
Corrected 
(Risk-set sampling)
Corrected 
(Risk-set sampling)
Corrected 
(Risk-set sampling)
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6.5.7 Sensitivity analyses: weighting, missing data, and censoring of 
treatment change 
6.5.7.1 Matching with replacement: down-weighting non-users  
Marginally lower relative risk estimates across all cancer types and bias analysis 
(immortal, protopathic, and prevalent user bias) were observed when applying a 
weighted analysis, down-weighting matched non-users that were matched on >1 
occasion (Appendix D, Tables 11.3-11.5). Confidence intervals were of similar width 
suggesting relatively minimal influence of matching with replacement on effect 
estimates. In addition, Δβ estimates from weighted analyses were similar to 
primary analyses estimates across all cancer types. 
6.5.7.2 Missing data 
Differential proportions of missing data (unknown value) were observed for BMI, 
alcohol status, and smoking status between new statin users and matched non-
users (Table 6.1 (a)). Sensitivity analyses assessed the impact of missing data and 
yielded similar relative risk estimates for imputed and missing category analyses 
compared to the primary complete case analysis (Appendix D, Tables 11.6-11.10). 
In addition, Δβ estimates from both imputed and missing category analyses were 
similar to primary analyses estimates across all cancer types. 
6.5.7.3 Censoring follow-up at treatment change 
Appendix D, Tables 11.11-11.13 present relative risk estimates from analyses 
censoring follow-up at treatment switch. For example, non-user follow-up time was 
censored when a first statin prescription was recorded during follow-up. Similarly, 
statin users follow-up time was censored when statin use was stopped for a 
continuous period of 6-months. Higher relative risk estimates were observed for all 
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analyses censoring follow-up at treatment switch. Possible reasons for the increase 
in relative risk might be explained by the higher proportion of exposed cases 
relative to non-user cases compared to primary analysis proportions. In addition, 
unmeasured confounding may have also increased relative risk estimates. 
6.6 Results: Impact of alternative outcome definitions 
6.6.1 Case definitions 
In comparison to the standard case definition, which required one definite 
malignant diagnosis code, higher relative risk estimates from the broader case 
definition were observed across all cancer types. However, the impact of 
alternative case definitions was minimal: Δβ ranged from -0.03 for lung (95% CI; -
0.13, 0.07) and prostate (95% CI; -0.11, 0.05) cancer to -0.01 for breast (95% CI; -
0.10, 0.08) and colorectal cancer (95% CI; -0.10, 0.08) (Table 6.7). The majority of 
additional cases were identified for lung (increase of 717 unexposed and 265 
exposed cases) and prostate cancer (increase of 832 unexposed and 327 exposed 
cases). These two cancer types yielded the most variability between relative risk 
estimates: lung and prostate cancer Δβ =-0.03. The proportion of events remained 
similar between exposed and unexposed groups, even when patients from 
probable and possible diagnostic groups were included, suggesting no differential 
early cancer detection between statin users and non-users. 
6.6.2 Linkage to the cancer registry 
Overall, the incorporation of patient-level linked data from the NCDR generated 
similar results to those that used only CPRD data restricted to linkage eligible 
patients and practices (Table 6.8). Δβ due to incorporating linked data (outcomes 
from all data sources, CPRD OR NCDR) ranged from 0.01 (95% CI; -0.09, 0.11) for 
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prostate cancer to 0.05 (95% CI; -0.06, 0.16) for colorectal cancer (Table 6.8). 
Similarly, analyses restricted to concordant diagnosis between the CPRD AND NCDR 
resulted in minimal impact on the statin-cancer association compared to analyses 
incorporating the CPRD alone. Δβ estimates when incorporating linked data (only 
concordant diagnoses, CPRD AND NCDR) ranged from -0.01 (95% CI; -0.11, 0.11) for 
breast cancer to 0.03 (95% CI; -0.11, 0.17) for lung cancer. Of all four cancer types, 
the most variability in terms of relative risk estimates for each linkage analysis was 
observed for colorectal cancer. In comparison to relative risk estimates from linked 
data analysis (AND or OR), slightly higher relative risk estimates were observed 
when the CPRD alone was used.  
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Table 6.7: Case definitions relative risk estimates, Δβ estimates and corresponding 
95% confidence intervals  
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(%)
Relative Riska 
(95% CI)
Δβb
(95% CI)
Breast Cancer
Unexposed 502 829 5.85 8 149 (1.6) 1.09 -0.01
Exposed 117 691 5.77 2 154 (1.8) (1.03, 1.16) (-0.10, 0.08)
Unexposed 502 829 5.83 8 342 (1.7) 1.11
Exposed 117 691 5.75 2 222 (1.9) (1.04, 1.18)
Colorectal Cancer
Unexposed 1 030 623 5.85 6 980 (0.7) 1.10 -0.01
Exposed 251 556 5.71 1 787 (0.7) (1.03, 1.17) (-0.10, 0.08)
Unexposed 1 030 623 5.84 7 149 (0.7) 1.11
Exposed 251 556 5.70 1 850 (0.7) (1.04, 1.18)
Lung Cancer
Unexposed 1 030 623 5.85 7 082 (0.7) 1.07 -0.03
Exposed 251 556 5.71 1 931 (0.8) (1.00, 1.16) (-0.13, 0.07)
Unexposed 1 030 623 5.84 7 799 (0.8) 1.10
Exposed 251 556 5.70 2 196 (0.9) (1.03, 1.18)
Prostate Cancer
Unexposed 527 794 5.85 9 606 (1.8) 1.13 -0.03
Exposed 133 865 5.66 2 517 (1.9) (1.07, 1.20) (-0.11, 0.05)
Unexposed 527 794 5.84 10 438 (2.0) 1.17
Exposed 133 865 5.64 2 844 (2.1) (1.11, 1.24)
Broad case definition
No. of 
outcomes (%)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Standard case 
definition
Standard case 
definition
Standard case 
definition
Standard case 
definition
Broad case definition
Broad case definition
Broad case definition
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Table 6.8: Linked data relative risk estimates, Δβ estimates and corresponding 
95% confidence intervals 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Relative Riskb 
(95% CI)
Δβc
(95% CI)
Breast Cancer
Unexposed 306 529 5.85 5 055 (1.6) 1.08
Exposed 71 631 5.80 1 336 (1.9) (1.00, 1.17)
Unexposed 304 987 5.85 5 484 (1.8) 1.06 0.02
Exposed 71 456 5.80 1 441 (2.0) (0.98, 1.14) (-0.09, 0.13)
Unexposed 304 987 5.85 3 877 (1.3) 1.09 -0.01
Exposed 71 456 5.80 1 029 (1.4) (1.00, 1.19) (-0.13, 0.11)
Colorectal Cancer
Unexposed 633 100 5.88 4 267 (0.7) 1.16
Exposed 154 039 5.77 1 119 (0.7) (1.07, 1.26)
Unexposed 630 217 5.88 5 595 (0.9) 1.11 0.05
Exposed 153 704 5.77 1 435 (0.9) (1.03, 1.19) (-0.06, 0.16)
Unexposed 630 217 5.88 3 441 (0.5) 1.14 0.02
Exposed 153 704 5.77 897 (0.6) (1.04, 1.26) (-0.11, 0.15)
Lung Cancer
Unexposed 633 100 5.88 4 276 (0.7) 1.06
Exposed 154 039 5.77 1 145 (0.7) (0.97, 1.16)
Unexposed 630 217 5.88 5 904 (0.9) 1.04 0.02
Exposed 153 704 5.77 1 586 (1.0) (0.96, 1.13) (-0.11, 0.14)
Unexposed 630 217 5.88 3 646 (0.6) 1.03 0.03
Exposed 153 704 5.77 966 (0.6) (0.93, 1.14) (-0.11, 0.17)
Prostate Cancer
Unexposed 326 571 5.90 6 226 (1.9) 1.09
Exposed 82 408 5.74 1 578 (1.9) (1.01, 1.17)
Unexposed 325 230 5.90 7 039 (2.2) 1.08 0.01
Exposed 82 248 5.74 1 810 (2.2) (1.01, 1.16) (-0.09, 0.11)
Unexposed 325 230 5.90 4 671 (1.4) 1.09 0.00
Exposed 82 248 5.74 1 192 (1.4) (1.00, 1.18) (-0.11, 0.11)
No. of 
outcomes (%)
CPRD data only
a
CPRD data only
a
CPRD data only
a
CPRD data only
a
CPRD OR linked NCDR and 
death registry data
CPRD OR linked NCDR and 
death registry data
CPRD OR linked NCDR and 
death registry data
a Restricted to CPRD linkage eligible patients;  
b Relative risk adjusted for all potential confounders listed in Table 6.2; 
cΔβ= Difference between "CPRD data only" and "linked" log relative risk estimates 
CPRD OR linked NCDR and 
death registry data
CPRD AND linked NCDR and 
death registry data
CPRD AND linked NCDR and 
death registry data
CPRD AND linked NCDR and 
death registry data
CPRD AND linked NCDR and 
death registry data
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6.7 Discussion 
6.7.1 Overview 
In this chapter, the impact of several potential drivers of discrepant results was 
systematically evaluated. Potential drivers included study design bias, different case 
definitions, and data linkage. These potential drivers have often been cited as 
potential reasons for conflicting findings between past observational studies, and 
also have the potential to influence future studies.69, 70, 116, 118, 119, 187 
The statin-cancer association was selected as a basis to evaluate the impact of 
these potential drivers. Findings from past RCTs40, 41, 50, 78, 198 and 
pharmacoepidemiological studies131, 206, 207 lead to the assumption that no causal 
link exists between statin use and cancer risk, and thus a “corrected” analysis 
should yield confidence interval estimates that include 1. Results observed in this 
chapter showed that six of the seven potential drivers had minimal effect on the 
overall conclusions of an example study examining statin use and cancer risk. On 
the other hand, the findings demonstrated how a single bias (time-window bias) 
can influence quantitative findings of a study if not mitigated appropriately. 
6.7.2 Impact of bias on the statin-cancer association 
In the context of the statin-cancer association, the impact of four of the five biases 
examined was minimal. Only time-window bias consistently drove the estimated 
statin-cancer association toward a protective effect. Immortal time, protopathic, 
prevalent user, and healthy user bias had minimal impact on the statin-cancer 
assoication. 
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6.7.2.1 Impact of time-window bias 
Time-window bias showed the greatest impact among all biases examined in this 
study. A consistent change from a protective effect (biased analysis) to a null 
association (corrected analysis) was observed across all four cancer types. Similar 
effects were observed to those presented by Suissa et al.119 who also examined 
lung cancer risk among statin users. 
6.7.2.2 Impact of immortal time bias 
The overall impact of immortal time bias in the context of this study was marginal. 
Point estimates of the direction of bias (biased vs corrected analyses) was 
consistently towards a lower relative risk across all four cancer types, although 
direction of Δβ was uncertain: 95% CIs including negative and positive Δβ estimates. 
Only confidence intervals corresponding to the corrected analysis for lung cancer 
spanned 1. Borderline confidence intervals were observed for the other three 
cancer types; the most pronounced effect observed was for prostate cancer.   
These findings contrast with those from past pharmacoepidemiological studies that 
might have been affected by immortal time bias.69 Importantly, two main 
components have been shown to drive the extent of this bias: (i) the proportion of 
immortal time relative to total exposed time; and (ii) the ratio of person time 
between exposed and unexposed groups.69 The relatively minimal impact of 
immortal time in this study can be partly explained by the low proportion of 
immortal time relative to the exposed person time (immortal time/total exposed 
time). Estimates ranged from 2% ((706491-693997)/706491) for treatment 
definition 1 to 9% ((608213-554289)/608213)  for treatment definition 2, which was 
not unexpected since the treatment definitions implemented were conservative 
198 
 
and representative of definitions utilised by most observational statin-cancer 
studies (Chapter 3). Furthermore, the ratio of observed person-years between 
unexposed and exposed was moderate (~4.2 across all cancer types) – a lower 
number of non-users relative to statin users would increase immortal time. These 
two measures were relatively low/high in comparison to figures reported by Suissa 
et al.69 The ratio of immortal time to total exposed time was 103% (316.5/308.1) 
(high proportion of immortal time among exposed). The ratio of person-years 
between exposed and unexposed was 0.8 (lower number of unexposed patients 
compared to exposed) which could partly explain the contrasting minimal impact of 
immortal time bias observed in this study. 
6.7.2.3 Impact of protopathic bias 
The impact of protopahic bias was minimal, with only breast and prostate cancer 
showing slight variability between biased and correct analyses. Although the overall 
impact of protopathic bias was relatively small, “corrected” relative risk estimates 
were less than or equal to “biased” estimates when no lag period was 
implemented. Based on the systematic review conducted in Chapter 3 which 
examined statin-cancer pharmacoepidemiogical studies, most studies implemented 
a lag-time across all cancer types to mitigate protopathic bias. Despite most studies 
implementing a lag period, the impact of protopathic bias in the statin-cancer 
setting may be minimal because there may not be a common pre-diagnosis cancer 
symptom(s) that would typically lead to a statin prescription. However, other 
situations may have a larger impact; for example, discontinuation of statin use in a 
case-control setting or symptoms such as cough treatment, gastro-intestinal 
problems, and pain.  
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6.7.2.4 Impact of prevalent user bias 
Relative risk estimates across all cancer types differed marginally when considering 
new statin users compared to the inclusion of both incident and prevalent statin 
users. However, the inclusion of prevalent statin users yielded consistently lower, 
albeit marginal, relative risk estimates compared to results from the new user 
analysis, suggesting an effect tending toward the null among prevalent statin users. 
The impact between a new user and prevalent user analysis observed in this study 
was similar to that observed in a past study by Schneeweiss et al.208 who 
investigated 1-year mortality among elderly patients in Pennsylvania, USA. Similar 
to this study, a small difference in risk was observed by Schneeweiss et al.208 Δβ=-
0.03. Over half of all statin users in this study were incident users, in contrast to 
that of Schneeweiss et al.208 where less than half of all statin users were new users. 
This may have brought about slight differences in results observed in this chapter in 
terms of power and sample size compared to Schneeweiss et al.208 The proportion 
of new and prevalent users of any such drug is dependent on the prevalence of the 
drug and the start point (treatment start date) at which new users are defined. 
6.7.2.5 Impact of healthy user bias 
Overall, the impact of healthy user bias was minimal, and corrected analyses 
confidence intervals crossed 1 for all cancer types except colorectal cancer. Healthy 
user analyses (corrected vs biased) showed the most variability within cancer type. 
This may have been caused by the lack of power in the study, or by a spurious 
association between glaucoma medication users and the risk of cancer; although, 
previous literature suggests otherwise for the latter.209, 210 Previous studies have 
argued that statin users are possibly healthier compared to their non-user 
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counterparts from the general population due to the health seeking behaviour of a 
patient receiving a preventative drug.118 At inception of statin use, descriptive 
analysis examining lifestyle factors, co-morbidities and medications suggest the 
contrary. A greater proportion of statin users were overweight, current smokers, 
with more co-morbidities compared to non-users. However, visits to the GP were 
generally higher among statin users compared to their counterpart non-users (11 vs 
6 visits per year). “Corrected” analysis relative risk estimates for both breast and 
prostate cancer moved toward the null, which could be partly explained by 
minimisation of detection bias. Although “corrected” relative risk estimates moved 
upward from the null for colorectal and lung cancer, which may be due to fatality of 
disease. 
6.7.3 Sensitivity analysis 
Three analytical aspects of the implemented study designs were examined in 
further sensitivity analyses: replacement of non-users in the matching process; 
missing data; and censoring patients at treatment switch. Overall, study findings 
were robust in terms of replacement of non-users and missing data. However, 
increased relative risk estimates were observed when censoring at treatment 
switch, in comparison to the primary analysis which utilised an intention to treat 
design. In the censored analysis, slightly higher proportions of exposed cases 
relative to non-users were observed compared to the primary analysis which could 
have contributed to the increased cancer risk associated with statin use. However, 
unmeasured confounding could have also influenced effect estimates. That being 
said, Δβ estimates were similar between primary ITT analyses compared to 
sensitivity analyses incorporating treatment switch. 
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6.7.4 Impact of outcome definition on the statin-cancer association 
Similar to the impact of bias, the implementation of alternative approaches to 
define cancer outcomes did not influence study findings substantially. 
6.7.4.1 Case definition 
Using a broader case definition to identify cancer events (addition of patients from 
possible and probable diagnostic groups) had relatively minimal impact on the 
effect of statin use on cancer risk. This was in part due to the relatively low number 
of additional cases included in the broad definition. The relatively low number of 
additional cases included in the broad definition can be explained by the majority of 
cases with a recorded malignant site-specific diagnosis in their patient profile. This 
is consistent with results observed in Chapter 5, and with previously published 
results from Charlton et al.187 and Haynes et al.188 
6.7.4.2 Linkage of primary care data to the cancer registry 
Linking of primary care data to external disease registries such as the NCDR is an 
evolving aspect of epidemiological studies that utilise electronic health records. 
Inclusion of cancer events from either primary care or cancer registry data sources 
had little impact on the effect of statin use on cancer risk. In Chapter 5, PPV 
estimates of CPRD recorded cancer diagnoses were high across all cancers. In the 
other direction, sensitivity estimates of NCDR diagnosis varied by cancer type. 
Based on the systematic review of identification of incident cancers in UK primary 
care databases (Chapter 2), a lower likelihood of confirmatory evidence would be 
found in the GP records of patients with a non-malignant diagnosis code. From the 
examination of NCDR linked data (Chapter 5); approximately 40% of cases 
identified in the NCDR alone (no concordant diagnosis in the CPRD) had a non-
specific or non-malignant diagnosis code in the CPRD. In both circumstances, within 
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the statin-cancer association, the addition of these cases (either a patient from the 
probable/possible diagnostic group or a discordant case identified in the NCDR) had 
no substantial effect on study findings in the context of the statin-cancer 
association. In comparison to linked data relative risk estimates, estimates from the 
CPRD alone were higher for colorectal, lung, and prostate cancer, which may be due 
to an underestimation of cases in primary care as observed in Chapter 6. Primary 
care data linkage to cancer registry data would lead to a more precise estimate of 
overall cancer in comparison to utilising primary care data alone.    
6.7.5 Residual bias in corrected analyses 
Confidence interval estimates from some “corrected” analyses did not cross 1. 
“Corrected” analysis of immortal, protopathic and prevalent user bias produced 
confidence intervals >1 for breast, colorectal, and lung cancer; an increased risk of 
prostate cancer was the most pronounced effect. Unmeasured confounding may 
explain why the corrected analysis showed a result that was in some cases further 
from the null (assumed true association) than the biased analysis. From the 
systematic review (Chapter 3), prostate cancer showed the most variation in terms 
of observed effect: 3 studies observed an increased risk, 4 observed a reduced risk, 
and 10 observed no association. Detection bias, particularly for prostate cancer, is 
the main argument given by previous studies that observed an increased risk of 
cancer among statin users.207 This study adjusted for consultation rate and also for 
healthy user bias by considering the comparison group of glaucoma medication 
users. Although the null effect observed for most cancer types in the healthy user 
analysis is consistent with detection bias circumvented by employing an active 
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comparison drug group, the impact of the bias is uncertain because of the lower 
power and precision due to smaller number of patients overall. 
In comparison to the cohort design analyses, corrected relative risk estimates from 
the nested case-control study were in range of what was assumed to be the true 
association between statin use and cancer risk. The variability between designs 
could have contributed to the differences observed between the corrected relative 
risk estimates from the cohort study designs (immortal, protopathic, prevalent user 
bias) compared to the nested case-control study design (time-window bias). As 
reported by Madigan et al.211 variability between study designs has been shown to 
be a driving factor between studies examining the same question. In contrast, 
variability within study design had a lower impact on study findings which is 
consistent with observed findings from bias analysis of immortal, protopathic, and 
prevalent user bias, which employed the matched cohort design. 
6.7.6 Limitations 
This study had several limitations. First, results are limited to one particular type of 
drug (statins) and to cancers of the breast, colorectum, lung, and prostate. In 
addition, the UK CPRD stores primary care data collected from UK general practices. 
Findings may have differed if other drug-cancer pairings had been investigated, or if 
another data source had been utilised. 
Second, the biases examined in this thesis are not exhaustive; for example, bias 
related to adjustment of unmeasured confounders, measurement error, or missing 
data were not examined. Although, in their own right, they are important design 
considerations to bear in mind when conducting an observational study, 
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examination of their impact in a pharmacoepidemiological setting was outside the 
scope of this thesis. 
Third, the choice of study design was not exhaustive; all possible design options 
were not implemented. For example, varying the ratio of controls to cases for time-
window bias, or changing the exposure definition to 1-year minimum exposure for 
immortal time bias would have been other possible options. The designs that were 
implemented in this study were intended to be representative of those used in past 
observational studies of the association between cancer and statin use (Chapter 3) 
or previous pharmacoepidemiological studies with cancer as the main outcome. 
Lastly, the main objective of this study was not to estimate the statin-cancer 
association, but to estimate the impact of bias in the context of this question. 
Adjustment for various potential confounders that could have affected the statin-
cancer association was implemented. However, as with all observational studies, 
there was a chance of unmeasured confounding affecting results. 
6.7.7 Future Studies 
Future studies may include further bias studies,212 particularly for other drug-
disease pairings. In addition, studies examining other biases, for example, those 
related to missing data, unmeasured confounding, or measurement error could be 
conducted in real settings i.e. empirically from an electronic healthcare database or 
alternatively by simulated data. 
6.7.8 Conclusion 
Pharmacoepidemiological studies have the possibility to impact public health and 
influence the decision making process of both clinician and patient. A major 
concern, however, has been conflicting findings from recent 
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pharmacoepidemiological studies,19, 21 which coulld put both clinician and patient in 
uncertain positions with regards to prescribing and either initiation or continuation 
of such medications, respectively. 
A number of observational studies examining the risk of cancer associated with 
statin use have shown conflicting findings (Chapter 3). A number of common design 
flaws and decisions have been postulated as drivers of these discrepant results. 
However, this chapter has demonstrated that in a practical study setting, these 
flaws and differences in study design do not uniformly lead to large changes in 
estimated associations between statin use and cancer risk. Only time-window bias 
lead to consistent differences between biased and corrected analyses. In contrast, 
none of the other postulated biases or differing case definitions substantially 
influenced the perceived risk of cancer associated with statin use. 
Nevertheless, study-specific factors are likely to affect the magnitude of different 
biases in different settings. Therefore, appropriate selection of design methods and 
sensitivity/bias analysis are needed to ensure transparency and confidence in study 
conclusions, particularly if results divert from past findings. 
6.8 Summary 
 A series of observational studies were undertaken within the context of the 
statin-cancer association to measure and compare the impact of several 
potential drivers of conflicting findings including study bias, case definitions, 
and data linkage. 
 Assessed biases included immortal time, protopathic, prevalent user, 
healthy user, and time-window bias. 
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 Of the seven potential drivers of discrepant results in the example study of 
statins and cancer, only time-window bias yielded substantial and consistent 
biased effects, with bias towards a protective association and corrected 
analyses yielding a null association.  
 Immortal time, protopathic, prevalent user, and healthy user bias had 
minimal impact on the estimated association between statin use and cancer 
risk. 
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7 Thesis summary and conclusions 
7.1 Introduction 
In this chapter, the main findings and key discussion points that have been 
described in this thesis are summarised and brought together. First, a summary of 
the research undertaken is outlined. Second, for each main analysis (Chapters 5 
and 6), key findings are compared with past research reviewed in Chapters 2-3, and 
their strengths and limitations summarised. Last, implications, areas of future 
research, and conclusions are outlined. 
7.2 Summary of research undertaken 
In recent years, an increasing number of pharmacoepidemiological studies have 
been undertaken using databases of routinely collected health records. However, 
there have been conflicting findings from studies examining the same question 
using similar databases.  
The primary aim of this thesis was to examine whether differences in case 
ascertainment or common design flaws could explain conflicting findings among 
studies examining the association between statin use and cancer risk.  
As a starting point, two systematic reviews of existing literature were undertaken. 
The first examined current practices used to identify incident cancer from UK 
primary care databases (Chapter 2). The second evaluated findings from 
observational studies examining the risk of cancer associated with statin use, with a 
focus on methodological considerations (Chapter 3). 
Two main analyses were conducted to address the main aim of this thesis. The first, 
a validation study of recorded cancer diagnoses in the CPRD (Chapter 5). The 
second, a series of observational studies using primary care data from the CPRD to 
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measure the impact of several study design flaws and decisions on the association 
between statin use and cancer risk (Chapter 6). 
7.3 Validity of cancer diagnosis in the CPRD (Chapter 5) 
7.3.1 Summary of main findings from Chapter 5 
i. Two case definitions were developed from primary care data to estimate 
cancer incidence rates: 
a.  Standard case definition: malignant site-specific diagnoses. 
b. Broad case definition: inclusion of cases with borderline, suspected 
or general codes with supporting evidence of diagnosis (broad 
definition) were. 
ii. In a random sample of 2 million patients from the CPRD, estimated 
incidence rates for breast, colorectal, lung, and prostate cancer were 
compared to national rates published by the ONS. In comparison to national 
rates, primary care incidence rates were lower across all cancer types 
examined. Disparities varied by age, sex, calendar year, and cancer type.  
iii. Estimated primary care incidence rates of cancer were marginally increased 
by the inclusion of non-specific cancer diagnoses (broad case definition), but 
remained lower than nationally published rates. 
iv. In an analysis of agreement between primary care data (CPRD) and linked 
cancer registry data (NCDR), in terms of capturing recorded cancer 
diagnoses the NCDR was treated as the gold standard. PPV estimates of 
CPRD recorded cancer diagnoses were generally high, ranging from 88% for 
prostate cancer to 90% for colorectal cancer. 
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a. 21% breast, 17% colorectal, 11% lung, and 21% of prostate cancer 
cases in primary care data with no match in the cancer registry had 
>1 Read code for the same diagnosis (Read codes mapped to the 
cancer ICD-10) within their CPRD computerised records. 
v. Sensitivity of primary care recorded diagnoses with respect to the cancer 
registry was lower, estimates ranging from 67% for lung cancer to 89% for 
breast cancer. 
a. Recorded diagnoses of cancer identified in the cancer registry but 
not in primary care were apparently related to death. This was 
particularly prominent for lung cancer, 40% of lung cancer cases 
identified in the cancer registry but not in primary care had a death 
recording in the CPRD within 1-year of the NCDR diagnosis date. 
b. Approximately 11% of colorectal/lung and 33% of breast/prostate 
cancer diagnoses recorded in the cancer registry without a match in 
primary care data had a cancer related diagnoses (in situ, borderline, 
suspected diagnosis of the same site) in primary care data. These 
varying proportions suggest some form of cancer related diagnosis 
was recorded in primary care, despite not being captured when 
using a site-specific malignant case definition. 
vi. In comparison to nationally available incidence rates, primary care data 
incorporating linked cancer registry data generated higher breast and 
prostate cancer incidence rates. However, similar rates were observed for 
colorectal and lung cancer in men.  
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vii. Higher (in comparison to ONS published rates) linked incidence rates may be 
partly explained by possible false-positive cases identified in primary care 
data, or cases that were not registered nationally. However, future studies 
need to confirm or refute this finding. 
7.3.2 Validity of recorded cancer diagnoses in the context of previous 
research 
i. Consistent with previous studies,187, 188 estimated cancer incidence rates 
from primary care data were lower compared to national rates. 
ii. Consistent with Charlton et al.187 the addition of colorectal cancer cases 
with non-specific cancer related codes resulted in marginal increases of 
estimated incidence rates. In this study, similar findings were also observed 
for breast, lung, and prostate cancer. 
iii. Consistent with previous studies, high estimates of positive predictive values 
of recorded primary care diagnosis with respect to recorded cancer 
registrations were observed. However, a small proportion of cases in the 
CPRD did not have a match in the cancer registry. Whether these cases were 
not registered nationally or are false-positive cases is uncertain. 
iv. In contrast to past cancer registry linkage studies,80, 194 sensitivity of 
recorded primary care cancer diagnoses with respect to the cancer registry 
in this study was low. Possible reasons why this may be the case include: 
a. Agreement was defined as specific matches of ICD-10 (breast: C50; 
colorectum: C18-C20; lung: C34; and prostate: C61) codes between 
all data sources. Whether previous studies utilised broader 
definitions is unclear from reported methods. 
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b. Cohorts with pre-existing conditions (diabetes,194 symptoms of 
cancer80 were used in previous studies, this might have 
overestimated agreement as these patients may be more likely to 
have cancer detected. 
c. A different version of the linked dataset was used. This study utilised 
Set 9, while previous studies may have used earlier versions. 
d. This study did not access linked hospital episodes statistics data or 
free-text, which may have increased sensitivity estimates if utilised.  
v. No other studies have estimated cancer incidence rates from linked primary 
care data. However, a study linking primary care data (CPRD) to the national 
registry of acute coronary syndromes (Myocardial Ischaemia National Audit 
Project, MINAP) also observed higher incidence rates of acute myocardial 
infarction compared to expected rates when using combined data from the 
CPRD, MINAP, Hospital Episodes Statistics, and ONS mortality.196 
7.3.3 Strengths of this study 
This validation study has several strengths:  
i. In this thesis, a random sample of the CPRD was used to evaluate agreement 
between linked data sources. In contrast, previous studies have focussed on 
specific clinical groups, e.g. diabetes patients,194 with limited 
generalisability. 
ii. This study used data from a 10-year period, and was one of the largest 
studies to examine cancer incidence rate estimates using primary care data. 
iii. The cancer outcome code list modified for purposes of this study included a 
broad range of codes for most cancer types. Both malignant and non-
212 
 
malignant cancer related diagnosis codes were included. The broad 
coverage of the code list enabled comprehensive identification of cases as 
well as identification of cancer related diagnoses from patient profiles in the 
CPRD or NCDR when discordance occurred. 
7.3.4 Limitations of the study 
Limitations of this study are detailed in Chapter 5. A brief summary of these 
limitations are listed below: 
i. Findings from this study were limited to cancers of the breast, colorectum, 
lung, and prostate and may not be generalised to other cancer types. 
ii. Linkage of primary care data to external sources were limited to 
participating patients and practices and may not be generalised to the CPRD 
as a whole. However, incidence rate differences were marginal when 
comparing estimates from the initial CPRD random sample to estimates 
from linkage eligible patients and practices. 
iii. In this study, agreement of recorded diagnoses was defined as a specific 
match of ICD-10 codes in all data sources (CPRD, NCDR, and ONS mortality), 
which may be considered narrow. For example, a Read code indicating 
malignant cancer of the colon (e.g. B13..00) would be mapped to C18 (C18: 
Malignant neoplasm of the colon). If this particular diagnosis was coded in 
the NCDR with a related code such as C26 (Malignant neoplasm of ill-
defined digestive organ), then this would be considered a discordant match. 
However, for all discordant cases, searches of other relevant recorded 
diagnoses in both the CPRD and NCDR were examined in an attempt to 
explain the disagreement between data sources.     
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7.4 Systematic evaluation of the impact of potential methodological 
drivers of discrepant results in a pharmacoepidemiological study 
of statin use and cancer risk (Chapter 6) 
7.4.1 Summary of main findings from Chapter 6 
i. In a cohort of new statin users matched to non-users, the impact of 
immortal time bias in the context of the statin-cancer association was 
marginal. There was a consistent direction of effect closer to the null, biased 
analyses resulted in lower relative risk estimates compared to corrected 
analyses. Δβ was consistently estimated at 0.01 across all cancer types 
examined. 
ii. Also in a new user matched cohort, the effect of protopathic bias was 
minimal. Δβ estimates for protopathic bias ranged from 0.00 for colorectal 
cancer to 0.03 for breast cancer. 
iii. In an analysis to assess the impact of prevalent user bias, a cohort consisting 
of both prevalent and new statin users was compared to a new user cohort 
of statin users. Inclusion of prevalent users moved the effect estimate 
toward the null suggesting a weak protective or null association from the 
inclusion of prevalent users. The impact of prevalent user bias was minimal, 
Δβ estimates for prevalent user bias ranged from -0.09 for breast cancer to -
0.05 for prostate cancer. 
iv. The impact of healthy user bias was assessed by comparing two cohorts. 
Cohort 1 (corrected analysis) included a comparison of new statin users and 
new users of glaucoma medication users. The second cohort (potentially 
biased analysis) comprised of statin users matched to non-users. Effects of 
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healthy user bias varied by cancer type: Δβ ranged from -0.05 (95% CI; -0.18, 
0.09) for colorectal cancer to 0.07 (95% CI; -0.06, 0.19) for breast cancer. 
v. Time-window bias yielded the largest impact among the different biases 
considered. For all cancer types, there was a consistent direction of effect 
from biased (protective association) to corrected analysis (null association). 
Δβ estimates between biased (time-independent sampling of controls) and 
corrected analyses (risk-set sampling of controls) ranged from -0.34 (95% CI; 
-0.37, -0.25) for lung cancer to -0.13 (95% CI; -0.19, -0.08) for prostate 
cancer.  
vi. From the systematic review described in Chapter 2 two case definitions 
were typically used to define cancer outcome in primary care data. In 
comparison to the standard case definition which required one definite 
malignant diagnosis code, differences in relative risk estimates from the 
broad case definition (addition cases with non-specific cancer related 
diagnosis codes) were marginal. Δβ ranged from -0.01 for breast and 
colorectal cancer to -0.03 for lung and prostate cancer. 
vii. Overall, the incorporation of patient-level linked data from both the cancer 
and death registry generated similar results to those that used only primary 
care data restricted to linkage eligible patients and practices. Δβ due to 
linked data (CPRD OR linked data) ranged from 0.01 (95% CI; -0.09, 0.11) for 
prostate cancer to 0.05 (95% CI; -0.06, 0.16) for colorectal cancer. 
7.4.2 Impact of potential drivers of conflicting results in the context of 
previous research 
i. There was generally varied methodology among 30 studies investigating the 
association between statin use and risk of breast, colorectal, and prostate 
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cancer (Chapter 3). Furthermore, several populations and sources of 
electronic data were utilised by these studies including routinely collected 
health data from GP surgeries, administrative data from insurance claims, 
and disease registries. Variables collected by these sources as well as 
reasons for data collection vary between these data sources. Comparisons 
of findings from the reviewed studies and the study presented in this thesis 
should be made cautiously. 
ii. From the 30 studies, there were several studies reporting a statistically 
significant increased or reduced risk of cancer, particularly for colorectal, 
lung and prostate cancer. Some evidence of consistent effects from 
prevalent user and time-window bias was observed. Correction for healthy 
user bias yielded the most variability in terms of relative risk estimates.  
iii. Many of the examples of immortal time bias described in literature have 
shown relatively large differences in risk estimates between biased and 
corrected analyses.69, 213 In contrast, findings from this study have shown 
minimal impact of immortal time bias. Two possible reasons could explain 
this conflict:  
a. In previous research, immortal time bias had not been examined in 
the context of the statin cancer association. Typical definitions of 
exposure status from studies may depend on the drug disease 
pairing (e.g acute diseases) investigated which may influence the 
magnitude of immortal time bias.   
b. Extreme design parameters may have been implemented in these 
examples leading to a greater impact of immortal time bias.   
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iv. In the context of the systematic review conducted in Chapter 3, 1 out of 16 
cohort studies may have potentially been affected by immortal time bias. 
The majority of studies in the review defined exposure status as ≥1 statin 
prescription. Based on these definitions, the potential impact of immortal 
time bias is likely to be minimal due to the direct correlation between 
exposure definitions and magnitude of immortal time. 
v. From the systematic review conducted in Chapter 3, 12 studies did not 
implement a lag-period to guard from protopathic bias. There were 
suggestions of this bias influencing findings, particularly when the 4/12 
studies linked short term statin use (≤12 months) with increased/decreased 
risk of cancer. However, these findings were difficult to un-tangle as many of 
these studies may have also been affected by prevalent user bias which may 
have jointly influenced spurious findings of short term associations. 
vi. In this study, the impact of prevalent user bias was minimal. However, weak 
evidence of a protective or null association from the inclusion of prevalent 
users was observed. This effect was consistent with studies reviewed in 
Chapter 3: two new user cohort studies, Smeeth et al. and Hippisley-Cox et 
al. presented higher relative risk estimates compared to their counterpart 
studies that included prevalent statin users.  
vii. The effects of healthy user bias in this study were minimal. An active 
comparison group consisting of glaucoma medication users (prevent 
progression of glaucoma) was utilised to minimise differences in risk due to 
attitudes toward disease prevention and healthcare utilisation. Although the 
comparison groups were similar in some respects such as rate of GP 
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consultations prior to treatment initiation, there were differences observed 
in terms of prior co-medications and co-morbidities.  
viii. 10 of 30 studies did not appear to account for healthy user bias (Chapter 3). 
None of 10 studies (i) used an active drug comparator group; or (ii) adjusted 
for health utilisation services such as screening or cancer related testing. 
Among the 30 review studies, attempts to minimise healthy user bias by 
either by (i) or (ii) yielded the most variability in study conclusions compared 
to other biases considered.  
ix. The current study was in line with reported findings from Setogchi et al.146 
(null association); in contrast, Clancy et al.214 reported a decreased risk of 
colorectal cancer when comparing new statin users to new glaucoma 
medication users. 
x. Time-window bias yielded the largest impact of all biases considered in this 
thesis. However, only one of the reviewed case-control studies was 
susceptible to this bias (Chapter 3). Consistent with findings from this study, 
the impact of this bias has been shown in case-control studies examining 
lung and pancreatic cancer risk associated with statin use.119 28 
xi. No other studies have evaluated the effect of alternative cancer case 
definitions on epidemiological study findings in UK primary care databases. 
xii. No other studies have looked at various forms of linked data in a 
pharmacoepidemiological setting. However, Boggon et al.88 compared 
cancer survival from the CPRD to CPRD linked cancer registry data, and 
found marginal difference in cancer survival estimates. 
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xiii. Importantly, absolute risk estimates of statin use and cancer risk were 
higher when utilising primary care data alone compared to estimates 
incorporating linked cancer registry data. In line with results from Chapter 5, 
cancer risk may be underestimated if only primary care data is utilised.  
7.4.3 Strengths of the study 
i. In comparison to previous studies of statin use and cancer risk in UK primary 
care databases,56, 128, 130, 131 this study had similar if not greater power. 
ii. Prescription data in the CPRD are automatically captured when GPs issue 
prescriptions. Therefore complete records of prescriptions written by the GP 
are stored on the CPRD which provides assurance about the quality of the 
data going into the varying definitions of exposure implemented in this 
thesis. However, there is no information on whether medications had 
actually been taken or adhered to the prescribed course. That being said, if 
repeat prescriptions had been written by the GP over several occasions the 
patient is likely to have been taking these medications.    
iii. Design parameters (such as exposure definition, outcome definitions) 
reflected those implemented by past studies described in Chapter 2 and 3. 
iv. Findings from this study appear to be robust. Several sensitivity analyses 
were conducted to assess the effect of missing data and matching with 
replacement. In both cases, similar Δβ estimates to those from the primary 
analyses were observed. 
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7.4.4 Limitations of the study  
i. Cancers of the breast, colorectum, lung, and prostate were examined in this 
study. Therefore, findings from this study may not be generalised to other 
cancer types. 
ii. This study was conducted in the UK CPRD and results may not be 
generalised to studies settings outside the UK. 
iii. Unlike a simulated data setting, not all design decisions could be controlled 
(e.g. unmeasured confounding). However, intricacies of “real” data such as 
recorded prescription data or variability in GP recorded diagnoses codes 
may be difficult to mimic in simulated data.  
iv. Potential for unmeasured confounding is a possibility in all observational 
studies. However, the main aim of this study was to estimate the impact of 
potential drivers of discrepant results and not the true association between 
statin use and cancer risk.  
7.4.5 Bias analyses considerations for application to other exemplars of 
pharmacoepidemiogical research 
While the present study has led to some clear conclusions regarding drivers of bias 
in statin-cancer studies, the same lessons will not all necessarily carry over to other 
drug-outcome association studies.  First, studies of drugs other than statins are 
likely to have different issues: statins are very commonly prescribed, used for long-
term prevention, indications may differ to other drugs, and intended to be taken for 
life. Other drugs may be less prevalent, used for acute conditions, or prescribed for 
the short term. Second, this study focussed on cancer outcomes, which are 
uncommon, latent diseases that may take some time to present. Other outcomes 
are likely to have different issues such as acute events including fracture risk or 
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myocardial infarction, which may occur directly after exposure, or soon after. Last, 
different data sources record patient data for different reasons; for example, 
smoking status is captured in the CPRD, in contrast, US claims databases may not 
necessarily record lifestyle factors such as smoking status, alcohol status, or BMI. 
Non-availability or non-inclusion of important confounders may lead to residual 
confounding and limit the interpretability of a study. Alternatively, simulation of 
drug-disease associations could act as a secondary or main analysis to circumvent 
residual confounding by assuming all confounding factors have been measured and 
included in the statistical model.  
Although both immortal time and protopathic bias had minimal impact on the 
statin-cancer association in this thesis, examples of their impact have been well 
noted in other drug-disease associations. For example, protopathic bias has been 
shown to drive an increased risk of gastric cancer among patients prescribed proton 
pump inhibitors (PPIs).116 Patients may be prescribed PPIs to address symptoms of 
undetected gastric cancer such as gastric ulcers, and in turn, use of PPIs may be 
incorrectly attributed to the cause of the gastric cancer once detected. In contrast, 
indications such as lipid levels, which may initiate statin therapy, may not be 
directly related to early symptoms of the cancer types examined in this thesis. 
Immortal time bias also had minimal effect on the statin-cancer association in this 
thesis. However, acute outcomes such as myocardial infarction or fracture risk may 
occur shortly after exposure which may influence immortal time bias and drive 
study conclusions.69 
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In spite of likely varying issues for different drug-disease studies, the overall broad 
approach to investigating bias was useful and could be carried over to examine the 
impact of methodological variation in other pharmacoepidemiology contexts. 
7.5 Implications of research undertaken 
In this thesis and previous studies, lower rates of recorded diagnoses have been 
observed for breast, colorectal, lung, and prostate cancer in primary care in 
comparison to national rates. However, linkage to the cancer registry has shown 
that some of these cases have been registered nationally, but not recorded in 
primary care data, particularly for the elderly and for cancer types with high 
mortality. Recording of events (e.g. clinical diagnoses, referrals) by GPs is mainly 
used for day-to-day management of patients and not for research purposes. 
However, an implication of this observed disparity between primary care and 
national estimates is the need for linked cancer registry data when complete 
ascertainment of events is important; a potential example may include population 
based studies investigating healthcare interventions. In the other direction, there 
were a small minority of cases identified in primary care data, but not in  cancer 
registry data. There is a possibility that these cases are being excluded from 
national registries due to inconclusive evidence of diagnosis; and case status in 
primary care not subsequently updated. This may call for better processes in 
consolidating records between data sources. However, this would be difficult with 
regard to the Read coding dictionary, as a code to refute or un-confirm previous 
diagnoses is not currently available, and would call for an update to the Read 
coding dictionary to enable recording of this process. 
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Recent years have seen a surge of methodological studies attempting to explain 
conflicting findings from studies utilising routine collected health data.69, 119, 208, 211, 
212, 215 From this study, most design flaws implemented did not show substantial 
impact on the statin cancer association. However, two implications for future 
pharmacoepidemiological studies arise based on findings from this study. First, 
careful consideration of how design choices might affect study results is needed e.g. 
choice of database or control sampling. Second, if study results have deviated from 
previous findings then relevant sensitivity analyses should be conducted to ensure 
robust findings.  
The empirical case-study conducted as part of this thesis  
7.6 Future research 
Part of this thesis utilised linked cancer registry data to assess the validity of 
recorded diagnoses by comparing linked primary care incidence rates to that of 
expected rates based on cancer registrations published by the ONS. Cancers of the 
breast, colorectum, lung, and prostate were examined; however, future studies 
could consider other cancer types. Moreover, future studies could confirm or refute 
the apparently higher incidence of cancer types investigated when incorporating 
linked cancer registry data as well as whether this increase occurs for other cancer 
types. In addition, the completeness and utilisation of additional cancer registry 
variables such as treatment and disease severity variables (e.g. stage and grade) 
could be used to add further dimensions to observational drug safety studies. 
In terms of conflicting findings between studies, part of the variability can be 
explained by design flaws examined in this thesis. However, further studies could 
examine alternative biases (e.g. measurement error, missing data) in settings which 
223 
 
use “real” or simulated data. With regards to the latter, a wider range of situations 
and design decisions could be explored which could help to identify specific 
situations that might lead to a larger impact. Additionally, other drug disease 
parings which have been of concern (e.g. diabetes and the risk of cancer) could also 
be examined in a bias study setting. Incidence of disease, utilisation of health 
services, and prevalence of prescribed medications vary between populations. 
Different populations may have contributed to part of the variation in conflicting 
findings between studies.215 A possible solution could be a meta-analysis or 
separate analyses by data source (population) based on a standardised protocol, 
then assessing whether findings are consistent between populations.215 
7.7 Conclusions 
In line with previous studies,196 findings from this study have shown that sole use of 
primary care data to identify particular cancer outcomes may be biased and lead to 
an underestimation of cancer incidence. Primary care data may misclassify case 
status without linkage to external data sources such as the cancer or death registry, 
particularly among elderly patients, and for cancer types that are captured at later 
stages of disease progression with high mortality. Failure to incorporate linked data 
from the cancer and death registry may result in the exclusion of false-negative 
cases that have not been identified in primary care data. On the other hand, 
utilisation of linked data may produce higher incidence of cancers either due to 
false-positive cases in primary care data or the possibility that they are simply not 
registered nationally. 
The effect of bias can influence results, and sway findings in either direction. 
However, their effect can also be minimal as shown in this thesis. Observational 
224 
 
studies are inherently prone to bias, and therefore the potential impact of such 
biases should be evaluated to ensure confidence and transparency in findings. This 
was once a difficult task for several reasons including: lack of computing power; 
difficulty in sharing large datasets; time-constraints; and the labour intensive nature 
of conducting an analysis. However, electronic health databases have made various 
sensitivity analyses and even re-analysis of studies a feasible option.19 Re-analysis 
using different methodologies could rule out or identify possible factors that could 
drive conflicting results between studies.
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8 Appendix A - Supplementary materials for Chapter 2 
 
Questionnaire A.1: Code list questionnaire 
PART 1 – SUMMARY INFORMATION 
1  In deciding which OXMIS/Read codes to include in your case definition(s), 
which of the following strategies did you employ? (please indicate with a X, 
all that apply) 
Key word/synonym search  
 
Utilisation of a code list from a previous study  
 
Consultation with a GP or health professional 
 
Other strategy/resource (please describe) 
2  How many researchers substantively participated in the 
development/review of the code list, and what is/are their specific 
professional background(s)? 
3 How were codes for borderline or suspected malignancies dealt with? 
(Please indicate, with a X, which apply) 
 Borderline codes were included along with “definite” codes 
 Borderline codes were excluded from the code list 
 Borderline codes identified and individually reviewed/ validated later  
 Borderline codes separately included in a sensitivity/secondary analysis 
 Other (please describe) 
 
PART 2 – SPECIFIC DETAILS 
To help us usefully summarize how researchers to date have gone about 
developing code lists for cancer studies, and how the final lists themselves vary, 
we would be grateful if you would be willing to share some specific details* on: 
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(i) the strategy you used to develop your code list: please briefly describe the 
overall process, significant updates from previous study code lists and give the 
keywords for any search. (Include details as a separate attachment if preferred). 
(ii) your final OXMIS/Read code list for identification of cases. Please insert list 
below or attach separately with your reply*. 
(iii) your borderline codes list. Please insert list below or attach separately with 
your reply 
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Table 8.1: Summary description table of included studies 
 
Author & 
Year 
Database Time-period Exposure 
Cancer(s) 
investigated 
Code list: 
methods* 
Code list 
availability 
stated in 
publication 
Confirmation of 
cancer(s) 
Additional inclusion 
criteria: cancer 
related codes 
Exclusion criteria: cancer 
related codes 
Follow-up 
requirements 
Case Description 
1 
Hippisley-
Cox 2013[1] 
QRESEARCH 2000-2012 Symptoms 
Colorectal 
Prostate 
None stated None stated None None stated None stated 
≥1 year registration 
with GP 
Diagnosis of incident cancer within 2 years 
after study entry using Read codes and/or 
ICD-9 (linked ONS data). 
2 
Hippisley-
Cox 2013[2] 
QRESEARCH 2000-2012 Symptoms 
Breast 
Colorectal 
None stated None stated None None stated None stated 
≥1 year registration 
with GP 
Diagnosis of incident cancer within 2 years 
after study entry using Read codes and/or 
ICD-9 (linked ONS data). 
3 
Osborn 
2013[3] 
THIN 1990-2008 None-incidence 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated 
Previous diagnosis of 
cancer of interest 
≥6 months of follow 
up 
Diagnosis of incident cancer (invasive and in 
situ) among patients with ≥6 months of 
follow up. 
4 
Vinogradova 
2013[4] 
QRESEARCH 
+ CPRD 
1997-2011 
Oral 
Bisphosphonates 
Colorectal None stated None stated None None stated None stated ≥2 years follow-up 
Diagnosis of incident cancer among patients 
with ≥2 years follow-up. 
5 
Azoulay 
2012[5] 
CPRD 1995-2008 
Angiotensin 
Receptor 
Blockers 
Breast 
Colon 
Prostate 
None stated None stated None None stated 
Previous diagnosis of 
cancer of interest 
≥2 years follow-up 
Diagnosis of incident cancer among patients 
with ≥2 years follow-up 
6 
Bhaskaran 
2012[6] 
CPRD 1995-2010 
Angiotensin 
Receptor 
Blockers 
Breast 
Colon 
Prostate 
Stated in 
publication* 
None stated None None stated 
Previous diagnosis of any 
cancer. 
Exclusion of borderline 
and suspected 
malignancy codes. 
≥1 year follow-up 
Diagnosis of incident cancer among patients 
with ≥1 year follow-up. Codes for borderline 
or suspected malignancies were excluded 
from the final code list. 
7 
Boggon 
2012[7] 
CPRD 1997-2006 
Diabetes and 
related therapy 
Breast 
Colorectal 
Prostate 
None stated None stated 
Linkage to UK cancer 
registry, Hospital Episode 
Statistics, and free-text 
None stated None stated None stated 
Diagnosis of incident cancer. In-situ or cases 
with non-malignant ICD-10 codes were 
defined as ‘other type’. 
8 
Cardwell 
2012[8] 
CPRD 1996-2006 
Oral 
Bisphosphonates 
Breast 
Colorectal 
Prostate 
Stated in 
publication* 
None stated None None stated 
Previous diagnosis of any 
cancer 
≥3 years UTS medical 
records 
Diagnosis of incident cancer after ≥3-years 
initial follow-up.  
9 
Collins 
2012[9] 
THIN 2000-2008 Symptoms Colorectal None stated None stated None None stated 
Previous diagnosis of 
colorectal cancer 
≥1 year UTS medical 
records 
Diagnosis of colorectal cancer after ≥1-year 
initial follow-up. 
10 
Dregan 
2012[10] 
CPRD 2001-2007 Symptoms Colorectal 
Stated in 
publication* 
Web 
appendix 
Linkage to UK cancer 
registry 
None stated None stated ≥1 year follow-up 
Diagnosis of cancer after ≥1 year UTS follow-
up. Patients were excluded if they had a 
previous diagnosis of cancer or had records 
of previous alarm symptoms prior to cohort 
entry. Inclusion of ICD-10 and ICD-0-2 codes. 
[Table 8.1 continued over] 
 
 
246 
 
 
 
 
 
[Table  8.1 continued] 
 
Author & 
Year 
Database Time-period Exposure 
Cancer(s) 
investigated 
Code list: 
methods 
Code list 
availability 
stated in 
publication 
Confirmation of 
cancer(s) 
Additional inclusion 
criteria: cancer 
related codes 
Exclusion criteria: cancer 
related codes 
Follow-up 
requirements 
Case Description 
11 
Jick 
2012[11] 
CPRD 1991-2009 
Testosterone 
therapy 
Prostate None stated None stated None None stated 
Previous diagnosis of 
prostate cancer 
≥2 years UTS medical 
records 
Diagnosis of prostate cancer after ≥2 years 
initial follow-up. Patients with an indication 
of pre-existing prostate cancer prior to 
cohort entry were excluded. 
12 
Mackenzie 
2012[12] 
CPRD 1987-2010 Spironolactone Breast 
Stated in 
publication* 
Provided 
within 
publication 
None None stated 
Previous diagnosis of 
breast cancer 
None stated 
Diagnosis of breast cancer in patients with 
UTS follow-up. Both invasive and in-situ 
cases were included.  
13 
Qiu 
2012[13] 
CPRD 1995-2008 
Metformin & 
sulphonylurea 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated None stated 
≥1 year of electronic 
medical records 
Diagnosis of invasive solid tumours in 
patients with ≥1 year UTS follow-up after 
index date.  
14 
Redaniel 
2012[14] 
CPRD 1987-2007 
Diabetes and 
related 
treatment 
Breast None stated None stated None None stated 
Previous diagnosis of 
breast cancer 
≥1 year electronic 
medical records 
Diagnosis of breast cancer among patients 
with ≥1 year UTS follow-up after index date. 
15 
Singh 
2012[15] 
CPRD 1987-1992 Epilepsy 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated 
Previous diagnosis of any 
cancer 
None stated 
Diagnosis of cancer after the cohort entry or 
before diagnosis of epilepsy. 
16 
Bodmer 
2012[16] 
CPRD 1995-2009 Metformin  Colorectal None stated None stated None None stated History of any cancer ≥3 years of follow-up 
Diagnosis of colorectal cancer in patients 
with ≥3 years active history prior to diagnosis 
date. 
17 
Charlton 
2012[17] 
CPRD 2007 
None incidence 
study 
Colorectal None stated None stated 
1. Diagnostic algorithm 
2. Free-text 
3. Comparison of rates 
Supporting evidence 
of diagnosis
1
 
Previous diagnosis of 
colorectal cancer 
≥6 months UTS 
records 
Diagnosis of colorectal cancer in patients 
with ≥6 months UTS follow-up. Codes 
including malignant neoplasms, neoplasms 
of uncertain behaviour, general codes were 
used to identify cases. 
18 
Hippisley-
Cox 
2012[18] 
QRESEARCH 2000-2010 Symptoms Colorectal None stated None stated None None stated 
History of colorectal 
cancer 
≥2 years of follow up 
Diagnosis of cancer within 2 years after study 
entry using Read codes or ICD-9 (linked ONS 
data). 
20 
Vinogradova 
2012[20] 
QRESEARCH 1996-2011 Bisphosphonates 
Breast 
Colorectal 
Prostate 
None stated 
Read 
dictionary: B 
chapter 
None None stated 
1.Previous diagnosis of 
any cancer;  
2.Secondary cancers 
(B56-58);  
3.Previous mastectomy 
≥2 years of electronic 
medical records 
Diagnosis of incident cancer in patients with 
≥2 years medical records prior to date of 
diagnosis. Female patients with a prior 
record of a mastectomy were excluded. 
21 
Walker AJ 
2011[21] 
CPRD Not stated 
Tricyclic 
antidepressants 
Breast 
Colorectal 
Prostate 
None stated 
Available on 
request 
None None stated 
Previous diagnosis of any 
cancer 
≥5 years of follow-up 
Diagnosis of colorectal cancer in patients 
with ≥5 years follow-up. 
[Table  8.1 continued over] 
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[Table 8.1 continued] 
 
Author & 
Year 
Database Time-period Exposure 
Cancer(s) 
investigated 
Code list: 
methods 
Code list 
availability 
stated in 
publication 
Confirmation of 
cancer(s) 
Additional inclusion 
criteria: cancer 
related codes 
Exclusion criteria: cancer 
related codes 
Follow-up 
requirements 
Case Description 
19 
Van Staa 
2012[19] 
CPRD 1997-2006 
Glucose lowering 
drugs 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated None stated None stated Diagnosis of incident cancer. 
22 
Green 
2011[22] 
CPRD 1995-2005 Hormone therapy Colorectal None stated None stated None None stated 
Previous diagnosis of 
gastrointestinal cancer 
≥1 year of follow-up 
Diagnosis of gastrointestinal cancer in female 
patients with ≥1 year follow-up. 
23 
Azoulay 
2011[23] 
CPRD 1988-2009 Metformin Prostate None stated None stated Diagnostic algorithm 
Supporting evidence 
of diagnosis
2
 
Previous diagnosis of 
prostate cancer 
≥1 year UTS medical 
records 
Diagnosis of prostate cancer among male 
patients with ≥1 year follow-up identified by 
an algorithm. The algorithm included 
medical codes for prostate cancer as well as 
codes for prostate biopsies, surgeries, 
radiation therapy, and androgen deprivation 
therapy.  
24 
Azoulay 
2011[24] 
CPRD 1988-2007 Antipsychotics Breast None stated None stated Diagnostic algorithm 
Supporting evidence 
of diagnosis
3
 
Previous diagnosis of 
breast cancer 
≥1 year UTS medical 
records 
Diagnosis of breast cancer among female 
patients with ≥1 year follow-up identified by 
an algorithm. The algorithm included 
medical codes for breast cancer as well as 
codes for mastectomies, lumpectomies, 
axillary node dissection, oncologist 
consultation, chemo-radiotherapy, and post-
operative hormone therapy. 
25 
Damery 
2011[25] 
THIN 2000-2006 
Iron deficiency 
anaemia 
Colorectal None stated None stated None None stated None stated None stated 
Diagnosis of colorectal cancer in patients 
with ≥1 year follow-up. 
26 
Suissa 
2011[26] 
CPRD 2002-2006 Insulin Glargine Breast None stated None stated Diagnostic algorithm 
Supporting evidence 
of diagnosis
3
 
Previous diagnosis of 
breast cancer 
≥1 year UTS medical 
records 
Diagnosis of breast cancer among female 
patients with ≥1 year UTS follow-up 
identified by an algorithm (see #24 for 
details). 
27 
Marshall 
2011[27] 
THIN 2001-2006 Symptoms Colorectal None stated 
Available on 
request 
None None stated None stated  
≥2 years of electronic 
medical records 
Diagnosis of colorectal cancer in patients 
with ≥2 years electronic records prior to date 
of diagnosis. 
28 
Vinogradova 
2011[28] 
QRESEARCH 1998-2008 Statins 
Breast 
Colorectal 
Prostate 
None stated 
Read 
dictionary: B 
chapter 
None None stated 
1. Previous diagnosis of 
any cancer;  
2. Secondary cancers 
(B56-58);  
3. Previous mastectomy, 
or tamoxifen 
prescription 
≥6 years of electronic 
medical records 
Diagnosis of incident cancer in patients with 
≥6 years of medical records prior to date of 
diagnosis. Female patients with a prior 
record of a mastectomy or prescription for 
tamoxifen were excluded. 
[Table 8.1 continued over] 
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[Table 8.1 continued] 
 
Author & 
Year 
Database Time-period Exposure 
Cancer(s) 
investigated 
Code list: 
methods 
Code list 
availability 
stated in 
publication 
Confirmation of 
cancer(s) 
Additional inclusion 
criteria: cancer 
related codes 
Exclusion criteria: cancer 
related codes 
Follow-up 
requirements 
Case Description 
29 
Vinogradova 
2011[29] 
QRESEARCH 1997-2008 
Cyclooxygenase-2 
inhibitors 
Breast 
Colorectal 
Prostate 
None stated 
Read 
dictionary: B 
chapter 
None None stated 
1. Previous diagnosis of 
any cancer;  
2. Secondary cancers 
(B56-58);  
3. Previous mastectomy, 
or tamoxifen 
prescription 
≥6 years electronic 
medical records 
Diagnosis of incident cancer in patients with 
≥6 years of medical records prior to date of 
diagnosis. Female patients with a prior 
record of a mastectomy or tamoxifen use 
≥12 months were excluded. 
30 
Hippisley-
Cox 
2010[30] 
QRESEARCH 2002-2008 Statins 
Breast  
Colon 
Prostate 
None stated 
Available on 
request 
None None stated 
Previous diagnosis of 
outcome of interest 
≥1 year registration 
with GP 
Diagnosis of incident cancer in patients with 
≥1 year registration with GP. 
31 
Becker 
2010[31] 
CPRD 1994-2005 
Parkinson’s 
Disease 
Breast 
Colorectal 
Prostate 
None stated None stated 
Manual Review (random 
sample of one third of 
cases) 
Chemotherapy, 
radiotherapy or cancer 
related surgery 
Previous diagnosis of any 
cancer 
≥3 years electronic 
medical records 
Diagnosis of incident cancer in patients with 
≥3 years of medical records prior to cohort 
entry. Validation of one-third of the cases 
required patients to have related surgery, or 
chemo-radiotherapy around the date of 
diagnosis  
32 
Schneider 
2010[32] 
CPRD 1995-2005 
Chronic 
obstructive 
pulmonary 
disease 
Breast None stated None stated None None stated 
Previous history of any 
cancer 
≥3 years electronic 
medical records 
Diagnosis of incident cancer in patients with 
≥3 years medical records. 
33 
Green 
2010[33] 
CPRD 1995-2005 
Oral 
Bisphosphonates 
Colorectal None stated None stated None None stated 
Previous diagnosis of 
gastrointestinal cancer 
≥1 year of follow-up 
Diagnosis of incident gastrointestinal cancer 
in patients with ≥1 year follow-up. 
34 
Bodmer 
2010[34] 
CPRD 1994-2005 
Diabetes-
Metformin 
Breast None stated None stated Manual Review 
Supportive evidence 
of diagnosis
3
 
History of any cancer 
≥3 years of electronic 
medical records 
Diagnosis of incident breast cancer (invasive 
or in situ) followed by breast surgery, 
chemo-radiotherapy, or antiestrogen 
therapy in patients with ≥3 years recorded 
medical records. 
35 
Armstrong 
2010[35] 
CPRD 1987-2001 
Inflammatory 
Bowel Disease 
Breast None stated None stated None None History of any cancer 
≥1 year of electronic  
medical records 
Diagnosis of iincident cancer (malignant 
diagnosis code) in patients with ≥1 year of 
medical records. Patients with non-specific 
codes only were not considered as cases.  
36 
Currie 
2009[36] 
THIN 
2000 
onwards 
Glucose lowering 
drugs 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated 
Previous diagnosis of any 
cancer 
≥6 months medical 
history 
First record of any solid tumour in patients 
with ≥6 months medical history. 
[Table 8.1 continued over]   
249 
 
 
 
 
[Table 8.1 continued]   
 
Author & 
Year 
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related codes 
Follow-up 
requirements 
Case Description 
37 
Schneider 
2009[37] 
CPRD Up to 2007 HRT Breast None stated None stated Diagnostic algorithm 
Chemotherapy, 
radiotherapy or cancer 
related surgery 
Previous diagnosis of any 
cancer 
None stated 
Diagnosis of incident gynaecological cancer 
in female patients.  
38 
Haynes 
2009[38] 
THIN 1992-2007 
None – Incidence 
study 
Colorectal None stated 
Available on 
request 
Comparison of rates None 
Previous diagnosis of any 
cancer 
Patients with 
unacceptable 
registration status 
excluded
4
 
Diagnosis of incident cancer in patients with 
an acceptable status of registration. Read 
codes were consistent with ICD-10 codes 
used by the UK cancer registry. Patients with 
codes for history of cancer, or cancer related 
treatment, and neoplasms of uncertain 
significance were added in a sensitivity 
analysis 
39 
Simon 
2009[39] 
CPRD 1987-2001 
Rheumatoid 
arthritis 
Breast 
Colorectal 
Stated in 
publication* 
None stated None None stated None stated None stated Diagnosis of incident cancer. 
40 
van Staa 
2009[40] 
CPRD + THIN Not stated 
Testosterone 
therapy 
Breast None stated None stated None None stated None stated None stated 
Diagnosis of incident breast cancer (ICD9, 
C74) 
41 
Brauchli 
2009[41] 
CPRD 1994-2005 Psoriasis 
Breast 
Colorectal 
Prostate 
None stated None stated 
1.Manual Review  
2. Diagnostic algorithm 
Radiotherapy; 
chemotherapy; 
endocrine therapy; 
referral to specialist, 
surgery; hospitalised; 
died within 180 days 
of diagnosis 
History of any cancer  
≥3 years of electronic 
medical records 
Diagnosis of incident cancer (malignant or in 
situ). Patients with evidence of diagnosis 
such as surgery, chemo-radiotherapy, 
endocrine therapy, referred to a specialist, 
or died within 180 days after diagnosis.  
42 
Smeeth 
2008[42] 
THIN 1995-2006 Statins  
Breast 
Prostate 
None stated None stated None None stated History of any cancer 
≥1 year continuous 
registration with GP 
Diagnosis of cancer in patients with ≥1 year 
continuous registration with their GP. 
43 
Opatrny 
2008[43] 
CPRD 1988-2004 HRT Breast None stated None stated Diagnostic algorithm 
Supporting evidence 
of diagnosis
3
 
Previous diagnosis of 
breast cancer 
Member of UTS 
practice  
Case definition same as #24 
44 
Weiner 
2008[44] 
CPRD 1990-1999 HRT 
Breast 
Colorectal 
None stated None stated None None stated 
1. History of any cancer;  
2. Previous hysterectomy 
None stated 
Diagnosis of incident cancer among female 
patients. 
45 
Lewis 
2008[45] 
CPRD 1987-2002 
Dermatitis 
Herpetiformis 
Breast None stated None stated None None stated None stated ≥1 year CPRD records 
Diagnosis of incident cancer among female 
patients with ≥1 year CPRD records. 
46 
van Staa 
2008[46] 
CPRD Not stated Hormone therapy 
Colorectal 
Breast 
None stated None stated None None stated None stated None stated 
Diagnosis of incident colorectal cancer 
among female patients. 
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47 
Yang 
2008[47] 
CPRD 1987-2002 Statins Colorectal None stated None stated None None stated 
Previous diagnosis of 
colorectal cancer 
≥5 years of follow up 
Diagnosis of incident colorectal cancer 
among patients with ≥5 years continuous 
follow-up in the CPRD. 
48 
Lewis 
2007[48] 
THIN 1986-2003 Aspirin Colon None stated 
Available on 
request 
None None stated 
Previous diagnosis of 
colon cancer 
≥1 year GP 
registration 
Diagnosis of incident colon cancer among 
patients with ≥1 year registration with their 
GP. 
49 
Parker 
2007[49] 
QRESEARCH 1998-2003 
Rectal and 
postmenopausal 
bleeding 
Colorectal None stated None stated None None stated 
Previous diagnosis of 
cancer of interest 
≥1 year GP 
registration 
Diagnosis of incident cancer among patients 
with ≥1 year registration with their GP. 
50 
Jones 
2007[50] 
CPRD 1994-2000 Alarm symptoms Colorectal None stated 
Available on 
request 
Manual review Unspecified 
Previous diagnosis of any 
cancer 
None stated Diagnosis of incident cancer. 
51 
Srinivasan 
2007[51] 
CPRD Not stated HRT Colorectal None stated None stated None None stated 
Previous diagnosis of any 
cancer 
≥1 year UTS follow-up 
Diagnosis of incident cancer after ≥1 year 
UTS follow-up. 
52 
Jackson 
2007[52] 
CPRD 1987-2002 
Ursodeoxycholic 
acid 
Breast None stated None stated None None stated None stated ≥1 year UTS follow-up 
Diagnosis of incident cancer after ≥1 year 
UTS follow-up. 
53 
Le Jeune 
2007[53] 
THIN Up to 2004 
Idiopathic 
pulmonary 
fibrosis 
Breast 
Prostate 
None stated None stated None None stated None stated ≥1 year follow-up 
Diagnosis of incident cancer after ≥1 year 
follow-up. 
54 
Hippisley-
Cox 
2007[54] 
QRESEARCH 1995-2005 Schizophrenia 
Breast 
Colon 
Prostate 
None stated None stated None None  stated 
Previous mastectomy, or 
tamoxifen prescription 
prior to first record of 
cancer 
≥1 year computerised 
records 
Diagnosis of incident cancer after ≥1 year 
follow-up. Patients with previous 
mastectomies or tamoxifen prescription 
were excluded. 
55 
Tannen 
2007[55] 
CPRD 1990-1999 HRT 
Breast 
Colorectal 
None stated None stated None None stated 
History of any cancer; 
previous hysterectomy 
None stated 
Diagnosis of incident cancer among female 
patients. 
56 
Tannen 
2007[56] 
CPRD 1990-1998 Estrogen 
Breast 
Colorectal 
None stated None stated None None stated 
History of any cancer; 
previous hysterectomy 
None stated Same case definition as #55.  
57 
Vinogradova 
2007[57] 
QRESEARCH 1995-2005 
Statins, NSAIDs & 
Cyclooxygenase-2 
Inhibitors 
Colorectal None stated None stated Comparison of rates None stated 
Previous diagnosis of any 
cancer 
≥6 years of electronic 
medical records 
Diagnosis of incident colorectal cancer. 
58 
Yang 
2007[58] 
CPRD 1987-2002 
Proton Pump 
Inhibitors 
Colorectal None stated None stated None None stated 
Previous diagnosis of 
colorectal cancer 
≥5 years UTS follow-
up 
Diagnosis of incident colorectal cancer 
among patients with ≥5 year continuous 
follow-up in the CPRD. 
59 
Gonzalez-
Perez 
2006[59] 
CPRD 1994-2001 Asthma 
Breast 
Colorectal 
Prostate 
None stated None stated 
1. Manual Review 
2. Questionnaire to GP 
Unspecified 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 since 
first prescription  
Diagnosis of incident cancer among patients 
with ≥1 year enrolment with GP. 
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60 
Gonzalez-
Perez 
2005[60] 
CPRD  1995-2001 Antidepressants Breast None stated None stated 
1. Manual Review 
2. Q to GP 
Supportive evidence 
of diagnosis
3
 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first prescription 
Diagnosis of incident breast cancer among 
patients with ≥1 year enrolment with GP. 
Requirement of supportive evidence of 
diagnosis. 
61 
Gonzalez-
Perez 
2005[61] 
CPRD 1995-2001 Diabetes Mellitus Prostate None stated None stated 
1. Manual Review 
2. Questionnaire to GP 
Unspecified 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first prescription 
Diagnosis of incident prostate cancer among 
patients with ≥1 year enrolment with GP. 
62 
Bradbury 
2005[62] 
CPRD 1991-2001 Obesity Prostate None stated None stated None 
Treatment or 
additional diagnosis of 
prostate cancer within 
6 months of diagnosis 
Previous diagnosis of any 
cancer 
≥1 year computerised 
records 
Diagnosis of incident prostate cancer among 
patients with ≥1 year computerised records. 
Treatment or follow-up visits within 6 
months of diagnosis. 
63 
Kaye 
2005[63] 
CPRD 1987-2002 Antibiotics Breast None stated None stated None Treatment unspecified 
Previous diagnosis of any 
cancer 
≥6 years electronic 
medical records 
Diagnosis of incident breast cancer among 
patients with ≥6 months recorded history. 
64 
Lewis 
2005[64] 
CPRD 1987-2003 
None – incidence 
study 
Breast 
Colon 
Prostate 
None stated None stated None None stated 
Previous diagnosis of any 
cancer 
Up to 3 years 
minimum registration 
with GP 
Diagnosis of incident cancer among patients 
with varying durations of history after 
registration with GP.  
65 
Garcıa 
Rodrıguez 
2005[65] 
CPRD 1995-2001 Antibiotics Breast None stated None stated 
1. Manual Review 
2. Questionnaire to GP 
Supportive evidence 
of diagnosis
3
 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first 
computerised 
prescription 
Diagnosis of incident breast cancer among 
patients with follow-up ≥1 year enrolment 
with GP. Diagnoses of invasive and in situ 
tumours were not distinguished. Additional 
confirmatory evidence of diagnosis was 
required to confirm case status. 
66 
Shao 
2005[66] 
CPRD 1987-2002 Cholecystectomy Colorectal None stated None stated None None stated 
Previous diagnosis of 
colorectal cancer 
≥ 1 year UTS follow-up 
Diagnosis of incident colorectal cancer 
among patients with follow-up ≥1 year UTS 
follow-up. 
67 
van Staa 
2005[67] 
CPRD 1987-2001 
5-
Aminosalicylates 
Colorectal None stated None stated Questionnaire to GP None stated 
History of colorectal 
cancer 
None stated 
Diagnosis of incident colorectal cancer 
according to ICD9 (154, 159) classification. 
68 
Yang 
2005[68] 
CPRD 1987-2002 Type 2 diabetes Colorectal None stated None stated None None stated 
Previous diagnosis of 
colorectal cancer 
≥ 1 year UTS follow-up 
Diagnosis of incident colorectal cancer 
following ≥ 1 year UTS follow-up. 
69 
Gonzalez-
Perez 
2004[69] 
CPRD 1995-2001 
Antihypertensive 
medications 
Breast  None stated None stated Manual Review 
Supportive evidence 
of diagnosis
3
 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first prescription 
Same case definition as #60 
70 
Ronquist 
2004[70] 
CPRD 1995-1999 
Antihypertensive 
medications 
Prostate None stated None stated 
1. Manual Review 
2. Request of records 
3. Comparison of rates 
None stated 
Previous diagnosis of any 
cancer 
≥2 years enrolment 
with GP and ≥1 year 
since first prescription 
Diagnosis of incident prostate cancer among 
patients with ≥2 years enrolment with GP. 
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71 
Kaye 
2004[71] 
CPRD 1990-2002 Statins 
Breast 
Colorectal 
Prostate 
None stated None stated None None stated 
Previous diagnosis of any 
cancer 
≥3 years of follow-up 
Diagnosis of incident cancer among patients 
with ≥3 years follow-up. 
72 
West 
2004[72] 
CPRD 1987-2002 Coeliac disease 
Breast 
Prostate 
None stated None stated None None stated None stated None stated 
Diagnosis of incident cancer. Read codes 
were mapped to ICD codes. 
73 
Garcıa 
Rodrıguez 
2004[73] 
CPRD 1995-2001 
Aspirin and other 
anti-
inflammatory 
drugs 
Breast None stated None stated 
1. Manual Review 
2. Questionnaire to GP 
3. Comparison of rates 
Unspecified 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first prescription 
Same case definition as #60 
74 
Garcıa 
Rodrıguez 
2004[74] 
CPRD 1995-2001 NSAIDs Prostate None stated None stated 
1. Manual Review 
2. Questionnaire to GP 
Unspecified 
Previous diagnosis of any 
cancer 
≥1 year enrolment 
with GP and ≥1 year 
since first prescription 
Same case definition as #61 
75 
Solaymani- 
Dodaran 
2004[75] 
CPRD Not stated 
Barrett’s 
Oesophagus 
Colorectal None stated None stated None None stated 
Previous diagnosis of any 
cancer 
Outcomes observed 
after 1 year from 
cohort entry 
Diagnosis of incident colorectal cancer 
following ≥ 1 year after cohort entry. 
76 
Yang 
2004[76] 
CPRD 1987-2002 Insulin therapy Colorectal None stated None stated Manual Review 
Clinical events (not 
stated) supportive of 
colorectal cancer 
diagnosis 
Previous diagnosis of 
colorectal cancer 
≥3 year follow-up 
Diagnosis of incident colorectal cancer 
following ≥ 3 years UTS follow-up. Additional 
evidence was required to confirm case 
status. 
77 
Meier 
2002[77] 
CPRD 1992-1997 NSAIDs 
Breast 
Colon 
None stated None stated Manual Review 
Required supportive 
evidence of diagnosis
3 
or GP recorded 
comments indicating 
“malignant” or 
“positive histology” 
Previous diagnosis of any 
cancer 
≥3 years of electronic 
medical records 
 
Diagnosis of incident among patients with ≥3 
years medical records. Additional evidence 
of diagnosis was required to confirm case 
status. 
78 
Kaye 
2002[78] 
CPRD 1992-1998 Statins Breast None stated None stated Manual Review Unspecified 
1. Previous diagnosis of 
any cancer 
2. Diagnoses with breast 
cancer at death 
3. Uncertain diagnosis of 
breast cancer 
None stated 
Diagnosis of incident breast cancer. Patients 
with an uncertain diagnosis, or diagnosis at 
death were excluded.  
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79 
Garcıa 
Rodrıguez 
2001[79] 
CPRD 1994-1997 NSAIDs Colorectal None stated None stated 
1. Manual review 
2. Request of records 
3. Comparison of rates 
Manual review 
unspecified 
External validation: 
required biopsy 
specimen to confirm 
case 
Previous diagnosis of 
colorectal adenoma, 
familial polyposis or any 
cancer prior to cohort 
entry 
≥2 years enrolment 
with GP 
Diagnosis of incident colorectal cancer 
following ≥ 2 years enrolment with GP.  
80 
Meier 
2000[80] 
CPRD 1992-1997 ACE inhibitors Breast None stated None stated 
1. Manual review 
2. Request of records 
Supportive evidence
3
; 
and or histological 
analysis 
Previous diagnosis of any 
cancer 
≥3 years drug 
prescription history 
Diagnosis of incident breast cancer following 
among patients with ≥3 years drug 
prescription history. Cases were grouped 
into 3 classifications based on additional 
supportive evidence of diagnosis.: definite, 
probable and uncertain  
81 
Kaye 
2000[81] 
CPRD 1990-1996 
None – incidence 
study 
Breast None stated None stated 
1. Manual Review 
2. Comparison of rates 
Breast lump or 
mammographic 
abnormality prior to 
breast cancer 
diagnosis, and post 
diagnosis related 
surgery or therapy 
Previous diagnosis of 
breast cancer 
None stated 
Potential cases were identified from 3 initial 
cohorts: (i) diagnosis of breast cancer; 
women prescribed tamoxifen (no diagnosis 
code); women with a record for breast 
cancer related surgery with a diagnosis of 
cancer unspecified. Potential cases were 
subsequently confirmed as cases by manual 
review 
82 
Langman 
2000[82] 
CPRD 1993-1995 
Anti-
inflammatory 
drugs 
Breast 
Colon 
Rectum 
Prostate 
None stated None stated None None stated None None stated Diagnosis of incident cancer. 
83 
Garcia 
Rodriguez 
2000[83] 
CPRD 1994-1997 NSAIDs Colorectal None stated None stated 
1. Manual Review 
2. Q to GP 
Unspecified 
Previous diagnosis of any 
cancer 
≥2 years enrolment 
with GP 
Diagnosis of incident colorectal adenoma 
among patients with ≥2 years enrolment 
with GP. 
84 
Jick 
1997[84] 
CPRD 
1987-
unspecified 
Calcium Channel 
Blockers 
Breast 
Prostate 
Bowel 
None stated None stated 
1. Q to GP 
2. Request of records 
None stated History of any cancer 
≥4 years electronic 
medical records 
Diagnosis of incident cancer among patients 
with ≥4 years medical records. 
1 
Colorectal cancer surgery, chemotherapy, radiotherapy, dukes staging, palliative care, terminal illness; 
2
 Prostate cancer surgery, prostate biopsy, chemotherapy, radiotherapy, and androgen deprivation therapy 
3
 Breast cancer surgery: mastectomies, lumpectomies, axillary node dissections; chemotherapy; radiotherapy; consultations with oncologist; and post-operative hormone therapy 
4
 Unacceptable registration status: not permanently registered; out of sequence year of birth or registration date; missing or invalid transfer out date; year of birth missing or invalid; missing sex information 
*At least one of the following was described in the publication: search of Read dictionary; utilisation of a previous code list; code list reviewed by medical professional 
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Table 8.2: Frequency of studies that included specific cancer related codes 
Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
Breast 
B34..00 MALIGNANT NEOPLASM OF FEMALE BREAST Malignant Cancer 17 (100) 
B340.00 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST Malignant Cancer 17 (100) 
B340000 MALIGNANT NEOPLASM OF NIPPLE OF FEMALE BREAST Malignant Cancer 17 (100) 
B340100 MALIGNANT NEOPLASM OF AREOLA OF FEMALE BREAST Malignant Cancer 17 (100) 
B340z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA OF FEMALE BREAST NOS Malignant Cancer 17 (100) 
B341.00 MALIGNANT NEOPLASM OF CENTRAL PART OF FEMALE BREAST Malignant Cancer 17 (100) 
B342.00 MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST Malignant Cancer 17 (100) 
B343.00 MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST Malignant Cancer 17 (100) 
B344.00 MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST Malignant Cancer 17 (100) 
B345.00 MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST Malignant Cancer 17 (100) 
B346.00 MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST Malignant Cancer 17 (100) 
B347.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF BREAST Malignant Cancer 17 (100) 
B34y.00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST Malignant Cancer 17 (100) 
B34y000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF FEMALE BREAST Malignant Cancer 17 (100) 
B34z.00 MALIGNANT NEOPLASM OF FEMALE BREAST NOS Malignant Cancer 17 (100) 
B34..11 CA FEMALE BREAST Malignant Cancer 16 (94) 
B34yz00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST NOS Malignant Cancer 16 (94) 
Byu6.00 [X]MALIGNANT NEOPLASM OF BREAST Malignant Cancer 15 (88) 
174 A NEOPLASM MALIGNANT BREAST Malignant Cancer 8 (47) 
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262 
 
[Table 8.2 continued] 
Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
174 C CARCINOMA BREAST Malignant Cancer 8 (47) 
174 CI CARCINOMA BREAST INDURATED Malignant Cancer 8 (47) 
174 DC ADENOCARCINOMA BREAST Malignant Cancer 8 (47) 
174 DL ADENOCARCINOMA BREAST ULCERATION Malignant Cancer 8 (47) 
174 AN MALIGNANT NEOPLASM NIPPLE Malignant Cancer 6 (35) 
B3...00 MALIG NEOP OF BONE, CONNECTIVE TISSUE, SKIN AND BREAST Malignant Cancer 5 (29) 
B3...11 CARCINOMA OF BONE, CONNECTIVE TISSUE, SKIN AND BREAST Malignant Cancer 5 (29) 
B325100 MALIGNANT MELANOMA OF BREAST Malignant Cancer 5 (29) 
B335100 MALIGNANT NEOPLASM OF SKIN OF CHEST, EXCLUDING BREAST Malignant Cancer 5 (29) 
B335200 MALIGNANT NEOPLASM OF SKIN OF BREAST Malignant Cancer 5 (29) 
B35..00 MALIGNANT NEOPLASM OF MALE BREAST Malignant Cancer 5 (29) 
B350.00 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST Malignant Cancer 5 (29) 
B350000 MALIGNANT NEOPLASM OF NIPPLE OF MALE BREAST Malignant Cancer 5 (29) 
B350100 MALIGNANT NEOPLASM OF AREOLA OF MALE BREAST Malignant Cancer 5 (29) 
B35z.00 MALIGNANT NEOPLASM OF OTHER SITE OF MALE BREAST Malignant Cancer 5 (29) 
B35z000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF MALE BREAST Malignant Cancer 5 (29) 
B35zz00 MALIGNANT NEOPLASM OF MALE BREAST NOS Malignant Cancer 5 (29) 
B3y..00 MALIG NEOP OF BONE, CONNECTIVE TISSUE, SKIN AND BREAST OS Malignant Cancer 5 (29) 
B3z..00 MALIG NEOP OF BONE, CONNECTIVE TISSUE, SKIN AND BREAST NOS Malignant Cancer 5 (29) 
B544.00 MALIGNANT NEOPLASM OF CAROTID BODY Malignant Cancer 4 (24) 
174 PB PAGET'S DISEASE BREAST Malignant Cancer 3 (18) 
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[Table 8.2 continued] 
Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
174 PN PAGET'S DISEASE NIPPLE Malignant Cancer 2 (12) 
B350z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA OF MALE BREAST NOS Malignant Cancer 2 (12) 
B83..00 CARCINOMA IN SITU OF BREAST AND GENITOURINARY SYSTEM In-Situ 11 (65) 
B830.00 CARCINOMA IN SITU OF BREAST In-Situ 11 (65) 
B830000 LOBULAR CARCINOMA IN SITU OF BREAST In-Situ 11 (65) 
B830100 INTRADUCTAL CARCINOMA IN SITU OF BREAST In-Situ 11 (65) 
ByuFG00 [X]OTHER CARCINOMA IN SITU OF BREAST In-Situ 10 (59) 
BB90.00 [M]INTRADUCTAL CARCINOMA, NONINFILTRATING NOS In-Situ 6 (35) 
B825000 CARCINOMA IN SITU OF SKIN OF BREAST In-Situ 5 (29) 
BB9E000 [M]INTRADUCTAL CARCINOMA AND LOBULAR CARCINOMA IN SITU In-Situ 5 (29) 
BB9E.00 [M]LOBULAR CARCINOMA IN SITU In-Situ 2 (12) 
BB92.00 [M] COMEDOCARCINOMA, NON-INFILTRATING In-Situ 1 (6) 
BB96.00 [M]NONINFILTRATING INTRADUCTAL PAPILLARY ADENOCARCINOMA In-Situ 1 (6) 
BB9K.00 [M]PAGET'S DISEASE AND INFILTRATING BREAST DUCT CARCINOMA Cancer Morphology 13 (76) 
BB91100 [M]INFILTRATING DUCT AND LOBULAR CARCINOMA Cancer Morphology 12 (71) 
BB94.00 [M]JUVENILE BREAST CARCINOMA Cancer Morphology 12 (71) 
BB94.11 [M]SECRETORY BREAST CARCINOMA Cancer Morphology 12 (71) 
BB9K000 [M]PAGET'S DISEASE AND INTRADUCTAL CARCINOMA OF BREAST Cancer Morphology 12 (71) 
BB91.00 [M]INFILTRATING DUCT CARCINOMA Cancer Morphology 11 (65) 
BB9F.00 [M]LOBULAR CARCINOMA NOS Cancer Morphology 11 (65) 
BB9G.00 [M]INFILTRATING DUCTULAR CARCINOMA Cancer Morphology 11 (65) 
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[Table 8.2 continued] 
Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
BB91000 [M]INTRADUCTAL PAPILLARY ADENOCARCINOMA WITH INVASION Cancer Morphology 10 (59) 
BB93.00 [M] COMEDOCARCINOMA NOS Cancer Morphology 10 (59) 
BB9H.00 [M]INFLAMMATORY CARCINOMA Cancer Morphology 10 (59) 
BB9J.11 [M]PAGET'S DISEASE, BREAST Cancer Morphology 9 (53) 
BBM9.00 [M]CYSTOSARCOMA PHYLLODES, MALIGNANT Cancer Morphology 9 (53) 
BB9J.00 [M]PAGET'S DISEASE, MAMMARY Cancer Morphology 8 (47) 
BB9D.00 [M]MEDULLARY CARCINOMA WITH LYMPHOID STROMA Cancer Morphology 6 (35) 
BB9B.00 [M] MEDULLARY CARCINOMA NOS Cancer Morphology 2 (12) 
BB91.11 [M] DUCT CARCINOMA NOS Cancer Morphology 1 (6) 
BB9B.11 [M] C CELL CARCINOMA Cancer Morphology 1 (6) 
BB9C.00 [M] MEDULLARY CARCINOMA WITH AMYLOID STROMA Cancer Morphology 1 (6) 
BB9L.00 [M] PAGET Cancer Morphology 1 (6) 
BB9M.00 [M] INTRACYSTIC CARCINOMA NOS Cancer Morphology 1 (6) 
B58y000 SECONDARY MALIGNANT NEOPLASM OF BREAST H/0 & Secondary 13 (76) 
B582600 SECONDARY MALIGNANT NEOPLASM OF SKIN OF BREAST H/0 & Secondary 5 (29) 
BB85111 [M]KRUKENBERG TUMOUR H/0 & Secondary 4 (24) 
ZV10300 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BREAST H/0 4 (24) 
ZV13A00 [V]PERSONAL HISTORY OF NON-NEOPLASTIC BREAST DISEASE H/0 2 (12) 
BA03.00 NEOPLASM OF UNSPECIFIED NATURE OF BREAST Borderline 6 (35) 
B933.00 NEOPLASM OF UNCERTAIN BEHAVIOUR OF BREAST Borderline 2 (12) 
4KJ0.00 *OESTROGEN RECEPTOR POSITIVE TUMOUR (ADDED 1
ST
 APR 2008) Borderline 1 (6) 
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Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
4KJ1.00 *PROGESTERONE RECEPTOR POSITIVE TUMOUR (ADDED 1
ST
 APR 2008) Borderline 1 (6) 
4KJ2.00 *OESTROGEN RECEPTOR NEGATIVE TUMOUR (ADDED 1
ST
 APR 2008) Borderline 1 (6) 
4KJ3.00 *PROGESTERONE RECEPTOR NEGATIVE TUMOUR (ADDED 1
ST
 APR 2008) Borderline 1 (6) 
BB9..00 [M] DUCTAL, LOBULAR, AND MEDULLARY NEOPLASMS Borderline 1 (6) 
BB9z.00 [M] DUCTAL, LOBULAR, OR MEDULLARY NEOPLASM NOS Borderline 1 (6) 
6862100 BREAST NEOPLASM SCREEN ABNORM Suspected 2 (12) 
1J0I.00 SUSPECTED BREAST CANCER Suspected 1 (6) 
8Hn2.00 *FAST TRACK REFERRAL FOR SUSPECTED BREAST CANCER (ADDED 1
ST
 APR 2007) Suspected 1 (6) 
9Np2.00 *SEEN IN FAST TRACK SUSPECTED BREAST CANCER CLINIC (ADDED 1
ST
 APR 2009) Suspected 1 (6) 
217 TUMOUR BREAST BENIGN Benign 1 (6) 
217 AF FIBROADENOMA BREAST Benign 1 (6) 
B765100 BENIGN NEOPLASM OF SKIN OF BREAST Benign 1 (6) 
B77..00 BENIGN NEOPLASM OF BREAST Benign 1 (6) 
B770.00 BENIGN NEOPLASM OF FEMALE BREAST Benign 1 (6) 
B771.00 BENIGN NEOPLASM OF MALE BREAST Benign 1 (6) 
B77z.00 BENIGN NEOPLASM OF BREAST NOS Benign 1 (6) 
122B.00 NO FH: BREAST CARCINOMA Not Cancer 1 (6) 
1243.11 FH: BREAST CANCER Not Cancer 1 (6) 
585C.00 US SCAN OF BREAST Not Cancer 1 (6) 
610 AC NONNEOPLASTIC BREAST CONDITION Not Cancer 1 (6) 
610 AD BREAST NON-NEOPLASTIC DISEASE Not Cancer 1 (6) 
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Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
6862 BREAST NEOPLASM SCREEN Not Cancer 1 (6) 
6862000 BREAST NEOPLASM SCREEN NORMAL Not Cancer 1 (6) 
6862Z00 BREAST NEOPLASM SCREEN NOS Not Cancer 1 (6) 
7135000 PERCUTANEOUS BIOPSY OF BREAST LESION Not Cancer 1 (6) 
7G26100 INSERTION SKIN EXPANDER INTO SUBCUTANEOUS TISSUE OF BREAST Not Cancer 1 (6) 
7G27200 REMOVAL OF SKIN EXPANDER FROM SUBCUTANEOUS TISSUE OF BREAST Not Cancer 1 (6) 
F1740C FAMILY HISTORY OF BREAST CARCINOMA Not Cancer 1 (6) 
M002100 CARBUNCLE OF BREAST Not Cancer 1 (6) 
Q007.00 FETUS/NEONATE AFFECTED BY POISON TRANSFERRED PLACENTA/BREAST Not Cancer 1 (6) 
Q007000 FETUS/NEONATE AFFECTED-PLACENTAL/BREAST TRANSFER UNSP POISON Not Cancer 1 (6) 
Q007100 FETUS/NEONATE AFFECTED BY PLACENTAL/BREAST TRANSFER ALCOHOL Not Cancer 1 (6) 
Q007200 FETUS/NEONATE AFFECTED BY PLACENTAL/BREAST TRANSFER NARCOTIC Not Cancer 1 (6) 
Q007300 FETUS/NEONATE AFFECTED-PLACENTA/BREAST TRANSFER HALLUCINOGEN Not Cancer 1 (6) 
Q007400 FETUS/NEONATE AFFECTED-PLACENTAL/BREAST TRANSFER ANTI-INFECT Not Cancer 1 (6) 
Q007411 FETUS/NEONATE AFFECTED-PLACENTAL/BREAST TRANSFER ANTIBIOTIC Not Cancer 1 (6) 
Q007500 FETUS/NEONATE AFFECTED-PLACENTAL/BREAST TRANSFER IMMUNE SERA Not Cancer 1 (6) 
Q007600 FETUS/NEONATE AFFECTED-PLAC./BREAST TRANSFER ANTICONVULSANT Not Cancer 1 (6) 
Q007700 FETUS/NEONATE AFFECTED-PLAC./BREAST TRANSFER ANTICOAGULANT Not Cancer 1 (6) 
Q007900 FETUS/NEONATE AFFECTED-PLAC./BREAST TRANSFER UTERINE DEPRESS Not Cancer 1 (6) 
Q007A00 FETUS/NEONATE AFFECT-PLAC./BREAST TRANSF HYPOGLYCAEMIC AGENT Not Cancer 1 (6) 
Q007B00 FETUS/NEONATE AFFECTED-PLAC./BREAST TRANSFER ENDOCRINE AGENT Not Cancer 1 (6) 
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Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
Q007C00 FETUS/NEONATE AFFECTED-PLAC./BREAST TRANSFER ADDICTIVE DRUG Not Cancer 1 (6) 
Q007w00 FETUS/NEONATE AFFECTED-PLACENTA/BREAST TRANSFER MEDICINE NEC Not Cancer 1 (6) 
Q007x00 FETUS/NEONATE AFFECTED - PLACENTAL/BREAST TRANSFER TOXIC NEC Not Cancer 1 (6) 
Q007y00 FETUS/NEONATE AFFECTED - POISON TRANSFER PLACENTA/BREAST OS Not Cancer 1 (6) 
Q007z00 FETUS/NEONATE AFFECTED - POISON TRANSFER PLACENTA/BREAST NOS Not Cancer 1 (6) 
Q433200 BREAST FEEDING INHIBITORS CAUSING NEONATAL JAUNDICE Not Cancer 1 (6) 
Q433A00 NEONATAL JAUNDICE FROM BREAST MILK INHIBITOR Not Cancer 1 (6) 
Z16..00 BREAST CARE PROCEDURE Not Cancer 1 (6) 
Z174B00 BREAST CARE Not Cancer 1 (6) 
ZL1G100 UNDER CARE OF BREAST SURGEON Not Cancer 1 (6) 
ZL22100 UNDER CARE OF BREAST CARE NURSE Not Cancer 1 (6) 
ZL62100 REFERRAL TO BREAST CARE NURSE Not Cancer 1 (6) 
ZLA2100 SEEN BY BREAST CARE NURSE Not Cancer 1 (6) 
ZV16300 [V]FAMILY HISTORY OF MALIGNANT NEOPLASM OF BREAST Not Cancer 1 (6) 
ZV6C100 [V]FOLLOW-UP CARE INVOLVING PLASTIC SURGERY OF BREAST Not Cancer 1 (6) 
ZV76100 [V]SCREENING FOR MALIGNANT NEOPLASM OF BREAST Not Cancer 1 (6) 
 
Colorectal 
B13..00 MALIGNANT NEOPLASM OF COLON Malignant Cancer 23 (100) 
B130.00 MALIGNANT NEOPLASM OF HEPATIC FLEXURE OF COLON Malignant Cancer 23 (100) 
B131.00 MALIGNANT NEOPLASM OF TRANSVERSE COLON Malignant Cancer 23 (100) 
B132.00 MALIGNANT NEOPLASM OF DESCENDING COLON Malignant Cancer 23 (100) 
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Description Classification 
No of studies that 
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specific code in 
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B133.00 MALIGNANT NEOPLASM OF SIGMOID COLON Malignant Cancer 23 (100) 
B136.00 MALIGNANT NEOPLASM OF ASCENDING COLON Malignant Cancer 23 (100) 
B137.00 MALIGNANT NEOPLASM OF SPLENIC FLEXURE OF COLON Malignant Cancer 23 (100) 
B138.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF COLON Malignant Cancer 23 (100) 
B13y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF COLON Malignant Cancer 23 (100) 
B13z.00 MALIGNANT NEOPLASM OF COLON NOS Malignant Cancer 23 (100) 
B13z.11 COLONIC CANCER Malignant Cancer 23 (100) 
B14..00 MALIGNANT NEOPLASM OF RECTUM, RECTOSIGMOID JUNCTION AND ANUS Malignant Cancer 23 (100) 
B140.00 MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION Malignant Cancer 23 (100) 
B141.00 MALIGNANT NEOPLASM OF RECTUM Malignant Cancer 23 (100) 
B141.11 CARCINOMA OF RECTUM Malignant Cancer 23 (100) 
B141.12 RECTAL CARCINOMA Malignant Cancer 23 (100) 
B14y.00 MALIG NEOP OTHER SITE RECTUM, RECTOSIGMOID JUNCTION AND ANUS Malignant Cancer 23 (100) 
B14z.00 MALIGNANT NEOPLASM RECTUM,RECTOSIGMOID JUNCTION AND ANUS NOS Malignant Cancer 23 (100) 
B134.00 MALIGNANT NEOPLASM OF CAECUM Malignant Cancer 21 (91) 
B134.11 CARCINOMA OF CAECUM Malignant Cancer 21 (91) 
B135.00 MALIGNANT NEOPLASM OF APPENDIX Malignant Cancer 21 (91) 
B142.00 MALIGNANT NEOPLASM OF ANAL CANAL Malignant Cancer 19 (83) 
B142.11 ANAL CARCINOMA Malignant Cancer 19 (83) 
B142000 MALIGNANT NEOPLASM OF CLOACOGENIC ZONE Malignant Cancer 19 (83) 
B143.00 MALIGNANT NEOPLASM OF ANUS UNSPECIFIED Malignant Cancer 19 (83) 
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Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
B18y200 MALIGNANT NEOPLASM OF MESORECTUM Malignant Cancer 17 (74) 
B1z0.11 CANCER OF BOWEL  Malignant Cancer 17 (74) 
1530AD ADENOCARCINOMA ASCENDING COLON Malignant Cancer 10 (43) 
1533AD ADENOCARCINOMA SIGMOID COLON Malignant Cancer 10 (43) 
1538AD ADENOCARCINOMA COLON Malignant Cancer 10 (43) 
1538AN MALIGNANT NEOPLASM LARGE BOWEL NONRECTAL Malignant Cancer 10 (43) 
1538C COLON CARCINOMA Malignant Cancer 10 (43) 
1538CN LARGE BOWEL CARCINOMA NONRECTAL Malignant Cancer 10 (43) 
1539A MALIGNANT NEOPLASM BOWEL Malignant Cancer 10 (43) 
1541A MALIGNANT NEOPLASM RECTUM Malignant Cancer 10 (43) 
1541C RECTUM CARCINOMA Malignant Cancer 10 (43) 
1539C CARCINOMA BOWEL Malignant Cancer 9 (39) 
1530AC MALIGNANT NEOPLASM CAECUM Malignant Cancer 8 (35) 
1530CC CARCINOMA CAECUM Malignant Cancer 8 (35) 
1533A MALIGNANT NEOPLASM SIGMOID Malignant Cancer 8 (35) 
1538B SARCOMA COLON Malignant Cancer 5 (22) 
1538A MALIGNANT NEOPLASM LARGE INTESTINE Malignant Cancer 4 (17) 
1539AT MALIGNANT NEOPLASM INTESTINE Malignant Cancer 3 (13) 
B18y000 MALIGNANT NEOPLASM OF MESOCOLON Malignant Cancer 3 (13) 
1529A MALIGNANT NEOPLASM SMALL INTESTINE Malignant Cancer 2 (9) 
1529C CARCINOMA SMALL INTESTINE Malignant Cancer 2 (9) 
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1542A MALIGNANT NEOPLASM ANAL CANAL Malignant Cancer 2 (9) 
1542C CARCINOMA ANAL CANAL Malignant Cancer 2 (9) 
1736AN MALIGNANT NEOPLASM ANUS Malignant Cancer 2 (9) 
1736CN CARCINOMA ANUS Malignant Cancer 2 (9) 
4M1..00 DUKES STAGING SYSTEM  Malignant Cancer 2 (9) 
4M10.00 DUKES STAGE A  Malignant Cancer 2 (9) 
4M11.00 DUKES STAGE B  Malignant Cancer 2 (9) 
4M12.00 DUKES STAGE C1  Malignant Cancer 2 (9) 
4M13.00 DUKES STAGE C2  Malignant Cancer 2 (9) 
4M14.00 DUKES STAGE D  Malignant Cancer 2 (9) 
9Ow1.00 
*BOWEL CANCER DETECTED BY NATIONAL SCREENING PROGRAMME (ADDED 1
ST
 
OCT 2007) 
Malignant Cancer 2 (9) 
B12..00 MALIGNANT NEOPLASM OF SMALL INTESTINE AND DUODENUM Malignant Cancer 2 (9) 
B124.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF SMALL INTESTINE Malignant Cancer 2 (9) 
B12y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITE SMALL INTESTINE Malignant Cancer 2 (9) 
B12z.00 MALIGNANT NEOPLASM OF SMALL INTESTINE NOS Malignant Cancer 2 (9) 
B139.00 *HEREDITARY NONPOLYPOSIS COLON CANCER (ADDED 1
ST
 OCT 2010) Malignant Cancer 2 (9) 
B180200 MALIGNANT NEOPLASM OF RETROCAECAL TISSUE Malignant Cancer 1 (4) 
B18y100 MALIGNANT NEOPLASM OF MESOCAECUM Malignant Cancer 1 (4) 
B803.00 CARCINOMA IN SITU OF COLON In-Situ 14 (61) 
B803000 CARCINOMA IN SITU OF HEPATIC FLEXURE OF COLON In-Situ 14 (61) 
B803100 CARCINOMA IN SITU OF TRANSVERSE COLON In-Situ 14 (61) 
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Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
B803200 CARCINOMA IN SITU OF DESCENDING COLON In-Situ 14 (61) 
B803300 CARCINOMA IN SITU OF SIGMOID COLON In-Situ 14 (61) 
B803600 CARCINOMA IN SITU OF ASCENDING COLON In-Situ 14 (61) 
B803700 CARCINOMA IN SITU OF SPLENIC FLEXURE OF COLON In-Situ 14 (61) 
B803z00 CARCINOMA IN SITU OF COLON NOS In-Situ 14 (61) 
B804.00 CARCINOMA IN SITU OF RECTUM AND RECTOSIGMOID JUNCTION In-Situ 14 (61) 
B804100 CARCINOMA IN SITU OF RECTUM In-Situ 14 (61) 
B804z00 CARCINOMA IN SITU OF RECTUM OR RECTOSIGMOID JUNCTION NOS In-Situ 14 (61) 
B804000 CARCINOMA IN SITU OF RECTOSIGMOID JUNCTION In-Situ 13 (57) 
B803400 CARCINOMA IN SITU OF CAECUM In-Situ 8 (35) 
B803500 CARCINOMA IN SITU OF APPENDIX In-Situ 3 (13) 
B805.00 CARCINOMA IN SITU OF ANAL CANAL In-Situ 3 (13) 
B806.00 CARCINOMA IN SITU OF ANUS NOS In-Situ 3 (13) 
B807.00 CARCINOMA IN SITU OF OTHER AND UNSPECIFIED SMALL INTESTINE In-Situ 2 (9) 
B807z00 CARCINOMA IN SITU OTHER AND UNSPECIFIED SMALL INTESTINE NOS In-Situ 2 (9) 
ByuF000 [X]CARCINOMA IN SITU/OTHER+UNSPECIFIED PARTS OF INTESTINE In-Situ 2 (9) 
B805000 *ANAL INTRAEPITHELIAL NEOPLASIA GRADE III (ADDED 1
ST
 MAR 2003) In-Situ 1 (4) 
BB5R600 [M]MUCOCARCINOID TUMOUR, MALIGNANT Cancer Morphology 10 (43) 
BB5N100 [M]ADENOCARCINOMA IN ADENOMATOUS POLPOSIS COLI Cancer Morphology 5 (22) 
BB48.00 [M]BASALOID CARCINOMA Cancer Morphology 1 (4) 
BB5L100 [M]ADENOCARCINOMA IN ADENOMATOUS POLYP Cancer Morphology 1 (4) 
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BB5L300 [M]ADENOCARCINOMA IN MULTIPLE ADENOMATOUS POLYPS Cancer Morphology 1 (4) 
BB82111 [M]COLLOID ADENOCARCINOMA Cancer Morphology 1 (4) 
B575.00 SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM H/0 & Secondary 19 (83) 
B575z00 SECONDARY MALIG NEOP OF LARGE INTESTINE OR RECTUM NOS H/0 & Secondary 18 (78) 
B575000 SECONDARY MALIGNANT NEOPLASM OF COLON H/0 & Secondary 17 (74) 
B575100 SECONDARY MALIGNANT NEOPLASM OF RECTUM H/0 & Secondary 16 (70) 
B574.00 SECONDARY MALIGNANT NEOPLASM OF SMALL INTESTINE AND DUODENUM H/0 & Secondary 2 (9) 
B574z00 SECONDARY MALIG NEOP OF SMALL INTESTINE OR DUODENUM NOS H/0 & Secondary 2 (9) 
ZV10017 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF RECTUM H/0 3 (13) 
ZV10013 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF INTESTINE H/0 2 (9) 
ZV10014 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF LARGE INTESTINE H/0 2 (9) 
ZV10011 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF ANUS H/0 1 (4) 
BB5N.00 [M]ADENOMATOUS AND ADENOCARCINOMATOUS POLYPS OF COLON Borderline 10 (43) 
BB5Nz00 [M]ADENOMATOUS OR ADENOCARCINOMATOUS POLYPS OF THE COLON NOS Borderline 10 (43) 
B902400 NEOPLASM OF UNCERTAIN BEHAVIOUR OF COLON Borderline 7 (30) 
B902500 NEOPLASM OF UNCERTAIN BEHAVIOUR OF RECTUM Borderline 7 (30) 
B902.00 NEOP OF UNCERTAIN BEHAVIOUR STOMACH, INTESTINES AND RECTUM Borderline 5 (22) 
2304 TUMOUR RECTAL Borderline 4 (17) 
B902z00 NEOP OF UNCERTAIN BEHAVIOUR STOMACH, INTESTINE OR RECTUM NOS Borderline 4 (17) 
B905200 NEOPLASM OF UNCERTAIN BEHAVIOUR OF ANAL CANAL AND SPHINCTER Borderline 4 (17) 
B902600 NEOPLASM OF UNCERTAIN OR UNKNOWN BEHAVIOUR OF APPENDIX Borderline 2 (9) 
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No of studies that 
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specific code in 
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BB5L.00 [M]ADENOMATOUS AND ADENOCARCINOMATOUS POLYPS Borderline 1 (4) 
BB5Lz00 [M]ADENOMATOUS OR ADENOCARCINOMATOUS POLYP NOS Borderline 1 (4) 
BB5N.11 [M]ADENOMA OR OR ADENOCARCINOMA IN POLYPOSIS COLI Borderline 1 (4) 
BB5U.00 [M]VILLOUS ADENOMAS AND ADENOCARCINOMAS Borderline 1 (4) 
8Hn4.00 
*FAST TRACK REFERRAL FOR SUSPECTED COLORECTAL CANCER (ADDED 1
ST
 APR 
2007) 
Suspected 2 (9) 
8CAo.00 *PATIENT GIVEN ADVICE ABOUT BOWEL CANCER (ADDED 1
ST
 OCT 2007) Suspected 1 (4) 
9Np7.00 
*SEEN IN FAST TRACK SUSPECTED COLORECTAL CANCER CLINIC (ADDED 1
ST
 APR 
2009) 
Suspected 1 (4) 
2114 BENIGN NEOPLASM RECTUM Benign 3 (13) 
2114B BENIGN NEOPLASM ANORECTAL Benign 3 (13) 
2114C BENIGN NEOPLASM RECTOSIGMOID JUNCTION Benign 3 (13) 
B713.00 BENIGN NEOPLASM OF COLON Benign 3 (13) 
B713000 BENIGN NEOPLASM OF HEPATIC FLEXURE OF COLON Benign 3 (13) 
B713100 BENIGN NEOPLASM OF TRANSVERSE COLON Benign 3 (13) 
B713200 BENIGN NEOPLASM OF DESCENDING COLON Benign 3 (13) 
B713300 BENIGN NEOPLASM OF SIGMOID COLON Benign 3 (13) 
B713600 BENIGN NEOPLASM OF ASCENDING COLON Benign 3 (13) 
B713700 BENIGN NEOPLASM OF SPLENIC FLEXURE OF COLON Benign 3 (13) 
B713z00 BENIGN NEOPLASM OF COLON NOS Benign 3 (13) 
B714.00 BENIGN NEOPLASM OF RECTUM AND ANAL CANAL Benign 3 (13) 
B714000 BENIGN NEOPLASM OF RECTOSIGMOID JUNCTION Benign 3 (13) 
[Table 8.2 continued over] 
274 
 
[Table 8.2 continued] 
Read/OXMIS 
Code 
Description Classification 
No of studies that 
included the 
specific code in 
their code list (%) 
B714100 BENIGN NEOPLASM OF RECTUM Benign 3 (13) 
B714z00 BENIGN NEOPLASM OF RECTUM OR ANAL CANAL NOS Benign 3 (13) 
B718300 BENIGN NEOPLASM OF MESOCOLON Benign 3 (13) 
2112N BENIGN NEOPLASM SMALL INTESTINE Benign 2 (9) 
2113 BENIGN NEOPLASM INTESTINE Benign 2 (9) 
B712.00 BENIGN NEOPLASM OF SMALL INTESTINE AND DUODENUM Benign 2 (9) 
B712z00 BENIGN NEOPLASM OF SMALL INTESTINE OR DUODENUM NOS Benign 2 (9) 
B718400 BENIGN NEOPLASM OF MESORECTUM Benign 2 (9) 
ByuG300 [X]BENIGN NEOPLASM/OTHER+UNSPECIFD PARTS OF SMALL INTESTINE Benign 2 (9) 
2113LC BENIGN LYMPHOMA COLON Benign 1 (4) 
2113PA POLYP ADENOMATOUS COLON Benign 1 (4) 
B713400 BENIGN NEOPLASM OF CAECUM Benign 1 (4) 
B713500 BENIGN NEOPLASM OF APPENDIX Benign 1 (4) 
B713800 BENIGN NEOPLASM OF COLOSTOMY SITE Benign 1 (4) 
B713900 BENIGN NEOPLASM OF ILEOCAECAL VALVE Benign 1 (4) 
B714111 BENIGN PAPILLOMA RECTUM Benign 1 (4) 
B714200 BENIGN NEOPLASM OF ANAL CANAL Benign 1 (4) 
B714300 BENIGN NEOPLASM OF ANUS NOS Benign 1 (4) 
BB5L000 [M]ADENOMATOUS POLYP NOS Benign 1 (4) 
BB5L011 [M]POLYPOID ADENOMA Benign 1 (4) 
BB5N000 [M]ADENOMATOUS POLYPOSIS COLI Benign 1 (4) 
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BB5N011 [M]ADENOMATOSIS NOS Benign 1 (4) 
BB5N012 [M]FAMILIAL POLYPOSIS COLI Benign 1 (4) 
BB5N200 [M]MULTIPLE ADENOMATOUS POLYPS Benign 1 (4) 
BB5N211 [M]MULTIPLE POLYPOSIS Benign 1 (4) 
PB2..00 ATRESIA AND STENOSIS OF LARGE INTESTINE/RECTUM/ANAL CANAL Not Cancer 4 (17) 
1241.12 FH: BOWEL CANCER Not Cancer 2 (9) 
6864 LARGE BOWEL NEOPLASM SCREEN Not Cancer 2 (9) 
6864.11 COLON NEOPLASM SCREEN Not Cancer 2 (9) 
6864.12 RECTAL NEOPLASM SCREEN Not Cancer 2 (9) 
7211200 CORRECTION OF EPICANTHUS Not Cancer 2 (9) 
7211300 CORRECTION OF TELECANTHUS, UNSPECIFIED Not Cancer 2 (9) 
7409011 PRIMARY CORRECTION OF ALAR CARTILAGE Not Cancer 2 (9) 
7733300 REANASTOMOSIS RECTUM-ANAL CANAL CORRECT CONG RECTAL ATRESIA Not Cancer 2 (9) 
773C000 LASER RECANALISATION OF BOWEL NEC Not Cancer 2 (9) 
7905000 CORRECT TOTAL ANOMAL PULM VENOUS CONNECT TO SUPRACARD VESSEL Not Cancer 2 (9) 
7A20300 ENDARTERECTOMY AND PATCH REPAIR OF CAROTID ARTERY Not Cancer 2 (9) 
7A20311 CAROTID ENDARTERECTOMY AND PATCH Not Cancer 2 (9) 
7A20400 ENDARTERECTOMY OF CAROTID ARTERY NEC Not Cancer 2 (9) 
7H01011 CORRECTION OF PECTUS CARINATUM Not Cancer 2 (9) 
7L0E200 CENTRALISATION CARPUS- CORRECTN CONGENITAL DEFORMITY FOREARM Not Cancer 2 (9) 
7L1H.12 DIRECT CURRENT CARDIAC SHOCK Not Cancer 2 (9) 
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7L1H000 DIRECT CURRENT CARDIOVERSION Not Cancer 2 (9) 
AB2yz17 CANDIDIASIS RECTUM Not Cancer 2 (9) 
F1539C FAMILY HISTORY OF BOWEL CANCER Not Cancer 2 (9) 
K0828 ENDARTERECTOMY CAROTID ARTERY Not Cancer 2 (9) 
L244012 RECTOCELE AFFECTING OBSTETRIC CARE Not Cancer 2 (9) 
L244312 RECTOCELE COMPLICATING ANTENATAL CARE - BABY NOT DELIVERED Not Cancer 2 (9) 
L244412 RECTOCELE COMPLICATING POSTPARTUM CARE - BABY DELIVERED PREV Not Cancer 2 (9) 
Q407300 NEONATAL CANDIDIASIS OF INTESTINE Not Cancer 2 (9) 
Z174A00 BOWEL CARE Not Cancer 2 (9) 
Z9...00 INDIRECT CARE PROCEDURES Not Cancer 2 (9) 
ZL1GG00 UNDER CARE OF COLORECTAL SURGEON Not Cancer 2 (9) 
ZV76400 [V]SCREENING FOR MALIGNANT NEOPLASM OF COLON OR RECTUM Not Cancer 2 (9) 
25Q3.00 O/E - PR - RECTAL MASS Not Cancer 1 (4) 
7411600 REMOVAL OF ANTROCHOANAL POLYP Not Cancer 1 (4) 
771G400 COLONOSCOPIC POLYPECTOMY Not Cancer 1 (4) 
7722.11 OPEN OPERATION ON RECTAL POLYP Not Cancer 1 (4) 
7722.12 OPEN POLYPECTOMY OF RECTUM Not Cancer 1 (4) 
7726111 PERANAL EXCISION OF RECTAL POLYP Not Cancer 1 (4) 
7726112 PERANAL POLYPECTOMY OF RECTUM Not Cancer 1 (4) 
7726212 PERANAL DESTRUCTION OF RECTAL POLYP Not Cancer 1 (4) 
7731200 EXCISION OF ANAL POLYP Not Cancer 1 (4) 
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B713.11 COLON POLYP Not Cancer 1 (4) 
H110000 CHOANAL POLYP Not Cancer 1 (4) 
J41y000 PSEUDOPOLYPOSIS OF COLON Not Cancer 1 (4) 
J570.00 ANAL AND RECTAL POLYP Not Cancer 1 (4) 
J570000 ANAL POLYP Not Cancer 1 (4) 
J570100 RECTAL POLYP Not Cancer 1 (4) 
J570z00 ANAL AND RECTAL POLYP NOS Not Cancer 1 (4) 
J578.00 *COLONIC POLYP (ADDED 1
ST
 JAN 2004) Not Cancer 1 (4) 
J578.11 *POLYP OF COLON (ADDED 1
ST
 JAN 2004) Not Cancer 1 (4) 
 
Prostate 
B46..00 MALIGNANT NEOPLASM OF PROSTATE Malignant Cancer 11 (100) 
4M0..00 GLEASON GRADING OF PROSTATE CANCER  Malignant Cancer 7 (64) 
4M00.00 GLEASON PROSTATE GRADE 2-4 (LOW)  Malignant Cancer 6 (55) 
4M01.00 GLEASON PROSTATE GRADE 5-7 (MEDIUM) Malignant Cancer 6 (55) 
4M02.00 GLEASON PROSTATE GRADE 8-10 (HIGH)  Malignant Cancer 6 (55) 
185 A MALIGNANT NEOPLASM PROSTATE Malignant Cancer 4 (36) 
185 C PROSTATE CARCINOMA Malignant Cancer 4 (36) 
185 CA ADENOCARCINOMA PROSTATE Malignant Cancer 4 (36) 
B834.00 CARCINOMA IN SITU OF PROSTATE In-Situ 6 (55) 
B58y500 SECONDARY MALIGNANT NEOPLASM OF PROSTATE H/0 & Secondary 8 (73) 
ZV10415 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF PROSTATE H/0 2 (18) 
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1427000 *H/O: PROSTATE CANCER (ADDED 1
ST
 APR 2011) H/0 1 (9) 
B915.00 NEOPLASM OF UNCERTAIN BEHAVIOUR OF PROSTATE Borderline 2 (18) 
1J08.00 SUSPECTED PROSTATE CANCER Suspected 1 (9) 
*Highlighted codes are those that were added to the Read code dictionary during the period the included 
studies were conducted. The earliest publication year among studies where code lists were provided was 
2005, therefore codes added to the dictionary from 2003 have been highlighted (allowing for a 2 year lag 
period between code list creation and publication). 
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9 Appendix B: Supplementary tables for Chapter 3 
Table 9.1: Detailed summary of bias assessment by study 
 Did the study suffer potentially from the following biases? 
Author & 
Year 
Immortal Time Bias Protopathic Bias Prevalent user bias Healthy user bias Time-window bias 
Chang 2011
68
 
Not examined: case-control study 
used 
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
No: adjusted for number of physician visits and 
number of hospitalisations 
No: Controls matched on case 
date of diagnosis 
Farwell 
2011
132
 
No: follow-up period for both 
treatment groups started after 2 
years of statin exposure. 
No: lag time of 2-years was 
implemented. 
Yes: both new and prevalent statin users 
included 
No: Active comparative group consisted of 
antihypertensive medication users used. 
Not examined: Cohort design 
used 
Tan 2011
133
 No: immortal time excluded 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included  
No: all patients underwent a PSA test or digital rectal 
examination 
Not examined: Cohort design 
used 
Vinogradova 
2011
130
 
Not examined: case-control study 
used 
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: risk-set sampling used to 
select controls 
Hippisley-Cox 
2010
131
 
Uncertain: unequal start dates 
between treatment groups   
Yes: no minimum period of exposure 
was implemented. 
No: new user design used for statin 
group 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
Not examined: Cohort design 
used 
Murtola 
2010
134
 
No: Cox-proportional hazards with 
time dependent exposure was used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
No: PSA screening arm of Finnish trial utilised as 
cohort of statin and non-statin users. 
Not examined: Cohort design 
used 
Robertson 
2010
135
 
Not examined: case-control study 
used. 
No: lag time of 2-years was 
implemented. 
Yes: both new and prevalent statin users 
included  
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: risk-set sampling used to 
select controls 
Wooditschka 
2010
136
 
Not examined: case-control study 
used. 
No: lag time of 101 days was 
implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: Controls matched to cases 
on duration of follow-up 
Flick 2009
137
 
No: Cox-proportional hazards with 
time dependent exposure was used. 
No: a 101 day minimum period of statin 
use was implemented. 
Yes: both new and prevalent statin users 
included 
No: adjusted for history of sigmoidoscopy. 
Not examined: Cohort design 
used 
Haukka 
2009
67
 
Uncertain: start of  follow-up not 
defined for non-users  
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
Not examined: Cohort design 
used 
Singh 2009
64
 
Yes: ≥2 statins exposure definition. 
However, follow-up started at the 
first statin, introducing immortal 
time. 
Yes: no minimum period of exposure 
was implemented. 
No: sensitivity analysis including only new 
statin users 
No: adjusted for lower GI endoscopy 
Not examined: Cohort design 
used 
Boudreau 
2008
139
 
No: Cox-proportional hazards with 
time dependent exposure was used 
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
No: Conduced secondary analyses of men who had a 
PSA test within 5 years of study start. 
Not examined: Cohort design 
used 
Boudreau 
2008
140
 
Not examined: case-control study 
used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: risk-set sampling used to 
select controls 
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 Did the study suffer potentially from the following biases? 
Author & 
Year 
Immortal Time Bias Protopathic Bias Prevalent user bias Healthy user bias Time-window bias 
Farwell 
2008
141
 
No: follow-up period for both 
treatment groups started after 2 
years of statin exposure. 
No: lag time of 2-years was 
implemented. 
Yes: both new and prevalent statin users 
included 
No: Active comparative group consisted of 
antihypertensive medication users used. 
Not examined: Cohort design 
used 
Friedman 
2008
142
 
No: Cox-proportional hazards with 
time dependent exposure was used. 
No: lag time of 2-years was 
implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No (prostate cancer): PSA adjusted 
Not examined: Cohort design 
used 
Hachem 
2008
138
 
Not examined: case-control study 
used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
No: adjusted for colorectal evaluation by imaging, 
endoscopy, and faecal occult blood testing 
No: Controls matched to cases 
on duration of follow-up 
Smeeth 
2008
56
 
No: immortal time excluded 
No: lag time of 2-years was 
implemented. 
No: new user design used for statin 
group 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
Not examined: Cohort design 
used 
Yang 2008
127
 
Not examined: case-control study 
used. 
No: lag time of 5-years was 
implemented. 
Yes: both new and prevalent statin users 
included 
No: adjustment for history of colonoscopy or 
sigmoidoscopy 
No: Controls matched to cases 
on duration of follow-up 
Boudreau 
2007
143
 
No: Cox-proportional hazards with 
time dependent exposure was used. 
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
No: adjusted for breast cancer screening 
Not examined: Cohort design 
used 
Flick 2007
144
 
No: Cox-proportional hazards with 
time dependent exposure was used. 
No: a 101 day minimum period of statin 
use was implemented. 
Yes: both new and prevalent statin users 
included 
No: Conduced secondary analyses of men who had a 
PSA test within 5 years of study start. 
Not examined: Cohort design 
used 
Murtola 
2007
145
 
Not examined: case-control study 
used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: risk-set sampling used to 
select controls 
Vinogradova 
2007
90
 
Not examined: case-control study 
used. 
No: lag time of 1-year was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
No: risk-set sampling used to 
select controls 
Khurana 2007 
Not examined: case-control study 
used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
Yes: time-independent sampling 
of controls 
Setoguchi 
2006
146
 
No: immortal time excluded 
No: lag time of 6-months was 
implemented. 
No: New user design implemented for 
both statin users and glaucoma 
medication users  
No: Active comparative group consisted of glaucoma 
medication groups 
Not examined: Cohort design 
used 
Friis 2004
147
 Uncertain: follow-up not defined 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
No: Comparative group consisted of other lipid-
lowering drug users. 
Not examined: Cohort design 
used 
Graaf 2004
148
 
Not examined: case-control study 
used. 
No: lag time of 6-months implemented. 
Yes: both new and prevalent statin users 
included 
No: Comparative group consisted of 
antihypertensive drug users. 
No: risk-set sampling used to 
select controls 
Kaye 2004
128
 
Not examined: case-control study 
used. 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
No: Comparative group consisted of other lipid-
lowering drug users. 
No: risk-set sampling used to 
select controls 
Beck 2003
149
 
No: start of follow-up at first 
prescription – immortal time 
excluded 
Yes: no minimum period of exposure 
was implemented. 
Yes: both new and prevalent statin users 
included 
Yes: comparison group of non-users used and no 
adjustment for health service utilisation was made. 
Not examined: Cohort design 
used 
[Table 9.1 continued over] 
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[Table 9.1 continued] 
 Did the study suffer potentially from the following biases? 
Author & 
Year 
Immortal Time Bias Protopathic Bias Prevalent user bias Healthy user bias Time-window bias 
Kaye 2002
129
 
Not examined: case-control study 
used. 
Yes: No minimum period of exposure 
Yes: both new and prevalent statin users 
included 
No: Comparative group consisted of other lipid-
lowering drug users. 
No: risk-set sampling used to 
select controls 
Blais 2000
150
 
Not examined: case-control study 
used. 
No: lag time of 1-year implemented. 
Yes: both new and prevalent statin users 
included  
No: Comparison group: bile acid-binding resins 
No: risk-set sampling used to 
select controls 
GI: Gastro-intestinal; PSA: Prostate-specific Antigen 
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Table 9.2: Updated review studies: Statin use associated with cancer risk - study details 
Author & 
Year 
Cancer(s) 
examined 
Study 
Population 
Data 
source for 
outcomes 
Invasive or 
non-
invasive 
cancer 
Data source 
for statin use 
Time period Study design 
Comparison 
group 
Statin exposure 
definition 
No of cases 
(cases 
exposed) 
Total cancer or site-specific 
cancer: point estimate (95% 
CI) 
Nordstrom 
2015 
Prostate 
Stockholm 
County 
undergoing a 
PSA test 
National 
Prostate 
Cancer 
registry 
Invasive 
Swedish 
prescribed 
drug register 
2007-2012 Cohort 
Non-Statin 
users 
≥1 statin prescription 
in2 years prior to 
cohort entry 
8430 (-) 1.16 (1.04, 1.29) 
Bjorkhem-
Bergman 
2014 
Colon 
Swedish 
population 
register 
Swedish 
cancer 
registry 
Invasive 
Swedish 
prescribed 
drug register 
2006-2010 Case-control 
Non-Statin 
users 
Three registrations of 
dispensed statins in a 
1 year period 
21143 (4218)  1.04 (1.00, 1.08) 
Chan 2014 Breast 
Taiwan 
National 
Health 
Insurance 
program 
Insurance 
database 
Invasive 
Prescription 
database 
1996-2010 Case-control 
Non-Statin 
users 
≥1 statin prescription 
at any time during 
the study period 
565 (130) 1.13 (0.84, 1.51) 
Jesperson 
2014 
Prostate 
Danish Civil 
Registration 
System 
Cancer 
registry 
Invasive 
Danish 
prescription 
registry 
1996-2010 Case-control 
Non-Statin 
users 
≥1 statin prescription 
0-12 months prior to 
date of diagnosis 
42480 (7125) 0.94 (0.91, 0.97) 
Lustman 
2014 
Prostate 
Clait health 
services 
registered 
patients; 
Israel 
Disease 
register 
Invasive 
Prescription 
database 
2000-2009 Cohort 
Non-Statin 
users 
≥1 statin prescription 
between 2001-2009 
306 (-) 0.68 (0.60, 0.79) 
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[Table 9.2 continued] 
Author & 
Year 
Cancer(s) 
examined 
Study 
Population 
Data 
source for 
outcomes 
Invasive or 
non-
invasive 
cancer 
Data source 
for statin use 
Time period Study design 
Comparison 
group 
Statin exposure 
definition 
No of cases 
(cases 
exposed) 
Total cancer or site-specific 
cancer: point estimate (95% 
CI) 
Clancy 
2013 
Colorectal 
Northern 
Italy -Emilia-
Romagna 
Region 
Hospital 
discharge 
data 
Invasive 
Outpatient 
pharmacy data 
2003-2009 Cohort 
Glaucoma 
medication 
users 
New user: 3 filled 
prescriptions within 
180days of the first 
prescription 
1870 
(215963) 
0.84 (0.76, 0.92) 
Lakha 2012 Colorectal 
Tayside, 
Scotland 
Hospital 
records 
Invasive 
Linked 
pharmacy data 
1996-2006 Case-control 
Non-Statin 
users 
≥1 statin prescription 
at 2 or 6 months 
prior to date of 
diagnosis 
309 (25) 0.49 (0.22, 1.08) 
Lutski 2012 
Breast 
Colorectal 
Prostate 
Lung 
Maccabi 
healthcare 
services, 
Israel 
Israel 
cancer 
registry 
Invasive 
Prescription 
database 
1998-2007 Cohort 
Non-Statin 
users 
≥1 year continuous 
statin exposure 
8662 (-) 0.90 (0.84–0.96) 
Cheng 
2012 
Lung 
Taiwan 
National 
Health 
Insurance 
program 
Insurance 
database 
Invasive 
Prescription 
database 
2005-2008 Case-control 
Non-Statin 
users 
≥1 statin prescription 
at any time during 
the study period 
297 (61) 0.82 (0.58, 1.15) 
Cheng 
2011 
Colorectal 
Taiwan 
National 
Health 
Insurance 
program 
Insurance 
database 
Invasive 
Prescription 
database 
1996-2008 Case-control 
Non-Statin 
users 
≥1 statin prescription 
at any time during 
the study period 
1156 (242) 1.09 (0.91, 1.30) 
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Table 9.3: Summary of Findings and Biases - Risk of breast, prostate, and colorectal and lung cancer associated with Statin Use 
Author & Year 
Cancer 
type 
No of cases (cases 
exposed) 
Im
m
o
rt
al
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t 
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Confounders 
Analysis 
method 
Main result  
(95% CI) 
Nordstrom 2015 Prostate 8430 (-) Yes Yes Yes No - 
age, psa (log transformed), psa quotient, Charlston morbidity index, 
education, aspirin use, antidiabetic medications  
Logistic 
regression 
1.24 (1.10, 1.42) 
Bjorkhem-Bergman 
2014 
Colon 21143 (4218) - Yes Yes Yes No 
age, sex, diabetes, education, cortisone, acetylsalicylic acid, NSAID, 
chemotherapy, chron's disease, ulcerous colitis  
Cox regression  1.04 (1.00, 1.08) 
Chan 2014 Breast 565 (130) - No Yes No No age, sex, index date, benign mammary dysphasia, mammography, NSAIDs 
Conditional 
logistic 
regression 
1.13 (0.84, 1.51) 
Jesperson 2014 Prostate 42480 (7125) - Yes Yes Yes No age, level of comorbidity, aspirin use, NSIAD use, education 
Conditional 
logistic 
regression 
0.94 (0.91, 0.97) 
Lustman 2014 Prostate 306 (-) No Yes Yes No - age, diabetes, BMI, CVD, smoking status 
Time 
dependent Cox 
regression 
0.68 (0.60, 0.79) 
Clancy 2013 Colorectal 1870 (215963) No No No No - 
age, sex, colonoscopy, bowel disease, NSAID, estrogen, obesity, no. of co-
medications, no. of chronic conditions, no. of hospitalisations, Charleston 
weighted index 
Cox regression 0.84 (0.76, 0.92) 
Lakha 2012 Colorectal 309 (25) - No Yes Yes U 
age, sex, region, family history of cancer, history of cancer, bowel disease, 
BMI, smoking, physical activity, NSAID 
Conditional 
logistic 
regression 
0.49 (0.22, 1.08) 
Lutski 2012 
Breast 
Colorectal 
Prostate 
8662 (-) No No No No - 
age, sex, marital status, area of residence, nationality, socioeconomic level, 
years of stay in Israel, obesity, diabetes mellitus, hypertension, 
cardiovascular disease, efficacy, hospitalizations and visits to physicians a 
year before first statin dispensation, as well as for asthma, and chronic 
obstructive pulmonary disease (for lung and bronchus cancers). 
Cox regression 
breast: 1.03 (0.87, 1.22) 
colorectal: 0.93 (0.78, 
1,11) 
prostate: 0.95 (0.81, 1.13) 
Cheng 2012 Lung  - Yes Yes Yes No 
Adjusted for matching variable, tuberculosis, diabetes, use of NSAID, HRT 
use, and use of other lipid-lowering drugs. 
Conditional 
logistic 
regression 
0.82 (0.58, 1.15) 
Cheng 2011 Colorectal 1156 (242) - Yes Yes No No 
age, sex, index date, diabetes, number of hospitalisations, 
cholecystectomy, liver disease, colorectal polyps, infammatory bowel 
disease, colonoscopy, fecal occult blood testing, NSAIDs, other lipid 
lowering drugs 
Conditional 
logistic 
regression 
1.09 (0.91, 1.30) 
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10 Appendix C: Supplementary tables for Chapter 4 
Appendix C.1: ISAC and LSHTM Ethics approval details 
ISAC approval (application number 12_068R) for this project was obtained in 15 August 
2013. London School of Hygiene & Tropical Medicine (LSHTM) ethics approval for this 
study was obtained on 29 May 2012 (Application Number 6202). 
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Table 10.1: Breast cancer code list 
Readcode Description Classification ICD-10 code 
B342.00 MALIGNANT NEOPLASM OF UPPER-INNER QUADRANT OF FEMALE BREAST Malignant Neoplasm C50 
B34z.00 MALIGNANT NEOPLASM OF FEMALE BREAST NOS Malignant Neoplasm C50 
B34yz00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST NOS Malignant Neoplasm C50 
B340z00 MALIGNANT NEOPLASM OF NIPPLE OR AREOLA OF FEMALE BREAST NOS Malignant Neoplasm C50 
B346.00 MALIGNANT NEOPLASM OF AXILLARY TAIL OF FEMALE BREAST Malignant Neoplasm C50 
B340000 MALIGNANT NEOPLASM OF NIPPLE OF FEMALE BREAST Malignant Neoplasm C50 
B340.00 MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST Malignant Neoplasm C50 
B34y000 MALIGNANT NEOPLASM OF ECTOPIC SITE OF FEMALE BREAST Malignant Neoplasm C50 
Byu6.00 [X]MALIGNANT NEOPLASM OF BREAST Malignant Neoplasm C50 
B344.00 MALIGNANT NEOPLASM OF UPPER-OUTER QUADRANT OF FEMALE BREAST Malignant Neoplasm C50 
B340100 MALIGNANT NEOPLASM OF AREOLA OF FEMALE BREAST Malignant Neoplasm C50 
B347.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF BREAST Malignant Neoplasm C50 
B34y.00 MALIGNANT NEOPLASM OF OTHER SITE OF FEMALE BREAST Malignant Neoplasm C50 
B34..00 MALIGNANT NEOPLASM OF FEMALE BREAST Malignant Neoplasm C50 
B34..11 CA FEMALE BREAST Malignant Neoplasm C50 
B341.00 MALIGNANT NEOPLASM OF CENTRAL PART OF FEMALE BREAST Malignant Neoplasm C50 
B343.00 MALIGNANT NEOPLASM OF LOWER-INNER QUADRANT OF FEMALE BREAST Malignant Neoplasm C50 
B345.00 MALIGNANT NEOPLASM OF LOWER-OUTER QUADRANT OF FEMALE BREAST Malignant Neoplasm C50 
BB9K000 [M]PAGET'S DISEASE AND INTRADUCTAL CARCINOMA OF BREAST Malignant Morphology C50 
BB9G.00 [M]INFILTRATING DUCTULAR CARCINOMA Malignant Morphology C50 
BB91.00 [M]INFILTRATING DUCT CARCINOMA Malignant Morphology C50 
BB91000 [M]INTRADUCTAL PAPILLARY ADENOCARCINOMA WITH INVASION Malignant Morphology C50 
Table 10.1 continued over    
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Table 10.1 continued    
Read/OXMIS code Description Classification  
BB9H.00 [M]INFLAMMATORY CARCINOMA Malignant Morphology C50 
BB94.11 [M]SECRETORY BREAST CARCINOMA Malignant Morphology C50 
BB9J.11 [M]PAGET'S DISEASE, BREAST Malignant Morphology C50 
BB9F.00 [M]LOBULAR CARCINOMA NOS Malignant Morphology C50 
BB94.00 [M]JUVENILE BREAST CARCINOMA Malignant Morphology C50 
BB93.00 [M]COMEDOCARCINOMA NOS Malignant Morphology C50 
BB9D.00 [M]MEDULLARY CARCINOMA WITH LYMPHOID STROMA Malignant Morphology C50 
BB91100 [M]INFILTRATING DUCT AND LOBULAR CARCINOMA Malignant Morphology C50 
BB9K.00 [M]PAGET'S DISEASE AND INFILTRATING BREAST DUCT CARCINOMA Malignant Morphology C50 
BB9J.00 [M]PAGET'S DISEASE, MAMMARY Malignant Morphology C50 
BBM9.00 [M]CYSTOSARCOMA PHYLLODES, MALIGNANT Malignant Morphology C50 
B83..00 CARCINOMA IN SITU OF BREAST AND GENITOURINARY SYSTEM Malignant in situ tumour D09 
B830.00 CARCINOMA IN SITU OF BREAST Malignant in situ tumour D05 
B830100 INTRADUCTAL CARCINOMA IN SITU OF BREAST Malignant in situ tumour D05 
ByuFG00 [X]OTHER CARCINOMA IN SITU OF BREAST Malignant in situ tumour D05 
B830000 LOBULAR CARCINOMA IN SITU OF BREAST Malignant in situ tumour D05 
4KJ1.00 PROGESTERONE RECEPTOR POSITIVE TUMOUR Borderline D48 
4KJ0.00 OESTROGEN RECEPTOR POSITIVE TUMOUR Borderline D48 
4KJ2.00 OESTROGEN RECEPTOR NEGATIVE TUMOUR Borderline D48 
BA03.00 NEOPLASM OF UNSPECIFIED NATURE OF BREAST Borderline D48 
4KJ3.00 PROGESTERONE RECEPTOR NEGATIVE TUMOUR Borderline D48 
B933.00 NEOPLASM OF UNCERTAIN BEHAVIOUR OF BREAST Borderline D48 
B58y000 SECONDARY MALIGNANT NEOPLASM OF BREAST Secondary or metastatic - 
Table 10.1 continued over    
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Table 10.1 continued    
Read/OXMIS code Description Classification  
ZV10300 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BREAST History of cancer - 
ZV13A00 [V]PERSONAL HISTORY OF NON-NEOPLASTIC BREAST DISEASE History of cancer - 
1J0I.00 SUSPECTED BREAST CANCER Suspected - 
6862100 BREAST NEOPLASM SCREEN ABNORM Suspected - 
8Hn2.00 FAST TRACK REFERRAL FOR SUSPECTED BREAST CANCER Suspected - 
9Np2.00 SEEN IN FAST TRACK SUSPECTED BREAST CANCER CLINIC Suspected - 
 
297 
 
Table 10.2: Colorectal cancer code list 
Readcode Description Classification ICD-10 Code 
B132.00 MALIGNANT NEOPLASM OF DESCENDING COLON Malignant Neoplasm C18 
B136.00 MALIGNANT NEOPLASM OF ASCENDING COLON Malignant Neoplasm C18 
B13z.11 COLONIC CANCER Malignant Neoplasm C18 
B134.00 MALIGNANT NEOPLASM OF CAECUM Malignant Neoplasm C18 
B139.00 HEREDITARY NONPOLYPOSIS COLON CANCER Malignant Neoplasm C18 
B130.00 MALIGNANT NEOPLASM OF HEPATIC FLEXURE OF COLON Malignant Neoplasm C18 
B135.00 MALIGNANT NEOPLASM OF APPENDIX Malignant Neoplasm C18 
9Ow1.00 BOWEL CANCER DETECTED BY NATIONAL SCREENING PROGRAMME Malignant Neoplasm C18 
B1z0.11 CANCER OF BOWEL Malignant Neoplasm C18 
B13z.00 MALIGNANT NEOPLASM OF COLON NOS Malignant Neoplasm C18 
B131.00 MALIGNANT NEOPLASM OF TRANSVERSE COLON Malignant Neoplasm C18 
B13y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF COLON Malignant Neoplasm C18 
B13..00 MALIGNANT NEOPLASM OF COLON Malignant Neoplasm C18 
B133.00 MALIGNANT NEOPLASM OF SIGMOID COLON Malignant Neoplasm C18 
B138.00 MALIGNANT NEOPLASM, OVERLAPPING LESION OF COLON Malignant Neoplasm C18 
B137.00 MALIGNANT NEOPLASM OF SPLENIC FLEXURE OF COLON Malignant Neoplasm C18 
B134.11 CARCINOMA OF CAECUM Malignant Neoplasm C18 
4M10.00 DUKES STAGE A Malignant Neoplasm C18 
4M11.00 DUKES STAGE B Malignant Neoplasm C18 
4M12.00 DUKES STAGE C1 Malignant Neoplasm C18 
4M13.00 DUKES STAGE C2 Malignant Neoplasm C18 
4M14.00 DUKES STAGE D Malignant Neoplasm C18 
Table 10.2 continued over    
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Table 10.2 continued     
Readcode Description Classification ICD-10 Code 
4M1..00 DUKES STAGING SYSTEM Malignant Neoplasm C18 
B140.00 MALIGNANT NEOPLASM OF RECTOSIGMOID JUNCTION Malignant Neoplasm C19 
B141.11 CARCINOMA OF RECTUM Malignant Neoplasm C20 
B141.12 RECTAL CARCINOMA Malignant Neoplasm C20 
B141.00 MALIGNANT NEOPLASM OF RECTUM Malignant Neoplasm C20 
B14z.00 MALIGNANT NEOPLASM RECTUM,RECTOSIGMOID JUNCTION AND ANUS NOS Malignant Neoplasm C21 
B142000 MALIGNANT NEOPLASM OF CLOACOGENIC ZONE Malignant Neoplasm C21 
B142.00 MALIGNANT NEOPLASM OF ANAL CANAL Malignant Neoplasm C21 
B14..00 MALIGNANT NEOPLASM OF RECTUM, RECTOSIGMOID JUNCTION AND ANUS Malignant Neoplasm C21 
B142.11 ANAL CARCINOMA Malignant Neoplasm C21 
B14y.00 MALIG NEOP OTHER SITE RECTUM, RECTOSIGMOID JUNCTION AND ANUS Malignant Neoplasm C21 
B143.00 MALIGNANT NEOPLASM OF ANUS UNSPECIFIED Malignant Neoplasm C21 
B18y200 MALIGNANT NEOPLASM OF MESORECTUM Malignant Neoplasm C48 
BB5N100 [M]ADENOCARCINOMA IN ADENOMATOUS POLPOSIS COLI Malignant Morphology C18 
BB5R600 [M]MUCOCARCINOID TUMOUR, MALIGNANT Malignant Morphology C18 
B803700 CARCINOMA IN SITU OF SPLENIC FLEXURE OF COLON Malignant in situ tumour D01 
B803200 CARCINOMA IN SITU OF DESCENDING COLON Malignant in situ tumour D01 
B803600 CARCINOMA IN SITU OF ASCENDING COLON Malignant in situ tumour D01 
B803z00 CARCINOMA IN SITU OF COLON NOS Malignant in situ tumour D01 
B803000 CARCINOMA IN SITU OF HEPATIC FLEXURE OF COLON Malignant in situ tumour D01 
B804.00 CARCINOMA IN SITU OF RECTUM AND RECTOSIGMOID JUNCTION Malignant in situ tumour D01 
B804100 CARCINOMA IN SITU OF RECTUM Malignant in situ tumour D01 
B803100 CARCINOMA IN SITU OF TRANSVERSE COLON Malignant in situ tumour D01 
Table 10.2 continued over    
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Table 10.2 continued     
Readcode Description Classification ICD-10 Code 
B804z00 CARCINOMA IN SITU OF RECTUM OR RECTOSIGMOID JUNCTION NOS Malignant in situ tumour D01 
B803.00 CARCINOMA IN SITU OF COLON Malignant in situ tumour D01 
B804000 CARCINOMA IN SITU OF RECTOSIGMOID JUNCTION Malignant in situ tumour D01 
B803300 CARCINOMA IN SITU OF SIGMOID COLON Malignant in situ tumour D01 
B902500 NEOPLASM OF UNCERTAIN BEHAVIOUR OF RECTUM Borderline D37 
BB5N.00 [M]ADENOMATOUS AND ADENOCARCINOMATOUS POLYPS OF COLON Borderline D37 
BB5Nz00 [M]ADENOMATOUS OR ADENOCARCINOMATOUS POLYPS OF THE COLON NOS Borderline D37 
B902400 NEOPLASM OF UNCERTAIN BEHAVIOUR OF COLON Borderline D37 
B902.00 NEOP OF UNCERTAIN BEHAVIOUR STOMACH, INTESTINES AND RECTUM Borderline D37 
B575.00 SECONDARY MALIGNANT NEOPLASM OF LARGE INTESTINE AND RECTUM Secondary or metastatic C78 
B575100 SECONDARY MALIGNANT NEOPLASM OF RECTUM Secondary or metastatic C78 
B575z00 SECONDARY MALIG NEOP OF LARGE INTESTINE OR RECTUM NOS Secondary or metastatic C78 
B575000 SECONDARY MALIGNANT NEOPLASM OF COLON Secondary or metastatic C78 
ZV10017 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF RECTUM History of cancer C20 
8Hn4.00 FAST TRACK REFERRAL FOR SUSPECTED COLORECTAL CANCER Suspected - 
8CAo.00 PATIENT GIVEN ADVICE ABOUT BOWEL CANCER Suspected - 
9Np7.00 SEEN IN FAST TRACK SUSPECTED COLORECTAL CANCER CLINIC Suspected - 
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Table 10.3: Prostate cancer code list 
Readcode Description Classification ICD-10 Code 
4M01.00 GLEASON PROSTATE GRADE 5-7 (MEDIUM) Malignant Neoplasm C61 
4M02.00 GLEASON PROSTATE GRADE 8-10 (HIGH) Malignant Neoplasm C61 
4M00.00 GLEASON PROSTATE GRADE 2-4 (LOW) Malignant Neoplasm C61 
4M0..00 GLEASON GRADING OF PROSTATE CANCER Malignant Neoplasm C61 
B46..00 MALIGNANT NEOPLASM OF PROSTATE Malignant Neoplasm C61 
B915.00 NEOPLASM OF UNCERTAIN BEHAVIOUR OF PROSTATE Borderline D40 
B834.00 CARCINOMA IN SITU OF PROSTATE Malignant in situ tumour D07 
B58y500 SECONDARY MALIGNANT NEOPLASM OF PROSTATE Secondary or metastatic - 
ZV10415 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF PROSTATE Secondary or metastatic - 
1427000 H/O: PROSTATE CANCER History of cancer - 
1J08.00 SUSPECTED PROSTATE CANCER Suspected - 
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Table 10.4: Lung Cancer Code list 
Readcode Description Classification 
ICD-10 Code 
B22..00 MALIGNANT NEOPLASM OF TRACHEA, BRONCHUS AND LUNG Malignant Neoplasm C34 
B220.00 MALIGNANT NEOPLASM OF TRACHEA Malignant Neoplasm C33 
B220100 MALIGNANT NEOPLASM OF MUCOSA OF TRACHEA Malignant Neoplasm C33 
B220z00 MALIGNANT NEOPLASM OF TRACHEA NOS Malignant Neoplasm C33 
B221.00 MALIGNANT NEOPLASM OF MAIN BRONCHUS Malignant Neoplasm C34 
B221000 MALIGNANT NEOPLASM OF CARINA OF BRONCHUS Malignant Neoplasm C34 
B221100 MALIGNANT NEOPLASM OF HILUS OF LUNG Malignant Neoplasm C34 
B221z00 MALIGNANT NEOPLASM OF MAIN BRONCHUS NOS Malignant Neoplasm C34 
B222.00 MALIGNANT NEOPLASM OF UPPER LOBE, BRONCHUS OR LUNG Malignant Neoplasm C34 
B222.11 PANCOAST'S SYNDROME Malignant Neoplasm C34 
B222000 MALIGNANT NEOPLASM OF UPPER LOBE BRONCHUS Malignant Neoplasm C34 
B222100 MALIGNANT NEOPLASM OF UPPER LOBE OF LUNG Malignant Neoplasm C34 
B222z00 MALIGNANT NEOPLASM OF UPPER LOBE, BRONCHUS OR LUNG NOS Malignant Neoplasm C34 
B223.00 MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG Malignant Neoplasm C34 
B223000 MALIGNANT NEOPLASM OF MIDDLE LOBE BRONCHUS Malignant Neoplasm C34 
B223100 MALIGNANT NEOPLASM OF MIDDLE LOBE OF LUNG Malignant Neoplasm C34 
B223z00 MALIGNANT NEOPLASM OF MIDDLE LOBE, BRONCHUS OR LUNG NOS Malignant Neoplasm C34 
B224.00 MALIGNANT NEOPLASM OF LOWER LOBE, BRONCHUS OR LUNG Malignant Neoplasm C34 
B224000 MALIGNANT NEOPLASM OF LOWER LOBE BRONCHUS Malignant Neoplasm C34 
B224100 MALIGNANT NEOPLASM OF LOWER LOBE OF LUNG Malignant Neoplasm C34 
B224z00 MALIGNANT NEOPLASM OF LOWER LOBE, BRONCHUS OR LUNG NOS Malignant Neoplasm C34 
B225.00 MALIGNANT NEOPLASM OF OVERLAPPING LESION OF BRONCHUS & LUNG Malignant Neoplasm C34 
B22y.00 MALIGNANT NEOPLASM OF OTHER SITES OF BRONCHUS OR LUNG Malignant Neoplasm C34 
B22z.00 MALIGNANT NEOPLASM OF BRONCHUS OR LUNG NOS Malignant Neoplasm C34 
Table 10.4 continued over 
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Table 10.4 continued     
Readcode Description Classification ICD-10 Code 
B22z.11 LUNG CANCER Malignant Neoplasm C34 
B23..00 MALIGNANT NEOPLASM OF PLEURA Malignant Neoplasm C38 
B230.00 MALIGNANT NEOPLASM OF PARIETAL PLEURA Malignant Neoplasm C38 
B23y.00 MALIGNANT NEOPLASM OF OTHER SPECIFIED PLEURA Malignant Neoplasm C38 
B23z.00 MALIGNANT NEOPLASM OF PLEURA NOS Malignant Neoplasm C38 
Byu2000 [X]MALIGNANT NEOPLASM OF BRONCHUS OR LUNG, UNSPECIFIED Malignant Neoplasm C34 
BB1K.00 [M]OAT CELL CARCINOMA Malignant Morphology C34 
BB1L.00 [M]SMALL CELL CARCINOMA, FUSIFORM CELL TYPE Malignant Morphology C34 
BB1M.00 [M]SMALL CELL CARCINOMA, INTERMEDIATE CELL Malignant Morphology C34 
BB1N.00 [M]SMALL CELL-LARGE CELL CARCINOMA Malignant Morphology C34 
BB5J.12 [M]CYLINDROID BRONCHIAL ADENOMA Malignant Morphology C34 
BB5R111 [M]CARCINOID BRONCHIAL ADENOMA Malignant Morphology C34 
BB5S200 [M]BRONCHIOLO-ALVEOLAR ADENOCARCINOMA Malignant Morphology C34 
BB5S211 [M]ALVEOLAR CELL CARCINOMA Malignant Morphology C34 
BB5S212 [M]BRONCHIOLAR CARCINOMA Malignant Morphology C34 
BB5S400 [M]ALVEOLAR ADENOCARCINOMA Malignant Morphology C34 
B811.00 CARCINOMA IN SITU OF TRACHEA Malignant in situ tumour  D02 
B812.00 CARCINOMA IN SITU OF BRONCHUS AND LUNG Malignant in situ tumour D02 
B812000 CARCINOMA IN SITU OF CARINA OF BRONCHUS Malignant in situ tumour D02 
B812100 CARCINOMA IN SITU OF MAIN BRONCHUS Malignant in situ tumour D02 
B812200 CARCINOMA IN SITU OF UPPER LOBE BRONCHUS AND LUNG Malignant in situ tumour D02 
B812300 CARCINOMA IN SITU OF MIDDLE LOBE BRONCHUS AND LUNG Malignant in situ tumour D02 
B812400 CARCINOMA IN SITU OF LOWER LOBE BRONCHUS AND LUNG Malignant in situ tumour D02 
B812z00 CARCINOMA IN SITU OF BRONCHUS OR LUNG NOS Malignant in situ tumour D02 
B81y000 CARCINOMA IN SITU OF PLEURA Malignant in situ tumour D02 
Table 10.4 continued over  
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Table 10.4 continued  
Readcode Description Classification ICD-10 Code 
B907000 NEOPLASM OF UNCERTAIN BEHAVIOUR OF TRACHEA Borderline D38 
B907100 NEOPLASM OF UNCERTAIN BEHAVIOUR OF BRONCHUS Borderline D38 
B907200 NEOPLASM OF UNCERTAIN BEHAVIOUR OF LUNG Borderline D38 
B907z00 NEOP OF UNCERTAIN BEHAVIOUR OF TRACHEA, BRONCHUS OR LUNG NOS Borderline D38 
B908000 NEOPLASM OF UNCERTAIN BEHAVIOUR OF PLEURA Borderline D38 
4D56.00 PLEURAL FLUID: MALIGNANT CELLS Secondary or metastatic C79 
B570.00 SECONDARY MALIGNANT NEOPLASM OF LUNG Secondary or metastatic C79 
B572.00 SECONDARY MALIGNANT NEOPLASM OF PLEURA Secondary or metastatic C79 
H51y700 MALIGNANT PLEURAL EFFUSION Secondary or metastatic C79 
ZV10100 [V]PERSONAL HISTORY OF MALIG NEOP OF TRACHEA/BRONCHUS/LUNG History of cancer C34 
ZV10111 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BRONCHUS History of cancer C34 
ZV10112 [V]PERSONAL HISTORY OF MALIGNANT NEOPLASM OF LUNG History of cancer C34 
1J00.00 SUSPECTED LUNG CANCER Suspected malignancy - 
8Hn7.00 FAST TRACK REFERRAL FOR SUSPECTED LUNG CANCER Suspected malignancy - 
B181.00 MESOTHELIOMA OF PERITONEUM MESOTHELIOMA - EXCLUDE C45 
B226.00 MESOTHELIOMA MESOTHELIOMA - EXCLUDE C45 
B232.00 MESOTHELIOMA OF PLEURA MESOTHELIOMA - EXCLUDE C45 
B241400 MESOTHELIOMA OF PERICARDIUM MESOTHELIOMA - EXCLUDE C45 
Byu5000 [X]MESOTHELIOMA OF OTHER SITES MESOTHELIOMA - EXCLUDE C45 
Byu5011 [X]MESOTHELIOMA OF LUNG MESOTHELIOMA - EXCLUDE C45 
Byu5100 [X]MESOTHELIOMA, UNSPECIFIED MESOTHELIOMA - EXCLUDE C45 
BBP1.00 [M]MESOTHELIOMA, MALIGNANT MESOTHELIOMA - EXCLUDE C45 
BBP5.00 [M]EPITHELIOID MESOTHELIOMA, MALIGNANT MESOTHELIOMA - EXCLUDE C45 
BBP7.00 [M]MESOTHELIOMA, BIPHASIC TYPE, MALIGNANT MESOTHELIOMA - EXCLUDE C45 
BBPX.00 [M]MESOTHELIOMA, UNSPECIFIED MESOTHELIOMA - EXCLUDE C45 
1J0L.00 SUSPECTED MALIGNANT MESOTHELIOMA MESOTHELIOMA - EXCLUDE C45 
BBP9.00 [M]CYSTIC MESOTHELIOMA MESOTHELIOMA - EXCLUDE C45 
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Table 10.5: Malignant Neoplasm (Site Unknown) codelist 
Readcode Description ICD-10 Code 
44a..00 TUMOUR MARKER LEVELS D48 
8A9..00 TUMOUR MARKER MONITORING D48 
B....00 NEOPLASMS D48 
B9...00 NEOPLASMS OF UNCERTAIN BEHAVIOUR D48 
B93y.00 NEOPLASM OF UNCERTAIN BEHAVIOUR OF OTHER SPECIFIED SITES D48 
B9y..00 NEOPLASM OF UNCERTAIN BEHAVIOUR OTHERWISE SPECIFIED D48 
B9z..00 NEOPLASM OF UNCERTAIN BEHAVIOUR NOS D48 
BA...00 UNSPECIFIED NATURE NEOPLASM D48 
BA0..00 NEOPLASM OF UNSPECIFIED NATURE D48 
BA0y.00 NEOPLASM OF UNSPECIFIED NATURE OF OTHER SPECIFIED SITES D48 
BA0z.00 NEOPLASM OF UNSPECIFIED NATURE NOS D48 
BAz..00 NEOPLASM OF UNSPECIFIED NATURE NOS D48 
BB...11 [M]TUMOUR MORPHOLOGY D48 
BB0..00 [M]NEOPLASMS NOS D48 
BB01.00 [M]NEOPLASM, UNCERTAIN WHETHER BENIGN OR MALIGNANT D48 
BB06.00 [M]TUMOUR CELLS, UNCERTAIN WHETHER BENIGN OR MALIGNANT D48 
BB5..00 [M]ADENOMAS AND ADENOCARCINOMAS D48 
BB5y.00 [M]ADENOMA AND ADENOCARCINOMS OS D48 
BB5z.00 [M]ADENOMA OR ADENOCARCINOMA NOS D48 
BB80.00 [M]CYSTADENOMA AND CARCINOMA D48 
BBL3.12 [M]MIXED TUMOUR NOS D48 
By...00 NEOPLASMS OTHERWISE SPECIFIED D48 
ByuH.00 [X]NEOPLASMS OF UNCERTAIN AND UNKNOWN BEHAVIOUR D48 
Bz...00 NEOPLASMS NOS D48 
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Table 10.6: Supporting evidence of diagnosis 
Cancer type Supportive evidence Description 
All cancer 
types 
Non-surgical 
treatment or support 
Chemotherapy, radiotherapy,  cancer care (review or plan), terminal illness, palliative care, 
diagnosis at death, visit to an oncology clinic within 2 years of diagnosis code 
Breast 
Surgery Mastectomy; lumpectomy; quadrantectomy; total, partial, or wedge excisions of the breast 
Hormonal Therapy 
Tamoxifen; Goserelin; Anastrazole; Exemestane; Letrozole; Aminoglutethimide; Formestane, 
Testosterone enantate; Toremifene citrate; Trilostane; Fulvestrant 
   
Colorectal Surgery 
Colectomy (transverse, left/right hemi, sigmoid ); colostomy bag; ileostomy; colo-anal 
anastomosis; colon/rectum excision; colonic polypectomy ; transanal resection; low anterior 
resection of the rectum; abdominoperineal. 
   
Lung Surgery Lobectomy of the lung, pneumonectomy, excision of the lung 
   
Prostate 
 
Surgery  Prostatectomy; orchidectomy; resection of prostate 
Hormonal Therapy 
Anti-androgens:  Bicalutamide, Flutamide; Pituitary down-regulators: Buserelin, Goserelin 
acetate; Histrelin, Leuprorelin, Triptorelin acetate; Gonadeotrophin releasing hormone 
blockers: Degarelix, Other: Abiraterone, Cyproterone 
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11 Appendix D: Supplementary materials for Chapter 6 
Table 11.1: Demographics for the cohort of any statin users; glaucoma cohort 
 
 a) Any statin vs matched non-users 
cohort  
 b) New statin 
users (Table 6.1) 
c) Unmatched cohort of new statin users 
and new users of glaucoma medications   
 
 
Any Statin 
 
Non-Statin 
P-
value 
New statin New statin 
 
New Glaucoma 
P-
valuea 
All Patients 418188 
  
2090482 
 
 307646  630814 
  
48310 
 
 
Age      
1.000   
     
<0.001 
30-39 20057 (4.8)  
100285 (4.8)  14368 (4.7) 14985 (2.4) 
 
2024 (4.2)  
40-49 69201 (16.5)  
346005 (16.6)  53773 (17.5) 64685 (10.3) 
 
4178 (8.6)  
50-59 117161 (28.0) 
 
585819 (28.0)  91622 (29.8) 148766 (23.6) 
 
7721 (16.0)  
60-69 110151 (26.3) 
 
550770 (26.3)  80903 (26.3) 201659 (32.0) 
 
11071 (22.9)  
70-79 67828 (16.2) 
 
339076 (16.2)  46576 (15.1) 144918 (23.0) 
 
13443 (27.8)  
80+ 33790 (8.1) 
 
168526 (8.1)  20404 (6.6) 55801 (8.8) 
 
9873 (20.4)  
Sex      
0.962   
     
<0.001 
Male 224770 (53.7)  
1123520 (53.7)  163667 (53.2) 343442 (54.4) 
 
22640 (46.9)  
Female 193418 (46.3) 
 
966962 (46.3)  143979 (46.8) 287372 (45.6) 
 
25670 (53.1)  
Smoking status 
     
<0.001   
     
<0.001 
Non 157388 (37.6) 
 
933690 (44.7)  115053 (37.4) 236121 (37.4) 
 
23668 (49.0)  
Current 99191 (23.7)  
443407 (21.2)  75132 (24.4) 136589 (21.7) 
 
7365 (15.2)  
Ex 155614 (37.2)  
608700 (29.1)  115704 (37.6) 255700 (40.5) 
 
16082 (33.3)  
Unknown 5995 (1.4) 
 
104685 (5.0)  1757 (0.6) 2404 (0.4) 
 
1195 (2.5)  
BMI 
     
<0.001   
     
<0.001 
<20 8923 (2.1) 
 
89183 (4.3)  6494 (2.1) 15704 (2.5) 
 
2620 (5.4)  
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20-25 87506 (20.9) 
 
608397 (29.1)  65977 (21.4) 144417 (22.9) 
 
15556 (32.2)  
>25 289653 (69.3) 
 
1086260 (52.0)  218815 (71.1) 439646 (69.7) 
 
24420 (50.5)  
Unknown 32106 (7.7) 
 
306642 (14.7)  16360 (5.3) 31047 (4.9) 
 
5714 (11.8)  
Alcohol status      
<0.001   
     
<0.001 
Non 62877 (15.0) 
 
232727 (11.1)  38768 (12.6) 74225 (11.8) 
 
6193 (12.8)  
Ex 15799 (3.8)  
53500 (2.6)  12350 (4.0) 29874 (4.7) 
 
1429 (3.0)  
Current 12394 (3.0) 
 
55472 (2.7)  8096 (2.6) 14922 (2.4) 
 
1327 (2.7)  
rare<2u/d 72350 (17.3) 
 
334447 (16.0)  56488 (18.4) 120633 (19.1) 
 
8657 (17.9)  
moderate3-6u/d 186966 (44.7) 
 
950951 (45.5)  146339 (47.6) 300606 (47.7) 
 
22289 (46.1)  
excessive >6u/d 36062 (8.6)  
169623 (8.1)  29005 (9.4) 58717 (9.3) 
 
3253 (6.7)  
Unknown 31740 (7.6)  
293762 (14.1)  16600 (5.4) 31837 (5.0) 
 
5162 (10.7)  
Diabetes 123753 (29.6)  
149989 (7.2) <0.001 88714 (28.8) 173030 (27.4) 
 
9007 (18.6) <0.001 
CHD 100648 (24.1) 
 
76875 (3.7) <0.001 69974 (22.7) 125597 (19.9) 
 
4659 (9.6) <0.001 
Heart Failure 16591 (4.0) 
 
31250 (1.5) <0.001 11877 (3.9) 24867 (3.9) 
 
3064 (6.3) <0.001 
Hypertension 200599 (48.0) 
 
454328 (21.7) <0.001 148318 (48.2) 328027 (52.0) 
 
19306 (40.0) <0.001 
Hyperlipidaemia 135470 (32.4)  
89673 (4.3) <0.001 99255 (32.3) 190140 (30.1) 
 
4757 (9.8) <0.001 
NSAIDs/Aspirin 134987 (32.3)  
457198 (21.9) <0.001 124978 (40.6) 260032 (41.2) 
 
13894 (28.8) <0.001 
Antihypertensives 184993 (44.2) 
 
490584 (23.5) <0.001 168613 (54.8) 359534 (57.0) 
 
16540 (34.2) <0.001 
OC 2708 (0.6) 
 
20830 (1.0) <0.001 2484 (0.8) 2800 (0.4) 
 
491 (1.0) <0.001 
HRT 17643 (4.2) 
 
97491 (4.7) <0.001 16550 (5.4) 26254 (4.2) 
 
1867 (3.9) <0.001 
Consultations 
     
   
     
<0.001 
Mean (SD) 8.5 (8.6)  
3 (6.1) <0.001 10.6 (8.9) 10.7 (9.0) 
 
9.2 (9.1)  
aP-values (two-sided) were from t tests (continuous factor) or chi-square test (categorical factor). 
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Table 11.2: Demographics for the Case-control design (time-independent 
sampling) 
 Control 
 
 Case 
 
P-valuea 
All Patients 4773887 
 
 106244 
 
 
Age 
  
 
  
<0.001 
30-39 802634 (16.8)  1429 (1.3)  
40-49 1114546 (23.3)  7536 (7.1)  
50-59 966910 (20.3)  17084 (16.1)  
60-69 777310 (16.3)  27524 (25.9)  
70-79 547708 (11.5)  30584 (28.8)  
80+ 564779 (11.8)  22087 (20.8)  
Sex 
  
 
  
<0.001 
Male 2362975 (49.5)  50479 (47.5)  
Female 2410912 (50.5)  55765 (52.5)  
Smoking status 
  
 
  
<0.001 
Non 2122891 (44.5)  40579 (38.2)  
Current 958166 (20.1)  22029 (20.7)  
Ex 1207647 (25.3)  39250 (36.9)  
Unknown 485183 (10.2)  4386 (4.1)  
BMI 
  
 
  
<0.001 
<20 232851 (4.9)  6513 (6.1)  
20-25 1355102 (28.4)  33503 (31.5)  
>25 2179559 (45.7)  51516 (48.5)  
Unknown 1006375 (21.1)  14712 (13.8)  
Alcohol status 
  
 
  
<0.001 
Non 496282 (10.4)  11141 (10.5)  
Ex 204295 (4.3)  4858 (4.6)  
Current 144999 (3.0)  2626 (2.5)  
rare<2u/d 731226 (15.3)  18954 (17.8)  
moderate3-6u/d 1923945 (40.3)  47270 (44.5)  
excessive >6u/d 351913 (7.4)  8068 (7.6)  
Unknown 921227 (19.3)  13327 (12.5)  
Diabetes 527076 (11.0)  16153 (15.2) <0.001 
CHD 277935 (5.8)  12587 (11.8) <0.001 
Heart Failure 132161 (2.8)  5483 (5.2) <0.001 
Hypertension 965782 (20.2)  36328 (34.2) <0.001 
Hyperlipidaemia 340481 (7.1)  11276 (10.6) <0.001 
NSAIDs/Aspirin 1104834 (23.1)  39900 (37.6) <0.001 
Antihypertensives 1280320 (26.8)  46742 (44.0) <0.001 
OC 138682 (2.9)  1206 (1.1) <0.001 
HRT 117649 (2.5)  5468 (5.1) <0.001 
Consultations 
  
 
  
<0.001 
Mean (SD) 6.8 (9.2)  15.2 (13.5)  
a
P-values (two-sided) were from t tests (continuous factor) or chi-square test (categorical factor). 
309 
 
Table 11.3: Immortal time bias weighted relative risk, Δβ estimates and 
corresponding 95% confidence intervals  
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Weighted 
Relative Riska 
(95% CI)
Weighted 
Δβb
(95% CI)
(a) Minimum of 2 statin 
prescriptions 
Breast Cancer
Unexposed 505 031 5.94 6496 (1.3) 1.05 -0.01
Exposed 117 691 5.88 2154 (1.8) (0.99, 1.10) (-0.09, 0.06)
Unexposed 502 829 5.85 6411 (1.3) 1.06
Exposed 117 691 5.77 2154 (1.8) (1.00, 1.12)
Colorectal Cancer
Unexposed 1 035 532 5.94 5393 (0.5) 1.03 -0.01
Exposed 251 556 5.83 1787 (0.7) (0.97, 1.09) (-0.09, 0.07)
Unexposed 1 030 623 5.85 5342 (0.5) 1.04
Exposed 251 556 5.71 1787 (0.7) (0.99, 1.10)
Lung Cancer
Unexposed 1 035 532 5.94 5382 (0.5) 1.03 -0.01
Exposed 251 556 5.83 1931 (0.8) (0.97, 1.10) (-0.10, 0.07)
Unexposed 1 030 623 5.85 5337 (0.5) 1.04
Exposed 251 556 5.71 1931 (0.8) (0.98, 1.11)
Prostate Cancer
Unexposed 530 501 5.94 7178 (1.4) 1.10 -0.01
Exposed 133 865 5.78 2517 (1.9) (1.05, 1.15) (-0.08, 0.06)
Unexposed 527 794 5.85 7128 (1.4) 1.11
Exposed 133 865 5.66 2517 (1.9) (1.06, 1.16)
(b) Minimum of 6 months 
follow-up
Breast Cancer
Unexposed 488 154 6.04 6426 (1.3) 0.98 -0.06
Exposed 113 735 6.06 2019 (1.8) (0.93, 1.03) (-0.14, 0.01)
Unexposed 478 769 5.65 6042 (1.3) 1.04
Exposed 113 735 5.56 2019 (1.8) (0.99, 1.10)
Colorectal Cancer
Unexposed 1 000 777 6.05 5311 (0.5) 0.99 -0.05
Exposed 242 986 6.02 1725 (0.7) (0.94, 1.05) (-0.14, 0.03)
Unexposed 980 554 5.65 5084 (0.5) 1.05
Exposed 242 986 5.52 1725 (0.7) (0.99, 1.11)
Lung Cancer
Unexposed 1 000 777 6.05 5318 (0.5) 0.99 -0.06
Exposed 242 986 6.02 1869 (0.8) (0.94, 1.06) (-0.15, 0.03)
Unexposed 980 554 5.65 5100 (0.5) 1.06
Exposed 242 986 5.52 1869 (0.8) (0.99, 1.12)
Prostate Cancer
Unexposed 512 623 6.05 7067 (1.4) 1.03 -0.05
Exposed 129 251 5.98 2403 (1.9) (0.98, 1.09) (-0.12, 0.02)
Unexposed 501 785 5.66 6796 (1.4) 1.08
Exposed 129 251 5.48 2403 (1.9) (1.03, 1.14)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
No. of 
outcomes (%)
Biased
Biased
Biased
Biased
Biased
Corrected
Biased
Biased
Biased
Corrected
Corrected
Corrected
Corrected
Corrected
Corrected
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Table 11.4: Protopathic bias weighted relative risk, Δβ estimates and 
corresponding 95% confidence intervals 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Weighted 
Relative Riska 
(95%CI)
Weighted 
Δβb
(95% CI)
Breast Cancer
Exposed 131 581 5.74 2 377 (1.8) 1.03 0.02
Unexposed 553 656 5.81 6 959 (1.3) (0.98, 1.08) (-0.05, 0.10)
Exposed 107 399 5.50 1 888 (1.8) 1.01
Unexposed 434 616 5.52 5 512 (1.3) (0.95, 1.07)
Colorectal Cancer
Exposed 281 347 5.67 1 948 (0.7) 1.03 -0.01
Unexposed 1 131 970 5.79 5 707 (0.5) (0.97, 1.08) (-0.09, 0.07)
Exposed 231 466 5.45 1 679 (0.7) 1.04
Unexposed 895 020 5.51 4 749 (0.5) (0.98, 1.10)
Lung Cancer
Exposed 281 347 5.67 2 119 (0.8) 1.04 0.01
Unexposed 1 131 970 5.79 5 713 (0.5) (0.98, 1.10) (-0.08, 0.09)
Exposed 231 466 5.45 1 797 (0.8) 1.03
Unexposed 895 020 5.51 4 812 (0.5) (0.97, 1.10)
Prostate Cancer
Exposed 149 766 5.60 2 726 (1.8) 1.09 0.02
Unexposed 578 314 5.77 7 549 (1.3) (1.04, 1.15) (-0.05, 0.09)
Exposed 124 067 5.41 2 336 (1.9) 1.07
Unexposed 460 404 5.51 6 410 (1.4) (1.02, 1.12)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
No. of 
outcomes (%)
Biased 
(0-day lag)
Biased 
(0-day lag)
Biased 
(0-day lag)
Biased 
(0-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
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Table 11.5: Prevalent user bias weighted relative risk, Δβ estimates and 
corresponding 95% confidence intervals 
Analysis Statin Exposure N
Median 
Follow-up 
(years)
Weighted 
Relative Riska 
(95%CI)
Weighted Δβb
(95% CI)
Breast Cancer
Unexposed 812 670 5.31 8 871 (1.1) 0.95 -0.11
Exposed 169 619 5.28 2 837 (1.7) (0.90, 0.99) (-0.18, -0.04)
Unexposed 502 829 5.85 6 411 (1.3) 1.06
Exposed 117 691 5.77 2 154 (1.8) (1.00, 1.12)
Colorectal Cancer
Unexposed 1 690 276 5.28 7 312 (0.4) 0.96 -0.09
Exposed 369 963 5.17 2 475 (0.7) (0.91, 1.00) (-0.16, -0.01)
Unexposed 1 030 623 5.85 5 342 (0.5) 1.04
Exposed 251 556 5.71 1 787 (0.7) (0.99, 1.10)
Lung Cancer
Unexposed 1 690 276 5.28 7 182 (0.4) 0.96 -0.09
Exposed 369 963 5.17 2 636 (0.7) (0.91, 1.01) (-0.17, 0.00)
Unexposed 1 030 623 5.85 5 337 (0.5) 1.04
Exposed 251 556 5.71 1 931 (0.8) (0.98, 1.11)
Prostate Cancer
Unexposed 877 606 5.26 9 453 (1.1) 1.03 -0.08
Exposed 200 344 5.07 3 380 (1.7) (0.99, 1.07) (-0.14, -0.01)
Unexposed 527 794 5.85 7 128 (1.4) 1.11
Exposed 133 865 5.66 2 517 (1.9) (1.06, 1.16)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
(New user)
Corrected
(New user)
No. of 
outcomes (%)
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Corrected
(New user)
Corrected
(New user)
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Table 11.6: Immortal time bias imputed, missing category relative risk estimates, 
Δβ estimates and corresponding 95% confidence intervals 
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Imputed 
Relative Riska 
(95% CI)
Imputed Δβb
(95% CI)
Missing category 
Relative Riska 
(95% CI)
Missing 
category Δβb
(95% CI)
(a) Minimum of 2 statin 
prescriptions 
Breast Cancer
Unexposed 642 227 5.67 10 012 (1.6) 1.09 -0.01 1.09 -0.01
Exposed 128 453 5.72 2 298 (1.8) (1.03, 1.16) (-.1.00, .07) (1.03, 1.16) (-0.09, 0.07)
Unexposed 638 649 5.59 9 870 (1.5) 1.10 1.10
Exposed 128 453 5.60 2 298 (1.8) (1.04, 1.17) (1.04, 1.17)
Colorectal Cancer
Unexposed 1 370 363 5.59 8 905 (0.6) 1.06 -0.02 1.07 -0.02
Exposed 274 109 5.65 1 904 (0.7) (1, 1.13) (-0.11, 0.07) (1.00, 1.14) (-0.11, 0.07)
Unexposed 1 362 156 5.51 8 790 (0.6) 1.08 1.09
Exposed 274 109 5.53 1 904 (0.7) (1.02, 1.15) (1.02, 1.16)
Lung Cancer
Unexposed 1 370 363 5.59 9 265 (0.7) 1.08 -0.02 1.08 -0.02
Exposed 274 109 5.65 2 138 (0.8) (1.01, 1.15) (-0.11, 0.07) (1.01, 1.16) (-0.11, 0.07)
Unexposed 1 362 156 5.51 9 157 (0.7) 1.10 1.10
Exposed 274 109 5.53 2 138 (0.8) (1.03, 1.17) (1.03, 1.18)
Prostate Cancer
Unexposed 728 136 5.52 11 642 (1.6) 1.15 -0.01 1.14 -0.01
Exposed 145 656 5.58 2 655 (1.8) (1.09, 1.21) (-0.09, 0.07) (1.08, 1.2) (-0.09, 0.07)
Unexposed 723 507 5.44 11 533 (1.6) 1.16 1.15
Exposed 145 656 5.47 2 655 (1.8) (1.1, 1.23) (1.09, 1.22)
(b) Minimum of 6 months 
follow-up
Breast Cancer
Unexposed 619 081 5.07 9 816 (1.6) 1.02 -0.07 1.02 -0.07
Exposed 123 823 5.17 2 153 (1.7) (.96, 1.08) (-0.15, 0.01) (0.96, 1.08) (-0.15, 0.01)
Unexposed 604 046 4.76 9 135 (1.5) 1.09 1.09
Exposed 123 823 4.75 2 145 (1.7) (1.03, 1.16) (1.03, 1.16)
Colorectal Cancer
Unexposed 1 319 720 5.00 8 692 (0.7) 1.02 -0.06 1.03 -0.06
Exposed 263 976 5.13 1 831 (0.7) (-0.16, 0.03) (0.96, 1.09) (-0.15, 0.03)
Unexposed 1 286 440 4.72 8 240 (0.6) 1.09 1.09
Exposed 263 976 4.72 1 829 (0.7) (1.02, 1.17)
Lung Cancer
Unexposed 1 319 720 5.00 9 083 (0.7) 1.04 -0.06 1.05 -0.06
Exposed 263 976 5.13 2 057 (0.8) (-0.16, 0.03) (0.98, 1.12) (-0.16, 0.03)
Unexposed 1 286 440 4.72 8 589 (0.7) 1.11 1.11
Exposed 263 976 4.72 2 054 (0.8) (1.04, 1.19)
Prostate Cancer
Unexposed 700 639 4.95 11 352 (1.6) 1.09 -0.05 1.08 -0.05
Exposed 140 153 5.09 2 525 (1.8) (-0.13, 0.03) (1.02, 1.14) (-0.13, 0.03)
Unexposed 682 394 4.68 10 855 (1.6) 1.14 1.13
Exposed 140 153 4.68 2 523 (1.8) (1.07, 1.2)
Corrected
Corrected
No. of 
outcomes (%)
Biased
Biased
Biased
Biased
Biased
Corrected
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Biased
Biased
Biased
Corrected
Corrected
Corrected
Corrected
Corrected
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Table 11.7: Protopathic bias imputed, missing category relative risk estimates, Δβ 
estimates and corresponding 95% confidence intervals 
Analysis Statin Exposure N
Median 
Follow-up 
(years)
Imputed 
Relative Riska 
(95%CI)
Imputed Δβb
(95% CI)
Missing category 
Relative Riska 
(95% CI)
Missing category 
Δβb
(95% CI)
Breast Cancer
Unexposed 719 853 5.58 10991 (1.5) 1.11 0.02 1.11 0.02
Exposed 143 979 5.59 2537 (1.8) (1.05, 1.17) (-0.07, .010) (1.05, 1.17) (-0.07, 0.10)
Unexposed 553 415 5.34 8304 (1.5) 1.09 1.09
Exposed 116 139 5.38 2012 (1.7) (1.02, 1.16) (1.02, 1.16)
Colorectal Cancer
Unexposed 1 538 020 5.48 9674 (0.6) 1.08 -0.01 1.08 -0.01
Exposed 307 646 5.49 2076 (0.7) (1.02, 1.15) (-0.10, 0.08) (1.02, 1.15) (-0.10, 0.08)
Unexposed 1 187 314 5.28 7638 (0.6) 1.09 1.09
Exposed 249 648 5.34 1779 (0.7) (1.02, 1.17) (1.02, 1.17)
Lung Cancer
Unexposed 1 538 020 5.48 10101 (0.7) 1.10 0.01 1.11 0.01
Exposed 307 646 5.49 2350 (0.8) (1.04, 1.18) (-0.08, 0.11) (1.04, 1.18) (-0.08, 0.11)
Unexposed 1 187 314 5.28 8013 (0.7) 1.09 1.10
Exposed 249 648 5.34 1968 (0.8) (1.02, 1.17) (1.02, 1.18)
Prostate Cancer
Unexposed 818 167 5.39 12597 (1.5) 1.17 0.02 1.16 0.02
Exposed 163 667 5.41 2875 (1.8) (1.11, 1.23) (-0.05, 0.10) (1.1, 1.22) (-0.05, 0.10)
Unexposed 633 899 5.21 10179 (1.6) 1.14 1.13
Exposed 133 509 5.29 2446 (1.8) (1.08, 1.21) (1.07, 1.20)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
(360-day lag)
No. of 
outcomes (%)
Biased 
(0-day lag)
Biased 
(0-day lag)
Biased 
(0-day lag)
Biased 
(0-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
Corrected
(360-day lag)
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Table 11.8: Prevalent user bias imputed, missing category relative risk estimates, 
Δβ estimates and corresponding 95% confidence intervals 
Analysis
Statin 
Exposure
N
Median Follow-
up (years)
Imputed 
Relative Riska 
(95%CI)
Imputed Δβb
(95% CI)
Missing category 
Relative Riska 
(95% CI)
Missing 
category Δβb
(95% CI)
Breast Cancer
Unexposed 966 962 5.08 14 405 (1.5) 1.01 -0.09 1.01 -0.09
Exposed 193 418 4.90 3 071 (1.6) (0.96, 1.06) (-0.17, -0.01) (0.96, 1.06) (-0.17, -0.01)
Unexposed 638 649 5.59 9 870 (1.5) 1.10 1.10
Exposed 128 453 5.60 2 298 (1.8) (1.04, 1.17) (1.04, 1.17)
Colorectal Cancer
Unexposed 2 090 482 5.01 12 767 (0.6) 1.03 -0.05 1.03 -0.06
Exposed 418 188 4.81 2 683 (0.6) (0.97, 1.08) (-0.14, 0.03) (0.97, 1.08) (-0.14, 0.03)
Unexposed 1 362 156 5.51 8 790 (0.6) 1.08 1.09
Exposed 274 109 5.53 1 904 (0.7) (1.02, 1.15) (1.02, 1.16)
Lung Cancer
Unexposed 2 090 482 5.01 13 058 (0.6) 1.03 -0.07 1.03 -0.07
Exposed 418 188 4.81 2 978 (0.7) (0.97, 1.09) (-0.15, 0.02) (0.97, 1.09) (-0.16, 0.02)
Unexposed 1 362 156 5.51 9 157 (0.7) 1.10 1.10
Exposed 274 109 5.53 2 138 (0.8) (1.03, 1.17) (1.03, 1.18)
Prostate Cancer
Unexposed 1 123 520 4.94 16 494 (1.5) 1.08 -0.07 1.08 -0.07
Exposed 224 770 4.73 3 581 (1.6) (1.03, 1.14) (-0.14, 0.00) (1.03, 1.13) (-0.14, 0.01)
Unexposed 723 507 5.44 11 533 (1.6) 1.16 1.15
Exposed 145 656 5.47 2 655 (1.8) (1.10, 1.23) (1.09, 1.22)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
(New user)
No. of 
outcomes (%)
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Corrected
(New user)
Corrected
(New user)
Corrected
(New user)
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Table 11.9: Healthy user bias imputed, missing category relative risk estimates, Δβ 
estimates and corresponding 95% confidence intervals 
  
 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Imputed 
Relative Riska 
(95%CI)
Imputed Δβb
(95% CI)
Missing category 
Relative Riska 
(95% CI)
Missing 
category Δβb
(95% CI)
Breast Cancer
Unexposed 638 649 5.59 9 870 (1.5) 1.10 0.08 1.10 0.08
Exposed 128 453 5.60 2 298 (1.8) (1.04, 1.17) (-0.04, 0.20) (1.04, 1.17) (-0.04, 0.20)
Unexposed 25 670 4.77 441 (1.7) 1.02 1.02
Exposed 277 236 4.82 4 485 (1.6) (.92, 1.13) (0.91, 1.13)
Colorectal Cancer
Unexposed 1 362 156 5.51 8 790 (0.6) 1.08 -0.07 1.09 -0.08
Exposed 274 109 5.53 1 904 (0.7) (1.02, 1.15) (-0.20, 0.05) (1.02, 1.16) (-0.04, 0.20)
Unexposed 48 310 4.69 410 (0.8) 1.17 1.18
Exposed 610 121 4.69 4 565 (0.7) (1.04, 1.3) (1.06, 1.32)
Lung Cancer
Unexposed 1 362 156 5.51 9 157 (0.7) 1.10 -0.01 1.10 -0.05
Exposed 274 109 5.53 2 138 (0.8) (1.03, 1.17) (-0.14, 0.12) (1.03, 1.18) (-0.18, 0.08)
Unexposed 48 310 4.69 397 (0.8) 1.11 1.16
Exposed 610 121 4.69 4 858 (0.8) (.99, 1.24) (1.04, 1.3)
Prostate Cancer
Unexposed 723 507 5.44 11 533 (1.6) 1.16 0.06 1.15 0.06
Exposed 145 656 5.47 2 655 (1.8) (1.1, 1.23) (-0.04, 0.17) (1.09, 1.22) (-0.04, 0.17)
Unexposed 22 640 4.57 589 (2.6) 1.09 1.08
Exposed 332 885 4.59 6 319 (1.9) (.99, 1.19) (0.99, 1.19)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected 
(glaucoma medication 
comparison group)
No. of 
outcomes 
(%)
Biased 
(non-user comparison group)
Biased 
(non-user comparison group)
Biased 
(non-user comparison group)
Biased 
(non-user comparison group)
Corrected 
(glaucoma medication 
comparison group)
Corrected 
(glaucoma medication 
comparison group)
Corrected 
(glaucoma medication 
comparison group)
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Table 11.10: Time-window bias imputed, missing category relative risk estimates, 
Δβ estimates and corresponding 95% confidence intervals 
 
 
 
Analysis
Case 
status
N
Median 
Follow-up 
(years)
Statin 
user(%)
Imputed 
Relativea Risk 
(95% CI)
Imputed Δβb
(95% CI)
Missing Category 
Relative Riska 
(95% CI)
Missing 
category Δβb
(95% CI)
Breast Cancer
Control 2 430 456 5.37 350 750 0.80 -0.24 0.76 -0.31
Case 36 221 5.06 350 750 (0.77, 0.83) (-0.29, -0.18) (0.73, 0.79) (-0.37, -0.26)
Control 552 548 6.07 128 880 1.01 1.04
Case 32 992 5.68 128 880 (0.97, 1.05) (1.00, 1.09)
Colorectal Cancer
Control 4 858 163 5.26 780 723 0.89 -0.12 0.84 -0.22
Case 21 968 5.68 780 723 (0.85, .92) (-0.18, -0.06) (0.81, 0.87) (-0.28, -0.16)
Control 565 219 6.04 128 747 1.00 1.04
Case 20 321 6.24 128 747 (0.95, 1.04) (1.00, 1.09)
Lung Cancer
Control 4 857 109 5.27 780 400 0.72 -0.25 0.70 -0.35
Case 23 022 5.18 780 400 (0.69, 0.75) (-0.31, -0.19) (0.67, 0.72) (-0.42, -0.29)
Control 564 461 6.06 128 467 0.92 0.99
Case 21 079 5.80 128 467 (0.88, 0.97) (0.94, 1.04)
Prostate Cancer
Control 2 388 421 5.18 422 280 0.93 -0.04 0.86 -0.15
Case 25 033 6.19 422 280 (0.90, .96) (-0.09, 0.01) (0.83, 0.89) (-0.20, -0.10)
Control 562 275 6.03 126 604 0.97 1.00
Case 23 265 6.71 126 604 (0.93, 1.01) (0.96, 1.04)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Biased
(Time independent 
sampling)
Corrected
(Risk set sampling)
Biased
(Time independent 
sampling)
Corrected
(Risk set sampling)
Corrected
(Risk set sampling)
Corrected
(Risk set sampling)
Biased
(Time independent 
sampling)
Biased
(Time independent 
sampling)
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Table 11.11: Immortal time bias censored relative risk, Δβ estimates and 
corresponding 95% confidence intervals 
 
Analysis Statin Exposure N
Median 
Follow-up 
(years)
Censored 
Relative Riska 
(95%CI)
Censored Δβb
(95% CI)
(a) Minimum of 2 
statin prescriptions 
Breast Cancer
Unexposed 505 031 4.57 6505 (1.3) 1.15 -0.02
Exposed 117 691 4.52 1797 (1.5) (1.07, 1.25) (-0.12, 0.09)
Unexposed 502 829 4.51 6400 (1.3) 1.17
Exposed 117 691 4.41 1797 (1.5) (1.09, 1.27)
Colorectal Cancer
Unexposed 1 035 532 4.45 4913 (0.5) 1.15 -0.02
Exposed 251 556 4.50 1497 (0.6) (1.06, 1.25) (-0.14, 0.10)
Unexposed 1 030 623 4.39 4834 (0.5) 1.17
Exposed 251 556 4.39 1497 (0.6) (1.08, 1.28)
Lung Cancer
Unexposed 1 035 532 4.45 4823 (0.5) 1.03 -0.02
Exposed 251 556 4.50 1561 (0.6) (0.94, 1.13) (-0.16, 0.12)
Unexposed 1 030 623 4.39 4761 (0.5) 1.05
Exposed 251 556 4.39 1561 (0.6) (0.96, 1.16)
Prostate Cancer
Unexposed 530 501 4.35 6467 (1.2) 1.24 -0.02
Exposed 133 865 4.49 2135 (1.6) (1.15, 1.34) (-0.13, 0.09)
Unexposed 527 794 4.29 6389 (1.2) 1.26
Exposed 133 865 4.37 2135 (1.6) (1.17, 1.36)
(b) Minimum of 6 
months follow-up
Breast Cancer
Unexposed 488 154 4.68 6407 (1.3) 1.05 -0.09
Exposed 113 735 4.72 1662 (1.5) (0.97, 1.14) (-0.20, 0.02)
Unexposed 478 769 4.40 5926 (1.2) 1.15
Exposed 113 735 4.22 1662 (1.5) (1.06, 1.25)
Colorectal Cancer
Unexposed 1 000 777 4.56 4821 (0.5) 1.08 -0.09
Exposed 242 986 4.70 1435 (0.6) (0.99, 1.18) (-0.21, 0.04)
Unexposed 980 554 4.29 4505 (0.5) 1.18
Exposed 242 986 4.20 1435 (0.6) (1.08, 1.29)
Lung Cancer
Unexposed 1 000 777 4.56 4755 (0.5) 0.97 -0.09
Exposed 242 986 4.70 1499 (0.6) (0.88, 1.07) (-0.23, 0.05)
Unexposed 980 554 4.29 4464 (0.5) 1.06
Exposed 242 986 4.20 1499 (0.6) (0.96, 1.18)
Prostate Cancer
Unexposed 512 623 4.45 6337 (1.2) 1.13 -0.08
Exposed 129 251 4.69 2022 (1.6) (1.05, 1.22) (-0.19, 0.03)
Unexposed 501 785 4.19 5959 (1.2) 1.22
Exposed 129 251 4.19 2022 (1.6) (1.13, 1.32)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Corrected
Biased
Biased
Biased
Biased
Biased
Biased
Corrected
No. of 
outcomes (%)
Biased
Biased
Corrected
Corrected
Corrected
Corrected
Corrected
Corrected
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Table 11.12: Protopathic bias censored relative risk, Δβ estimates and 
corresponding 95% confidence intervals 
Analysis
Statin 
Exposure
N
Median 
Follow-up 
(years)
Censored 
Relative Riska 
(95% CI)
Censored 
Δβb
(95% CI)
Breast Cancer
Unexposed 553 656 4.47 7 131 (1.3) 1.13 0.03
Exposed 131 581 4.14 1 920 (1.5) (1.05, 1.22) (-0.09, 0.14)
Unexposed 434 616 4.35 5 281 (1.2) 1.10
Exposed 107 399 4.07 1 437 (1.3) (1.01, 1.2)
Colorectal Cancer
Unexposed 1 131 970 4.34 5 349 (0.5) 1.13 -0.01
Exposed 281 347 4.10 1 570 (0.6) (1.04, 1.23) (-0.14, 0.11)
Unexposed 895 020 4.23 4 078 (0.5) 1.15
Exposed 231 466 4.07 1 307 (0.6) (1.04, 1.27)
Lung Cancer
Unexposed 1 131 970 4.34 5 254 (0.5) 1.01 0.04
Exposed 281 347 4.10 1 632 (0.6) (0.92, 1.11) (-0.11, 0.18)
Unexposed 895 020 4.23 4 113 (0.5) 0.98
Exposed 231 466 4.07 1 331 (0.6) (0.87, 1.09)
Prostate Cancer
Unexposed 578 314 4.22 6 987 (1.2) 1.23 0.03
Exposed 149 766 4.05 2 241 (1.5) (1.14, 1.32) (-0.08, 0.14)
Unexposed 460 404 4.11 5 471 (1.2) 1.19
Exposed 124 067 4.05 1 860 (1.5) (1.09, 1.3)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
Biased 
(0-day lag)
Corrected
(360-day lag)
No. of 
outcomes (%)
Biased 
(0-day lag)
Corrected
(360-day lag)
biased 
(0-day lag)
Corrected
(360-day lag)
Biased 
(0-day lag)
Corrected
(360-day lag)
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Table 11.13: Prevalent user bias censored and primary analysis relative 
risk estimates, corresponding 95% confidence intervals, and percentage 
difference in risk attributable to prevalent user bias 
 
Analysis Statin Exposure N
Median 
Follow-up 
(years)
Censored 
Relative Riska 
(95%CI)
Censored 
Δβb
(95% CI)
Breast Cancer
Unexposed 812 670 4.13 9 990 (1.2) 0.99 -0.17
Exposed 169 619 3.82 2 286 (1.3) (0.93, 1.06) (-0.27, -0.07)
Unexposed 502 829 4.51 6 400 (1.3) 1.17
Exposed 117 691 4.41 1 797 (1.5) (1.09, 1.27)
Colorectal Cancer
Unexposed 1 690 276 4.02 7 640 (0.5) 1.05 -0.12
Exposed 369 963 3.76 1 994 (0.5) (0.97, 1.13) (-0.23, 0.00)
Unexposed 1 030 623 4.39 4 834 (0.5) 1.17
Exposed 251 556 4.39 1 497 (0.6) (1.08, 1.28)
Lung Cancer
Unexposed 1 690 276 4.02 7 374 (0.4) 0.96 -0.09
Exposed 369 963 3.76 2 075 (0.6) (0.88, 1.04) (-0.22, 0.03)
Unexposed 1 030 623 4.39 4 761 (0.5) 1.05
Exposed 251 556 4.39 1 561 (0.6) (0.96, 1.16)
Prostate Cancer
Unexposed 877 606 3.93 9 993 (1.1) 1.10 -0.14
Exposed 200 344 3.70 2 741 (1.4) (1.03, 1.17) (-0.24, -0.04)
Unexposed 527 794 4.29 6 389 (1.2) 1.26
Exposed 133 865 4.37 2 135 (1.6) (1.17, 1.36)
Corrected
(New user)
a Relative risk adjusted for all potential confounders listed in Table 6.2; 
bΔβ= Difference between "biased" and "corrected" log relative risk estimates 
No. of 
outcomes (%
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Biased
(Prevalent user)
Corrected
(New user)
Corrected
(New user)
Corrected
(New user)
